data_2kpe_residue save_MolProbity _Software.Sf_category software _Software.Sf_framecode MolProbity _Software.Entry_ID ? _Software.ID 1 _Software.Name MolProbity _Software.Version 4.0 _Software.Details . save_ save_CYRANGE _Software.Sf_category software _Software.Sf_framecode CYRANGE _Software.Entry_ID ? _Software.ID 2 _Software.Name CYRANGE _Software.Version 2.0 _Software.Details . save_ save_Structure_validation_residue _Structure_validation_residue.Sf_category structure_validation _Structure_validation_residue.Sf_framecode Structure_validation_residue _Structure_validation_residue.Entry_ID ? _Structure_validation_residue.List_ID 1 _Structure_validation_residue.PDB_accession_code 2kpe _Structure_validation_residue.Date_analyzed 2016-10-07 loop_ _Residue_analysis_software.Software_ID _Residue_analysis_software.Software_label _Residue_analysis_software.Method_ID _Residue_analysis_software.Method_label _Residue_analysis_software.Entry_ID _Residue_analysis_software.Structure_validation_oneline_list_ID 1 MolProbity . . ? 1 2 CYRANGE . . ? 1 stop_ loop_ _Residue_analysis.ID _Residue_analysis.PDB_model_num _Residue_analysis.Hydrogen_positions _Residue_analysis.MolProbity_flips _Residue_analysis.Cyrange_core_flag _Residue_analysis.Two_letter_chain_ID _Residue_analysis.PDB_strand_ID _Residue_analysis.PDB_residue_no _Residue_analysis.PDB_ins_code _Residue_analysis.PDB_residue_name _Residue_analysis.Assembly_ID _Residue_analysis.Entity_assembly_ID _Residue_analysis.Entity_ID _Residue_analysis.Comp_ID _Residue_analysis.Comp_index_ID _Residue_analysis.Clash_value _Residue_analysis.Clash_source_PDB_atom_name _Residue_analysis.Clash_destination_PDB_atom_name _Residue_analysis.Clash_destination_PDB_strand_ID _Residue_analysis.Clash_destination_PDB_residue_no _Residue_analysis.Clash_destination_PDB_ins_code _Residue_analysis.Clash_destination_PDB_residue_name _Residue_analysis.Cbeta_deviation_value _Residue_analysis.Rotamer_score _Residue_analysis.Rotamer_name _Residue_analysis.Ramachandran_phi _Residue_analysis.Ramachandran_psi _Residue_analysis.Ramachandran_score _Residue_analysis.Ramachandran_evaluation _Residue_analysis.Ramachandran_type _Residue_analysis.Bond_outlier_count _Residue_analysis.Worst_bond _Residue_analysis.Worst_bond_value _Residue_analysis.Worst_bond_sigma _Residue_analysis.Angle_outlier_count _Residue_analysis.Worst_angle _Residue_analysis.Worst_angle_value _Residue_analysis.Worst_angle_sigma _Residue_analysis.RNA_phosphate_perpendicular_outlier _Residue_analysis.RNA_suitness_score _Residue_analysis.RNA_suite_conformer _Residue_analysis.RNA_suite_triage _Residue_analysis.Max_b_factor _Residue_analysis.Tau_angle _Residue_analysis.Omega_dihedral _Residue_analysis.Disulfide_chi1 _Residue_analysis.Disulfide_chi2 _Residue_analysis.Disulfide_chi3 _Residue_analysis.Disulfide_ss_angle _Residue_analysis.Disulfide_ss _Residue_analysis.Disulfide_ss_angle_prime _Residue_analysis.Disulfide_chi2prime _Residue_analysis.Disulfide_chi1prime _Residue_analysis.Outlier_count_separate_geometry _Residue_analysis.Outlier_count _Residue_analysis.Entry_ID _Residue_analysis.Structure_validation_residue_list_ID . 001 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 22.8 mt . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.781 0.324 . . . . 0.0 110.863 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 58.8 mt -65.95 -41.99 90.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.187 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.1 mm -66.15 -57.3 11.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.125 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.18 -31.22 69.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.95 -64.53 2.98 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 78.5 t -56.52 -35.45 44.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.792 0.329 . . . . 0.0 111.111 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.0 mmt -65.4 -47.31 76.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.863 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.43 90.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.087 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.22 -56.59 5.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 99.6 t -54.83 -49.05 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.802 0.334 . . . . 0.0 111.121 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.1 mm -63.44 -48.3 87.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.76 -36.11 91.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.49 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 88.8 m -68.58 -58.35 4.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.83 0.348 . . . . 0.0 111.186 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.8 mt -56.37 -37.98 53.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 15.7 mt -65.26 -53.45 44.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.962 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -55.0 -48.95 72.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.9 mt -64.96 -56.74 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.3 t -55.19 -24.8 28.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 41.0 t80 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.907 -179.896 . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.0 mt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.762 0.315 . . . . 0.0 110.907 . . . . . . . . . 0 0 . 1 . 001 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 36.7 mm -66.97 -42.87 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.133 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.3 mm -66.04 -57.62 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.145 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -61.06 -31.03 70.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.04 -64.6 2.94 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.472 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 97.2 t -56.87 -35.66 47.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.802 0.334 . . . . 0.0 111.102 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 42.7 mmm -65.3 -47.08 77.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.6 91.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.23 -56.41 5.7 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 98.6 t -54.89 -49.02 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.813 0.339 . . . . 0.0 111.122 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.0 mm -63.41 -48.34 87.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.17 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.8 -36.18 91.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.5 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 91.8 m -68.44 -57.51 5.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.775 0.321 . . . . 0.0 111.118 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 76.6 mt -57.69 -37.6 60.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 16.4 mt -65.23 -53.01 50.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.923 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.2 -49.36 72.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.77 -56.8 14.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 29.8 t -55.16 -24.94 29.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 22.9 t80 . . . . . 0 C--N 1.327 -0.375 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.911 -179.86 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 25.1 mt . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.792 0.329 . . . . 0.0 110.921 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.4 mm -66.39 -43.02 91.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.155 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.0 mm -66.04 -57.74 9.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.1 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.56 -30.71 69.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.12 -64.29 3.07 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.474 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 91.4 t -56.93 -35.5 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.808 0.337 . . . . 0.0 111.117 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 2.7 mmt -65.54 -47.43 75.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.83 92.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.068 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.7 -56.62 5.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.523 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 99.2 t -54.94 -50.91 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.813 0.339 . . . . 0.0 111.154 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.3 mm -60.45 -50.56 79.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.78 -40.7 95.35 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.478 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 87.9 m -62.62 -59.02 5.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.728 0.299 . . . . 0.0 111.127 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 77.8 mt -54.14 -44.2 62.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.145 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 12.7 mt -56.46 -51.12 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.53 -42.02 91.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.936 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.9 mm -65.53 -63.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.148 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 3.8 m -51.65 -30.55 22.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.87 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 42.2 t80 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.906 -179.832 . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 13.9 mt . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.762 0.315 . . . . 0.0 110.879 . . . . . . . . . 0 0 . 1 . 002 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.4 mm -67.08 -39.98 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.152 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 26.9 mt -66.39 -58.49 6.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.097 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -60.8 -31.5 70.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.78 -64.92 2.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.432 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 82.2 t -56.32 -35.34 42.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.776 0.322 . . . . 0.0 111.115 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 27.8 mmt -65.24 -47.93 75.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.879 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.87 -37.88 88.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.24 -55.8 6.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.477 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 92.8 t -54.78 -48.38 73.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.833 0.349 . . . . 0.0 111.146 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 61.9 mt -63.6 -48.45 86.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.154 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.19 -36.58 91.1 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.464 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 53.0 m -68.46 -58.22 4.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.32 . . . . 0.0 111.144 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 72.6 mt -56.66 -37.8 54.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.136 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 18.2 mt -65.16 -53.54 43.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -54.97 -49.18 72.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.6 mt -64.67 -57.01 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 75.7 m -54.97 -25.08 27.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 38.3 t80 . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.947 -179.938 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 27.3 mt . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.754 0.311 . . . . 0.0 110.908 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.1 mm -66.44 -42.98 91.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.0 mm -65.97 -58.08 8.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.121 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.36 -30.94 69.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.98 -64.69 2.9 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 80.5 t -56.48 -35.6 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 3.0 mmt -65.41 -47.16 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.05 -38.47 91.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.088 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.12 -56.66 5.61 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.461 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -54.9 -49.72 67.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.825 0.345 . . . . 0.0 111.134 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.71 -49.12 84.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.02 -35.61 87.79 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.477 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 86.7 m -68.57 -58.19 4.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.769 0.319 . . . . 0.0 111.098 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.2 mt -56.03 -38.28 52.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.115 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.5 mt -65.21 -53.39 45.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.1 -49.01 72.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.934 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.87 -56.71 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 34.6 t -55.2 -25.04 30.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 68.6 t80 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.93 -179.882 . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 31.3 mt . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.816 0.341 . . . . 0.0 110.877 . . . . . . . . . 0 0 . 1 . 003 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 40.2 mm -66.54 -40.46 86.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 25.7 mt -66.28 -58.39 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.117 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -60.58 -31.33 70.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.66 -64.7 2.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.515 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 79.6 t -56.63 -35.1 44.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.839 0.352 . . . . 0.0 111.137 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.1 mtt -65.34 -48.04 74.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.37 90.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.62 -56.55 5.96 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.486 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 98.9 t -54.88 -51.16 55.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.794 0.331 . . . . 0.0 111.138 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 62.4 mt -60.13 -50.19 81.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.133 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.27 -41.15 94.8 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 56.0 m -62.67 -59.53 4.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.81 0.338 . . . . 0.0 111.162 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.04 -42.96 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 20.6 mt -57.48 -50.76 71.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.915 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.7 tt -59.56 -42.48 92.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 27.4 mm -65.42 -62.08 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.106 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 1.3 m -54.9 -26.1 33.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 83.6 t80 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.96 -179.916 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 16.8 mt . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.749 0.309 . . . . 0.0 110.865 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.5 mm -66.63 -41.89 88.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.166 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.6 mm -66.2 -57.99 8.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -60.59 -31.23 70.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.871 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.0 -63.9 3.26 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.513 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 71.4 t -56.65 -35.93 46.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.868 0.366 . . . . 0.0 111.131 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 19.7 mtp -65.37 -47.31 76.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.847 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.11 -38.16 90.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.041 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.41 -56.73 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.478 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 92.9 t -54.92 -48.91 74.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.811 0.339 . . . . 0.0 111.109 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.8 mm -63.94 -48.13 87.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.145 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.78 -36.76 92.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.51 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 84.4 m -68.54 -58.73 3.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 111.115 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 80.0 mt -56.12 -37.7 50.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 15.1 mt -65.27 -54.25 32.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -54.4 -48.66 71.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.7 mt -65.11 -56.29 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.149 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 83.5 p -55.02 -25.11 27.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.85 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 57.8 t80 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.862 . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 10.1 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.843 0.354 . . . . 0.0 110.916 . . . . . . . . . 0 0 . 1 . 004 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.3 mm -66.74 -42.4 89.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.169 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 17.3 mm -66.09 -57.86 8.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.112 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 45.8 t80 -60.64 -31.22 70.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.98 -64.04 3.19 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.472 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 72.7 t -56.65 -35.85 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.824 0.345 . . . . 0.0 111.125 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.35 -47.4 76.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.98 -38.12 89.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.105 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.43 -56.64 5.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 93.7 t -54.97 -48.66 75.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.785 0.326 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.6 mm -64.09 -48.05 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.113 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.92 -36.52 92.26 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.485 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.1 m -68.82 -58.27 4.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.75 0.309 . . . . 0.0 111.113 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 76.9 mt -57.1 -37.78 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.092 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 16.6 mt -65.18 -53.19 48.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.963 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.04 -49.29 71.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.84 -56.91 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 60.5 p -55.0 -24.95 26.71 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 52.8 t80 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.947 -179.898 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 36.8 mt . . . . . 0 C--O 1.232 0.155 0 CA-C-O 120.755 0.312 . . . . 0.0 110.901 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 51.2 mt -66.78 -39.91 84.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.114 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 25.0 mt -66.29 -58.11 7.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -60.36 -31.7 70.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.43 -65.05 2.8 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 90.1 t -56.37 -35.28 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.186 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 4.1 mmt -65.43 -47.15 77.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -39.07 92.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.101 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.08 -56.54 5.7 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.425 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.17 -49.62 70.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.798 0.332 . . . . 0.0 111.146 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.66 -49.72 82.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.139 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.47 -35.32 84.88 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 91.3 m -68.76 -59.3 3.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.759 0.314 . . . . 0.0 111.127 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.09 -37.98 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.174 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 19.2 mt -65.17 -55.14 20.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.75 -48.9 69.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.889 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.7 -55.92 18.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.6 p -55.32 -24.5 29.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.817 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 19.8 t80 . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.926 -179.896 . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 20.4 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.775 0.321 . . . . 0.0 110.92 . . . . . . . . . 0 0 . 1 . 005 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.26 -43.38 91.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.2 mm -65.97 -57.36 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.12 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -30.99 70.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.03 -65.05 2.75 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.533 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 93.7 t -56.57 -35.27 44.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.823 0.344 . . . . 0.0 111.169 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 35.0 mmm -65.54 -47.71 74.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.49 -38.56 90.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.101 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.14 -56.2 5.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.476 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 94.6 t -54.91 -49.39 70.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.832 0.348 . . . . 0.0 111.128 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 74.7 mt -62.75 -49.98 81.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.56 -35.16 84.6 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 92.7 m -68.61 -58.48 4.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 65.3 mt -56.65 -37.74 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.19 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 16.7 mt -65.2 -53.53 43.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -55.03 -49.19 72.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.64 -56.81 14.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.135 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 23.0 t -55.19 -24.92 29.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.887 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 77.6 t80 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.908 -179.875 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.2 mt . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.773 0.32 . . . . 0.0 110.961 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.56 -44.11 90.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.135 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.93 -58.07 8.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.129 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.94 -30.51 70.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.21 -64.72 2.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 88.8 t -56.73 -35.68 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.856 0.36 . . . . 0.0 111.144 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 11.2 mmt -65.6 -47.05 77.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.79 92.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.18 -56.48 5.68 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 98.1 t -55.02 -49.55 70.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.767 0.318 . . . . 0.0 111.088 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.79 -49.95 81.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -34.95 85.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.49 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 97.5 m -68.79 -59.77 2.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.73 0.3 . . . . 0.0 111.129 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.2 mt -54.93 -38.25 44.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.139 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 16.4 mt -65.05 -54.99 21.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.97 -49.34 69.01 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 66.5 mt -64.07 -56.33 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.107 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.4 t -54.65 -25.56 27.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.837 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 37.1 t80 . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.883 . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.3 mt . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 006 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 59.2 mt -66.54 -42.75 90.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.101 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.7 mm -66.07 -57.01 12.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -60.33 -31.28 70.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.88 -64.67 2.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.488 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 95.1 t -56.57 -35.52 45.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.831 0.348 . . . . 0.0 111.111 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.37 -47.32 76.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.57 91.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.14 -56.04 5.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.49 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 95.8 t -54.92 -49.06 73.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.806 0.336 . . . . 0.0 111.099 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 60.4 mt -63.13 -49.33 83.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.77 -35.69 87.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 88.4 m -68.87 -59.29 3.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.762 0.315 . . . . 0.0 111.131 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 73.8 mt -55.53 -38.43 49.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.131 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 23.0 mt -65.19 -53.44 44.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.881 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.1 -49.26 72.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.56 -57.2 12.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 52.3 p -54.91 -25.08 26.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.849 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 75.7 t80 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.904 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 4.6 mt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.812 0.339 . . . . 0.0 110.923 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.2 mt -66.68 -44.97 89.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.193 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.1 mm -66.02 -57.06 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -61.42 -30.33 70.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.42 -64.21 3.07 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 98.3 t -56.94 -35.95 48.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.808 0.337 . . . . 0.0 111.099 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.4 mmt -65.46 -47.14 77.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.873 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.85 -38.76 92.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.102 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.25 -56.5 5.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.6 t -54.86 -48.9 73.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.813 0.339 . . . . 0.0 111.171 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.1 mm -63.59 -48.14 88.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.151 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.66 -37.37 93.36 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.492 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 63.4 m -67.93 -58.65 4.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.758 0.314 . . . . 0.0 111.126 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 77.6 mt -55.02 -37.87 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 27.2 mt -65.04 -55.84 16.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.5 tt -53.16 -49.19 67.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.939 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.8 mt -64.35 -56.11 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 12.8 t -53.16 -26.95 18.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 11.4 t80 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.907 -179.846 . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.9 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.781 0.325 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 007 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 56.0 mt -65.95 -43.93 92.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.82 -58.11 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.109 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.44 -30.28 69.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.15 -64.25 3.08 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.498 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 96.2 t -56.92 -35.82 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.83 0.347 . . . . 0.0 111.134 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 9.1 mmt -65.46 -47.01 77.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.897 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.13 -38.45 91.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.138 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.29 -56.57 5.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.481 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 99.0 t -54.86 -48.84 73.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.853 0.359 . . . . 0.0 111.198 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.1 mm -63.74 -47.96 88.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.141 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.7 -37.3 93.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 61.5 m -68.26 -58.88 3.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.746 0.308 . . . . 0.0 111.12 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.7 mt -54.79 -37.73 41.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.14 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 19.3 mt -65.33 -55.5 17.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.875 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -53.86 -48.13 70.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 67.6 mt -65.12 -55.34 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 57.1 p -57.06 -22.4 38.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 21.8 t80 . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.928 -179.892 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.7 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.82 0.343 . . . . 0.0 110.897 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 48.0 mt -65.89 -40.83 88.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 31.0 mt -66.2 -58.32 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -59.76 -31.12 69.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.66 -64.68 2.95 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.466 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 67.3 t -56.4 -35.63 44.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.348 . . . . 0.0 111.173 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 13.9 mmt -65.38 -47.06 77.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.868 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.81 91.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.155 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.22 -56.78 5.49 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.5 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 92.3 t -54.89 -49.51 69.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.775 0.321 . . . . 0.0 111.152 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.8 mm -63.03 -49.42 83.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.192 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.44 86.71 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.434 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.6 m -68.8 -58.79 3.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 111.17 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 64.7 mt -56.69 -37.91 55.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.074 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 32.1 mt -65.08 -53.62 42.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.87 -49.41 71.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 62.4 mt -64.52 -56.92 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.131 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 53.7 p -55.04 -24.94 27.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 55.9 t80 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.944 -179.93 . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.813 0.34 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 008 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 58.0 mt -66.13 -43.96 91.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.9 mm -65.9 -57.94 8.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -60.7 -30.34 69.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.27 -64.67 2.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.48 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 87.3 t -56.86 -35.79 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.824 0.345 . . . . 0.0 111.132 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.9 mmm -65.57 -46.99 77.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.871 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.99 -38.74 92.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.1 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.17 -56.62 5.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.479 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 99.3 t -54.93 -49.64 68.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 111.109 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.4 mm -62.73 -49.79 82.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.1 -34.82 85.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.47 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 97.0 m -68.74 -58.73 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.795 0.331 . . . . 0.0 111.201 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 62.1 mt -56.55 -37.79 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 17.8 mt -65.29 -53.51 42.87 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -54.98 -49.07 72.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 62.9 mt -64.77 -56.74 14.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.149 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.4 m -55.25 -24.87 30.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 66.0 t80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.909 -179.893 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 26.0 mt . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.834 0.349 . . . . 0.0 110.933 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.8 mt -66.36 -42.97 91.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.109 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.6 mm -66.02 -57.77 9.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.123 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -60.32 -30.98 69.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.866 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.08 -64.89 2.81 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 82.5 t -56.41 -35.2 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.809 0.338 . . . . 0.0 111.124 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 26.8 mmt -65.45 -47.84 74.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.28 89.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.113 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.08 -56.05 5.97 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 93.6 t -54.83 -49.25 71.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.3 mt -62.71 -48.68 86.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.127 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.11 -37.45 91.69 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.475 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 39.1 m -67.94 -57.77 5.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.759 0.314 . . . . 0.0 111.169 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 82.2 mt -55.55 -37.72 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.6 mt -65.21 -55.19 19.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.871 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.84 -48.74 69.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.939 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.73 -56.23 17.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 t -55.31 -24.49 28.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 23.1 t80 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.904 -179.865 . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 10.6 mt . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.758 0.313 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 009 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.2 mm -66.47 -43.02 91.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.148 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.5 mm -66.06 -58.0 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.65 -30.96 70.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.889 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.07 -65.03 2.75 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.524 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 90.8 t -56.46 -35.35 43.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.347 . . . . 0.0 111.15 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.3 mmt -65.47 -47.65 75.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.39 90.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.039 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.08 -56.02 5.98 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 94.4 t -54.89 -48.88 73.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.753 0.311 . . . . 0.0 111.124 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 84.7 mt -63.21 -47.94 89.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.76 -38.66 94.23 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.463 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 30.9 m -67.34 -58.75 4.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.805 0.336 . . . . 0.0 111.129 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.7 mt -54.2 -37.61 36.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.086 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 24.6 mt -65.02 -56.26 14.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.06 -49.94 70.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.925 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 78.2 mt -60.33 -53.74 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.083 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 25.8 p -64.4 -15.48 60.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.976 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 14.2 mt . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.821 0.343 . . . . 0.0 110.955 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 36.4 mm -67.11 -39.95 84.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.134 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 30.7 mt -66.5 -59.04 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -60.71 -31.6 70.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.78 -64.91 2.83 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.507 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 72.6 t -56.22 -34.88 40.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 111.124 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -65.42 -48.67 71.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.15 -38.7 90.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.082 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.07 -57.37 5.77 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.6 t -53.77 -50.54 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.817 0.342 . . . . 0.0 111.154 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 95.9 mt -60.41 -45.01 97.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.083 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.12 -37.35 91.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -69.56 -58.33 4.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.785 0.326 . . . . 0.0 111.133 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 77.0 mt -56.49 -37.96 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.06 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.3 mt -65.19 -54.48 29.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.964 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.87 -49.15 69.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.2 mt -64.85 -56.3 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 56.5 p -54.26 -25.51 23.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.84 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 39.4 t80 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.881 -179.83 . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 14.1 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.769 0.319 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 010 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 53.4 mt -65.66 -44.16 93.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.146 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 18.8 mm -65.9 -57.02 12.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.32 -30.3 69.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.921 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.47 -64.4 2.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 95.4 t -56.68 -35.94 47.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.34 . . . . 0.0 111.117 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.1 mmt -65.69 -47.7 74.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.54 -39.49 91.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.87 -57.24 5.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.504 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 93.3 t -55.1 -49.92 67.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.8 mm -62.37 -47.36 93.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.26 -38.92 91.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.455 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 19.8 m -68.2 -58.05 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.749 0.309 . . . . 0.0 111.16 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.8 mt -55.1 -38.39 46.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.077 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 19.7 mt -65.18 -54.17 33.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.904 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.77 -48.81 72.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.64 -56.72 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 13.2 t -54.87 -25.54 29.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.2 t80 . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.945 -179.934 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.767 0.318 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 57.6 mt -66.02 -41.96 90.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 23.9 mm -66.04 -57.03 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.144 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -60.03 -31.27 69.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.85 -64.61 2.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.501 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 87.0 t -56.64 -35.39 45.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.835 0.35 . . . . 0.0 111.152 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.37 -47.41 76.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.894 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.38 90.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.115 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.1 -55.89 6.05 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 94.3 t -54.85 -48.75 73.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.804 0.335 . . . . 0.0 111.168 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.3 mt -63.54 -47.99 88.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.129 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.37 -37.3 92.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.536 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 48.4 m -68.22 -58.87 3.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.748 0.309 . . . . 0.0 111.142 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 75.8 mt -54.91 -37.84 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 24.9 mt -65.14 -55.78 16.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.37 -49.17 67.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.3 mt -64.19 -55.9 19.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.176 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 23.3 t -53.2 -27.2 20.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 8.7 t80 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.888 -179.821 . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 9.8 mt . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.782 0.325 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 011 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.8 mm -67.11 -43.35 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.5 mm -66.05 -58.01 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.077 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -61.33 -30.92 70.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.97 -64.67 2.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.485 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 99.1 t -57.02 -35.69 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 0.0 111.091 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.9 mmm -65.49 -46.92 77.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.09 -38.8 92.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.13 -56.54 5.67 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.507 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 97.9 t -54.84 -49.19 71.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.813 0.339 . . . . 0.0 111.163 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.9 mm -63.19 -48.72 86.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.24 90.32 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.451 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 90.9 m -68.41 -58.38 4.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.777 0.322 . . . . 0.0 111.1 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 75.7 mt -55.15 -38.77 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 17.9 mt -65.15 -53.41 45.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.916 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.08 -48.89 72.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.6 mt -65.0 -56.86 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.098 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 7.4 t -54.89 -25.35 28.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.858 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 46.6 t80 . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.96 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 5.0 mt . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.827 0.346 . . . . 0.0 110.902 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.6 mt -66.53 -41.18 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 36.2 mt -66.11 -58.62 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.64 -30.84 70.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.74 -64.53 3.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.554 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 42.0 t -56.74 -35.81 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 111.154 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.8 mmt -65.43 -46.93 78.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.875 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -39.18 93.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.8 -56.67 5.78 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.516 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 94.7 t -55.2 -50.49 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.139 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -61.53 -48.74 87.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.95 -39.5 95.68 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.458 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 74.9 m -64.8 -58.07 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.799 0.333 . . . . 0.0 111.143 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.9 mt -54.44 -42.3 58.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.13 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 12.9 mt -59.76 -54.75 42.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.38 -51.07 69.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.936 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -57.32 -59.54 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.169 179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 80.4 p -53.67 -29.49 38.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 36.0 t80 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.937 -179.911 . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 5.9 mt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.82 0.343 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 012 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 53.8 mt -65.04 -43.98 95.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.131 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 24.2 mm -65.75 -57.31 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -59.98 -30.07 68.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.41 -63.85 3.22 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.501 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 99.1 t -56.99 -36.23 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.856 0.36 . . . . 0.0 111.158 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -47.08 77.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.886 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.67 -38.7 91.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.075 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.25 -56.52 5.63 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.474 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 96.4 t -54.84 -49.21 71.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.857 0.36 . . . . 0.0 111.194 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 83.2 mt -63.29 -49.23 83.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.081 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.08 -35.56 87.88 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.475 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.9 m -68.88 -59.28 3.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.755 0.312 . . . . 0.0 111.114 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 76.2 mt -55.62 -38.44 50.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 26.4 mt -65.12 -53.12 50.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -55.44 -49.0 73.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.913 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.2 mt -64.88 -57.12 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.1 m -55.02 -25.26 29.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.845 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 29.2 t80 . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.884 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 15.9 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.771 0.319 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 42.5 mm -66.52 -42.71 90.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 21.0 mm -66.03 -57.5 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.171 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -60.74 -31.03 70.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.881 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.09 -64.66 2.91 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 90.2 t -56.74 -35.46 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.835 0.35 . . . . 0.0 111.097 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.7 mmt -65.48 -47.56 75.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.64 91.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.12 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.66 -56.84 5.76 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.534 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 98.1 t -54.84 -51.07 56.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.819 0.342 . . . . 0.0 111.149 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.7 mm -60.41 -50.23 81.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.133 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.73 -41.11 95.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.483 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 77.0 m -62.7 -59.08 5.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.783 0.325 . . . . 0.0 111.129 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 79.4 mt -54.13 -43.92 61.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.3 mt -56.8 -51.04 70.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.52 -42.12 91.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.6 mm -65.42 -63.85 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.181 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 2.2 t -51.53 -30.68 21.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 71.2 t80 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 -179.856 . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 17.9 mt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.744 0.307 . . . . 0.0 110.935 . . . . . . . . . 0 0 . 1 . 013 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 56.4 mt -68.03 -41.41 84.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.099 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.4 mm -66.31 -57.74 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.161 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -61.16 -31.73 71.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.79 -64.03 3.23 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 57.8 t -56.84 -35.6 47.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.094 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.1 mmm -65.29 -47.42 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.857 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.16 90.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.22 -56.65 5.57 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.442 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -54.8 -48.81 73.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.785 0.326 . . . . 0.0 111.101 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.8 mm -63.52 -47.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.163 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.85 -37.78 93.05 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.504 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 27.5 m -68.79 -59.51 3.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.757 0.313 . . . . 0.0 111.159 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 72.5 mt -54.92 -38.16 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.132 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 18.8 mt -65.15 -55.1 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.914 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.91 -48.91 69.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.92 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.0 mt -64.58 -56.32 16.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.162 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 59.1 m -54.15 -25.95 25.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 18.1 t80 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 -179.904 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 17.6 mt . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.78 0.324 . . . . 0.0 110.887 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 61.0 mt -66.37 -46.42 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.5 mm -65.73 -56.81 13.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.135 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -61.33 -29.86 70.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.31 -63.69 3.3 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 98.3 t -57.47 -36.08 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.802 0.334 . . . . 0.0 111.114 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.44 -46.78 78.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.826 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.06 -38.85 92.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.137 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.04 -56.43 5.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.511 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 95.6 t -55.16 -49.95 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.788 0.327 . . . . 0.0 111.133 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.0 mm -62.35 -49.93 81.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -36.17 88.86 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 96.8 m -67.55 -59.17 3.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.724 0.297 . . . . 0.0 111.148 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.2 mt -54.73 -40.04 49.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 14.5 mt -62.77 -56.41 17.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -52.7 -53.56 45.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.0 mt -59.58 -55.25 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.17 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.3 p -55.12 -25.45 31.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 3.7 t80 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.879 . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 6.2 mt . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.764 0.316 . . . . 0.0 110.9 . . . . . . . . . 0 0 . 1 . 014 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 59.9 mt -66.26 -44.66 91.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.5 mm -65.8 -57.17 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.2 t80 -60.47 -30.25 69.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.08 -63.44 3.45 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.501 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 39.5 t -57.28 -36.04 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.155 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.3 mmt -65.38 -46.93 78.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.934 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.84 92.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.059 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.06 -56.33 5.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.474 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 98.7 t -54.95 -49.28 72.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.342 . . . . 0.0 111.133 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 77.6 mt -63.03 -49.4 83.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.171 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.5 -35.66 86.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.486 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 87.1 m -68.97 -58.67 3.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.753 0.311 . . . . 0.0 111.171 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.94 -37.91 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 16.9 mt -65.12 -53.25 48.13 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -49.41 71.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.64 -57.02 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.118 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 80.8 p -54.79 -25.18 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.843 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 43.7 t80 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 -179.879 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 5.0 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.805 0.336 . . . . 0.0 110.925 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 52.3 mt -66.02 -41.31 89.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.137 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 27.4 mt -66.1 -58.75 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -59.68 -31.06 69.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.913 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.81 -65.79 2.51 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 99.0 t -55.46 -34.73 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.878 0.371 . . . . 0.0 111.13 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.9 mmt -65.31 -50.21 66.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.11 80.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.19 -55.36 6.29 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 91.1 t -54.96 -49.99 66.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 111.139 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 1.7 mp -63.45 -47.83 89.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.15 -36.66 91.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.456 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 73.1 m -68.88 -58.73 3.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.775 0.322 . . . . 0.0 111.164 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.1 mt -55.61 -38.47 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.9 mt -65.2 -53.41 45.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -55.0 -49.33 71.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.9 mt -64.58 -56.68 14.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 60.6 p -55.24 -24.97 30.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.88 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 26.7 t80 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.93 -179.872 . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 4.6 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.842 0.353 . . . . 0.0 110.947 . . . . . . . . . 0 0 . 1 . 015 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 36.6 mt -65.77 -43.33 93.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.126 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.2 mm -65.84 -58.03 8.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.1 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -60.15 -30.29 69.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.02 -63.83 3.28 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.439 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 94.0 t -56.99 -35.81 48.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.808 0.337 . . . . 0.0 111.093 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.4 mmt -65.49 -47.12 77.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.849 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.71 -39.03 92.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.114 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.82 -56.82 5.68 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 91.2 t -55.14 -50.65 62.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.802 0.334 . . . . 0.0 111.146 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.6 mm -61.61 -49.22 85.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -39.27 95.06 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.487 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 85.5 m -64.66 -58.01 7.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.757 0.313 . . . . 0.0 111.115 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 76.4 mt -54.46 -43.17 62.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.13 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 14.9 mt -59.02 -53.76 54.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.44 -51.71 68.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -56.44 -59.61 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 30.9 t -56.34 -27.11 54.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 59.9 t80 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.918 -179.876 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 66.3 mt . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.746 0.307 . . . . 0.0 110.844 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 41.2 mm -66.3 -40.02 85.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 34.2 mt -66.24 -58.26 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.097 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -60.04 -31.44 69.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.867 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.76 -65.03 2.78 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 99.4 t -56.15 -35.45 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.344 . . . . 0.0 111.122 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.39 -47.9 74.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.92 -38.91 90.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.11 -56.53 5.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.4 t -55.03 -49.33 72.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.844 0.354 . . . . 0.0 111.129 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 92.7 mt -62.75 -49.71 82.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.074 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.32 -35.66 85.73 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.479 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 86.7 m -68.67 -58.71 3.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.783 0.325 . . . . 0.0 111.154 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.8 mt -56.46 -37.78 53.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 22.3 mt -65.25 -53.54 42.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.941 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.06 -49.09 72.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.917 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.66 -56.66 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.151 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 54.4 p -55.56 -24.5 32.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.7 t80 . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.916 -179.857 . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.1 mt . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.825 0.345 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 016 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 41.6 mm -66.53 -40.14 85.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.094 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 29.2 mt -66.38 -57.86 8.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.125 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -60.52 -31.72 70.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.58 -64.03 3.26 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.507 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 95.2 t -56.78 -35.69 46.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 111.145 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 18.0 mmm -65.33 -47.02 77.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -39.05 93.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.093 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.05 -56.26 5.87 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.482 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 96.6 t -54.97 -49.54 70.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.793 0.33 . . . . 0.0 111.14 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.4 mm -62.72 -49.32 84.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.163 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.71 -35.69 87.1 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.496 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.1 m -68.64 -59.27 3.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.749 0.309 . . . . 0.0 111.126 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 67.5 mt -54.91 -37.95 43.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 29.0 mt -65.19 -55.44 18.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -53.83 -48.7 69.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.62 -54.68 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 42.8 t -53.76 -27.83 31.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.847 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 6.0 t80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.869 . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 29.0 mt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.78 0.324 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.8 mm -66.52 -40.09 85.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.085 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 37.8 mt -66.33 -58.56 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -60.39 -31.57 70.49 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.897 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.65 -65.06 2.78 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.521 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 72.0 t -56.24 -35.37 42.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 111.118 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 16.4 mtp -65.37 -47.4 76.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.69 -38.78 91.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.12 -56.48 5.71 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.8 t -55.0 -49.43 71.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.845 0.355 . . . . 0.0 111.158 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.8 mm -62.83 -48.66 87.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -37.8 93.09 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 62.6 m -67.25 -58.93 3.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.788 0.328 . . . . 0.0 111.138 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 78.4 mt -54.24 -38.64 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.152 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 15.5 mt -64.03 -55.81 19.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.36 -49.8 71.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 84.7 mt -60.51 -53.43 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 36.1 t -64.92 -14.92 61.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.913 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.4 mt . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.728 0.299 . . . . 0.0 110.912 . . . . . . . . . 0 0 . 1 . 017 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.8 mm -66.14 -42.63 91.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.161 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 16.9 mm -66.0 -57.23 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.24 -31.05 69.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.02 -64.52 2.98 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.468 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 97.2 t -56.58 -35.55 45.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.817 0.342 . . . . 0.0 111.136 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.3 mmm -65.43 -47.38 76.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -38.75 91.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.2 -56.63 5.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.509 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 98.8 t -54.92 -49.54 69.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.853 0.359 . . . . 0.0 111.14 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.4 mm -62.76 -49.61 83.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.31 86.3 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.518 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 91.8 m -68.71 -58.78 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.775 0.321 . . . . 0.0 111.179 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 70.4 mt -56.02 -38.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.102 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 34.2 mt -65.28 -53.5 43.24 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.14 -49.06 72.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.5 mt -64.71 -56.79 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 28.4 t -55.27 -24.98 30.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.9 t80 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 -179.886 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 36.4 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.815 0.34 . . . . 0.0 110.919 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.6 mt -67.62 -39.54 82.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.145 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.0 mt -66.35 -58.81 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -61.11 -31.68 71.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.42 -65.17 2.76 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.458 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 77.2 t -56.46 -35.67 44.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.783 0.325 . . . . 0.0 111.116 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 10.8 mmt -65.41 -46.9 78.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.98 93.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.2 -56.48 5.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 99.2 t -54.97 -49.02 74.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.865 0.364 . . . . 0.0 111.147 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.9 mm -63.41 -48.18 88.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.17 -37.38 92.82 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.488 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 57.4 m -68.0 -58.16 4.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.814 0.34 . . . . 0.0 111.165 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 79.0 mt -55.5 -37.74 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 15.8 mt -65.19 -55.29 19.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.919 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -53.54 -48.94 68.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.919 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 62.0 mt -64.72 -56.38 16.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.2 t -54.22 -25.59 23.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 15.4 t80 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.916 -179.882 . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 24.8 mt . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.746 0.308 . . . . 0.0 110.906 . . . . . . . . . 0 0 . 1 . 018 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 53.6 mt -66.2 -40.44 86.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 29.8 mt -66.32 -57.89 8.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.115 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -60.15 -31.35 70.01 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.75 -64.81 2.88 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.463 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 36.3 t -56.51 -35.52 44.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.794 0.33 . . . . 0.0 111.134 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.2 mmm -65.37 -47.59 75.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.834 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.66 -38.33 89.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.23 -56.12 5.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.45 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 96.1 t -54.93 -48.81 74.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 111.144 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 81.9 mt -63.61 -48.24 87.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.129 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.99 -37.05 92.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 54.7 m -68.46 -58.77 3.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.805 0.336 . . . . 0.0 111.202 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 75.5 mt -55.7 -38.19 49.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.151 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 17.7 mt -65.13 -53.72 40.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.05 -49.08 72.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.959 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.4 mt -64.59 -56.99 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.165 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 50.0 p -55.18 -24.88 29.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 54.3 t80 . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.947 -179.926 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 mt . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.783 0.325 . . . . 0.0 110.899 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.1 mt -66.27 -41.71 89.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.145 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.9 mm -66.06 -57.86 8.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.123 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -60.15 -31.27 69.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.66 -64.48 3.04 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.547 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 65.7 t -56.56 -35.5 44.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.863 0.363 . . . . 0.0 111.172 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 17.2 mmm -65.29 -47.21 77.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.64 91.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.08 -56.5 5.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 95.4 t -54.94 -49.34 71.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.161 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.6 mm -62.99 -47.62 91.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -61.09 -39.33 96.96 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.488 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 54.1 m -65.96 -57.45 7.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.781 0.324 . . . . 0.0 111.139 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 79.0 mt -57.15 -45.55 84.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.1 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.47 -52.96 63.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.93 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.7 -55.81 25.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.908 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 74.8 mt -57.3 -59.42 3.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.7 p -53.07 -27.52 20.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.4 t80 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.949 -179.878 . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 10.7 mt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.812 0.339 . . . . 0.0 110.942 . . . . . . . . . 0 0 . 1 . 019 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.1 mm -67.19 -44.4 87.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.082 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.1 mm -66.05 -57.7 9.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -61.45 -30.8 70.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.911 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.16 -64.5 2.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.506 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 77.1 t -56.96 -35.83 48.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.789 0.328 . . . . 0.0 111.12 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 1.6 mmt -65.31 -47.21 77.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.49 91.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.107 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.31 -56.25 5.74 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.478 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 96.1 t -54.91 -48.85 74.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 111.121 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.5 mm -63.51 -48.6 86.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.7 92.03 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.526 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 90.0 m -68.12 -58.47 4.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.738 0.304 . . . . 0.0 111.186 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 75.7 mt -55.36 -37.88 46.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.132 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 28.7 mt -65.18 -55.06 20.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.97 -48.97 69.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.87 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.6 mt -64.45 -56.23 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 13.6 t -54.46 -25.55 25.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.86 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 34.6 t80 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.948 -179.872 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 38.7 mt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.803 0.335 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 37.4 mm -65.68 -48.39 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.32 -54.81 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -60.79 -30.91 70.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.891 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.89 -64.06 3.07 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.496 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 95.6 t -57.0 -35.64 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 111.145 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.4 mmt -65.66 -47.61 74.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.867 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.95 -39.23 91.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.97 -56.45 5.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.516 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 93.7 t -54.94 -49.38 71.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.809 0.337 . . . . 0.0 111.153 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.2 mm -62.52 -49.7 82.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.171 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -35.15 85.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.519 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.7 m -68.57 -59.6 3.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.153 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.9 mt -55.3 -37.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.101 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 13.3 mt -65.12 -55.18 20.21 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.901 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.58 -49.01 68.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.943 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.2 mt -64.72 -55.77 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 67.3 m -53.97 -26.14 24.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 20.5 t80 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.941 -179.89 . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.5 mt . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.763 0.316 . . . . 0.0 110.913 . . . . . . . . . 0 0 . 1 . 020 nuclear orig core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 37.2 mt -66.64 -41.13 87.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.106 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.6 mm -66.11 -56.83 12.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.165 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -31.87 70.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.58 -65.05 2.79 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.515 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 88.1 t -56.68 -35.07 44.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 111.161 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -47.01 77.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.86 -38.89 92.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.085 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.08 -56.39 5.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.509 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 97.6 t -54.86 -49.21 71.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.849 0.357 . . . . 0.0 111.119 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.0 mm -62.96 -49.29 84.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.133 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.01 -35.31 86.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.495 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 84.8 m -68.91 -59.17 3.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.762 0.315 . . . . 0.0 111.115 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.3 mt -55.85 -38.09 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.135 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 13.7 mt -65.25 -53.56 42.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.889 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -48.96 72.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.1 mt -64.86 -56.89 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.151 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 8.7 t -55.18 -24.94 29.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.834 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 76.4 t80 . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.883 -179.824 . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.9 pm0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.652 0.739 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 102.48 1.03 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.723 2.282 . . . . 0.0 112.331 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER -108.32 -57.96 2.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.915 179.959 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 80.1 mt -50.82 -31.53 10.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.8 m -63.96 -50.7 67.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.153 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 22.8 mt -64.44 -37.31 87.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.863 179.974 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 58.8 mt -65.95 -41.99 90.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.187 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.1 mm -66.15 -57.3 11.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.125 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.18 -31.22 69.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.95 -64.53 2.98 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.459 -179.972 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 78.5 t -56.52 -35.45 44.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.792 0.329 . . . . 0.0 111.111 -179.964 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.0 mmt -65.4 -47.31 76.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.863 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.43 90.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.087 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.22 -56.59 5.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 -179.921 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 99.6 t -54.83 -49.05 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.802 0.334 . . . . 0.0 111.121 -179.949 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.1 mm -63.44 -48.3 87.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 179.927 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.76 -36.11 91.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.49 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 88.8 m -68.58 -58.35 4.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.83 0.348 . . . . 0.0 111.186 -179.875 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.8 mt -56.37 -37.98 53.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 179.861 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 15.7 mt -65.26 -53.45 44.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.962 179.908 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -55.0 -48.95 72.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.9 mt -64.96 -56.74 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.3 t -55.19 -24.8 28.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -70.21 -52.93 19.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.907 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -61.7 -26.35 66.73 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 179.968 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 44.0 mt -77.25 -27.68 16.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.861 0.363 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.4 -24.66 67.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.839 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 9.0 ttm180 -85.04 -36.58 21.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.927 179.992 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.682 0.753 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 001 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 167.07 25.51 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.672 2.248 . . . . 0.0 112.343 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 4.8 mt-10 71.65 -69.45 0.18 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.999 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 45.0 mm -50.69 -30.76 8.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 85.3 m -65.89 -47.72 73.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.0 mt -66.24 -36.87 84.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.907 179.986 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 36.7 mm -66.97 -42.87 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.133 179.828 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.3 mm -66.04 -57.62 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.145 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -61.06 -31.03 70.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.04 -64.6 2.94 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.472 -179.989 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 97.2 t -56.87 -35.66 47.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.802 0.334 . . . . 0.0 111.102 -179.954 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 42.7 mmm -65.3 -47.08 77.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.6 91.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.23 -56.41 5.7 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.945 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 98.6 t -54.89 -49.02 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.813 0.339 . . . . 0.0 111.122 -179.967 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.0 mm -63.41 -48.34 87.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.17 179.902 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.8 -36.18 91.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.5 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 91.8 m -68.44 -57.51 5.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.775 0.321 . . . . 0.0 111.118 -179.867 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 76.6 mt -57.69 -37.6 60.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.928 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 16.4 mt -65.23 -53.01 50.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.923 179.885 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.2 -49.36 72.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.77 -56.8 14.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 29.8 t -55.16 -24.94 29.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 22.9 t80 -75.12 -50.92 14.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.911 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.89 -36.18 92.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.45 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.1 tt -75.69 -21.54 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.804 0.335 . . . . 0.0 111.136 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.05 -26.3 68.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -145.76 42.95 1.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.88 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 3.4 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.926 -179.973 . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.648 0.737 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 97.0 0.62 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.695 2.263 . . . . 0.0 112.313 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -164.08 -48.72 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.906 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 54.5 mt -50.62 -31.05 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.111 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.0 m -65.49 -48.17 73.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.126 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 25.1 mt -65.95 -37.07 85.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.4 mm -66.39 -43.02 91.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.155 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.0 mm -66.04 -57.74 9.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.1 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.56 -30.71 69.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.12 -64.29 3.07 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.474 -179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 91.4 t -56.93 -35.5 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.808 0.337 . . . . 0.0 111.117 -179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 2.7 mmt -65.54 -47.43 75.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.83 92.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.068 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.7 -56.62 5.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.523 -179.944 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 99.2 t -54.94 -50.91 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.813 0.339 . . . . 0.0 111.154 -179.99 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.3 mm -60.45 -50.56 79.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.78 -40.7 95.35 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.478 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 87.9 m -62.62 -59.02 5.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.728 0.299 . . . . 0.0 111.127 -179.844 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 77.8 mt -54.14 -44.2 62.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.145 179.896 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 12.7 mt -56.46 -51.12 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.53 -42.02 91.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.936 179.88 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.9 mm -65.53 -63.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.148 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 3.8 m -51.65 -30.55 22.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.87 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -70.69 -52.9 18.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.906 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.71 -25.67 74.96 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.509 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.6 mm -76.87 -29.88 17.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.345 . . . . 0.0 111.132 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -67.34 -56.45 9.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.879 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.22 43.92 0.47 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.865 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.94 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 121.672 0.749 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 002 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 136.63 33.45 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.663 2.242 . . . . 0.0 112.381 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER -126.21 -51.54 1.53 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.888 -179.998 . . . . . . . . 2 2 . 1 . 002 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 4.4 mt -50.13 -33.57 9.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.149 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 94.5 m -63.29 -51.2 67.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.132 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 13.9 mt -62.35 -36.96 83.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.879 179.977 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.4 mm -67.08 -39.98 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.152 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 26.9 mt -66.39 -58.49 6.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.097 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -60.8 -31.5 70.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.78 -64.92 2.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.432 -179.951 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 82.2 t -56.32 -35.34 42.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.776 0.322 . . . . 0.0 111.115 -179.903 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 27.8 mmt -65.24 -47.93 75.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.879 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.87 -37.88 88.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.24 -55.8 6.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.477 -179.97 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 92.8 t -54.78 -48.38 73.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.833 0.349 . . . . 0.0 111.146 -179.955 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 61.9 mt -63.6 -48.45 86.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.154 179.898 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.19 -36.58 91.1 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.464 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 53.0 m -68.46 -58.22 4.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.32 . . . . 0.0 111.144 -179.9 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 72.6 mt -56.66 -37.8 54.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.136 179.887 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 18.2 mt -65.16 -53.54 43.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.89 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -54.97 -49.18 72.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.6 mt -64.67 -57.01 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 75.7 m -54.97 -25.08 27.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 38.3 t80 -71.17 -52.61 18.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.947 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -62.33 -30.88 77.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 10.6 mt -76.52 -29.33 18.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.763 0.316 . . . . 0.0 111.145 -179.984 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ttp180 -64.81 -25.67 68.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.857 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 13.1 ttm180 -145.01 43.35 1.33 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.842 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.889 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 121.621 0.724 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 90.01 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.695 2.263 . . . . 0.0 112.305 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -179.2 -49.28 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.894 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 5.4 mt -51.05 -30.29 9.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.103 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.6 m -64.69 -49.66 70.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.127 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 27.3 mt -66.0 -37.63 86.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.1 mm -66.44 -42.98 91.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.0 mm -65.97 -58.08 8.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.121 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.36 -30.94 69.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.98 -64.69 2.9 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.928 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 80.5 t -56.48 -35.6 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.999 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 3.0 mmt -65.41 -47.16 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.05 -38.47 91.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.088 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.12 -56.66 5.61 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.461 -179.955 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -54.9 -49.72 67.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.825 0.345 . . . . 0.0 111.134 -179.97 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.71 -49.12 84.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.02 -35.61 87.79 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.477 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 86.7 m -68.57 -58.19 4.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.769 0.319 . . . . 0.0 111.098 -179.81 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.2 mt -56.03 -38.28 52.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.115 179.904 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.5 mt -65.21 -53.39 45.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.1 -49.01 72.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.934 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.87 -56.71 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 34.6 t -55.2 -25.04 30.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -69.48 -51.71 33.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.93 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.61 -25.21 75.76 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.48 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.5 mm -75.68 -23.91 16.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.83 0.347 . . . . 0.0 111.102 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.52 -12.59 54.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.87 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -143.67 37.44 1.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 93.8 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.915 -179.99 . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 . . . . . 0 C--O 1.231 0.1 0 CA-C-O 121.663 0.744 . . . . 0.0 110.885 . . . . . . . . . 0 0 . 1 . 003 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 154.62 67.69 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.722 2.281 . . . . 0.0 112.349 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -125.11 -42.54 2.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 4.3 mt -50.02 -33.73 9.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.101 179.987 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 93.5 m -62.96 -51.58 66.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.151 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 31.3 mt -62.21 -36.94 83.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 -179.988 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 40.2 mm -66.54 -40.46 86.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 25.7 mt -66.28 -58.39 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.117 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -60.58 -31.33 70.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.66 -64.7 2.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.515 -179.981 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 79.6 t -56.63 -35.1 44.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.839 0.352 . . . . 0.0 111.137 -179.968 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.1 mtt -65.34 -48.04 74.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.37 90.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.62 -56.55 5.96 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.486 -179.921 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 98.9 t -54.88 -51.16 55.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.794 0.331 . . . . 0.0 111.138 -179.977 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 62.4 mt -60.13 -50.19 81.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.133 179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.27 -41.15 94.8 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 56.0 m -62.67 -59.53 4.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.81 0.338 . . . . 0.0 111.162 -179.91 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.04 -42.96 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 20.6 mt -57.48 -50.76 71.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.915 179.923 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.7 tt -59.56 -42.48 92.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 27.4 mm -65.42 -62.08 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.106 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 1.3 m -54.9 -26.1 33.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 83.6 t80 -72.47 -57.83 3.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.96 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -61.8 -36.32 92.58 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.457 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.2 tt -75.53 -18.51 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.851 0.357 . . . . 0.0 111.138 -179.946 . . . . . . . . 1 1 . 1 . 003 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.21 -42.15 93.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.831 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.78 -60.05 2.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.838 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.923 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 121.641 0.734 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 78.57 1.0 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.705 2.27 . . . . 0.0 112.344 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -83.47 -44.19 14.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.931 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 51.0 mm -50.68 -30.77 8.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.144 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.9 m -64.24 -50.12 69.25 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.137 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 16.8 mt -65.5 -37.51 87.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.865 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.5 mm -66.63 -41.89 88.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.166 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.6 mm -66.2 -57.99 8.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -60.59 -31.23 70.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.871 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.0 -63.9 3.26 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.513 -179.955 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 71.4 t -56.65 -35.93 46.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.868 0.366 . . . . 0.0 111.131 179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 19.7 mtp -65.37 -47.31 76.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.847 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.11 -38.16 90.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.041 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.41 -56.73 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.478 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 92.9 t -54.92 -48.91 74.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.811 0.339 . . . . 0.0 111.109 179.978 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.8 mm -63.94 -48.13 87.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.145 179.918 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.78 -36.76 92.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.51 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 84.4 m -68.54 -58.73 3.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 111.115 -179.845 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 80.0 mt -56.12 -37.7 50.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.944 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 15.1 mt -65.27 -54.25 32.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.912 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -54.4 -48.66 71.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.7 mt -65.11 -56.29 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.149 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 83.5 p -55.02 -25.11 27.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.85 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 57.8 t80 -65.14 -47.7 76.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -105.28 36.98 4.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.442 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.8 mt -156.5 -48.25 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.843 0.354 . . . . 0.0 111.185 179.954 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.79 -42.16 58.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.869 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -90.72 -40.91 11.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.83 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.676 0.751 . . . . 0.0 110.847 . . . . . . . . . 0 0 . 1 . 004 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -47.48 0.91 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.693 2.262 . . . . 0.0 112.32 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 53.9 mt-10 -53.54 -46.87 70.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.893 -180.0 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 80.7 mt -50.96 -30.02 8.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.133 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 2.6 m -64.79 -49.34 71.08 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 10.1 mt -66.49 -37.87 86.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.916 179.961 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.3 mm -66.74 -42.4 89.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.169 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 17.3 mm -66.09 -57.86 8.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.112 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 45.8 t80 -60.64 -31.22 70.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.98 -64.04 3.19 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.472 -179.962 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 72.7 t -56.65 -35.85 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.824 0.345 . . . . 0.0 111.125 -179.953 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.35 -47.4 76.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.98 -38.12 89.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.105 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.43 -56.64 5.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 93.7 t -54.97 -48.66 75.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.785 0.326 . . . . 0.0 111.134 -179.983 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.6 mm -64.09 -48.05 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.113 179.892 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.92 -36.52 92.26 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.485 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.1 m -68.82 -58.27 4.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.75 0.309 . . . . 0.0 111.113 -179.826 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 76.9 mt -57.1 -37.78 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.092 179.936 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 16.6 mt -65.18 -53.19 48.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.963 179.865 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.04 -49.29 71.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.84 -56.91 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 60.5 p -55.0 -24.95 26.71 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -74.0 -51.44 15.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.947 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -70.11 -27.06 73.45 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.509 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.8 mm -76.48 -29.21 18.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.793 0.33 . . . . 0.0 111.1 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.87 -23.29 67.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.856 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.54 59.47 1.27 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.905 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 C--O 1.231 0.098 0 CA-C-O 121.663 0.744 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -179.46 2.92 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.682 2.254 . . . . 0.0 112.376 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 34.4 mm-40 -140.03 101.83 4.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.867 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 2.9 mp -50.84 -35.85 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.075 -179.976 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.7 m -58.5 -56.05 27.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.101 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 36.8 mt -60.72 -36.92 80.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.901 179.967 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 51.2 mt -66.78 -39.91 84.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.114 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 25.0 mt -66.29 -58.11 7.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -60.36 -31.7 70.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.43 -65.05 2.8 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.5 -179.978 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 90.1 t -56.37 -35.28 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.186 179.987 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 4.1 mmt -65.43 -47.15 77.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -39.07 92.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.101 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.08 -56.54 5.7 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.425 -179.941 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 98.9 t -55.17 -49.62 70.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.798 0.332 . . . . 0.0 111.146 -179.91 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.66 -49.72 82.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.139 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.47 -35.32 84.88 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 91.3 m -68.76 -59.3 3.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.759 0.314 . . . . 0.0 111.127 -179.844 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.09 -37.98 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.174 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 19.2 mt -65.17 -55.14 20.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.75 -48.9 69.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.889 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.7 -55.92 18.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.6 p -55.32 -24.5 29.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.817 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -64.88 -43.97 91.18 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.926 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -109.85 37.38 3.8 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.452 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.3 mt -156.57 -52.44 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.161 -179.972 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.13 -26.74 65.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.882 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -153.1 26.7 0.53 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 1.2 mt . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.95 -179.959 . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 121.66 0.743 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 005 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -178.24 2.26 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 69.11 -75.77 0.07 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.833 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 51.0 mm -51.04 -29.91 8.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.158 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 42.5 m -65.42 -48.85 71.38 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.122 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 20.4 mt -66.5 -37.44 85.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.92 179.986 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.26 -43.38 91.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.2 mm -65.97 -57.36 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.12 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -30.99 70.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.03 -65.05 2.75 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.533 -179.992 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 93.7 t -56.57 -35.27 44.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.823 0.344 . . . . 0.0 111.169 -179.979 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 35.0 mmm -65.54 -47.71 74.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.49 -38.56 90.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.101 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.14 -56.2 5.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.476 -179.919 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 94.6 t -54.91 -49.39 70.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.832 0.348 . . . . 0.0 111.128 -179.973 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 74.7 mt -62.75 -49.98 81.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.894 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.56 -35.16 84.6 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 92.7 m -68.61 -58.48 4.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.862 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 65.3 mt -56.65 -37.74 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.19 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 16.7 mt -65.2 -53.53 43.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.903 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -55.03 -49.19 72.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.64 -56.81 14.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.135 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 23.0 t -55.19 -24.92 29.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.887 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -69.89 -51.82 29.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.908 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -77.69 -22.82 68.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.473 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.5 mm -76.54 -29.45 18.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.815 0.341 . . . . 0.0 111.134 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.85 -28.32 69.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.86 -61.15 1.78 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.882 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.935 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 121.666 0.746 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 78.8 0.99 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.664 2.242 . . . . 0.0 112.333 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 27.8 mt-10 -123.82 -44.03 2.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.891 -179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 50.7 mm -50.8 -30.79 9.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.113 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.3 m -62.4 -51.81 66.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.2 mt -66.17 -36.65 83.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.961 179.909 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.56 -44.11 90.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.135 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.93 -58.07 8.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.129 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.94 -30.51 70.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.21 -64.72 2.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 -179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 88.8 t -56.73 -35.68 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.856 0.36 . . . . 0.0 111.144 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 11.2 mmt -65.6 -47.05 77.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.79 92.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.18 -56.48 5.68 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.485 -179.931 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 98.1 t -55.02 -49.55 70.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.767 0.318 . . . . 0.0 111.088 -179.949 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.79 -49.95 81.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -34.95 85.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.49 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 97.5 m -68.79 -59.77 2.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.73 0.3 . . . . 0.0 111.129 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.2 mt -54.93 -38.25 44.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.139 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 16.4 mt -65.05 -54.99 21.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.97 -49.34 69.01 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 66.5 mt -64.07 -56.33 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.107 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.4 t -54.65 -25.56 27.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.837 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -65.36 -42.72 92.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -109.32 38.85 3.13 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.515 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.3 mt -156.6 -49.91 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.839 0.352 . . . . 0.0 111.126 -179.996 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.15 -26.43 59.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.872 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.01 -62.8 1.41 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.925 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.923 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 64.0 mt-10 . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.676 0.75 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 006 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 131.1 20.57 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.69 2.26 . . . . 0.0 112.346 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -111.36 -61.48 1.69 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 69.4 mt -51.17 -30.05 9.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.146 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 84.9 m -66.59 -46.75 74.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.3 mt -67.12 -37.97 84.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.895 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 59.2 mt -66.54 -42.75 90.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.101 179.853 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.7 mm -66.07 -57.01 12.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -60.33 -31.28 70.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.88 -64.67 2.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.488 -179.971 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 95.1 t -56.57 -35.52 45.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.831 0.348 . . . . 0.0 111.111 -179.958 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.37 -47.32 76.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.57 91.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.14 -56.04 5.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.49 -179.978 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 95.8 t -54.92 -49.06 73.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.806 0.336 . . . . 0.0 111.099 -179.947 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 60.4 mt -63.13 -49.33 83.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.943 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.77 -35.69 87.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 88.4 m -68.87 -59.29 3.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.762 0.315 . . . . 0.0 111.131 -179.816 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 73.8 mt -55.53 -38.43 49.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.131 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 23.0 mt -65.19 -53.44 44.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.881 179.953 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.1 -49.26 72.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.56 -57.2 12.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 52.3 p -54.91 -25.08 26.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.849 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 75.7 t80 -74.53 -51.58 14.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -67.79 -35.04 84.5 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.483 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.7 tt -75.51 -16.96 15.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.82 0.343 . . . . 0.0 111.128 -179.965 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.38 -13.79 62.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.869 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 45.5 ttm-85 -144.79 -67.46 0.32 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.845 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 121.619 0.723 . . . . 0.0 110.918 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 154.35 67.94 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.644 2.23 . . . . 0.0 112.328 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 39.3 mt-10 -102.93 -47.83 4.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.854 -179.996 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 3.4 mt -53.75 -26.47 13.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.115 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.6 m -66.35 -48.75 69.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.122 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 4.6 mt -69.52 -38.96 77.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.2 mt -66.68 -44.97 89.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.193 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.1 mm -66.02 -57.06 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -61.42 -30.33 70.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.42 -64.21 3.07 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 -179.972 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 98.3 t -56.94 -35.95 48.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.808 0.337 . . . . 0.0 111.099 -179.963 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.4 mmt -65.46 -47.14 77.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.873 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.85 -38.76 92.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.102 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.25 -56.5 5.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.971 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.6 t -54.86 -48.9 73.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.813 0.339 . . . . 0.0 111.171 -179.994 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.1 mm -63.59 -48.14 88.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.151 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.66 -37.37 93.36 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.492 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 63.4 m -67.93 -58.65 4.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.758 0.314 . . . . 0.0 111.126 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 77.6 mt -55.02 -37.87 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 179.959 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 27.2 mt -65.04 -55.84 16.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.5 tt -53.16 -49.19 67.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.939 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.8 mt -64.35 -56.11 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 12.8 t -53.16 -26.95 18.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -64.81 -36.08 83.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.907 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -114.5 40.19 2.55 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.501 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.5 mt -156.53 -52.13 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.825 0.345 . . . . 0.0 111.161 179.997 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -68.48 -44.94 73.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 5.4 ttm180 -95.26 27.28 3.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.829 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 3.1 mp . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.909 -179.972 . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 121.618 0.723 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 007 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -171.0 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.687 2.258 . . . . 0.0 112.325 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER -57.71 -44.0 85.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 179.992 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 50.9 mm -51.12 -30.44 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.168 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 81.8 m -63.88 -50.92 66.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.117 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.9 mt -65.75 -37.14 85.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.894 179.999 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 56.0 mt -65.95 -43.93 92.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 179.807 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.82 -58.11 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.109 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.44 -30.28 69.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.15 -64.25 3.08 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.498 -179.969 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 96.2 t -56.92 -35.82 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.83 0.347 . . . . 0.0 111.134 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 9.1 mmt -65.46 -47.01 77.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.897 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.13 -38.45 91.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.138 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.29 -56.57 5.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.481 -179.987 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 99.0 t -54.86 -48.84 73.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.853 0.359 . . . . 0.0 111.198 -179.985 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.1 mm -63.74 -47.96 88.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.141 179.905 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.7 -37.3 93.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 61.5 m -68.26 -58.88 3.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.746 0.308 . . . . 0.0 111.12 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.7 mt -54.79 -37.73 41.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.14 179.883 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 19.3 mt -65.33 -55.5 17.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.875 179.924 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -53.86 -48.13 70.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 67.6 mt -65.12 -55.34 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 57.1 p -57.06 -22.4 38.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 21.8 t80 -64.71 -54.82 25.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.928 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -162.24 67.37 0.24 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.463 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 16.1 mt -156.59 -45.88 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.805 0.336 . . . . 0.0 111.101 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mtm180 -64.94 -33.49 76.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.869 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -85.51 -61.54 1.74 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.857 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.623 0.725 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 008 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -171.2 0.45 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.672 2.248 . . . . 0.0 112.367 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -140.52 101.86 4.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 45.7 mm -51.03 -33.55 13.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.128 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.1 m -59.84 -56.74 18.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.146 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 13.7 mt -60.76 -36.92 80.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.897 179.976 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 48.0 mt -65.89 -40.83 88.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 31.0 mt -66.2 -58.32 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -59.76 -31.12 69.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.66 -64.68 2.95 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.466 -179.917 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 67.3 t -56.4 -35.63 44.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.348 . . . . 0.0 111.173 -179.997 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 13.9 mmt -65.38 -47.06 77.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.868 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.81 91.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.155 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.22 -56.78 5.49 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.5 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 92.3 t -54.89 -49.51 69.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.775 0.321 . . . . 0.0 111.152 179.975 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.8 mm -63.03 -49.42 83.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.192 179.882 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.44 86.71 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.434 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.6 m -68.8 -58.79 3.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 111.17 -179.883 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 64.7 mt -56.69 -37.91 55.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.074 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 32.1 mt -65.08 -53.62 42.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.87 -49.41 71.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.907 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 62.4 mt -64.52 -56.92 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.131 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 53.7 p -55.04 -24.94 27.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 55.9 t80 -70.74 -51.91 24.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.944 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -58.27 -40.45 93.96 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.477 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.9 mt -75.18 -21.74 16.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 0.0 111.132 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -14.89 59.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 15.2 ttm180 -144.18 -69.8 0.31 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.846 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.937 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.699 0.761 . . . . 0.0 110.897 . . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 82.12 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.654 2.236 . . . . 0.0 112.328 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 33.8 mt-10 -115.77 -49.21 2.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.907 179.973 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.0 mt -51.1 -30.42 9.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.088 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 22.3 m -64.2 -50.35 68.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.184 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 5.7 mt -66.0 -36.99 84.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 58.0 mt -66.13 -43.96 91.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.9 mm -65.9 -57.94 8.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -60.7 -30.34 69.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.27 -64.67 2.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.48 -179.965 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 87.3 t -56.86 -35.79 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.824 0.345 . . . . 0.0 111.132 -179.98 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.9 mmm -65.57 -46.99 77.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.871 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.99 -38.74 92.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.1 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.17 -56.62 5.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.479 -179.938 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 99.3 t -54.93 -49.64 68.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 111.109 -179.951 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.4 mm -62.73 -49.79 82.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 179.891 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.1 -34.82 85.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.47 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 97.0 m -68.74 -58.73 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.795 0.331 . . . . 0.0 111.201 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 62.1 mt -56.55 -37.79 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 17.8 mt -65.29 -53.51 42.87 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -54.98 -49.07 72.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 62.9 mt -64.77 -56.74 14.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.149 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.4 m -55.25 -24.87 30.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 66.0 t80 -69.74 -51.74 31.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.909 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.59 -22.4 75.12 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.485 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . 0.409 ' C ' ' H ' ' B' ' 97' ' ' ARG . 19.0 mm -76.66 -27.96 17.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 0.0 111.118 -179.994 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 1.9 ttp180 -80.64 24.07 0.49 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . 0.409 ' H ' ' C ' ' B' ' 95' ' ' ILE . 6.4 ttm180 -149.43 -48.43 0.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.867 -179.93 . . . . . . . . 2 2 . 1 . 008 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 121.662 0.744 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 139.91 41.45 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.69 2.26 . . . . 0.0 112.377 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -108.11 -48.75 3.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.867 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 79.3 mt -51.27 -29.84 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.141 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.9 m -66.22 -48.0 72.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.141 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 26.0 mt -66.5 -37.69 85.6 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.933 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.8 mt -66.36 -42.97 91.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.109 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.6 mm -66.02 -57.77 9.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.123 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -60.32 -30.98 69.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.866 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.08 -64.89 2.81 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.933 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 82.5 t -56.41 -35.2 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.809 0.338 . . . . 0.0 111.124 -179.962 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 26.8 mmt -65.45 -47.84 74.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.28 89.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.113 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.08 -56.05 5.97 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 -179.958 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 93.6 t -54.83 -49.25 71.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.972 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 61.3 mt -62.71 -48.68 86.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.127 179.905 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.11 -37.45 91.69 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.475 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 39.1 m -67.94 -57.77 5.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.759 0.314 . . . . 0.0 111.169 -179.882 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 82.2 mt -55.55 -37.72 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.915 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.6 mt -65.21 -55.19 19.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.871 179.931 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.84 -48.74 69.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.939 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.73 -56.23 17.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 t -55.31 -24.49 28.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -65.1 -45.16 86.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.904 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -110.66 40.58 2.5 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.3 mt -156.58 -48.21 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.834 0.349 . . . . 0.0 111.131 -179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.14 -27.97 59.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.861 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 23.4 ttm180 -86.27 -42.54 13.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.902 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 121.638 0.732 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 009 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 78.89 0.98 Allowed 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.694 2.263 . . . . 0.0 112.34 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -106.58 -43.76 4.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 2.8 mt -50.69 -30.87 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 9.5 m -65.3 -49.07 70.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.141 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 10.6 mt -65.48 -36.68 84.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.922 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.2 mm -66.47 -43.02 91.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.148 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.5 mm -66.06 -58.0 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.65 -30.96 70.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.889 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.07 -65.03 2.75 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.524 -179.987 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 90.8 t -56.46 -35.35 43.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.347 . . . . 0.0 111.15 -180.0 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.3 mmt -65.47 -47.65 75.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.39 90.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.039 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.08 -56.02 5.98 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 -179.935 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 94.4 t -54.89 -48.88 73.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.753 0.311 . . . . 0.0 111.124 -179.952 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 84.7 mt -63.21 -47.94 89.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.76 -38.66 94.23 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.463 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 30.9 m -67.34 -58.75 4.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.805 0.336 . . . . 0.0 111.129 -179.86 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.7 mt -54.2 -37.61 36.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.086 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 24.6 mt -65.02 -56.26 14.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.06 -49.94 70.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.925 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 78.2 mt -60.33 -53.74 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.083 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 25.8 p -64.4 -15.48 60.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -63.43 -19.23 64.52 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.976 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 130.23 33.56 0.49 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 mm -77.8 -27.97 15.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 111.156 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -64.47 -26.44 68.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -85.41 -65.56 1.0 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.822 -179.89 . . . . . . . . 2 2 . 1 . 009 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.918 -179.941 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.616 0.722 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -171.06 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.713 2.275 . . . . 0.0 112.389 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 10.9 tt0 -137.96 103.45 4.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.901 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 2.9 mp -49.67 -33.94 8.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.188 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 4.5 m -60.08 -54.64 43.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.106 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 14.2 mt -61.92 -37.03 83.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.955 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 36.4 mm -67.11 -39.95 84.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.134 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 30.7 mt -66.5 -59.04 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -60.71 -31.6 70.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.78 -64.91 2.83 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.507 -179.976 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 72.6 t -56.22 -34.88 40.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 111.124 -179.969 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -65.42 -48.67 71.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.15 -38.7 90.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.082 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.07 -57.37 5.77 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 -179.966 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.6 t -53.77 -50.54 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.817 0.342 . . . . 0.0 111.154 179.989 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 95.9 mt -60.41 -45.01 97.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.083 179.936 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.12 -37.35 91.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 0.7 OUTLIER -69.56 -58.33 4.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.785 0.326 . . . . 0.0 111.133 -179.859 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 77.0 mt -56.49 -37.96 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.06 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.3 mt -65.19 -54.48 29.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.964 179.893 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.87 -49.15 69.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.2 mt -64.85 -56.3 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 56.5 p -54.26 -25.51 23.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.84 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -64.94 -43.7 91.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.881 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -108.54 36.24 4.48 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.481 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.8 mt -156.47 -52.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.801 0.334 . . . . 0.0 111.129 -179.997 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.45 -31.05 69.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.854 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -147.35 26.98 1.04 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 4.7 mp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.932 -179.982 . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 121.671 0.748 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 010 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 -177.04 1.7 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.657 2.238 . . . . 0.0 112.338 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER 69.26 -75.36 0.07 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.871 179.986 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 50.9 mm -51.56 -29.85 10.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 23.5 m -62.69 -52.54 62.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.16 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 14.1 mt -66.31 -37.52 85.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.91 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 53.4 mt -65.66 -44.16 93.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.146 179.843 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 18.8 mm -65.9 -57.02 12.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.32 -30.3 69.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.921 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.47 -64.4 2.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.994 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 95.4 t -56.68 -35.94 47.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.34 . . . . 0.0 111.117 -179.946 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.1 mmt -65.69 -47.7 74.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.54 -39.49 91.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.87 -57.24 5.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.504 -179.977 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 93.3 t -55.1 -49.92 67.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.971 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.8 mm -62.37 -47.36 93.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.913 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.26 -38.92 91.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.455 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 19.8 m -68.2 -58.05 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.749 0.309 . . . . 0.0 111.16 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.8 mt -55.1 -38.39 46.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.077 179.898 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 19.7 mt -65.18 -54.17 33.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.904 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.77 -48.81 72.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.932 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.64 -56.72 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 13.2 t -54.87 -25.54 29.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.2 t80 -75.19 -47.62 27.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.945 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -73.01 -31.39 61.92 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.502 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.4 tt -75.55 -23.59 16.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.884 0.373 . . . . 0.0 111.161 -179.993 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.91 -25.42 67.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 10.2 ttm180 -147.44 41.14 1.04 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.891 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 121.643 0.735 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -46.52 1.19 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.682 2.255 . . . . 0.0 112.343 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.6 mt-10 71.57 -69.26 0.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 -179.974 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 50.0 mm -50.31 -34.28 11.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.117 179.995 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 94.5 m -62.75 -50.29 71.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 14.8 mt -63.13 -36.76 84.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.928 179.936 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 57.6 mt -66.02 -41.96 90.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 179.863 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 23.9 mm -66.04 -57.03 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.144 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -60.03 -31.27 69.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.85 -64.61 2.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.501 -179.968 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 87.0 t -56.64 -35.39 45.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.835 0.35 . . . . 0.0 111.152 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.37 -47.41 76.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.894 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.38 90.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.115 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.1 -55.89 6.05 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.52 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 94.3 t -54.85 -48.75 73.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.804 0.335 . . . . 0.0 111.168 -179.994 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.3 mt -63.54 -47.99 88.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.129 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.37 -37.3 92.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.536 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 48.4 m -68.22 -58.87 3.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.748 0.309 . . . . 0.0 111.142 -179.864 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 75.8 mt -54.91 -37.84 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 24.9 mt -65.14 -55.78 16.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.37 -49.17 67.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.3 mt -64.19 -55.9 19.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.176 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 23.3 t -53.2 -27.2 20.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -64.91 -32.79 74.67 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.888 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -113.94 45.16 1.35 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.465 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.7 mt -156.45 -40.5 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.893 0.377 . . . . 0.0 111.203 179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.4 ptm180 -64.47 -25.42 67.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.862 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 9.8 ttp85 -87.55 -39.73 14.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.872 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.934 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 . . . . . 0 C--O 1.232 0.146 0 CA-C-O 121.627 0.727 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 011 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 165.38 31.09 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.742 2.295 . . . . 0.0 112.324 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 71.57 -69.44 0.18 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.999 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.7 mt -50.15 -31.69 8.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.116 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 94.4 m -65.76 -47.16 76.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.2 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 9.8 mt -66.09 -36.56 83.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 179.965 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.8 mm -67.11 -43.35 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.5 mm -66.05 -58.01 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.077 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -61.33 -30.92 70.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.97 -64.67 2.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.485 -179.959 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 99.1 t -57.02 -35.69 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 0.0 111.091 -179.961 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.9 mmm -65.49 -46.92 77.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.09 -38.8 92.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.13 -56.54 5.67 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.507 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 97.9 t -54.84 -49.19 71.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.813 0.339 . . . . 0.0 111.163 -179.979 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.9 mm -63.19 -48.72 86.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.895 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.24 90.32 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.451 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 90.9 m -68.41 -58.38 4.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.777 0.322 . . . . 0.0 111.1 -179.825 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 75.7 mt -55.15 -38.77 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 17.9 mt -65.15 -53.41 45.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.916 179.912 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -55.08 -48.89 72.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.897 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.6 mt -65.0 -56.86 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.098 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 7.4 t -54.89 -25.35 28.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.858 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 46.6 t80 -68.16 -50.92 51.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -80.74 -19.32 68.31 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.511 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.8 mm -77.12 -27.54 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.846 0.355 . . . . 0.0 111.107 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -64.47 -25.6 68.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 30.9 ttm180 -145.04 41.45 1.28 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 121.638 0.733 . . . . 0.0 110.907 . . . . . . . . . 0 0 . 1 . 012 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -32.07 19.14 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.651 2.234 . . . . 0.0 112.371 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.7 tt0 -58.78 -63.96 1.11 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 47.2 mm -50.47 -31.79 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.134 179.963 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 33.5 m -64.32 -50.61 67.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.16 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 5.0 mt -63.59 -37.31 86.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.902 179.96 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.6 mt -66.53 -41.18 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.879 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 36.2 mt -66.11 -58.62 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.64 -30.84 70.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.74 -64.53 3.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.554 179.98 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 42.0 t -56.74 -35.81 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 111.154 -179.999 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.8 mmt -65.43 -46.93 78.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.875 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -39.18 93.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.8 -56.67 5.78 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.516 -179.987 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 94.7 t -55.2 -50.49 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.139 -179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -61.53 -48.74 87.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.95 -39.5 95.68 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.458 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 74.9 m -64.8 -58.07 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.799 0.333 . . . . 0.0 111.143 -179.861 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.9 mt -54.44 -42.3 58.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.13 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 12.9 mt -59.76 -54.75 42.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.87 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.38 -51.07 69.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.936 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -57.32 -59.54 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.169 179.825 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 80.4 p -53.67 -29.49 38.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 36.0 t80 -65.03 -43.32 92.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.937 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -107.0 35.22 5.17 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.494 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.0 mt -156.57 -52.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.858 0.361 . . . . 0.0 111.157 -179.946 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.77 -37.33 62.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.876 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.4 tpp180 -92.3 -50.09 5.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.881 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.145 0 CA-C-O 121.657 0.741 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 174.89 8.85 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.71 2.273 . . . . 0.0 112.343 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 10.9 pt-20 -126.07 -45.15 1.72 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.898 -179.989 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 2.7 mp -50.99 -32.85 12.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.107 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 27.2 m -61.74 -52.96 62.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.172 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 5.9 mt -63.45 -36.39 83.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 179.971 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 53.8 mt -65.04 -43.98 95.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.131 179.88 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 24.2 mm -65.75 -57.31 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -59.98 -30.07 68.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.41 -63.85 3.22 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.501 -179.929 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 99.1 t -56.99 -36.23 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.856 0.36 . . . . 0.0 111.158 179.968 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -47.08 77.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.886 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.67 -38.7 91.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.075 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.25 -56.52 5.63 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.474 -179.931 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 96.4 t -54.84 -49.21 71.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.857 0.36 . . . . 0.0 111.194 179.962 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 83.2 mt -63.29 -49.23 83.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.081 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.08 -35.56 87.88 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.475 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.9 m -68.88 -59.28 3.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.755 0.312 . . . . 0.0 111.114 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 76.2 mt -55.62 -38.44 50.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 179.916 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 26.4 mt -65.12 -53.12 50.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.895 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -55.44 -49.0 73.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.913 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.2 mt -64.88 -57.12 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.1 m -55.02 -25.26 29.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.845 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -75.13 -51.37 13.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -62.67 -37.53 94.94 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 179.97 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.4 tt -75.77 -21.25 15.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.838 0.351 . . . . 0.0 111.149 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.01 -27.78 69.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 16.4 ttm180 -87.04 -34.47 19.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.942 -179.937 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 38.4 mt-10 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 121.641 0.734 . . . . 0.0 110.945 . . . . . . . . . 0 0 . 1 . 013 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -43.29 2.76 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.678 2.252 . . . . 0.0 112.374 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 5.9 tt0 -177.74 -51.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.913 179.999 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 51.0 mm -50.54 -30.93 8.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.102 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 89.9 m -65.44 -48.53 72.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.111 179.938 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 15.9 mt -65.79 -36.94 84.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.911 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 42.5 mm -66.52 -42.71 90.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 21.0 mm -66.03 -57.5 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.171 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -60.74 -31.03 70.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.881 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.09 -64.66 2.91 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 90.2 t -56.74 -35.46 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.835 0.35 . . . . 0.0 111.097 -179.939 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.7 mmt -65.48 -47.56 75.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.64 91.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.12 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.66 -56.84 5.76 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.534 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 98.1 t -54.84 -51.07 56.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.819 0.342 . . . . 0.0 111.149 -179.983 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.7 mm -60.41 -50.23 81.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.133 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.73 -41.11 95.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.483 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 77.0 m -62.7 -59.08 5.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.783 0.325 . . . . 0.0 111.129 -179.847 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 79.4 mt -54.13 -43.92 61.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 179.905 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.3 mt -56.8 -51.04 70.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -59.52 -42.12 91.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.841 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.6 mm -65.42 -63.85 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.181 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 2.2 t -51.53 -30.68 21.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -70.42 -51.99 25.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.08 -28.12 72.39 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.461 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 43.6 mt -76.42 -29.6 18.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.982 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.9 ttm180 -64.81 -32.07 73.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 18.6 ttp85 -86.24 -46.12 10.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.864 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.909 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . 0.476 ' N ' ' HD2' ' B' ' 71' ' ' PRO . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.669 0.747 . . . . 0.0 110.879 . . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . 0.476 ' HD2' ' N ' ' B' ' 70' ' ' GLU . 53.8 Cg_endo -69.79 -49.93 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.652 2.235 . . . . 0.0 112.322 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 177.52 -45.58 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.4 mt -49.62 -32.2 6.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.165 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 99.6 m -66.39 -45.69 79.18 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.145 179.974 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 17.9 mt -66.59 -37.64 85.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.935 179.922 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 56.4 mt -68.03 -41.41 84.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.099 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.4 mm -66.31 -57.74 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.161 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -61.16 -31.73 71.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.79 -64.03 3.23 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.96 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 57.8 t -56.84 -35.6 47.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.094 -179.911 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.1 mmm -65.29 -47.42 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.857 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.16 90.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.22 -56.65 5.57 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.442 -179.94 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 97.5 t -54.8 -48.81 73.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.785 0.326 . . . . 0.0 111.101 -179.946 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.8 mm -63.52 -47.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.163 179.909 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.85 -37.78 93.05 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.504 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 27.5 m -68.79 -59.51 3.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.757 0.313 . . . . 0.0 111.159 -179.843 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 72.5 mt -54.92 -38.16 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.132 179.864 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 18.8 mt -65.15 -55.1 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.914 179.893 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.91 -48.91 69.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.92 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.0 mt -64.58 -56.32 16.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.162 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 59.1 m -54.15 -25.95 25.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 18.1 t80 -75.02 -41.97 58.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -88.61 -3.24 77.95 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.503 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.3 tt -76.46 -13.48 14.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.825 0.345 . . . . 0.0 111.102 179.987 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.55 -13.21 60.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.854 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 18.8 ttm180 -88.42 -39.94 13.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.877 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 121.66 0.743 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -173.44 0.72 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.665 2.244 . . . . 0.0 112.348 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 46.1 mm-40 -141.9 102.49 4.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.91 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 51.1 mm -53.61 -26.53 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.143 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.6 m -64.69 -50.36 67.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 17.6 mt -69.86 -38.68 76.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 -179.988 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 61.0 mt -66.37 -46.42 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 179.835 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.5 mm -65.73 -56.81 13.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.135 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -61.33 -29.86 70.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.31 -63.69 3.3 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 179.999 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 98.3 t -57.47 -36.08 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.802 0.334 . . . . 0.0 111.114 -179.985 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.44 -46.78 78.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.826 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.06 -38.85 92.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.137 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.04 -56.43 5.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.511 -179.983 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 95.6 t -55.16 -49.95 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.788 0.327 . . . . 0.0 111.133 -179.969 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.0 mm -62.35 -49.93 81.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -36.17 88.86 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 96.8 m -67.55 -59.17 3.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.724 0.297 . . . . 0.0 111.148 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.2 mt -54.73 -40.04 49.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 14.5 mt -62.77 -56.41 17.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -52.7 -53.56 45.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.0 mt -59.58 -55.25 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.17 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.3 p -55.12 -25.45 31.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -65.17 -27.08 68.46 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -114.02 -59.59 0.39 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.492 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.553 ' O ' ' CG2' ' A' ' 95' ' ' ILE . 4.6 mp -79.13 54.63 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.825 0.345 . . . . 0.0 111.103 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -174.47 -36.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -90.7 -31.19 16.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.848 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 97.7 mt . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.921 -179.953 . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.624 0.726 . . . . 0.0 110.852 . . . . . . . . . 0 0 . 1 . 014 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -48.59 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.135 0 C-N-CA 122.706 2.271 . . . . 0.0 112.308 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 0.9 OUTLIER -171.31 -63.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.866 -179.97 . . . . . . . . 2 2 . 1 . 014 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 53.7 mt -51.25 -29.43 8.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.133 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 88.0 m -62.7 -50.6 70.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 6.2 mt -68.16 -38.29 81.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 179.97 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 59.9 mt -66.26 -44.66 91.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.5 mm -65.8 -57.17 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.2 t80 -60.47 -30.25 69.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.08 -63.44 3.45 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.501 -179.997 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 39.5 t -57.28 -36.04 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.155 179.993 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.3 mmt -65.38 -46.93 78.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.934 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.84 92.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.059 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.06 -56.33 5.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.474 -179.926 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 98.7 t -54.95 -49.28 72.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.342 . . . . 0.0 111.133 -179.947 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 77.6 mt -63.03 -49.4 83.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.171 179.896 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.5 -35.66 86.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.486 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 87.1 m -68.97 -58.67 3.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.753 0.311 . . . . 0.0 111.171 -179.847 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.94 -37.91 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 16.9 mt -65.12 -53.25 48.13 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.92 179.907 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -49.41 71.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.64 -57.02 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.118 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 80.8 p -54.79 -25.18 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.843 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 43.7 t80 -71.56 -54.27 11.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -53.24 -35.63 50.45 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.504 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.8 mm -76.46 -29.36 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.832 0.349 . . . . 0.0 111.159 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 2.5 ttp180 -64.87 -40.47 95.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.87 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 5.9 ttm180 -94.2 40.42 1.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.9 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 2.5 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.935 -179.957 . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 68.2 mm-40 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 121.635 0.731 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 169.03 19.9 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.65 2.233 . . . . 0.0 112.306 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.4 mp0 -117.81 -44.77 2.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 -179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 58.2 mt -50.9 -34.25 13.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.134 179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.0 m -60.23 -55.18 36.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.159 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 5.0 mt -61.24 -36.71 80.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.925 179.912 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 52.3 mt -66.02 -41.31 89.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.137 179.848 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 27.4 mt -66.1 -58.75 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -59.68 -31.06 69.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.913 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.81 -65.79 2.51 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.466 -179.939 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 99.0 t -55.46 -34.73 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.878 0.371 . . . . 0.0 111.13 -179.992 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.9 mmt -65.31 -50.21 66.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.11 80.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.19 -55.36 6.29 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.465 -179.955 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 91.1 t -54.96 -49.99 66.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 111.139 -179.963 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 1.7 mp -63.45 -47.83 89.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.15 -36.66 91.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.456 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 73.1 m -68.88 -58.73 3.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.775 0.322 . . . . 0.0 111.164 -179.894 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.1 mt -55.61 -38.47 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.885 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.9 mt -65.2 -53.41 45.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -55.0 -49.33 71.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.9 mt -64.58 -56.68 14.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 60.6 p -55.24 -24.97 30.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.88 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 26.7 t80 -70.08 -54.36 13.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.93 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -58.15 -29.04 62.13 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.458 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.8 mt -76.48 -29.41 18.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.799 0.333 . . . . 0.0 111.106 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.2 -40.26 93.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.897 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -87.08 -32.76 19.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.84 -179.934 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.915 -179.948 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 . . . . . 0 C--O 1.232 0.135 0 CA-C-O 121.592 0.711 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 015 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 179.71 3.51 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.69 2.26 . . . . 0.0 112.318 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -125.85 -44.19 1.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.932 179.977 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 48.5 mm -51.11 -36.03 15.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.119 179.982 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 18.6 m -57.03 -57.03 14.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.179 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 4.6 mt -61.8 -35.79 79.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.947 179.934 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 36.6 mt -65.77 -43.33 93.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.126 179.871 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.2 mm -65.84 -58.03 8.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.1 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -60.15 -30.29 69.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.02 -63.83 3.28 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.439 -179.926 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 94.0 t -56.99 -35.81 48.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.808 0.337 . . . . 0.0 111.093 -179.917 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.4 mmt -65.49 -47.12 77.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.849 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.71 -39.03 92.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.114 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.82 -56.82 5.68 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 -179.966 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 91.2 t -55.14 -50.65 62.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.802 0.334 . . . . 0.0 111.146 -179.993 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.6 mm -61.61 -49.22 85.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -39.27 95.06 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.487 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 85.5 m -64.66 -58.01 7.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.757 0.313 . . . . 0.0 111.115 -179.857 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 76.4 mt -54.46 -43.17 62.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.13 179.911 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 14.9 mt -59.02 -53.76 54.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.44 -51.71 68.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -56.44 -59.61 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.86 . . . . . . . . 2 2 . 1 . 015 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 30.9 t -56.34 -27.11 54.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.961 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 59.9 t80 -75.1 -51.31 13.79 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.918 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.6 -32.98 75.42 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.529 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.6 tt -75.71 -22.2 16.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.817 0.342 . . . . 0.0 111.135 179.995 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 5.2 ttm180 -65.3 -30.65 71.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.932 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 7.9 ttp180 -90.67 -41.81 11.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 -179.904 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . 0.517 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 4.7 tt0 . . . . . 0 C--O 1.232 0.141 0 CA-C-O 121.64 0.733 . . . . 0.0 110.869 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . 0.517 ' HD2' ' N ' ' A' ' 70' ' ' GLU . 53.6 Cg_endo -69.78 -48.44 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.693 2.262 . . . . 0.0 112.361 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -162.37 89.55 0.69 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 2.9 mp -50.21 -32.72 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.127 179.997 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.1 m -60.77 -54.19 48.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.101 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 66.3 mt -62.45 -37.97 87.98 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.844 -179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 41.2 mm -66.3 -40.02 85.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 34.2 mt -66.24 -58.26 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.097 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -60.04 -31.44 69.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.867 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.76 -65.03 2.78 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 -179.97 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 99.4 t -56.15 -35.45 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.344 . . . . 0.0 111.122 179.996 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.39 -47.9 74.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.92 -38.91 90.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.11 -56.53 5.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.4 t -55.03 -49.33 72.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.844 0.354 . . . . 0.0 111.129 -179.898 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 92.7 mt -62.75 -49.71 82.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.074 179.935 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.32 -35.66 85.73 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.479 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 86.7 m -68.67 -58.71 3.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.783 0.325 . . . . 0.0 111.154 -179.837 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.8 mt -56.46 -37.78 53.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 22.3 mt -65.25 -53.54 42.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.941 179.9 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.06 -49.09 72.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.917 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.66 -56.66 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.151 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 54.4 p -55.56 -24.5 32.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -75.02 -50.87 15.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.916 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.34 -32.72 72.15 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.487 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 5.5 tt -75.72 -22.39 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 0.0 111.129 -179.965 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.16 -30.93 71.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.842 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.5 ttm180 -90.96 -43.42 9.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.92 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.958 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.67 0.748 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 78.5 1.02 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.724 2.283 . . . . 0.0 112.32 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -114.41 -67.95 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.892 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 4.6 mt -50.32 -33.27 10.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.134 179.985 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 5.0 m -63.06 -51.36 66.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.153 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.1 mt -62.72 -37.21 85.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.892 179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 41.6 mm -66.53 -40.14 85.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.094 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 29.2 mt -66.38 -57.86 8.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.125 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -60.52 -31.72 70.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.58 -64.03 3.26 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.507 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 95.2 t -56.78 -35.69 46.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 111.145 -179.991 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 18.0 mmm -65.33 -47.02 77.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -39.05 93.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.093 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.05 -56.26 5.87 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.482 -179.978 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 96.6 t -54.97 -49.54 70.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.793 0.33 . . . . 0.0 111.14 -179.949 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.4 mm -62.72 -49.32 84.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.163 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.71 -35.69 87.1 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.496 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.1 m -68.64 -59.27 3.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.749 0.309 . . . . 0.0 111.126 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 67.5 mt -54.91 -37.95 43.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 29.0 mt -65.19 -55.44 18.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.914 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -53.83 -48.7 69.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.62 -54.68 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 42.8 t -53.76 -27.83 31.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.847 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -75.39 -31.49 60.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -60.86 -22.61 60.2 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.507 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.6 tt -75.69 -21.83 16.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.869 0.366 . . . . 0.0 111.15 179.999 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.55 -42.56 91.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 39.0 ttp180 -94.58 -36.7 11.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 17.1 mt . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.874 -179.993 . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 C--O 1.232 0.141 0 CA-C-O 121.647 0.737 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 017 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.84 159.54 52.97 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.648 2.232 . . . . 0.0 112.321 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 33.2 mt-10 -140.52 102.94 4.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 -179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 4.6 mt -50.14 -31.69 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.145 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 11.5 m -63.02 -52.92 61.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.109 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 29.0 mt -62.58 -37.47 86.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.893 -179.995 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.8 mm -66.52 -40.09 85.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.085 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 37.8 mt -66.33 -58.56 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -60.39 -31.57 70.49 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.897 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.65 -65.06 2.78 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.521 -179.971 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 72.0 t -56.24 -35.37 42.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 111.118 179.982 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 16.4 mtp -65.37 -47.4 76.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.69 -38.78 91.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.12 -56.48 5.71 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.979 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 97.8 t -55.0 -49.43 71.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.845 0.355 . . . . 0.0 111.158 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.8 mm -62.83 -48.66 87.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -37.8 93.09 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 62.6 m -67.25 -58.93 3.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.788 0.328 . . . . 0.0 111.138 -179.879 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 78.4 mt -54.24 -38.64 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.152 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 15.5 mt -64.03 -55.81 19.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.919 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.36 -49.8 71.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 84.7 mt -60.51 -53.43 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 36.1 t -64.92 -14.92 61.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -63.33 -19.38 64.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.913 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 130.39 33.19 0.5 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.48 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . 0.515 ' O ' ' CG2' ' A' ' 95' ' ' ILE . 25.3 mm -78.69 -3.96 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.882 0.372 . . . . 0.0 111.167 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.01 -38.35 0.06 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.839 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.5 ttm-85 -95.41 -5.91 42.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.867 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.952 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 121.614 0.721 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -49.11 0.59 Allowed 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.693 2.262 . . . . 0.0 112.346 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER -129.28 -37.1 1.67 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.883 -179.985 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 49.3 mm -48.67 -31.08 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.117 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 99.7 m -61.43 -52.6 63.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.099 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 11.4 mt -66.01 -37.86 87.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.912 179.959 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.8 mm -66.14 -42.63 91.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.161 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 16.9 mm -66.0 -57.23 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.24 -31.05 69.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.02 -64.52 2.98 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.468 180.0 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 97.2 t -56.58 -35.55 45.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.817 0.342 . . . . 0.0 111.136 -179.933 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.3 mmm -65.43 -47.38 76.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -38.75 91.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.2 -56.63 5.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.509 -179.945 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 98.8 t -54.92 -49.54 69.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.853 0.359 . . . . 0.0 111.14 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.4 mm -62.76 -49.61 83.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.31 86.3 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.518 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 91.8 m -68.71 -58.78 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.775 0.321 . . . . 0.0 111.179 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 70.4 mt -56.02 -38.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.102 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 34.2 mt -65.28 -53.5 43.24 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.929 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.14 -49.06 72.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.5 mt -64.71 -56.79 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 28.4 t -55.27 -24.98 30.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -69.46 -51.97 31.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.92 -28.16 73.28 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.984 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 59.8 mt -76.5 -29.56 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.805 0.336 . . . . 0.0 111.108 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.83 -27.59 68.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 6.9 ttp85 -87.0 -43.07 12.62 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.891 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.885 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.669 0.747 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 018 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -170.4 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.727 2.285 . . . . 0.0 112.319 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 2.7 tt0 -76.91 -48.37 18.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.883 -179.939 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 5.2 mt -51.15 -38.8 19.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.114 179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 81.3 m -57.62 -56.11 26.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.168 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 36.4 mt -59.02 -36.24 74.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.6 mt -67.62 -39.54 82.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.145 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.0 mt -66.35 -58.81 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -61.11 -31.68 71.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.42 -65.17 2.76 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.458 -179.944 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 77.2 t -56.46 -35.67 44.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.783 0.325 . . . . 0.0 111.116 -179.994 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 10.8 mmt -65.41 -46.9 78.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.98 93.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.2 -56.48 5.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.954 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 99.2 t -54.97 -49.02 74.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.865 0.364 . . . . 0.0 111.147 -179.982 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.9 mm -63.41 -48.18 88.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.17 -37.38 92.82 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.488 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 57.4 m -68.0 -58.16 4.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.814 0.34 . . . . 0.0 111.165 -179.826 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 79.0 mt -55.5 -37.74 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 179.872 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 15.8 mt -65.19 -55.29 19.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.919 179.916 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -53.54 -48.94 68.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.919 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 62.0 mt -64.72 -56.38 16.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.2 t -54.22 -25.59 23.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 15.4 t80 -67.15 -43.59 81.93 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.916 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -107.92 36.83 4.14 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.502 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 16.1 mt -156.45 -51.09 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.815 0.34 . . . . 0.0 111.126 -179.966 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.9 -23.7 60.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.875 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -144.88 27.5 1.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . 0.475 ' N ' ' HD2' ' B' ' 71' ' ' PRO . 1.5 mp0 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 121.694 0.759 . . . . 0.0 110.875 . . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . 0.475 ' HD2' ' N ' ' B' ' 70' ' ' GLU . 54.2 Cg_endo -69.74 178.89 4.1 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.673 2.249 . . . . 0.0 112.343 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -147.88 98.85 3.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 47.5 mm -50.75 -34.03 12.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.127 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 25.2 m -60.42 -54.73 42.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.121 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 24.8 mt -61.51 -37.26 83.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.949 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 53.6 mt -66.2 -40.44 86.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.844 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 29.8 mt -66.32 -57.89 8.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.115 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -60.15 -31.35 70.01 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.75 -64.81 2.88 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.463 -179.932 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 36.3 t -56.51 -35.52 44.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.794 0.33 . . . . 0.0 111.134 -179.936 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.2 mmm -65.37 -47.59 75.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.834 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.66 -38.33 89.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.23 -56.12 5.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.45 -179.919 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 96.1 t -54.93 -48.81 74.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 111.144 -179.962 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 81.9 mt -63.61 -48.24 87.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.129 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.99 -37.05 92.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 54.7 m -68.46 -58.77 3.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.805 0.336 . . . . 0.0 111.202 -179.873 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 75.5 mt -55.7 -38.19 49.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.151 179.887 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 17.7 mt -65.13 -53.72 40.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.907 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.05 -49.08 72.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.959 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.4 mt -64.59 -56.99 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.165 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 50.0 p -55.18 -24.88 29.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -72.37 -53.38 12.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.947 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -58.25 -35.35 77.8 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.549 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.1 mt -76.65 -29.53 18.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.812 0.339 . . . . 0.0 111.108 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.53 -25.5 68.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.885 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 14.0 ttm180 -145.19 42.74 1.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.879 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 2.4 mt . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.877 -179.999 . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.667 0.746 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 177.62 5.36 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.652 2.234 . . . . 0.0 112.383 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 -132.42 -43.35 0.93 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 51.2 mm -51.08 -36.88 16.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.113 179.975 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 14.0 m -58.49 -54.87 42.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 12.4 mt -61.05 -36.24 79.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.899 179.984 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.1 mt -66.27 -41.71 89.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.145 179.828 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.9 mm -66.06 -57.86 8.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.123 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -60.15 -31.27 69.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.66 -64.48 3.04 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.547 -180.0 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 65.7 t -56.56 -35.5 44.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.863 0.363 . . . . 0.0 111.172 179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 17.2 mmm -65.29 -47.21 77.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.64 91.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.08 -56.5 5.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 -179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 95.4 t -54.94 -49.34 71.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.161 179.966 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.6 mm -62.99 -47.62 91.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -61.09 -39.33 96.96 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.488 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 54.1 m -65.96 -57.45 7.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.781 0.324 . . . . 0.0 111.139 -179.873 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 79.0 mt -57.15 -45.55 84.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.1 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.47 -52.96 63.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.93 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -54.7 -55.81 25.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.908 179.871 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 74.8 mt -57.3 -59.42 3.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.7 p -53.07 -27.52 20.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -75.07 -51.5 13.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.949 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.45 -26.81 74.12 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.465 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 mm -76.45 -29.33 18.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.854 0.359 . . . . 0.0 111.159 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.69 -23.23 67.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.878 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 21.4 ttp85 -145.05 43.08 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 . . . . . 0 C--O 1.231 0.084 0 CA-C-O 121.661 0.743 . . . . 0.0 110.879 . . . . . . . . . 0 0 . 1 . 019 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 179.51 3.66 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.631 2.221 . . . . 0.0 112.339 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 0.7 OUTLIER 69.31 -75.26 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 -179.99 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.1 mt -50.87 -29.86 8.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.121 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 88.1 m -62.94 -50.24 71.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.169 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 10.7 mt -68.05 -37.32 81.17 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 179.93 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.1 mm -67.19 -44.4 87.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.082 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.1 mm -66.05 -57.7 9.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -61.45 -30.8 70.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.911 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.16 -64.5 2.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.506 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 77.1 t -56.96 -35.83 48.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.789 0.328 . . . . 0.0 111.12 -179.983 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 1.6 mmt -65.31 -47.21 77.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.49 91.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.107 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.31 -56.25 5.74 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.478 -179.98 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 96.1 t -54.91 -48.85 74.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 111.121 -179.956 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.5 mm -63.51 -48.6 86.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.7 92.03 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.526 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 90.0 m -68.12 -58.47 4.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.738 0.304 . . . . 0.0 111.186 -179.937 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 75.7 mt -55.36 -37.88 46.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.132 179.906 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 28.7 mt -65.18 -55.06 20.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.97 -48.97 69.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.87 179.896 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.6 mt -64.45 -56.23 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 13.6 t -54.46 -25.55 25.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.86 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 34.6 t80 -64.97 -42.92 94.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.948 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -111.64 39.25 2.95 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.46 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 16.5 mt -156.39 -50.15 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.796 0.331 . . . . 0.0 111.152 -179.986 . . . . . . . . 1 1 . 1 . 019 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.06 -32.38 61.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.855 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -95.46 26.69 3.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 1.7 mt . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.933 179.974 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 36.8 mm-40 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 121.643 0.735 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.75 178.25 4.76 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.72 2.28 . . . . 0.0 112.345 -179.981 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 13.8 tp10 52.03 72.13 0.41 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.902 -179.966 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.2 mm -54.75 -23.85 12.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.128 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 m -69.88 -45.44 67.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.145 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 38.7 mt -71.37 -38.94 71.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.991 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 37.4 mm -65.68 -48.39 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.873 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 1.1 mp -65.32 -54.81 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 179.819 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.7 t80 -60.79 -30.91 70.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.891 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.89 -64.06 3.07 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.496 -179.963 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 80' ' ' VAL . . . . . . . . . . . . . 95.6 t -57.0 -35.64 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 111.145 -179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.4 mmt -65.66 -47.61 74.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.867 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.95 -39.23 91.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.97 -56.45 5.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.516 -179.958 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 84' ' ' VAL . . . . . . . . . . . . . 93.7 t -54.94 -49.38 71.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.809 0.337 . . . . 0.0 111.153 -179.954 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.2 mm -62.52 -49.7 82.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.171 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -35.15 85.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.519 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.7 m -68.57 -59.6 3.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.153 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.9 mt -55.3 -37.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.101 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 13.3 mt -65.12 -55.18 20.21 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.901 179.925 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.58 -49.01 68.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.943 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.2 mt -64.72 -55.77 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 67.3 m -53.97 -26.14 24.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 20.5 t80 -64.81 -38.75 92.02 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.941 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -112.3 43.86 1.63 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.45 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 17.1 mt -156.49 -40.42 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.849 0.357 . . . . 0.0 111.13 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 ptt85 -64.6 -28.52 69.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.855 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 13.1 ttp180 -150.8 35.27 0.61 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.879 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 5.3 mp . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.935 -179.949 . . . . . . . . 0 0 . 1 . 020 nuclear orig full ' B' B ' 70' ' ' GLU . . . . . 0.477 ' N ' ' HD2' ' B' ' 71' ' ' PRO . 1.3 mt-10 . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.572 0.701 . . . . 0.0 110.812 . . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 71' ' ' PRO . . . . . 0.477 ' HD2' ' N ' ' B' ' 70' ' ' GLU . 53.6 Cg_endo -69.76 162.99 39.94 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.652 2.235 . . . . 0.0 112.392 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -149.62 -49.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 51.0 mm -51.69 -38.01 21.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.088 179.979 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 35.5 m -58.77 -53.71 55.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.19 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 12.5 mt -61.01 -36.24 78.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 179.931 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 37.2 mt -66.64 -41.13 87.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.106 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.6 mm -66.11 -56.83 12.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.165 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -31.87 70.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 79' ' ' GLY . . . . . . . . . . . . . . . -68.58 -65.05 2.79 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.515 179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 80' ' ' VAL . . . . . . . . . . . . . 88.1 t -56.68 -35.07 44.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 111.161 -179.995 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -47.01 77.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.86 -38.89 92.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.085 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.08 -56.39 5.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.509 -179.967 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 84' ' ' VAL . . . . . . . . . . . . . 97.6 t -54.86 -49.21 71.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.849 0.357 . . . . 0.0 111.119 -179.978 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.0 mm -62.96 -49.29 84.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.133 179.913 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.01 -35.31 86.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.495 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 84.8 m -68.91 -59.17 3.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.762 0.315 . . . . 0.0 111.115 -179.839 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.3 mt -55.85 -38.09 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.135 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 13.7 mt -65.25 -53.56 42.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.889 179.916 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -48.96 72.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.1 mt -64.86 -56.89 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.151 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 8.7 t -55.18 -24.94 29.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.834 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 76.4 t80 -72.27 -51.66 19.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.883 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -62.66 -32.06 82.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.507 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 32.9 mt -76.47 -29.59 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.781 0.324 . . . . 0.0 111.125 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.72 -32.56 74.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.839 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear orig full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 16.0 ttp180 -90.8 -35.55 14.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear orig full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.92 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.846 HD12 HD12 ' B' ' 75' ' ' LEU . 22.8 mt . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.781 0.324 . . . . 0.0 110.863 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 58.8 mt -65.95 -41.99 90.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.187 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.1 mm -66.15 -57.3 11.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.125 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.18 -31.22 69.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.587 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.95 -64.53 2.98 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.459 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.559 HG22 ' O ' ' B' ' 79' ' ' GLY . 78.5 t -56.52 -35.45 44.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.792 0.329 . . . . 0.0 111.111 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.0 mmt -65.4 -47.31 76.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.863 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.43 90.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.087 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.534 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.22 -56.59 5.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 80' ' ' VAL . 99.6 t -54.83 -49.05 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.802 0.334 . . . . 0.0 111.121 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.604 HG22 HD12 ' A' ' 89' ' ' LEU . 34.1 mm -63.44 -48.3 87.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.76 -36.11 91.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.49 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 88' ' ' ILE . 88.8 m -68.58 -58.35 4.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.83 0.348 . . . . 0.0 111.186 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.568 HG13 HG21 ' B' ' 87' ' ' THR . 70.8 mt -56.37 -37.98 53.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.604 HD12 HG22 ' A' ' 85' ' ' ILE . 15.7 mt -65.26 -53.45 44.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.962 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -55.0 -48.95 72.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.9 mt -64.96 -56.74 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.3 t -55.19 -24.8 28.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 41.0 t80 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.907 -179.896 . . . . . . . . 0 0 . 1 . 001 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.846 HD12 HD12 ' A' ' 75' ' ' LEU . 11.0 mt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.762 0.315 . . . . 0.0 110.907 . . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.426 HD11 HD22 ' A' ' 75' ' ' LEU . 36.7 mm -66.97 -42.87 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.133 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.3 mm -66.04 -57.62 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.145 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -61.06 -31.03 70.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.559 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.04 -64.6 2.94 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.472 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 79' ' ' GLY . 97.2 t -56.87 -35.66 47.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.802 0.334 . . . . 0.0 111.102 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 42.7 mmm -65.3 -47.08 77.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.6 91.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.507 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.23 -56.41 5.7 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.513 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.6 t -54.89 -49.02 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.813 0.339 . . . . 0.0 111.122 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.619 HG22 HD12 ' B' ' 89' ' ' LEU . 34.0 mm -63.41 -48.34 87.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.17 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.8 -36.18 91.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.5 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.568 HG21 HG13 ' A' ' 88' ' ' ILE . 91.8 m -68.44 -57.51 5.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.775 0.321 . . . . 0.0 111.118 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.558 HG13 HG21 ' A' ' 87' ' ' THR . 76.6 mt -57.69 -37.6 60.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.619 HD12 HG22 ' B' ' 85' ' ' ILE . 16.4 mt -65.23 -53.01 50.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.923 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.2 -49.36 72.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.77 -56.8 14.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 29.8 t -55.16 -24.94 29.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 22.9 t80 . . . . . 0 C--N 1.327 -0.375 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.911 -179.86 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 1.027 HD12 HD12 ' B' ' 75' ' ' LEU . 25.1 mt . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.792 0.329 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.4 mm -66.39 -43.02 91.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.155 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.0 mm -66.04 -57.74 9.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.1 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.56 -30.71 69.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.555 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.12 -64.29 3.07 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.474 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.6 HG22 ' O ' ' B' ' 79' ' ' GLY . 91.4 t -56.93 -35.5 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.808 0.337 . . . . 0.0 111.117 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 2.7 mmt -65.54 -47.43 75.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.83 92.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.068 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.511 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.7 -56.62 5.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.523 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.592 HG13 ' OG1' ' B' ' 87' ' ' THR . 99.2 t -54.94 -50.91 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.813 0.339 . . . . 0.0 111.154 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.3 mm -60.45 -50.56 79.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.78 -40.7 95.35 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.478 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.552 HG21 HG13 ' B' ' 88' ' ' ILE . 87.9 m -62.62 -59.02 5.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.728 0.299 . . . . 0.0 111.127 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.565 HG13 HG21 ' B' ' 87' ' ' THR . 77.8 mt -54.14 -44.2 62.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.145 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 12.7 mt -56.46 -51.12 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -59.53 -42.02 91.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.936 179.88 . . . . . . . . 3 3 . 1 . 002 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.9 mm -65.53 -63.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.148 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 3.8 m -51.65 -30.55 22.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.87 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 42.2 t80 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.906 -179.832 . . . . . . . . 0 0 . 1 . 002 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 1.027 HD12 HD12 ' A' ' 75' ' ' LEU . 13.9 mt . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.762 0.315 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.4 mm -67.08 -39.98 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.152 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 26.9 mt -66.39 -58.49 6.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.097 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -60.8 -31.5 70.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.6 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.78 -64.92 2.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.432 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.555 HG22 ' O ' ' A' ' 79' ' ' GLY . 82.2 t -56.32 -35.34 42.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.776 0.322 . . . . 0.0 111.115 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 27.8 mmt -65.24 -47.93 75.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.879 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.87 -37.88 88.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.588 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.24 -55.8 6.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.477 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' B' ' 80' ' ' VAL . 92.8 t -54.78 -48.38 73.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.833 0.349 . . . . 0.0 111.146 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.503 HG22 HD12 ' B' ' 89' ' ' LEU . 61.9 mt -63.6 -48.45 86.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.154 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.19 -36.58 91.1 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.464 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.592 ' OG1' HG13 ' A' ' 84' ' ' VAL . 53.0 m -68.46 -58.22 4.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.32 . . . . 0.0 111.144 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.552 HG13 HG21 ' A' ' 87' ' ' THR . 72.6 mt -56.66 -37.8 54.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.136 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.503 HD12 HG22 ' B' ' 85' ' ' ILE . 18.2 mt -65.16 -53.54 43.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -54.97 -49.18 72.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.6 mt -64.67 -57.01 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 75.7 m -54.97 -25.08 27.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 38.3 t80 . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.947 -179.938 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.973 HD12 HD12 ' B' ' 75' ' ' LEU . 27.3 mt . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.754 0.311 . . . . 0.0 110.908 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.1 mm -66.44 -42.98 91.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.0 mm -65.97 -58.08 8.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.121 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.36 -30.94 69.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.577 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.98 -64.69 2.9 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.563 HG22 ' O ' ' B' ' 79' ' ' GLY . 80.5 t -56.48 -35.6 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 3.0 mmt -65.41 -47.16 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.05 -38.47 91.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.088 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.525 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.12 -56.66 5.61 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.461 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.5 t -54.9 -49.72 67.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.825 0.345 . . . . 0.0 111.134 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.71 -49.12 84.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.02 -35.61 87.79 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.477 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.427 ' OG1' HG13 ' B' ' 84' ' ' VAL . 86.7 m -68.57 -58.19 4.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.769 0.319 . . . . 0.0 111.098 -179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.406 HG13 HG21 ' B' ' 87' ' ' THR . 67.2 mt -56.03 -38.28 52.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.115 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.5 mt -65.21 -53.39 45.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.1 -49.01 72.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.934 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.87 -56.71 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 34.6 t -55.2 -25.04 30.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 68.6 t80 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.93 -179.882 . . . . . . . . 0 0 . 1 . 003 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.973 HD12 HD12 ' A' ' 75' ' ' LEU . 31.3 mt . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.816 0.341 . . . . 0.0 110.877 . . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 40.2 mm -66.54 -40.46 86.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 25.7 mt -66.28 -58.39 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.117 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -60.58 -31.33 70.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.563 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.66 -64.7 2.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.515 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 79' ' ' GLY . 79.6 t -56.63 -35.1 44.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.839 0.352 . . . . 0.0 111.137 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.1 mtt -65.34 -48.04 74.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.37 90.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.534 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.62 -56.55 5.96 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.486 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.521 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.9 t -54.88 -51.16 55.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.794 0.331 . . . . 0.0 111.138 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.452 HG22 HD12 ' B' ' 89' ' ' LEU . 62.4 mt -60.13 -50.19 81.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.133 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.27 -41.15 94.8 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.421 ' OG1' HG13 ' A' ' 84' ' ' VAL . 56.0 m -62.67 -59.53 4.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.81 0.338 . . . . 0.0 111.162 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.04 -42.96 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.452 HD12 HG22 ' B' ' 85' ' ' ILE . 20.6 mt -57.48 -50.76 71.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.915 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.7 tt -59.56 -42.48 92.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 27.4 mm -65.42 -62.08 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.106 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 1.3 m -54.9 -26.1 33.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 83.6 t80 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.96 -179.916 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 1.078 HD12 HD12 ' B' ' 75' ' ' LEU . 16.8 mt . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.749 0.309 . . . . 0.0 110.865 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.5 mm -66.63 -41.89 88.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.166 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.6 mm -66.2 -57.99 8.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -60.59 -31.23 70.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.871 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.432 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.0 -63.9 3.26 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.513 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.529 ' O ' HG23 ' A' ' 84' ' ' VAL . 71.4 t -56.65 -35.93 46.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.868 0.366 . . . . 0.0 111.131 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 19.7 mtp -65.37 -47.31 76.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.847 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.11 -38.16 90.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.041 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.41 -56.73 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.478 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 80' ' ' VAL . 92.9 t -54.92 -48.91 74.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.811 0.339 . . . . 0.0 111.109 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.45 HG22 HD12 ' A' ' 89' ' ' LEU . 34.8 mm -63.94 -48.13 87.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.145 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.78 -36.76 92.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.51 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.56 HG21 HG13 ' B' ' 88' ' ' ILE . 84.4 m -68.54 -58.73 3.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 111.115 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.581 HG13 HG21 ' B' ' 87' ' ' THR . 80.0 mt -56.12 -37.7 50.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.45 HD12 HG22 ' A' ' 85' ' ' ILE . 15.1 mt -65.27 -54.25 32.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -54.4 -48.66 71.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.7 mt -65.11 -56.29 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.149 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 83.5 p -55.02 -25.11 27.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.85 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 57.8 t80 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.862 . . . . . . . . 0 0 . 1 . 004 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 1.078 HD12 HD12 ' A' ' 75' ' ' LEU . 10.1 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.843 0.354 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.3 mm -66.74 -42.4 89.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.169 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 17.3 mm -66.09 -57.86 8.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.112 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 45.8 t80 -60.64 -31.22 70.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.431 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.98 -64.04 3.19 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.472 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.517 ' O ' HG23 ' B' ' 84' ' ' VAL . 72.7 t -56.65 -35.85 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.824 0.345 . . . . 0.0 111.125 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.35 -47.4 76.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.98 -38.12 89.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.105 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.43 -56.64 5.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 93.7 t -54.97 -48.66 75.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.785 0.326 . . . . 0.0 111.134 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.467 HG22 HD12 ' B' ' 89' ' ' LEU . 34.6 mm -64.09 -48.05 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.113 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.92 -36.52 92.26 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.485 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.581 HG21 HG13 ' A' ' 88' ' ' ILE . 86.1 m -68.82 -58.27 4.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.75 0.309 . . . . 0.0 111.113 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.56 HG13 HG21 ' A' ' 87' ' ' THR . 76.9 mt -57.1 -37.78 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.092 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.467 HD12 HG22 ' B' ' 85' ' ' ILE . 16.6 mt -65.18 -53.19 48.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.963 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.04 -49.29 71.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.84 -56.91 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 60.5 p -55.0 -24.95 26.71 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 52.8 t80 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.947 -179.898 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.997 HD12 HD12 ' B' ' 75' ' ' LEU . 36.8 mt . . . . . 0 C--O 1.232 0.155 0 CA-C-O 120.755 0.312 . . . . 0.0 110.901 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 51.2 mt -66.78 -39.91 84.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.114 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 25.0 mt -66.29 -58.11 7.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -60.36 -31.7 70.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.639 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.43 -65.05 2.8 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.5 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.567 HG22 ' O ' ' B' ' 79' ' ' GLY . 90.1 t -56.37 -35.28 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.186 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 4.1 mmt -65.43 -47.15 77.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -39.07 92.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.101 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.602 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.54 5.7 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.425 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.9 t -55.17 -49.62 70.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.798 0.332 . . . . 0.0 111.146 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.66 -49.72 82.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.139 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.47 -35.32 84.88 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.427 ' OG1' HG13 ' B' ' 84' ' ' VAL . 91.3 m -68.76 -59.3 3.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.759 0.314 . . . . 0.0 111.127 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.09 -37.98 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.174 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 19.2 mt -65.17 -55.14 20.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.75 -48.9 69.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.889 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.7 -55.92 18.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.6 p -55.32 -24.5 29.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.817 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 19.8 t80 . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.926 -179.896 . . . . . . . . 0 0 . 1 . 005 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.997 HD12 HD12 ' A' ' 75' ' ' LEU . 20.4 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.775 0.321 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.26 -43.38 91.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.2 mm -65.97 -57.36 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.12 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -30.99 70.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.567 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.03 -65.05 2.75 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.533 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.639 HG22 ' O ' ' A' ' 79' ' ' GLY . 93.7 t -56.57 -35.27 44.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.823 0.344 . . . . 0.0 111.169 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 35.0 mmm -65.54 -47.71 74.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.49 -38.56 90.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.101 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.527 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.14 -56.2 5.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.476 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 94.6 t -54.91 -49.39 70.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.832 0.348 . . . . 0.0 111.128 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.475 HG22 HD12 ' B' ' 89' ' ' LEU . 74.7 mt -62.75 -49.98 81.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.56 -35.16 84.6 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.424 ' OG1' HG13 ' A' ' 84' ' ' VAL . 92.7 m -68.61 -58.48 4.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 65.3 mt -56.65 -37.74 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.19 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.475 HD12 HG22 ' B' ' 85' ' ' ILE . 16.7 mt -65.2 -53.53 43.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -55.03 -49.19 72.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.64 -56.81 14.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.135 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 23.0 t -55.19 -24.92 29.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.887 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 77.6 t80 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.908 -179.875 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.928 HD12 HD12 ' B' ' 75' ' ' LEU . 13.2 mt . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.773 0.32 . . . . 0.0 110.961 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.56 -44.11 90.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.135 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.93 -58.07 8.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.129 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.94 -30.51 70.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.573 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.21 -64.72 2.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.646 HG22 ' O ' ' B' ' 79' ' ' GLY . 88.8 t -56.73 -35.68 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.856 0.36 . . . . 0.0 111.144 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 11.2 mmt -65.6 -47.05 77.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.79 92.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.432 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.18 -56.48 5.68 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.485 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.1 t -55.02 -49.55 70.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.767 0.318 . . . . 0.0 111.088 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.79 -49.95 81.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -34.95 85.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.49 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 97.5 m -68.79 -59.77 2.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.73 0.3 . . . . 0.0 111.129 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.2 mt -54.93 -38.25 44.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.139 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 16.4 mt -65.05 -54.99 21.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.97 -49.34 69.01 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 66.5 mt -64.07 -56.33 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.107 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.4 t -54.65 -25.56 27.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.837 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 37.1 t80 . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.883 . . . . . . . . 0 0 . 1 . 006 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.928 HD12 HD12 ' A' ' 75' ' ' LEU . 12.3 mt . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 . . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.401 HD11 HD22 ' A' ' 75' ' ' LEU . 59.2 mt -66.54 -42.75 90.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.101 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.7 mm -66.07 -57.01 12.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -60.33 -31.28 70.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.646 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.88 -64.67 2.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.488 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.1 t -56.57 -35.52 45.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.831 0.348 . . . . 0.0 111.111 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.37 -47.32 76.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.57 91.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.6 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.14 -56.04 5.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.49 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 95.8 t -54.92 -49.06 73.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.806 0.336 . . . . 0.0 111.099 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.525 HG22 HD12 ' B' ' 89' ' ' LEU . 60.4 mt -63.13 -49.33 83.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.77 -35.69 87.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.421 ' OG1' HG13 ' A' ' 84' ' ' VAL . 88.4 m -68.87 -59.29 3.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.762 0.315 . . . . 0.0 111.131 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 73.8 mt -55.53 -38.43 49.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.131 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.525 HD12 HG22 ' B' ' 85' ' ' ILE . 23.0 mt -65.19 -53.44 44.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.881 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.1 -49.26 72.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.56 -57.2 12.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 52.3 p -54.91 -25.08 26.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.849 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 75.7 t80 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.904 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.786 HD12 HD12 ' B' ' 75' ' ' LEU . 4.6 mt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.812 0.339 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.2 mt -66.68 -44.97 89.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.193 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.1 mm -66.02 -57.06 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -61.42 -30.33 70.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.621 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.42 -64.21 3.07 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.653 HG22 ' O ' ' B' ' 79' ' ' GLY . 98.3 t -56.94 -35.95 48.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.808 0.337 . . . . 0.0 111.099 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.4 mmt -65.46 -47.14 77.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.873 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.85 -38.76 92.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.102 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.457 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.25 -56.5 5.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.6 t -54.86 -48.9 73.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.813 0.339 . . . . 0.0 111.171 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.1 mm -63.59 -48.14 88.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.151 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.66 -37.37 93.36 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.492 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.548 HG21 HG13 ' B' ' 88' ' ' ILE . 63.4 m -67.93 -58.65 4.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.758 0.314 . . . . 0.0 111.126 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.56 HG13 HG21 ' B' ' 87' ' ' THR . 77.6 mt -55.02 -37.87 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 27.2 mt -65.04 -55.84 16.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.5 tt -53.16 -49.19 67.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.939 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.8 mt -64.35 -56.11 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 12.8 t -53.16 -26.95 18.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 11.4 t80 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.907 -179.846 . . . . . . . . 0 0 . 1 . 007 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.786 HD12 HD12 ' A' ' 75' ' ' LEU . 12.9 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.781 0.325 . . . . 0.0 110.894 . . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.563 HD11 HD22 ' A' ' 75' ' ' LEU . 56.0 mt -65.95 -43.93 92.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.82 -58.11 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.109 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.44 -30.28 69.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.653 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.15 -64.25 3.08 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.498 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 79' ' ' GLY . 96.2 t -56.92 -35.82 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.83 0.347 . . . . 0.0 111.134 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 9.1 mmt -65.46 -47.01 77.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.897 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.13 -38.45 91.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.138 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.51 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.29 -56.57 5.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.481 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.514 HG23 ' O ' ' B' ' 80' ' ' VAL . 99.0 t -54.86 -48.84 73.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.853 0.359 . . . . 0.0 111.198 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.55 HG22 HD12 ' B' ' 89' ' ' LEU . 34.1 mm -63.74 -47.96 88.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.141 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.7 -37.3 93.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.56 HG21 HG13 ' A' ' 88' ' ' ILE . 61.5 m -68.26 -58.88 3.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.746 0.308 . . . . 0.0 111.12 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.548 HG13 HG21 ' A' ' 87' ' ' THR . 78.7 mt -54.79 -37.73 41.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.14 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.55 HD12 HG22 ' B' ' 85' ' ' ILE . 19.3 mt -65.33 -55.5 17.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.875 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -53.86 -48.13 70.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 67.6 mt -65.12 -55.34 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 57.1 p -57.06 -22.4 38.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 21.8 t80 . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.928 -179.892 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.554 HD22 HD11 ' B' ' 76' ' ' ILE . 13.7 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.82 0.343 . . . . 0.0 110.897 . . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 48.0 mt -65.89 -40.83 88.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 31.0 mt -66.2 -58.32 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -59.76 -31.12 69.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.64 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.66 -64.68 2.95 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.466 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.533 HG22 ' O ' ' B' ' 79' ' ' GLY . 67.3 t -56.4 -35.63 44.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.348 . . . . 0.0 111.173 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 13.9 mmt -65.38 -47.06 77.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.868 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.81 91.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.155 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.568 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.22 -56.78 5.49 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.5 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 80' ' ' VAL . 92.3 t -54.89 -49.51 69.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.775 0.321 . . . . 0.0 111.152 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.495 HG22 HD12 ' A' ' 89' ' ' LEU . 34.8 mm -63.03 -49.42 83.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.192 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.44 86.71 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.434 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.446 ' OG1' HG13 ' B' ' 84' ' ' VAL . 90.6 m -68.8 -58.79 3.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 111.17 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 64.7 mt -56.69 -37.91 55.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.074 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.495 HD12 HG22 ' A' ' 85' ' ' ILE . 32.1 mt -65.08 -53.62 42.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.407 ' HA ' HD22 ' A' ' 90' ' ' LEU . 0.4 OUTLIER -54.87 -49.41 71.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 62.4 mt -64.52 -56.92 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.131 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 53.7 p -55.04 -24.94 27.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 55.9 t80 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.944 -179.93 . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.813 0.34 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 008 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.554 HD11 HD22 ' A' ' 75' ' ' LEU . 58.0 mt -66.13 -43.96 91.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.9 mm -65.9 -57.94 8.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -60.7 -30.34 69.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.533 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.27 -64.67 2.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.48 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.64 HG22 ' O ' ' A' ' 79' ' ' GLY . 87.3 t -56.86 -35.79 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.824 0.345 . . . . 0.0 111.132 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.9 mmm -65.57 -46.99 77.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.871 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.99 -38.74 92.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.1 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.435 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.17 -56.62 5.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.479 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.507 HG23 ' O ' ' B' ' 80' ' ' VAL . 99.3 t -54.93 -49.64 68.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 111.109 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.629 HG22 HD12 ' B' ' 89' ' ' LEU . 34.4 mm -62.73 -49.79 82.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.1 -34.82 85.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.47 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 97.0 m -68.74 -58.73 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.795 0.331 . . . . 0.0 111.201 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 62.1 mt -56.55 -37.79 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.629 HD12 HG22 ' B' ' 85' ' ' ILE . 17.8 mt -65.29 -53.51 42.87 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -54.98 -49.07 72.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 62.9 mt -64.77 -56.74 14.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.149 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.4 m -55.25 -24.87 30.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 66.0 t80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.909 -179.893 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.972 HD12 HD12 ' B' ' 75' ' ' LEU . 26.0 mt . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.834 0.349 . . . . 0.0 110.933 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.8 mt -66.36 -42.97 91.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.109 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.6 mm -66.02 -57.77 9.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.123 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -60.32 -30.98 69.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.866 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.623 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.08 -64.89 2.81 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.56 HG22 ' O ' ' B' ' 79' ' ' GLY . 82.5 t -56.41 -35.2 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.809 0.338 . . . . 0.0 111.124 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 26.8 mmt -65.45 -47.84 74.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.28 89.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.113 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.585 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.05 5.97 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 93.6 t -54.83 -49.25 71.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.427 HG22 HD12 ' A' ' 89' ' ' LEU . 61.3 mt -62.71 -48.68 86.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.127 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.11 -37.45 91.69 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.475 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.525 HG21 HG13 ' B' ' 88' ' ' ILE . 39.1 m -67.94 -57.77 5.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.759 0.314 . . . . 0.0 111.169 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.458 HG13 HG21 ' B' ' 87' ' ' THR . 82.2 mt -55.55 -37.72 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.427 HD12 HG22 ' A' ' 85' ' ' ILE . 17.6 mt -65.21 -55.19 19.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.871 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.84 -48.74 69.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.939 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.73 -56.23 17.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 t -55.31 -24.49 28.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 23.1 t80 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.904 -179.865 . . . . . . . . 0 0 . 1 . 009 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.972 HD12 HD12 ' A' ' 75' ' ' LEU . 10.6 mt . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.758 0.313 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.2 mm -66.47 -43.02 91.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.148 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.5 mm -66.06 -58.0 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.65 -30.96 70.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.889 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.56 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.07 -65.03 2.75 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.524 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 79' ' ' GLY . 90.8 t -56.46 -35.35 43.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.347 . . . . 0.0 111.15 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.3 mmt -65.47 -47.65 75.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.39 90.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.039 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.516 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.08 -56.02 5.98 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.513 HG23 ' O ' ' B' ' 80' ' ' VAL . 94.4 t -54.89 -48.88 73.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.753 0.311 . . . . 0.0 111.124 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 84.7 mt -63.21 -47.94 89.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.76 -38.66 94.23 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.463 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.458 HG21 HG13 ' A' ' 88' ' ' ILE . 30.9 m -67.34 -58.75 4.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.805 0.336 . . . . 0.0 111.129 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.525 HG13 HG21 ' A' ' 87' ' ' THR . 78.7 mt -54.2 -37.61 36.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.086 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 24.6 mt -65.02 -56.26 14.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.06 -49.94 70.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.925 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 78.2 mt -60.33 -53.74 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.083 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 25.8 p -64.4 -15.48 60.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.976 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.591 HD22 ' CG1' ' B' ' 76' ' ' ILE . 14.2 mt . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.821 0.343 . . . . 0.0 110.955 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 36.4 mm -67.11 -39.95 84.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.134 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 30.7 mt -66.5 -59.04 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -60.71 -31.6 70.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.611 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.78 -64.91 2.83 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.507 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.533 ' O ' HG23 ' A' ' 84' ' ' VAL . 72.6 t -56.22 -34.88 40.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 111.124 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -65.42 -48.67 71.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.15 -38.7 90.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.082 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.599 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.07 -57.37 5.77 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.533 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.6 t -53.77 -50.54 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.817 0.342 . . . . 0.0 111.154 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.588 HG22 HD12 ' A' ' 89' ' ' LEU . 95.9 mt -60.41 -45.01 97.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.083 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.12 -37.35 91.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.462 HG21 HG13 ' B' ' 88' ' ' ILE . 0.7 OUTLIER -69.56 -58.33 4.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.785 0.326 . . . . 0.0 111.133 -179.859 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 77.0 mt -56.49 -37.96 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.06 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.588 HD12 HG22 ' A' ' 85' ' ' ILE . 17.3 mt -65.19 -54.48 29.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.964 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.87 -49.15 69.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.2 mt -64.85 -56.3 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 56.5 p -54.26 -25.51 23.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.84 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 39.4 t80 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.881 -179.83 . . . . . . . . 0 0 . 1 . 010 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.496 HD12 ' CD1' ' A' ' 75' ' ' LEU . 14.1 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.769 0.319 . . . . 0.0 110.91 . . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.591 ' CG1' HD22 ' A' ' 75' ' ' LEU . 53.4 mt -65.66 -44.16 93.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.146 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 18.8 mm -65.9 -57.02 12.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.32 -30.3 69.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.921 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.494 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.47 -64.4 2.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.4 t -56.68 -35.94 47.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.34 . . . . 0.0 111.117 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.1 mmt -65.69 -47.7 74.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.54 -39.49 91.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.43 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.87 -57.24 5.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.504 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.496 HG23 ' O ' ' B' ' 80' ' ' VAL . 93.3 t -55.1 -49.92 67.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.461 HG22 HD12 ' B' ' 89' ' ' LEU . 34.8 mm -62.37 -47.36 93.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.26 -38.92 91.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.455 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 19.8 m -68.2 -58.05 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.749 0.309 . . . . 0.0 111.16 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.462 HG13 HG21 ' A' ' 87' ' ' THR . 78.8 mt -55.1 -38.39 46.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.077 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.461 HD12 HG22 ' B' ' 85' ' ' ILE . 19.7 mt -65.18 -54.17 33.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.429 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -54.77 -48.81 72.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.932 . . . . . . . . 3 3 . 1 . 010 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.64 -56.72 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 13.2 t -54.87 -25.54 29.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.2 t80 . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.945 -179.934 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.767 0.318 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 011 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.547 ' CG1' HD22 ' B' ' 75' ' ' LEU . 57.6 mt -66.02 -41.96 90.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 23.9 mm -66.04 -57.03 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.144 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -60.03 -31.27 69.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.612 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.85 -64.61 2.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.501 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.599 HG22 ' O ' ' B' ' 79' ' ' GLY . 87.0 t -56.64 -35.39 45.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.835 0.35 . . . . 0.0 111.152 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.37 -47.41 76.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.894 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.38 90.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.115 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.555 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.1 -55.89 6.05 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.52 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 94.3 t -54.85 -48.75 73.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.804 0.335 . . . . 0.0 111.168 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.3 mt -63.54 -47.99 88.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.129 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.37 -37.3 92.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.536 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.576 HG21 HG13 ' B' ' 88' ' ' ILE . 48.4 m -68.22 -58.87 3.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.748 0.309 . . . . 0.0 111.142 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.569 HG13 HG21 ' B' ' 87' ' ' THR . 75.8 mt -54.91 -37.84 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 24.9 mt -65.14 -55.78 16.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.37 -49.17 67.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.3 mt -64.19 -55.9 19.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.176 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 23.3 t -53.2 -27.2 20.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 8.7 t80 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.888 -179.821 . . . . . . . . 0 0 . 1 . 011 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.547 HD22 ' CG1' ' A' ' 76' ' ' ILE . 9.8 mt . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.782 0.325 . . . . 0.0 110.894 . . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.8 mm -67.11 -43.35 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.5 mm -66.05 -58.01 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.077 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -61.33 -30.92 70.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.599 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.97 -64.67 2.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.485 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 79' ' ' GLY . 99.1 t -57.02 -35.69 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 0.0 111.091 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.9 mmm -65.49 -46.92 77.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.09 -38.8 92.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.516 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.13 -56.54 5.67 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.507 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.511 HG13 ' OG1' ' A' ' 87' ' ' THR . 97.9 t -54.84 -49.19 71.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.813 0.339 . . . . 0.0 111.163 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.508 HG22 HD12 ' B' ' 89' ' ' LEU . 33.9 mm -63.19 -48.72 86.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.24 90.32 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.451 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.569 HG21 HG13 ' A' ' 88' ' ' ILE . 90.9 m -68.41 -58.38 4.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.777 0.322 . . . . 0.0 111.1 -179.825 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.576 HG13 HG21 ' A' ' 87' ' ' THR . 75.7 mt -55.15 -38.77 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.508 HD12 HG22 ' B' ' 85' ' ' ILE . 17.9 mt -65.15 -53.41 45.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.916 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -55.08 -48.89 72.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.897 . . . . . . . . 3 3 . 1 . 011 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.6 mt -65.0 -56.86 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.098 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 7.4 t -54.89 -25.35 28.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.858 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 46.6 t80 . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.96 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.512 HD22 HD11 ' B' ' 76' ' ' ILE . 5.0 mt . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.827 0.346 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.46 ' O ' HG23 ' A' ' 80' ' ' VAL . 60.6 mt -66.53 -41.18 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 36.2 mt -66.11 -58.62 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.64 -30.84 70.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.7 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.74 -64.53 3.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.554 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.521 ' O ' HG23 ' A' ' 84' ' ' VAL . 42.0 t -56.74 -35.81 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 111.154 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.8 mmt -65.43 -46.93 78.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.875 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -39.18 93.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.578 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.8 -56.67 5.78 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.516 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 80' ' ' VAL . 94.7 t -55.2 -50.49 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.139 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.537 HG22 HD12 ' A' ' 89' ' ' LEU . 34.3 mm -61.53 -48.74 87.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.95 -39.5 95.68 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.458 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.551 HG21 HG13 ' B' ' 88' ' ' ILE . 74.9 m -64.8 -58.07 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.799 0.333 . . . . 0.0 111.143 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.9 mt -54.44 -42.3 58.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.13 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.537 HD12 HG22 ' A' ' 85' ' ' ILE . 12.9 mt -59.76 -54.75 42.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.38 -51.07 69.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.936 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -57.32 -59.54 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.169 179.825 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 80.4 p -53.67 -29.49 38.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 36.0 t80 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.937 -179.911 . . . . . . . . 0 0 . 1 . 012 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.401 HD22 HD11 ' A' ' 76' ' ' ILE . 5.9 mt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.82 0.343 . . . . 0.0 110.9 . . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.512 HD11 HD22 ' A' ' 75' ' ' LEU . 53.8 mt -65.04 -43.98 95.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.131 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 24.2 mm -65.75 -57.31 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -59.98 -30.07 68.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.497 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.41 -63.85 3.22 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.501 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.7 HG22 ' O ' ' A' ' 79' ' ' GLY . 99.1 t -56.99 -36.23 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.856 0.36 . . . . 0.0 111.158 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -47.08 77.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.886 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.67 -38.7 91.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.075 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.433 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.25 -56.52 5.63 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.474 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.4 t -54.84 -49.21 71.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.857 0.36 . . . . 0.0 111.194 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.46 HG22 HD12 ' B' ' 89' ' ' LEU . 83.2 mt -63.29 -49.23 83.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.081 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.08 -35.56 87.88 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.475 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.9 m -68.88 -59.28 3.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.755 0.312 . . . . 0.0 111.114 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.551 HG13 HG21 ' A' ' 87' ' ' THR . 76.2 mt -55.62 -38.44 50.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.46 HD12 HG22 ' B' ' 85' ' ' ILE . 26.4 mt -65.12 -53.12 50.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -55.44 -49.0 73.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.913 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.2 mt -64.88 -57.12 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.1 m -55.02 -25.26 29.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.845 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 29.2 t80 . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.884 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 1.054 HD12 HD12 ' B' ' 75' ' ' LEU . 15.9 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.771 0.319 . . . . 0.0 110.911 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 42.5 mm -66.52 -42.71 90.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 21.0 mm -66.03 -57.5 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.171 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -60.74 -31.03 70.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.881 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.09 -64.66 2.91 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.582 HG22 ' O ' ' B' ' 79' ' ' GLY . 90.2 t -56.74 -35.46 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.835 0.35 . . . . 0.0 111.097 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.7 mmt -65.48 -47.56 75.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.64 91.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.12 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.66 -56.84 5.76 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.534 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.1 t -54.84 -51.07 56.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.819 0.342 . . . . 0.0 111.149 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.7 mm -60.41 -50.23 81.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.133 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.73 -41.11 95.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.483 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.542 HG21 HG13 ' B' ' 88' ' ' ILE . 77.0 m -62.7 -59.08 5.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.783 0.325 . . . . 0.0 111.129 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.55 HG13 HG21 ' B' ' 87' ' ' THR . 79.4 mt -54.13 -43.92 61.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.3 mt -56.8 -51.04 70.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -59.52 -42.12 91.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.841 . . . . . . . . 3 3 . 1 . 013 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.6 mm -65.42 -63.85 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.181 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 2.2 t -51.53 -30.68 21.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 71.2 t80 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 -179.856 . . . . . . . . 0 0 . 1 . 013 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 1.054 HD12 HD12 ' A' ' 75' ' ' LEU . 17.9 mt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.744 0.307 . . . . 0.0 110.935 . . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 56.4 mt -68.03 -41.41 84.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.099 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.4 mm -66.31 -57.74 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.161 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -61.16 -31.73 71.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.582 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.79 -64.03 3.23 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.517 ' O ' HG23 ' B' ' 84' ' ' VAL . 57.8 t -56.84 -35.6 47.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.094 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.1 mmm -65.29 -47.42 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.857 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.16 90.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.557 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.22 -56.65 5.57 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.442 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 97.5 t -54.8 -48.81 73.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.785 0.326 . . . . 0.0 111.101 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.544 HG22 HD12 ' B' ' 89' ' ' LEU . 33.8 mm -63.52 -47.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.163 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.85 -37.78 93.05 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.504 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.55 HG21 HG13 ' A' ' 88' ' ' ILE . 27.5 m -68.79 -59.51 3.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.757 0.313 . . . . 0.0 111.159 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.542 HG13 HG21 ' A' ' 87' ' ' THR . 72.5 mt -54.92 -38.16 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.132 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.544 HD12 HG22 ' B' ' 85' ' ' ILE . 18.8 mt -65.15 -55.1 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.914 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.91 -48.91 69.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.92 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.0 mt -64.58 -56.32 16.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.162 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 59.1 m -54.15 -25.95 25.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 18.1 t80 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 -179.904 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.789 HD22 HD11 ' B' ' 76' ' ' ILE . 17.6 mt . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.78 0.324 . . . . 0.0 110.887 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.619 HD11 HD22 ' B' ' 75' ' ' LEU . 61.0 mt -66.37 -46.42 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.5 mm -65.73 -56.81 13.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.135 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -61.33 -29.86 70.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.499 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.31 -63.69 3.3 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.688 HG22 ' O ' ' B' ' 79' ' ' GLY . 98.3 t -57.47 -36.08 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.802 0.334 . . . . 0.0 111.114 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.44 -46.78 78.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.826 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.06 -38.85 92.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.137 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.44 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.04 -56.43 5.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.511 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 80' ' ' VAL . 95.6 t -55.16 -49.95 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.788 0.327 . . . . 0.0 111.133 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.0 mm -62.35 -49.93 81.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -36.17 88.86 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 96.8 m -67.55 -59.17 3.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.724 0.297 . . . . 0.0 111.148 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.2 mt -54.73 -40.04 49.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 14.5 mt -62.77 -56.41 17.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -52.7 -53.56 45.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.0 mt -59.58 -55.25 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.17 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.3 p -55.12 -25.45 31.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 3.7 t80 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.879 . . . . . . . . 0 0 . 1 . 014 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.619 HD22 HD11 ' A' ' 76' ' ' ILE . 6.2 mt . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.764 0.316 . . . . 0.0 110.9 . . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.789 HD11 HD22 ' A' ' 75' ' ' LEU . 59.9 mt -66.26 -44.66 91.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.5 mm -65.8 -57.17 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.2 t80 -60.47 -30.25 69.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.688 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.08 -63.44 3.45 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.501 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.515 ' O ' HG23 ' B' ' 84' ' ' VAL . 39.5 t -57.28 -36.04 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.155 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.3 mmt -65.38 -46.93 78.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.934 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.84 92.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.059 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.575 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.06 -56.33 5.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.474 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.515 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.7 t -54.95 -49.28 72.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.342 . . . . 0.0 111.133 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.505 HG22 HD12 ' B' ' 89' ' ' LEU . 77.6 mt -63.03 -49.4 83.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.171 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.5 -35.66 86.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.486 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.434 ' OG1' HG13 ' A' ' 84' ' ' VAL . 87.1 m -68.97 -58.67 3.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.753 0.311 . . . . 0.0 111.171 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.94 -37.91 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.505 HD12 HG22 ' B' ' 85' ' ' ILE . 16.9 mt -65.12 -53.25 48.13 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.92 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -49.41 71.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.64 -57.02 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.118 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 80.8 p -54.79 -25.18 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.843 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 43.7 t80 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 -179.879 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.495 ' CD1' HD12 ' B' ' 75' ' ' LEU . 5.0 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.805 0.336 . . . . 0.0 110.925 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.449 HD11 HD22 ' B' ' 75' ' ' LEU . 52.3 mt -66.02 -41.31 89.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.137 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 27.4 mt -66.1 -58.75 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -59.68 -31.06 69.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.913 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.623 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.81 -65.79 2.51 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.466 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.671 HG22 ' O ' ' B' ' 79' ' ' GLY . 99.0 t -55.46 -34.73 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.878 0.371 . . . . 0.0 111.13 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.9 mmt -65.31 -50.21 66.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.11 80.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.526 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.19 -55.36 6.29 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.465 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 80' ' ' VAL . 91.1 t -54.96 -49.99 66.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 111.139 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 1.7 mp -63.45 -47.83 89.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.15 -36.66 91.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.456 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.651 ' OG1' HG13 ' B' ' 84' ' ' VAL . 73.1 m -68.88 -58.73 3.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.775 0.322 . . . . 0.0 111.164 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.57 HG13 HG21 ' B' ' 87' ' ' THR . 72.1 mt -55.61 -38.47 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.9 mt -65.2 -53.41 45.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -55.0 -49.33 71.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.9 mt -64.58 -56.68 14.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 60.6 p -55.24 -24.97 30.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.88 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 26.7 t80 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.93 -179.872 . . . . . . . . 0 0 . 1 . 015 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.495 HD12 ' CD1' ' A' ' 75' ' ' LEU . 4.6 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.842 0.353 . . . . 0.0 110.947 . . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.433 HD11 HD22 ' A' ' 75' ' ' LEU . 36.6 mt -65.77 -43.33 93.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.126 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.2 mm -65.84 -58.03 8.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.1 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -60.15 -30.29 69.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.671 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.02 -63.83 3.28 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.439 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 79' ' ' GLY . 94.0 t -56.99 -35.81 48.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.808 0.337 . . . . 0.0 111.093 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.4 mmt -65.49 -47.12 77.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.849 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.71 -39.03 92.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.114 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.509 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.82 -56.82 5.68 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.651 HG13 ' OG1' ' A' ' 87' ' ' THR . 91.2 t -55.14 -50.65 62.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.802 0.334 . . . . 0.0 111.146 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.6 mm -61.61 -49.22 85.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -39.27 95.06 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.487 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.57 HG21 HG13 ' A' ' 88' ' ' ILE . 85.5 m -64.66 -58.01 7.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.757 0.313 . . . . 0.0 111.115 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.573 HG13 HG21 ' A' ' 87' ' ' THR . 76.4 mt -54.46 -43.17 62.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.13 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 14.9 mt -59.02 -53.76 54.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.44 -51.71 68.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 91' ' ' ILE . . . . . 0.401 HG22 ' N ' ' B' ' 92' ' ' SER . 0.8 OUTLIER -56.44 -59.61 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.86 . . . . . . . . 3 3 . 1 . 015 nuclear build core ' B' B ' 92' ' ' SER . . . . . 0.401 ' N ' HG22 ' B' ' 91' ' ' ILE . 30.9 t -56.34 -27.11 54.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 59.9 t80 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.918 -179.876 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 1.061 HD12 HD12 ' B' ' 75' ' ' LEU . 66.3 mt . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.746 0.307 . . . . 0.0 110.844 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 41.2 mm -66.3 -40.02 85.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 34.2 mt -66.24 -58.26 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.097 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -60.04 -31.44 69.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.867 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.537 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.76 -65.03 2.78 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.525 ' O ' HG23 ' A' ' 84' ' ' VAL . 99.4 t -56.15 -35.45 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.344 . . . . 0.0 111.122 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.39 -47.9 74.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.92 -38.91 90.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.527 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.11 -56.53 5.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.4 t -55.03 -49.33 72.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.844 0.354 . . . . 0.0 111.129 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.51 HG22 HD12 ' A' ' 89' ' ' LEU . 92.7 mt -62.75 -49.71 82.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.074 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.32 -35.66 85.73 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.479 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.426 ' OG1' HG13 ' B' ' 84' ' ' VAL . 86.7 m -68.67 -58.71 3.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.783 0.325 . . . . 0.0 111.154 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.8 mt -56.46 -37.78 53.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.51 HD12 HG22 ' A' ' 85' ' ' ILE . 22.3 mt -65.25 -53.54 42.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.941 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.06 -49.09 72.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.917 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.66 -56.66 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.151 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 54.4 p -55.56 -24.5 32.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.7 t80 . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.916 -179.857 . . . . . . . . 0 0 . 1 . 016 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 1.061 HD12 HD12 ' A' ' 75' ' ' LEU . 12.1 mt . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.825 0.345 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 41.6 mm -66.53 -40.14 85.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.094 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 29.2 mt -66.38 -57.86 8.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.125 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -60.52 -31.72 70.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.512 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.58 -64.03 3.26 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.507 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.537 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.2 t -56.78 -35.69 46.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 111.145 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 18.0 mmm -65.33 -47.02 77.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -39.05 93.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.093 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.513 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.05 -56.26 5.87 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.482 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.507 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.6 t -54.97 -49.54 70.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.793 0.33 . . . . 0.0 111.14 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.465 HG22 HD12 ' B' ' 89' ' ' LEU . 33.4 mm -62.72 -49.32 84.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.163 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.71 -35.69 87.1 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.496 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.1 m -68.64 -59.27 3.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.749 0.309 . . . . 0.0 111.126 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 67.5 mt -54.91 -37.95 43.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.465 HD12 HG22 ' B' ' 85' ' ' ILE . 29.0 mt -65.19 -55.44 18.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -53.83 -48.7 69.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.62 -54.68 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 42.8 t -53.76 -27.83 31.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.847 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 6.0 t80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.869 . . . . . . . . 0 0 . 1 . 017 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 1.051 HD12 HD12 ' B' ' 75' ' ' LEU . 29.0 mt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.78 0.324 . . . . 0.0 110.893 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.8 mm -66.52 -40.09 85.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.085 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 37.8 mt -66.33 -58.56 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -60.39 -31.57 70.49 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.897 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.526 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.65 -65.06 2.78 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.521 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.522 ' O ' HG23 ' A' ' 84' ' ' VAL . 72.0 t -56.24 -35.37 42.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 111.118 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 16.4 mtp -65.37 -47.4 76.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.69 -38.78 91.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.484 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.12 -56.48 5.71 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.8 t -55.0 -49.43 71.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.845 0.355 . . . . 0.0 111.158 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.439 HG22 HD12 ' A' ' 89' ' ' LEU . 33.8 mm -62.83 -48.66 87.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -37.8 93.09 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.401 ' OG1' HG13 ' B' ' 84' ' ' VAL . 62.6 m -67.25 -58.93 3.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.788 0.328 . . . . 0.0 111.138 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 78.4 mt -54.24 -38.64 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.152 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.439 HD12 HG22 ' A' ' 85' ' ' ILE . 15.5 mt -64.03 -55.81 19.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.36 -49.8 71.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 84.7 mt -60.51 -53.43 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 36.1 t -64.92 -14.92 61.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.913 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 1.051 HD12 HD12 ' A' ' 75' ' ' LEU . 11.4 mt . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.728 0.299 . . . . 0.0 110.912 . . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.8 mm -66.14 -42.63 91.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.161 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 16.9 mm -66.0 -57.23 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.24 -31.05 69.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.02 -64.52 2.98 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.468 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.526 HG22 ' O ' ' A' ' 79' ' ' GLY . 97.2 t -56.58 -35.55 45.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.817 0.342 . . . . 0.0 111.136 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.3 mmm -65.43 -47.38 76.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -38.75 91.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.503 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.2 -56.63 5.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.509 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.8 t -54.92 -49.54 69.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.853 0.359 . . . . 0.0 111.14 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.433 HG22 HD12 ' B' ' 89' ' ' LEU . 34.4 mm -62.76 -49.61 83.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.31 86.3 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.518 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 91.8 m -68.71 -58.78 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.775 0.321 . . . . 0.0 111.179 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 70.4 mt -56.02 -38.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.102 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.433 HD12 HG22 ' B' ' 85' ' ' ILE . 34.2 mt -65.28 -53.5 43.24 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.14 -49.06 72.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.5 mt -64.71 -56.79 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 28.4 t -55.27 -24.98 30.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.9 t80 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 -179.886 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.625 HD12 HD12 ' B' ' 75' ' ' LEU . 36.4 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.815 0.34 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.6 mt -67.62 -39.54 82.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.145 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.0 mt -66.35 -58.81 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -61.11 -31.68 71.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.443 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.42 -65.17 2.76 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.458 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.545 HG22 ' O ' ' B' ' 79' ' ' GLY . 77.2 t -56.46 -35.67 44.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.783 0.325 . . . . 0.0 111.116 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 10.8 mmt -65.41 -46.9 78.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.98 93.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.491 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.2 -56.48 5.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 80' ' ' VAL . 99.2 t -54.97 -49.02 74.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.865 0.364 . . . . 0.0 111.147 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.503 HG22 HD12 ' A' ' 89' ' ' LEU . 33.9 mm -63.41 -48.18 88.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.17 -37.38 92.82 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.488 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.554 HG21 HG13 ' B' ' 88' ' ' ILE . 57.4 m -68.0 -58.16 4.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.814 0.34 . . . . 0.0 111.165 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.583 HG13 HG21 ' B' ' 87' ' ' THR . 79.0 mt -55.5 -37.74 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.503 HD12 HG22 ' A' ' 85' ' ' ILE . 15.8 mt -65.19 -55.29 19.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.919 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -53.54 -48.94 68.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.919 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 62.0 mt -64.72 -56.38 16.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.2 t -54.22 -25.59 23.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 15.4 t80 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.916 -179.882 . . . . . . . . 0 0 . 1 . 018 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.625 HD12 HD12 ' A' ' 75' ' ' LEU . 24.8 mt . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.746 0.308 . . . . 0.0 110.906 . . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 76' ' ' ILE . . . . . 0.473 ' O ' HG23 ' B' ' 80' ' ' VAL . 53.6 mt -66.2 -40.44 86.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 29.8 mt -66.32 -57.89 8.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.115 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -60.15 -31.35 70.01 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.545 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.75 -64.81 2.88 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.463 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.516 ' O ' HG23 ' B' ' 84' ' ' VAL . 36.3 t -56.51 -35.52 44.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.794 0.33 . . . . 0.0 111.134 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.2 mmm -65.37 -47.59 75.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.834 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.66 -38.33 89.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.521 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.23 -56.12 5.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.45 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.516 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.1 t -54.93 -48.81 74.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 111.144 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.451 HG22 HD12 ' B' ' 89' ' ' LEU . 81.9 mt -63.61 -48.24 87.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.129 179.899 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.99 -37.05 92.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.583 HG21 HG13 ' A' ' 88' ' ' ILE . 54.7 m -68.46 -58.77 3.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.805 0.336 . . . . 0.0 111.202 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.554 HG13 HG21 ' A' ' 87' ' ' THR . 75.5 mt -55.7 -38.19 49.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.151 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.451 HD12 HG22 ' B' ' 85' ' ' ILE . 17.7 mt -65.13 -53.72 40.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.05 -49.08 72.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.959 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.4 mt -64.59 -56.99 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.165 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 50.0 p -55.18 -24.88 29.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 54.3 t80 . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.947 -179.926 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' A' A ' 75' ' ' LEU . . . . . 0.497 HD12 ' CD1' ' B' ' 75' ' ' LEU . 12.4 mt . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.783 0.325 . . . . 0.0 110.899 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.48 HD11 HD22 ' B' ' 75' ' ' LEU . 38.1 mt -66.27 -41.71 89.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.145 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.9 mm -66.06 -57.86 8.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.123 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -60.15 -31.27 69.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.595 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.66 -64.48 3.04 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.547 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.531 ' O ' HG23 ' A' ' 84' ' ' VAL . 65.7 t -56.56 -35.5 44.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.863 0.363 . . . . 0.0 111.172 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 17.2 mmm -65.29 -47.21 77.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.64 91.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.544 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.5 5.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 95.4 t -54.94 -49.34 71.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.161 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.6 mm -62.99 -47.62 91.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -61.09 -39.33 96.96 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.488 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 87' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 88' ' ' ILE . 54.1 m -65.96 -57.45 7.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.781 0.324 . . . . 0.0 111.139 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 88' ' ' ILE . . . . . 0.532 HG13 HG21 ' B' ' 87' ' ' THR . 79.0 mt -57.15 -45.55 84.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.1 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.47 -52.96 63.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.93 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' A' A ' 90' ' ' LEU . . . . . 0.406 ' HA ' HD22 ' A' ' 90' ' ' LEU . 0.4 OUTLIER -54.7 -55.81 25.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.908 179.871 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 74.8 mt -57.3 -59.42 3.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.7 p -53.07 -27.52 20.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.4 t80 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.949 -179.878 . . . . . . . . 0 0 . 1 . 019 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.497 ' CD1' HD12 ' A' ' 75' ' ' LEU . 10.7 mt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.812 0.339 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.1 mm -67.19 -44.4 87.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.082 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.1 mm -66.05 -57.7 9.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -61.45 -30.8 70.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.911 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.517 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.16 -64.5 2.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.506 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 79' ' ' GLY . 77.1 t -56.96 -35.83 48.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.789 0.328 . . . . 0.0 111.12 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 1.6 mmt -65.31 -47.21 77.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.49 91.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.107 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.454 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.31 -56.25 5.74 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.478 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.1 t -54.91 -48.85 74.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 111.121 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.5 mm -63.51 -48.6 86.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.7 92.03 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.526 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.532 HG21 HG13 ' A' ' 88' ' ' ILE . 90.0 m -68.12 -58.47 4.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.738 0.304 . . . . 0.0 111.186 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 88' ' ' ILE . . . . . 0.558 HG13 HG21 ' A' ' 87' ' ' THR . 75.7 mt -55.36 -37.88 46.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.132 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 28.7 mt -65.18 -55.06 20.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 90' ' ' LEU . . . . . 0.427 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -53.97 -48.97 69.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.87 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.6 mt -64.45 -56.23 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 13.6 t -54.46 -25.55 25.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.86 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 34.6 t80 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.948 -179.872 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 38.7 mt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.803 0.335 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 020 nuclear build core ' A' A ' 76' ' ' ILE . . . . . 0.457 HD11 HD22 ' B' ' 75' ' ' LEU . 37.4 mm -65.68 -48.39 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 77' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 78' ' ' PHE . 1.1 mp -65.32 -54.81 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 78' ' ' PHE . . . . . 0.401 ' N ' HG22 ' A' ' 77' ' ' ILE . 42.7 t80 -60.79 -30.91 70.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.891 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 79' ' ' GLY . . . . . 0.614 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.89 -64.06 3.07 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.496 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 80' ' ' VAL . . . . . 0.649 HG22 ' O ' ' B' ' 79' ' ' GLY . 95.6 t -57.0 -35.64 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 111.145 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.4 mmt -65.66 -47.61 74.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.867 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.95 -39.23 91.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 83' ' ' GLY . . . . . 0.546 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.97 -56.45 5.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.516 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 84' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 80' ' ' VAL . 93.7 t -54.94 -49.38 71.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.809 0.337 . . . . 0.0 111.153 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 85' ' ' ILE . . . . . 0.576 HG22 HD12 ' A' ' 89' ' ' LEU . 33.2 mm -62.52 -49.7 82.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.171 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -35.15 85.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.519 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.7 m -68.57 -59.6 3.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.153 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.9 mt -55.3 -37.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.101 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 89' ' ' LEU . . . . . 0.576 HD12 HG22 ' A' ' 85' ' ' ILE . 13.3 mt -65.12 -55.18 20.21 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.901 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.58 -49.01 68.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.943 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.2 mt -64.72 -55.77 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 67.3 m -53.97 -26.14 24.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 20.5 t80 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.941 -179.89 . . . . . . . . 0 0 . 1 . 020 nuclear build core ' B' B ' 75' ' ' LEU . . . . . 0.457 HD22 HD11 ' A' ' 76' ' ' ILE . 12.5 mt . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.763 0.316 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 37.2 mt -66.64 -41.13 87.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.106 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.6 mm -66.11 -56.83 12.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.165 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -31.87 70.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 79' ' ' GLY . . . . . 0.649 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.58 -65.05 2.79 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.515 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 80' ' ' VAL . . . . . 0.614 HG22 ' O ' ' A' ' 79' ' ' GLY . 88.1 t -56.68 -35.07 44.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 111.161 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -47.01 77.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.86 -38.89 92.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.085 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 83' ' ' GLY . . . . . 0.615 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.08 -56.39 5.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.509 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 84' ' ' VAL . . . . . 0.51 HG23 ' O ' ' B' ' 80' ' ' VAL . 97.6 t -54.86 -49.21 71.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.849 0.357 . . . . 0.0 111.119 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 85' ' ' ILE . . . . . 0.524 HG22 HD12 ' B' ' 89' ' ' LEU . 33.0 mm -62.96 -49.29 84.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.133 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.01 -35.31 86.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.495 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 87' ' ' THR . . . . . 0.422 ' OG1' HG13 ' A' ' 84' ' ' VAL . 84.8 m -68.91 -59.17 3.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.762 0.315 . . . . 0.0 111.115 -179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.3 mt -55.85 -38.09 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.135 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 89' ' ' LEU . . . . . 0.524 HD12 HG22 ' B' ' 85' ' ' ILE . 13.7 mt -65.25 -53.56 42.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.889 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -48.96 72.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.1 mt -64.86 -56.89 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.151 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 8.7 t -55.18 -24.94 29.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.834 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 76.4 t80 . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.883 -179.824 . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.9 pm0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.652 0.739 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 102.48 1.03 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.723 2.282 . . . . 0.0 112.331 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.542 ' HG2' HD13 ' B' ' 75' ' ' LEU . 0.5 OUTLIER -108.32 -57.96 2.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.915 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 80.1 mt -50.82 -31.53 10.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.8 m -63.96 -50.7 67.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.153 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.846 HD12 HD12 ' B' ' 75' ' ' LEU . 22.8 mt -64.44 -37.31 87.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.863 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 58.8 mt -65.95 -41.99 90.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.187 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.1 mm -66.15 -57.3 11.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.125 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.18 -31.22 69.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.587 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.95 -64.53 2.98 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.459 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.559 HG22 ' O ' ' B' ' 79' ' ' GLY . 78.5 t -56.52 -35.45 44.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.792 0.329 . . . . 0.0 111.111 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.0 mmt -65.4 -47.31 76.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.863 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.43 90.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.087 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.534 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.22 -56.59 5.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 80' ' ' VAL . 99.6 t -54.83 -49.05 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.802 0.334 . . . . 0.0 111.121 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.604 HG22 HD12 ' A' ' 89' ' ' LEU . 34.1 mm -63.44 -48.3 87.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.76 -36.11 91.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.49 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 88' ' ' ILE . 88.8 m -68.58 -58.35 4.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.83 0.348 . . . . 0.0 111.186 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.568 HG13 HG21 ' B' ' 87' ' ' THR . 70.8 mt -56.37 -37.98 53.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.604 HD12 HG22 ' A' ' 85' ' ' ILE . 15.7 mt -65.26 -53.45 44.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.962 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -55.0 -48.95 72.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.9 mt -64.96 -56.74 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.3 t -55.19 -24.8 28.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -70.21 -52.93 19.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.907 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 94' ' ' GLY . . . . . 0.475 ' O ' HD12 ' A' ' 98' ' ' LEU . . . -61.7 -26.35 66.73 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 44.0 mt -77.25 -27.68 16.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.861 0.363 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.4 -24.66 67.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.839 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 9.0 ttm180 -85.04 -36.58 21.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.475 HD12 ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.682 0.753 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 001 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 167.07 25.51 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.672 2.248 . . . . 0.0 112.343 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.556 ' HA ' HD13 ' A' ' 75' ' ' LEU . 4.8 mt-10 71.65 -69.45 0.18 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 45.0 mm -50.69 -30.76 8.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 85.3 m -65.89 -47.72 73.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.846 HD12 HD12 ' A' ' 75' ' ' LEU . 11.0 mt -66.24 -36.87 84.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.907 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.426 HD11 HD22 ' A' ' 75' ' ' LEU . 36.7 mm -66.97 -42.87 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.133 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.3 mm -66.04 -57.62 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.145 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -61.06 -31.03 70.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.559 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.04 -64.6 2.94 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.472 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 79' ' ' GLY . 97.2 t -56.87 -35.66 47.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.802 0.334 . . . . 0.0 111.102 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 42.7 mmm -65.3 -47.08 77.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.6 91.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.507 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.23 -56.41 5.7 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.513 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.6 t -54.89 -49.02 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.813 0.339 . . . . 0.0 111.122 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.619 HG22 HD12 ' B' ' 89' ' ' LEU . 34.0 mm -63.41 -48.34 87.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.17 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.8 -36.18 91.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.5 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.568 HG21 HG13 ' A' ' 88' ' ' ILE . 91.8 m -68.44 -57.51 5.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.775 0.321 . . . . 0.0 111.118 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.558 HG13 HG21 ' A' ' 87' ' ' THR . 76.6 mt -57.69 -37.6 60.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.619 HD12 HG22 ' B' ' 85' ' ' ILE . 16.4 mt -65.23 -53.01 50.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.923 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.2 -49.36 72.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.77 -56.8 14.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 29.8 t -55.16 -24.94 29.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 22.9 t80 -75.12 -50.92 14.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.911 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.89 -36.18 92.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.45 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.1 tt -75.69 -21.54 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.804 0.335 . . . . 0.0 111.136 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.05 -26.3 68.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -145.76 42.95 1.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.88 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 3.4 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.926 -179.973 . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.648 0.737 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 97.0 0.62 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.695 2.263 . . . . 0.0 112.313 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -164.08 -48.72 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.906 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 54.5 mt -50.62 -31.05 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.111 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.0 m -65.49 -48.17 73.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.126 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 1.027 HD12 HD12 ' B' ' 75' ' ' LEU . 25.1 mt -65.95 -37.07 85.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.4 mm -66.39 -43.02 91.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.155 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.0 mm -66.04 -57.74 9.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.1 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.56 -30.71 69.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.555 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.12 -64.29 3.07 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.474 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.6 HG22 ' O ' ' B' ' 79' ' ' GLY . 91.4 t -56.93 -35.5 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.808 0.337 . . . . 0.0 111.117 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 2.7 mmt -65.54 -47.43 75.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.83 92.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.068 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.511 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.7 -56.62 5.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.523 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.592 HG13 ' OG1' ' B' ' 87' ' ' THR . 99.2 t -54.94 -50.91 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.813 0.339 . . . . 0.0 111.154 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.3 mm -60.45 -50.56 79.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.78 -40.7 95.35 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.478 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.552 HG21 HG13 ' B' ' 88' ' ' ILE . 87.9 m -62.62 -59.02 5.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.728 0.299 . . . . 0.0 111.127 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.565 HG13 HG21 ' B' ' 87' ' ' THR . 77.8 mt -54.14 -44.2 62.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.145 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 12.7 mt -56.46 -51.12 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -59.53 -42.02 91.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.936 179.88 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.9 mm -65.53 -63.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.148 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 3.8 m -51.65 -30.55 22.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.87 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -70.69 -52.9 18.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.906 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.71 -25.67 74.96 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.509 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.6 mm -76.87 -29.88 17.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.345 . . . . 0.0 111.132 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -67.34 -56.45 9.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.879 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.22 43.92 0.47 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.865 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.94 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 121.672 0.749 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 002 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 136.63 33.45 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.663 2.242 . . . . 0.0 112.381 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.437 ' HA ' HD13 ' A' ' 75' ' ' LEU . 0.0 OUTLIER -126.21 -51.54 1.53 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.888 -179.998 . . . . . . . . 3 3 . 1 . 002 nuclear build full ' B' B ' 73' ' ' ILE . . . . . 0.633 HG22 HD11 ' B' ' 77' ' ' ILE . 4.4 mt -50.13 -33.57 9.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.149 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 94.5 m -63.29 -51.2 67.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.132 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 1.027 HD12 HD12 ' A' ' 75' ' ' LEU . 13.9 mt -62.35 -36.96 83.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.879 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.4 mm -67.08 -39.98 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.152 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 77' ' ' ILE . . . . . 0.633 HD11 HG22 ' B' ' 73' ' ' ILE . 26.9 mt -66.39 -58.49 6.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.097 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -60.8 -31.5 70.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.6 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.78 -64.92 2.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.432 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.555 HG22 ' O ' ' A' ' 79' ' ' GLY . 82.2 t -56.32 -35.34 42.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.776 0.322 . . . . 0.0 111.115 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 27.8 mmt -65.24 -47.93 75.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.879 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.87 -37.88 88.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.588 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.24 -55.8 6.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.477 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' B' ' 80' ' ' VAL . 92.8 t -54.78 -48.38 73.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.833 0.349 . . . . 0.0 111.146 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.503 HG22 HD12 ' B' ' 89' ' ' LEU . 61.9 mt -63.6 -48.45 86.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.154 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.19 -36.58 91.1 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.464 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.592 ' OG1' HG13 ' A' ' 84' ' ' VAL . 53.0 m -68.46 -58.22 4.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.32 . . . . 0.0 111.144 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.552 HG13 HG21 ' A' ' 87' ' ' THR . 72.6 mt -56.66 -37.8 54.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.136 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.503 HD12 HG22 ' B' ' 85' ' ' ILE . 18.2 mt -65.16 -53.54 43.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -54.97 -49.18 72.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.52 HG22 HD12 ' B' ' 95' ' ' ILE . 65.6 mt -64.67 -57.01 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 75.7 m -54.97 -25.08 27.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 38.3 t80 -71.17 -52.61 18.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.947 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -62.33 -30.88 77.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 95' ' ' ILE . . . . . 0.52 HD12 HG22 ' B' ' 91' ' ' ILE . 10.6 mt -76.52 -29.33 18.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.763 0.316 . . . . 0.0 111.145 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ttp180 -64.81 -25.67 68.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.857 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 13.1 ttm180 -145.01 43.35 1.33 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.842 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.889 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 121.621 0.724 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 90.01 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.695 2.263 . . . . 0.0 112.305 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -179.2 -49.28 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.894 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 5.4 mt -51.05 -30.29 9.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.103 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.6 m -64.69 -49.66 70.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.127 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.973 HD12 HD12 ' B' ' 75' ' ' LEU . 27.3 mt -66.0 -37.63 86.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.1 mm -66.44 -42.98 91.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.0 mm -65.97 -58.08 8.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.121 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.36 -30.94 69.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.577 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.98 -64.69 2.9 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.563 HG22 ' O ' ' B' ' 79' ' ' GLY . 80.5 t -56.48 -35.6 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 3.0 mmt -65.41 -47.16 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.05 -38.47 91.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.088 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.525 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.12 -56.66 5.61 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.461 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.5 t -54.9 -49.72 67.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.825 0.345 . . . . 0.0 111.134 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.71 -49.12 84.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.02 -35.61 87.79 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.477 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.427 ' OG1' HG13 ' B' ' 84' ' ' VAL . 86.7 m -68.57 -58.19 4.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.769 0.319 . . . . 0.0 111.098 -179.81 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.406 HG13 HG21 ' B' ' 87' ' ' THR . 67.2 mt -56.03 -38.28 52.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.115 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.5 mt -65.21 -53.39 45.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.1 -49.01 72.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.934 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.87 -56.71 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 34.6 t -55.2 -25.04 30.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -69.48 -51.71 33.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.93 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.61 -25.21 75.76 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.48 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.5 mm -75.68 -23.91 16.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.83 0.347 . . . . 0.0 111.102 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.52 -12.59 54.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.87 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -143.67 37.44 1.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 93.8 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.915 -179.99 . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 . . . . . 0 C--O 1.231 0.1 0 CA-C-O 121.663 0.744 . . . . 0.0 110.885 . . . . . . . . . 0 0 . 1 . 003 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 154.62 67.69 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.722 2.281 . . . . 0.0 112.349 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -125.11 -42.54 2.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 73' ' ' ILE . . . . . 0.634 HG22 HD11 ' B' ' 77' ' ' ILE . 4.3 mt -50.02 -33.73 9.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.101 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 93.5 m -62.96 -51.58 66.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.151 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.973 HD12 HD12 ' A' ' 75' ' ' LEU . 31.3 mt -62.21 -36.94 83.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 40.2 mm -66.54 -40.46 86.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 77' ' ' ILE . . . . . 0.634 HD11 HG22 ' B' ' 73' ' ' ILE . 25.7 mt -66.28 -58.39 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.117 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -60.58 -31.33 70.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.563 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.66 -64.7 2.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.515 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 79' ' ' GLY . 79.6 t -56.63 -35.1 44.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.839 0.352 . . . . 0.0 111.137 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.1 mtt -65.34 -48.04 74.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.37 90.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.534 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.62 -56.55 5.96 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.486 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.521 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.9 t -54.88 -51.16 55.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.794 0.331 . . . . 0.0 111.138 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.452 HG22 HD12 ' B' ' 89' ' ' LEU . 62.4 mt -60.13 -50.19 81.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.133 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.27 -41.15 94.8 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.421 ' OG1' HG13 ' A' ' 84' ' ' VAL . 56.0 m -62.67 -59.53 4.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.81 0.338 . . . . 0.0 111.162 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.04 -42.96 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.452 HD12 HG22 ' B' ' 85' ' ' ILE . 20.6 mt -57.48 -50.76 71.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.915 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.7 tt -59.56 -42.48 92.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 27.4 mm -65.42 -62.08 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.106 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 92' ' ' SER . . . . . 0.462 ' HA ' HG22 ' B' ' 95' ' ' ILE . 1.3 m -54.9 -26.1 33.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 83.6 t80 -72.47 -57.83 3.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.96 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -61.8 -36.32 92.58 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.457 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear build full ' B' B ' 95' ' ' ILE . . . . . 0.462 HG22 ' HA ' ' B' ' 92' ' ' SER . 5.2 tt -75.53 -18.51 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.851 0.357 . . . . 0.0 111.138 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.21 -42.15 93.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.831 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.78 -60.05 2.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.838 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.923 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 121.641 0.734 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 78.57 1.0 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.705 2.27 . . . . 0.0 112.344 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -83.47 -44.19 14.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.931 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 51.0 mm -50.68 -30.77 8.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.144 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.9 m -64.24 -50.12 69.25 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.137 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 1.078 HD12 HD12 ' B' ' 75' ' ' LEU . 16.8 mt -65.5 -37.51 87.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.865 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.5 mm -66.63 -41.89 88.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.166 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.6 mm -66.2 -57.99 8.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -60.59 -31.23 70.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.871 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.432 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.0 -63.9 3.26 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.513 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.529 ' O ' HG23 ' A' ' 84' ' ' VAL . 71.4 t -56.65 -35.93 46.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.868 0.366 . . . . 0.0 111.131 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 19.7 mtp -65.37 -47.31 76.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.847 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.11 -38.16 90.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.041 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.41 -56.73 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.478 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 80' ' ' VAL . 92.9 t -54.92 -48.91 74.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.811 0.339 . . . . 0.0 111.109 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.45 HG22 HD12 ' A' ' 89' ' ' LEU . 34.8 mm -63.94 -48.13 87.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.145 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.78 -36.76 92.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.51 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.56 HG21 HG13 ' B' ' 88' ' ' ILE . 84.4 m -68.54 -58.73 3.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 111.115 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.581 HG13 HG21 ' B' ' 87' ' ' THR . 80.0 mt -56.12 -37.7 50.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.45 HD12 HG22 ' A' ' 85' ' ' ILE . 15.1 mt -65.27 -54.25 32.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -54.4 -48.66 71.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.522 HG23 HD12 ' A' ' 95' ' ' ILE . 64.7 mt -65.11 -56.29 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.149 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 83.5 p -55.02 -25.11 27.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.85 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 57.8 t80 -65.14 -47.7 76.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -105.28 36.98 4.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.442 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.522 HD12 HG23 ' A' ' 91' ' ' ILE . 16.8 mt -156.5 -48.25 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.843 0.354 . . . . 0.0 111.185 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.79 -42.16 58.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.869 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -90.72 -40.91 11.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.83 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.676 0.751 . . . . 0.0 110.847 . . . . . . . . . 0 0 . 1 . 004 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -47.48 0.91 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.693 2.262 . . . . 0.0 112.32 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.468 ' HG2' HD11 ' A' ' 75' ' ' LEU . 53.9 mt-10 -53.54 -46.87 70.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.893 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 80.7 mt -50.96 -30.02 8.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.133 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 2.6 m -64.79 -49.34 71.08 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 1.078 HD12 HD12 ' A' ' 75' ' ' LEU . 10.1 mt -66.49 -37.87 86.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.916 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.3 mm -66.74 -42.4 89.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.169 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 17.3 mm -66.09 -57.86 8.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.112 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 45.8 t80 -60.64 -31.22 70.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.431 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.98 -64.04 3.19 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.472 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.517 ' O ' HG23 ' B' ' 84' ' ' VAL . 72.7 t -56.65 -35.85 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.824 0.345 . . . . 0.0 111.125 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.35 -47.4 76.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.98 -38.12 89.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.105 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.43 -56.64 5.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 93.7 t -54.97 -48.66 75.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.785 0.326 . . . . 0.0 111.134 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.467 HG22 HD12 ' B' ' 89' ' ' LEU . 34.6 mm -64.09 -48.05 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.113 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.92 -36.52 92.26 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.485 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.581 HG21 HG13 ' A' ' 88' ' ' ILE . 86.1 m -68.82 -58.27 4.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.75 0.309 . . . . 0.0 111.113 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.56 HG13 HG21 ' A' ' 87' ' ' THR . 76.9 mt -57.1 -37.78 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.092 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.467 HD12 HG22 ' B' ' 85' ' ' ILE . 16.6 mt -65.18 -53.19 48.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.963 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.04 -49.29 71.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.84 -56.91 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 60.5 p -55.0 -24.95 26.71 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -74.0 -51.44 15.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.947 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -70.11 -27.06 73.45 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.509 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.8 mm -76.48 -29.21 18.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.793 0.33 . . . . 0.0 111.1 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.87 -23.29 67.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.856 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.54 59.47 1.27 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.905 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 C--O 1.231 0.098 0 CA-C-O 121.663 0.744 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -179.46 2.92 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.682 2.254 . . . . 0.0 112.376 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.52 ' H ' HD13 ' B' ' 75' ' ' LEU . 34.4 mm-40 -140.03 101.83 4.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.867 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.76 HG22 HD11 ' A' ' 77' ' ' ILE . 2.9 mp -50.84 -35.85 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.075 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.7 m -58.5 -56.05 27.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.101 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.997 HD12 HD12 ' B' ' 75' ' ' LEU . 36.8 mt -60.72 -36.92 80.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.901 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.43 HD12 ' HA ' ' A' ' 73' ' ' ILE . 51.2 mt -66.78 -39.91 84.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.114 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.76 HD11 HG22 ' A' ' 73' ' ' ILE . 25.0 mt -66.29 -58.11 7.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -60.36 -31.7 70.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.639 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.43 -65.05 2.8 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.5 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.567 HG22 ' O ' ' B' ' 79' ' ' GLY . 90.1 t -56.37 -35.28 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.186 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 4.1 mmt -65.43 -47.15 77.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -39.07 92.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.101 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.602 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.54 5.7 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.425 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.9 t -55.17 -49.62 70.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.798 0.332 . . . . 0.0 111.146 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.66 -49.72 82.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.139 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.47 -35.32 84.88 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.427 ' OG1' HG13 ' B' ' 84' ' ' VAL . 91.3 m -68.76 -59.3 3.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.759 0.314 . . . . 0.0 111.127 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.09 -37.98 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.174 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 19.2 mt -65.17 -55.14 20.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.75 -48.9 69.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.889 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.523 ' CG2' HD12 ' A' ' 95' ' ' ILE . 65.9 mt -64.7 -55.92 18.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.6 p -55.32 -24.5 29.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.817 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -64.88 -43.97 91.18 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.926 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -109.85 37.38 3.8 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.452 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.523 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.3 mt -156.57 -52.44 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.161 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.13 -26.74 65.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.882 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -153.1 26.7 0.53 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 1.2 mt . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.95 -179.959 . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 121.66 0.743 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 005 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -178.24 2.26 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 69.11 -75.77 0.07 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.833 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 51.0 mm -51.04 -29.91 8.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.158 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 42.5 m -65.42 -48.85 71.38 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.122 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.997 HD12 HD12 ' A' ' 75' ' ' LEU . 20.4 mt -66.5 -37.44 85.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.92 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.26 -43.38 91.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.2 mm -65.97 -57.36 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.12 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -30.99 70.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.567 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.03 -65.05 2.75 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.533 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.639 HG22 ' O ' ' A' ' 79' ' ' GLY . 93.7 t -56.57 -35.27 44.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.823 0.344 . . . . 0.0 111.169 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 35.0 mmm -65.54 -47.71 74.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.49 -38.56 90.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.101 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.527 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.14 -56.2 5.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.476 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 94.6 t -54.91 -49.39 70.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.832 0.348 . . . . 0.0 111.128 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.475 HG22 HD12 ' B' ' 89' ' ' LEU . 74.7 mt -62.75 -49.98 81.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.56 -35.16 84.6 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.424 ' OG1' HG13 ' A' ' 84' ' ' VAL . 92.7 m -68.61 -58.48 4.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 65.3 mt -56.65 -37.74 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.19 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.475 HD12 HG22 ' B' ' 85' ' ' ILE . 16.7 mt -65.2 -53.53 43.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -55.03 -49.19 72.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.64 -56.81 14.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.135 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 23.0 t -55.19 -24.92 29.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.887 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -69.89 -51.82 29.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.908 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -77.69 -22.82 68.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.473 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.5 mm -76.54 -29.45 18.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.815 0.341 . . . . 0.0 111.134 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.85 -28.32 69.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.86 -61.15 1.78 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.882 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.935 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 121.666 0.746 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 78.8 0.99 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.664 2.242 . . . . 0.0 112.333 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.614 ' HB3' HD13 ' B' ' 75' ' ' LEU . 27.8 mt-10 -123.82 -44.03 2.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.891 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 50.7 mm -50.8 -30.79 9.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.113 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.3 m -62.4 -51.81 66.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.928 HD12 HD12 ' B' ' 75' ' ' LEU . 13.2 mt -66.17 -36.65 83.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.961 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.56 -44.11 90.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.135 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.93 -58.07 8.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.129 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.94 -30.51 70.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.573 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.21 -64.72 2.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.646 HG22 ' O ' ' B' ' 79' ' ' GLY . 88.8 t -56.73 -35.68 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.856 0.36 . . . . 0.0 111.144 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 11.2 mmt -65.6 -47.05 77.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.79 92.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.432 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.18 -56.48 5.68 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.485 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.1 t -55.02 -49.55 70.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.767 0.318 . . . . 0.0 111.088 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.79 -49.95 81.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -34.95 85.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.49 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 97.5 m -68.79 -59.77 2.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.73 0.3 . . . . 0.0 111.129 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.2 mt -54.93 -38.25 44.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.139 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 16.4 mt -65.05 -54.99 21.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.97 -49.34 69.01 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.576 ' CG2' HD12 ' A' ' 95' ' ' ILE . 66.5 mt -64.07 -56.33 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.107 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.4 t -54.65 -25.56 27.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.837 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -65.36 -42.72 92.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -109.32 38.85 3.13 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.515 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.576 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.3 mt -156.6 -49.91 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.839 0.352 . . . . 0.0 111.126 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.15 -26.43 59.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.872 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.01 -62.8 1.41 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.925 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.923 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 64.0 mt-10 . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.676 0.75 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 006 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 131.1 20.57 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.69 2.26 . . . . 0.0 112.346 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -111.36 -61.48 1.69 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 69.4 mt -51.17 -30.05 9.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.146 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 84.9 m -66.59 -46.75 74.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.928 HD12 HD12 ' A' ' 75' ' ' LEU . 12.3 mt -67.12 -37.97 84.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.401 HD11 HD22 ' A' ' 75' ' ' LEU . 59.2 mt -66.54 -42.75 90.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.101 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.7 mm -66.07 -57.01 12.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -60.33 -31.28 70.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.646 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.88 -64.67 2.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.488 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.1 t -56.57 -35.52 45.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.831 0.348 . . . . 0.0 111.111 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.37 -47.32 76.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.57 91.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.6 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.14 -56.04 5.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.49 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 95.8 t -54.92 -49.06 73.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.806 0.336 . . . . 0.0 111.099 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.525 HG22 HD12 ' B' ' 89' ' ' LEU . 60.4 mt -63.13 -49.33 83.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.77 -35.69 87.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.421 ' OG1' HG13 ' A' ' 84' ' ' VAL . 88.4 m -68.87 -59.29 3.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.762 0.315 . . . . 0.0 111.131 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 73.8 mt -55.53 -38.43 49.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.131 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.525 HD12 HG22 ' B' ' 85' ' ' ILE . 23.0 mt -65.19 -53.44 44.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.881 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.1 -49.26 72.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.56 -57.2 12.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 92' ' ' SER . . . . . 0.452 ' HA ' HG22 ' B' ' 95' ' ' ILE . 52.3 p -54.91 -25.08 26.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.849 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 75.7 t80 -74.53 -51.58 14.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -67.79 -35.04 84.5 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.483 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 95' ' ' ILE . . . . . 0.452 HG22 ' HA ' ' B' ' 92' ' ' SER . 5.7 tt -75.51 -16.96 15.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.82 0.343 . . . . 0.0 111.128 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.38 -13.79 62.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.869 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 45.5 ttm-85 -144.79 -67.46 0.32 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.845 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 121.619 0.723 . . . . 0.0 110.918 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 154.35 67.94 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.644 2.23 . . . . 0.0 112.328 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.42 ' HB3' HD13 ' B' ' 75' ' ' LEU . 39.3 mt-10 -102.93 -47.83 4.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.854 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 3.4 mt -53.75 -26.47 13.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.115 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.6 m -66.35 -48.75 69.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.122 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.786 HD12 HD12 ' B' ' 75' ' ' LEU . 4.6 mt -69.52 -38.96 77.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.2 mt -66.68 -44.97 89.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.193 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.1 mm -66.02 -57.06 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -61.42 -30.33 70.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.621 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.42 -64.21 3.07 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.653 HG22 ' O ' ' B' ' 79' ' ' GLY . 98.3 t -56.94 -35.95 48.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.808 0.337 . . . . 0.0 111.099 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.4 mmt -65.46 -47.14 77.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.873 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.85 -38.76 92.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.102 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.457 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.25 -56.5 5.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.6 t -54.86 -48.9 73.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.813 0.339 . . . . 0.0 111.171 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.1 mm -63.59 -48.14 88.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.151 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.66 -37.37 93.36 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.492 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.548 HG21 HG13 ' B' ' 88' ' ' ILE . 63.4 m -67.93 -58.65 4.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.758 0.314 . . . . 0.0 111.126 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.56 HG13 HG21 ' B' ' 87' ' ' THR . 77.6 mt -55.02 -37.87 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 27.2 mt -65.04 -55.84 16.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.5 tt -53.16 -49.19 67.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.939 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.595 ' CG2' HD12 ' A' ' 95' ' ' ILE . 63.8 mt -64.35 -56.11 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 12.8 t -53.16 -26.95 18.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -64.81 -36.08 83.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.907 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -114.5 40.19 2.55 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.501 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.595 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.5 mt -156.53 -52.13 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.825 0.345 . . . . 0.0 111.161 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -68.48 -44.94 73.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 5.4 ttm180 -95.26 27.28 3.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.829 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 3.1 mp . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.909 -179.972 . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 121.618 0.723 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 007 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -171.0 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.687 2.258 . . . . 0.0 112.325 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.464 ' HA ' HD13 ' A' ' 75' ' ' LEU . 0.6 OUTLIER -57.71 -44.0 85.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 50.9 mm -51.12 -30.44 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.168 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 81.8 m -63.88 -50.92 66.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.117 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.786 HD12 HD12 ' A' ' 75' ' ' LEU . 12.9 mt -65.75 -37.14 85.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.894 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.563 HD11 HD22 ' A' ' 75' ' ' LEU . 56.0 mt -65.95 -43.93 92.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 179.807 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.82 -58.11 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.109 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.44 -30.28 69.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.653 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.15 -64.25 3.08 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.498 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 79' ' ' GLY . 96.2 t -56.92 -35.82 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.83 0.347 . . . . 0.0 111.134 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 9.1 mmt -65.46 -47.01 77.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.897 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.13 -38.45 91.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.138 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.51 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.29 -56.57 5.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.481 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.514 HG23 ' O ' ' B' ' 80' ' ' VAL . 99.0 t -54.86 -48.84 73.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.853 0.359 . . . . 0.0 111.198 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.55 HG22 HD12 ' B' ' 89' ' ' LEU . 34.1 mm -63.74 -47.96 88.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.141 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.7 -37.3 93.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.56 HG21 HG13 ' A' ' 88' ' ' ILE . 61.5 m -68.26 -58.88 3.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.746 0.308 . . . . 0.0 111.12 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.548 HG13 HG21 ' A' ' 87' ' ' THR . 78.7 mt -54.79 -37.73 41.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.14 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.55 HD12 HG22 ' B' ' 85' ' ' ILE . 19.3 mt -65.33 -55.5 17.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.875 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -53.86 -48.13 70.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 67.6 mt -65.12 -55.34 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 57.1 p -57.06 -22.4 38.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 21.8 t80 -64.71 -54.82 25.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.928 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -162.24 67.37 0.24 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.463 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 16.1 mt -156.59 -45.88 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.805 0.336 . . . . 0.0 111.101 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mtm180 -64.94 -33.49 76.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.869 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -85.51 -61.54 1.74 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.857 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.623 0.725 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 008 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -171.2 0.45 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.672 2.248 . . . . 0.0 112.367 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -140.52 101.86 4.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.706 HG22 ' CD1' ' A' ' 77' ' ' ILE . 45.7 mm -51.03 -33.55 13.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.128 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.1 m -59.84 -56.74 18.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.146 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.554 HD22 HD11 ' B' ' 76' ' ' ILE . 13.7 mt -60.76 -36.92 80.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.897 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.469 HD12 ' HA ' ' A' ' 73' ' ' ILE . 48.0 mt -65.89 -40.83 88.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.706 ' CD1' HG22 ' A' ' 73' ' ' ILE . 31.0 mt -66.2 -58.32 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -59.76 -31.12 69.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.64 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.66 -64.68 2.95 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.466 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.533 HG22 ' O ' ' B' ' 79' ' ' GLY . 67.3 t -56.4 -35.63 44.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.348 . . . . 0.0 111.173 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 13.9 mmt -65.38 -47.06 77.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.868 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.81 91.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.155 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.568 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.22 -56.78 5.49 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.5 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 80' ' ' VAL . 92.3 t -54.89 -49.51 69.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.775 0.321 . . . . 0.0 111.152 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.495 HG22 HD12 ' A' ' 89' ' ' LEU . 34.8 mm -63.03 -49.42 83.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.192 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.44 86.71 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.434 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.446 ' OG1' HG13 ' B' ' 84' ' ' VAL . 90.6 m -68.8 -58.79 3.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 111.17 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 64.7 mt -56.69 -37.91 55.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.074 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.495 HD12 HG22 ' A' ' 85' ' ' ILE . 32.1 mt -65.08 -53.62 42.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.407 ' HA ' HD22 ' A' ' 90' ' ' LEU . 0.4 OUTLIER -54.87 -49.41 71.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 62.4 mt -64.52 -56.92 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.131 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 53.7 p -55.04 -24.94 27.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 55.9 t80 -70.74 -51.91 24.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.944 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -58.27 -40.45 93.96 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.477 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.9 mt -75.18 -21.74 16.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 0.0 111.132 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -14.89 59.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 15.2 ttm180 -144.18 -69.8 0.31 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.846 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.937 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.699 0.761 . . . . 0.0 110.897 . . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 82.12 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.654 2.236 . . . . 0.0 112.328 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.408 ' HA ' HD13 ' A' ' 75' ' ' LEU . 33.8 mt-10 -115.77 -49.21 2.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.0 mt -51.1 -30.42 9.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.088 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 22.3 m -64.2 -50.35 68.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.184 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 5.7 mt -66.0 -36.99 84.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.554 HD11 HD22 ' A' ' 75' ' ' LEU . 58.0 mt -66.13 -43.96 91.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.9 mm -65.9 -57.94 8.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -60.7 -30.34 69.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.533 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.27 -64.67 2.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.48 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.64 HG22 ' O ' ' A' ' 79' ' ' GLY . 87.3 t -56.86 -35.79 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.824 0.345 . . . . 0.0 111.132 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.9 mmm -65.57 -46.99 77.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.871 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.99 -38.74 92.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.1 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.435 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.17 -56.62 5.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.479 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.507 HG23 ' O ' ' B' ' 80' ' ' VAL . 99.3 t -54.93 -49.64 68.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 111.109 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.629 HG22 HD12 ' B' ' 89' ' ' LEU . 34.4 mm -62.73 -49.79 82.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.1 -34.82 85.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.47 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 97.0 m -68.74 -58.73 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.795 0.331 . . . . 0.0 111.201 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 62.1 mt -56.55 -37.79 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.629 HD12 HG22 ' B' ' 85' ' ' ILE . 17.8 mt -65.29 -53.51 42.87 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -54.98 -49.07 72.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 62.9 mt -64.77 -56.74 14.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.149 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.4 m -55.25 -24.87 30.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 66.0 t80 -69.74 -51.74 31.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.909 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.59 -22.4 75.12 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.485 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 mm -76.66 -27.96 17.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 0.0 111.118 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 1.9 ttp180 -80.64 24.07 0.49 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 6.4 ttm180 -149.43 -48.43 0.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.867 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 121.662 0.744 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 139.91 41.45 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.69 2.26 . . . . 0.0 112.377 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -108.11 -48.75 3.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.867 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 79.3 mt -51.27 -29.84 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.141 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.9 m -66.22 -48.0 72.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.141 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.972 HD12 HD12 ' B' ' 75' ' ' LEU . 26.0 mt -66.5 -37.69 85.6 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.933 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.8 mt -66.36 -42.97 91.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.109 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.6 mm -66.02 -57.77 9.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.123 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -60.32 -30.98 69.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.866 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.623 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.08 -64.89 2.81 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.56 HG22 ' O ' ' B' ' 79' ' ' GLY . 82.5 t -56.41 -35.2 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.809 0.338 . . . . 0.0 111.124 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 26.8 mmt -65.45 -47.84 74.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.28 89.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.113 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.585 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.05 5.97 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 93.6 t -54.83 -49.25 71.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.427 HG22 HD12 ' A' ' 89' ' ' LEU . 61.3 mt -62.71 -48.68 86.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.127 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.11 -37.45 91.69 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.475 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.525 HG21 HG13 ' B' ' 88' ' ' ILE . 39.1 m -67.94 -57.77 5.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.759 0.314 . . . . 0.0 111.169 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.458 HG13 HG21 ' B' ' 87' ' ' THR . 82.2 mt -55.55 -37.72 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.427 HD12 HG22 ' A' ' 85' ' ' ILE . 17.6 mt -65.21 -55.19 19.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.871 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.84 -48.74 69.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.939 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.677 ' CG2' HD12 ' A' ' 95' ' ' ILE . 65.9 mt -64.73 -56.23 17.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 t -55.31 -24.49 28.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -65.1 -45.16 86.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.904 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -110.66 40.58 2.5 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.677 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.3 mt -156.58 -48.21 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.834 0.349 . . . . 0.0 111.131 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.14 -27.97 59.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.861 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 23.4 ttm180 -86.27 -42.54 13.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.902 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 121.638 0.732 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 009 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 78.89 0.98 Allowed 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.694 2.263 . . . . 0.0 112.34 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -106.58 -43.76 4.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 2.8 mt -50.69 -30.87 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 9.5 m -65.3 -49.07 70.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.141 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.972 HD12 HD12 ' A' ' 75' ' ' LEU . 10.6 mt -65.48 -36.68 84.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.2 mm -66.47 -43.02 91.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.148 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.5 mm -66.06 -58.0 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.65 -30.96 70.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.889 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.56 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.07 -65.03 2.75 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.524 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 79' ' ' GLY . 90.8 t -56.46 -35.35 43.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.347 . . . . 0.0 111.15 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.3 mmt -65.47 -47.65 75.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.39 90.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.039 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.516 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.08 -56.02 5.98 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.513 HG23 ' O ' ' B' ' 80' ' ' VAL . 94.4 t -54.89 -48.88 73.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.753 0.311 . . . . 0.0 111.124 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 84.7 mt -63.21 -47.94 89.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.76 -38.66 94.23 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.463 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.458 HG21 HG13 ' A' ' 88' ' ' ILE . 30.9 m -67.34 -58.75 4.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.805 0.336 . . . . 0.0 111.129 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.525 HG13 HG21 ' A' ' 87' ' ' THR . 78.7 mt -54.2 -37.61 36.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.086 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 24.6 mt -65.02 -56.26 14.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.06 -49.94 70.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.925 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 78.2 mt -60.33 -53.74 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.083 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 25.8 p -64.4 -15.48 60.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -63.43 -19.23 64.52 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.976 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 130.23 33.56 0.49 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 mm -77.8 -27.97 15.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 111.156 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -64.47 -26.44 68.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear build full ' B' B ' 97' ' ' ARG . . . . . 0.714 ' O ' HD23 ' B' ' 98' ' ' LEU . 0.8 OUTLIER -85.41 -65.56 1.0 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.822 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear build full ' B' B ' 98' ' ' LEU . . . . . 0.714 HD23 ' O ' ' B' ' 97' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.918 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.616 0.722 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -171.06 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.713 2.275 . . . . 0.0 112.389 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.401 ' HB3' HD12 ' A' ' 75' ' ' LEU . 10.9 tt0 -137.96 103.45 4.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.901 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.738 HG22 HD11 ' A' ' 77' ' ' ILE . 2.9 mp -49.67 -33.94 8.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.188 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 4.5 m -60.08 -54.64 43.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.106 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.591 HD22 ' CG1' ' B' ' 76' ' ' ILE . 14.2 mt -61.92 -37.03 83.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.955 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 36.4 mm -67.11 -39.95 84.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.134 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.738 HD11 HG22 ' A' ' 73' ' ' ILE . 30.7 mt -66.5 -59.04 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -60.71 -31.6 70.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.611 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.78 -64.91 2.83 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.507 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.533 ' O ' HG23 ' A' ' 84' ' ' VAL . 72.6 t -56.22 -34.88 40.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 111.124 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -65.42 -48.67 71.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.15 -38.7 90.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.082 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.599 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.07 -57.37 5.77 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.533 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.6 t -53.77 -50.54 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.817 0.342 . . . . 0.0 111.154 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.588 HG22 HD12 ' A' ' 89' ' ' LEU . 95.9 mt -60.41 -45.01 97.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.083 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.12 -37.35 91.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.462 HG21 HG13 ' B' ' 88' ' ' ILE . 0.7 OUTLIER -69.56 -58.33 4.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.785 0.326 . . . . 0.0 111.133 -179.859 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 77.0 mt -56.49 -37.96 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.06 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.588 HD12 HG22 ' A' ' 85' ' ' ILE . 17.3 mt -65.19 -54.48 29.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.964 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.87 -49.15 69.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.518 ' CG2' HD12 ' A' ' 95' ' ' ILE . 64.2 mt -64.85 -56.3 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 56.5 p -54.26 -25.51 23.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.84 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -64.94 -43.7 91.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.881 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -108.54 36.24 4.48 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.481 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.518 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.8 mt -156.47 -52.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.801 0.334 . . . . 0.0 111.129 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.45 -31.05 69.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.854 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -147.35 26.98 1.04 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 4.7 mp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.932 -179.982 . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 121.671 0.748 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 010 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 -177.04 1.7 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.657 2.238 . . . . 0.0 112.338 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.483 ' HA ' HD13 ' A' ' 75' ' ' LEU . 0.0 OUTLIER 69.26 -75.36 0.07 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.871 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 50.9 mm -51.56 -29.85 10.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 23.5 m -62.69 -52.54 62.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.16 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.496 HD12 ' CD1' ' A' ' 75' ' ' LEU . 14.1 mt -66.31 -37.52 85.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.91 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.591 ' CG1' HD22 ' A' ' 75' ' ' LEU . 53.4 mt -65.66 -44.16 93.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.146 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 18.8 mm -65.9 -57.02 12.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.32 -30.3 69.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.921 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.494 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.47 -64.4 2.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.4 t -56.68 -35.94 47.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.34 . . . . 0.0 111.117 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.1 mmt -65.69 -47.7 74.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.54 -39.49 91.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.43 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.87 -57.24 5.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.504 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.496 HG23 ' O ' ' B' ' 80' ' ' VAL . 93.3 t -55.1 -49.92 67.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.461 HG22 HD12 ' B' ' 89' ' ' LEU . 34.8 mm -62.37 -47.36 93.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.26 -38.92 91.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.455 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 19.8 m -68.2 -58.05 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.749 0.309 . . . . 0.0 111.16 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.462 HG13 HG21 ' A' ' 87' ' ' THR . 78.8 mt -55.1 -38.39 46.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.077 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.461 HD12 HG22 ' B' ' 85' ' ' ILE . 19.7 mt -65.18 -54.17 33.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.429 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -54.77 -48.81 72.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.932 . . . . . . . . 3 3 . 1 . 010 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.64 -56.72 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 92' ' ' SER . . . . . 0.46 ' HA ' HG22 ' B' ' 95' ' ' ILE . 13.2 t -54.87 -25.54 29.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.2 t80 -75.19 -47.62 27.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.945 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -73.01 -31.39 61.92 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.502 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 95' ' ' ILE . . . . . 0.46 HG22 ' HA ' ' B' ' 92' ' ' SER . 5.4 tt -75.55 -23.59 16.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.884 0.373 . . . . 0.0 111.161 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.91 -25.42 67.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 10.2 ttm180 -147.44 41.14 1.04 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.891 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 121.643 0.735 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -46.52 1.19 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.682 2.255 . . . . 0.0 112.343 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.525 ' HA ' HD13 ' B' ' 75' ' ' LEU . 5.6 mt-10 71.57 -69.26 0.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.441 ' HA ' HD12 ' A' ' 76' ' ' ILE . 50.0 mm -50.31 -34.28 11.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.117 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 94.5 m -62.75 -50.29 71.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.611 HD13 ' HA ' ' B' ' 72' ' ' GLU . 14.8 mt -63.13 -36.76 84.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.928 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.547 ' CG1' HD22 ' B' ' 75' ' ' LEU . 57.6 mt -66.02 -41.96 90.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 23.9 mm -66.04 -57.03 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.144 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -60.03 -31.27 69.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.612 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.85 -64.61 2.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.501 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.599 HG22 ' O ' ' B' ' 79' ' ' GLY . 87.0 t -56.64 -35.39 45.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.835 0.35 . . . . 0.0 111.152 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.37 -47.41 76.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.894 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.38 90.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.115 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.555 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.1 -55.89 6.05 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.52 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 94.3 t -54.85 -48.75 73.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.804 0.335 . . . . 0.0 111.168 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.3 mt -63.54 -47.99 88.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.129 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.37 -37.3 92.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.536 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.576 HG21 HG13 ' B' ' 88' ' ' ILE . 48.4 m -68.22 -58.87 3.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.748 0.309 . . . . 0.0 111.142 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.569 HG13 HG21 ' B' ' 87' ' ' THR . 75.8 mt -54.91 -37.84 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 24.9 mt -65.14 -55.78 16.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.37 -49.17 67.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.489 HG22 HD12 ' A' ' 95' ' ' ILE . 65.3 mt -64.19 -55.9 19.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.176 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 23.3 t -53.2 -27.2 20.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -64.91 -32.79 74.67 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.888 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -113.94 45.16 1.35 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.465 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.489 HD12 HG22 ' A' ' 91' ' ' ILE . 16.7 mt -156.45 -40.5 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.893 0.377 . . . . 0.0 111.203 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.4 ptm180 -64.47 -25.42 67.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.862 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 9.8 ttp85 -87.55 -39.73 14.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.872 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.934 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 . . . . . 0 C--O 1.232 0.146 0 CA-C-O 121.627 0.727 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 011 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 165.38 31.09 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.742 2.295 . . . . 0.0 112.324 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.611 ' HA ' HD13 ' A' ' 75' ' ' LEU . 3.2 mt-10 71.57 -69.44 0.18 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.7 mt -50.15 -31.69 8.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.116 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 94.4 m -65.76 -47.16 76.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.2 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.547 HD22 ' CG1' ' A' ' 76' ' ' ILE . 9.8 mt -66.09 -36.56 83.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.8 mm -67.11 -43.35 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.5 mm -66.05 -58.01 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.077 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -61.33 -30.92 70.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.599 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.97 -64.67 2.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.485 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 79' ' ' GLY . 99.1 t -57.02 -35.69 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 0.0 111.091 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.9 mmm -65.49 -46.92 77.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.09 -38.8 92.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.516 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.13 -56.54 5.67 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.507 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.511 HG13 ' OG1' ' A' ' 87' ' ' THR . 97.9 t -54.84 -49.19 71.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.813 0.339 . . . . 0.0 111.163 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.508 HG22 HD12 ' B' ' 89' ' ' LEU . 33.9 mm -63.19 -48.72 86.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.24 90.32 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.451 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.569 HG21 HG13 ' A' ' 88' ' ' ILE . 90.9 m -68.41 -58.38 4.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.777 0.322 . . . . 0.0 111.1 -179.825 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.576 HG13 HG21 ' A' ' 87' ' ' THR . 75.7 mt -55.15 -38.77 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.508 HD12 HG22 ' B' ' 85' ' ' ILE . 17.9 mt -65.15 -53.41 45.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.916 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -55.08 -48.89 72.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.897 . . . . . . . . 3 3 . 1 . 011 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.6 mt -65.0 -56.86 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.098 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 7.4 t -54.89 -25.35 28.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.858 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 46.6 t80 -68.16 -50.92 51.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -80.74 -19.32 68.31 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.511 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.8 mm -77.12 -27.54 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.846 0.355 . . . . 0.0 111.107 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -64.47 -25.6 68.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 30.9 ttm180 -145.04 41.45 1.28 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 121.638 0.733 . . . . 0.0 110.907 . . . . . . . . . 0 0 . 1 . 012 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -32.07 19.14 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.651 2.234 . . . . 0.0 112.371 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.489 ' HA ' HD13 ' B' ' 75' ' ' LEU . 8.7 tt0 -58.78 -63.96 1.11 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.605 HG22 HD11 ' A' ' 77' ' ' ILE . 47.2 mm -50.47 -31.79 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.134 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 33.5 m -64.32 -50.61 67.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.16 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.512 HD22 HD11 ' B' ' 76' ' ' ILE . 5.0 mt -63.59 -37.31 86.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.902 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.46 ' O ' HG23 ' A' ' 80' ' ' VAL . 60.6 mt -66.53 -41.18 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.605 HD11 HG22 ' A' ' 73' ' ' ILE . 36.2 mt -66.11 -58.62 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.141 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.64 -30.84 70.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.7 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.74 -64.53 3.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.554 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.521 ' O ' HG23 ' A' ' 84' ' ' VAL . 42.0 t -56.74 -35.81 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 111.154 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.8 mmt -65.43 -46.93 78.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.875 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -39.18 93.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.578 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.8 -56.67 5.78 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.516 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 80' ' ' VAL . 94.7 t -55.2 -50.49 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.139 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.537 HG22 HD12 ' A' ' 89' ' ' LEU . 34.3 mm -61.53 -48.74 87.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.95 -39.5 95.68 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.458 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.551 HG21 HG13 ' B' ' 88' ' ' ILE . 74.9 m -64.8 -58.07 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.799 0.333 . . . . 0.0 111.143 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.9 mt -54.44 -42.3 58.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.13 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.537 HD12 HG22 ' A' ' 85' ' ' ILE . 12.9 mt -59.76 -54.75 42.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.38 -51.07 69.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.936 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.758 HG23 HD12 ' A' ' 95' ' ' ILE . 0.8 OUTLIER -57.32 -59.54 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.169 179.825 . . . . . . . . 3 3 . 1 . 012 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 80.4 p -53.67 -29.49 38.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 36.0 t80 -65.03 -43.32 92.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.937 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -107.0 35.22 5.17 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.494 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.758 HD12 HG23 ' A' ' 91' ' ' ILE . 16.0 mt -156.57 -52.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.858 0.361 . . . . 0.0 111.157 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.77 -37.33 62.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.876 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.4 tpp180 -92.3 -50.09 5.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.881 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.145 0 CA-C-O 121.657 0.741 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 174.89 8.85 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.71 2.273 . . . . 0.0 112.343 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.428 ' HA ' HD13 ' A' ' 75' ' ' LEU . 10.9 pt-20 -126.07 -45.15 1.72 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.898 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 73' ' ' ILE . . . . . 0.515 ' HA ' HD12 ' B' ' 76' ' ' ILE . 2.7 mp -50.99 -32.85 12.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.107 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 27.2 m -61.74 -52.96 62.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.172 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.489 HD13 ' HA ' ' A' ' 72' ' ' GLU . 5.9 mt -63.45 -36.39 83.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.515 HD12 ' HA ' ' B' ' 73' ' ' ILE . 53.8 mt -65.04 -43.98 95.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.131 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 24.2 mm -65.75 -57.31 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -59.98 -30.07 68.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.497 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.41 -63.85 3.22 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.501 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.7 HG22 ' O ' ' A' ' 79' ' ' GLY . 99.1 t -56.99 -36.23 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.856 0.36 . . . . 0.0 111.158 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -47.08 77.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.886 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.67 -38.7 91.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.075 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.433 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.25 -56.52 5.63 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.474 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.4 t -54.84 -49.21 71.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.857 0.36 . . . . 0.0 111.194 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.46 HG22 HD12 ' B' ' 89' ' ' LEU . 83.2 mt -63.29 -49.23 83.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.081 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.08 -35.56 87.88 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.475 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.9 m -68.88 -59.28 3.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.755 0.312 . . . . 0.0 111.114 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.551 HG13 HG21 ' A' ' 87' ' ' THR . 76.2 mt -55.62 -38.44 50.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.46 HD12 HG22 ' B' ' 85' ' ' ILE . 26.4 mt -65.12 -53.12 50.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -55.44 -49.0 73.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.913 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.2 mt -64.88 -57.12 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.1 m -55.02 -25.26 29.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.845 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -75.13 -51.37 13.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.472 ' O ' HD12 ' B' ' 98' ' ' LEU . . . -62.67 -37.53 94.94 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.4 tt -75.77 -21.25 15.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.838 0.351 . . . . 0.0 111.149 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.01 -27.78 69.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 16.4 ttm180 -87.04 -34.47 19.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear build full ' B' B ' 98' ' ' LEU . . . . . 0.472 HD12 ' O ' ' B' ' 94' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.942 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.424 ' HG2' HG21 ' A' ' 74' ' ' THR . 38.4 mt-10 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 121.641 0.734 . . . . 0.0 110.945 . . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -43.29 2.76 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.678 2.252 . . . . 0.0 112.374 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.671 ' HG3' HD13 ' B' ' 75' ' ' LEU . 5.9 tt0 -177.74 -51.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.913 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 51.0 mm -50.54 -30.93 8.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.102 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 74' ' ' THR . . . . . 0.424 HG21 ' HG2' ' A' ' 70' ' ' GLU . 89.9 m -65.44 -48.53 72.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.111 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 1.054 HD12 HD12 ' B' ' 75' ' ' LEU . 15.9 mt -65.79 -36.94 84.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.911 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 42.5 mm -66.52 -42.71 90.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 21.0 mm -66.03 -57.5 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.171 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -60.74 -31.03 70.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.881 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.09 -64.66 2.91 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.582 HG22 ' O ' ' B' ' 79' ' ' GLY . 90.2 t -56.74 -35.46 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.835 0.35 . . . . 0.0 111.097 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.7 mmt -65.48 -47.56 75.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.64 91.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.12 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.66 -56.84 5.76 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.534 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.1 t -54.84 -51.07 56.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.819 0.342 . . . . 0.0 111.149 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.7 mm -60.41 -50.23 81.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.133 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.73 -41.11 95.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.483 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.542 HG21 HG13 ' B' ' 88' ' ' ILE . 77.0 m -62.7 -59.08 5.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.783 0.325 . . . . 0.0 111.129 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.55 HG13 HG21 ' B' ' 87' ' ' THR . 79.4 mt -54.13 -43.92 61.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.3 mt -56.8 -51.04 70.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -59.52 -42.12 91.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.841 . . . . . . . . 3 3 . 1 . 013 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.523 HG22 HD12 ' A' ' 95' ' ' ILE . 27.6 mm -65.42 -63.85 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.181 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 2.2 t -51.53 -30.68 21.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -70.42 -51.99 25.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.08 -28.12 72.39 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.461 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.523 HD12 HG22 ' A' ' 91' ' ' ILE . 43.6 mt -76.42 -29.6 18.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.9 ttm180 -64.81 -32.07 73.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 18.6 ttp85 -86.24 -46.12 10.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.864 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.909 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 70' ' ' GLU . . . . . 0.683 ' N ' ' HG1' ' B' ' 74' ' ' THR . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.669 0.747 . . . . 0.0 110.879 . . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 71' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' B' ' 70' ' ' GLU . 53.8 Cg_endo -69.79 -49.93 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.652 2.235 . . . . 0.0 112.322 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 177.52 -45.58 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.4 mt -49.62 -32.2 6.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.165 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 74' ' ' THR . . . . . 0.683 ' HG1' ' N ' ' B' ' 70' ' ' GLU . 99.6 m -66.39 -45.69 79.18 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.145 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 1.054 HD12 HD12 ' A' ' 75' ' ' LEU . 17.9 mt -66.59 -37.64 85.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.935 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 56.4 mt -68.03 -41.41 84.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.099 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.4 mm -66.31 -57.74 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.161 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -61.16 -31.73 71.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.582 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.79 -64.03 3.23 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.517 ' O ' HG23 ' B' ' 84' ' ' VAL . 57.8 t -56.84 -35.6 47.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.094 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.1 mmm -65.29 -47.42 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.857 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.16 90.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.557 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.22 -56.65 5.57 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.442 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 97.5 t -54.8 -48.81 73.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.785 0.326 . . . . 0.0 111.101 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.544 HG22 HD12 ' B' ' 89' ' ' LEU . 33.8 mm -63.52 -47.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.163 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.85 -37.78 93.05 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.504 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.55 HG21 HG13 ' A' ' 88' ' ' ILE . 27.5 m -68.79 -59.51 3.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.757 0.313 . . . . 0.0 111.159 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.542 HG13 HG21 ' A' ' 87' ' ' THR . 72.5 mt -54.92 -38.16 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.132 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.544 HD12 HG22 ' B' ' 85' ' ' ILE . 18.8 mt -65.15 -55.1 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.914 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.91 -48.91 69.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.92 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.0 mt -64.58 -56.32 16.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.162 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 92' ' ' SER . . . . . 0.704 ' O ' HG22 ' B' ' 95' ' ' ILE . 59.1 m -54.15 -25.95 25.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 18.1 t80 -75.02 -41.97 58.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -88.61 -3.24 77.95 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.503 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 95' ' ' ILE . . . . . 0.704 HG22 ' O ' ' B' ' 92' ' ' SER . 5.3 tt -76.46 -13.48 14.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.825 0.345 . . . . 0.0 111.102 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.55 -13.21 60.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.854 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 18.8 ttm180 -88.42 -39.94 13.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.877 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 121.66 0.743 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -173.44 0.72 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.665 2.244 . . . . 0.0 112.348 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.478 ' HB2' HD12 ' A' ' 75' ' ' LEU . 46.1 mm-40 -141.9 102.49 4.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.91 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 51.1 mm -53.61 -26.53 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.143 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.6 m -64.69 -50.36 67.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.789 HD22 HD11 ' B' ' 76' ' ' ILE . 17.6 mt -69.86 -38.68 76.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.619 HD11 HD22 ' B' ' 75' ' ' LEU . 61.0 mt -66.37 -46.42 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.5 mm -65.73 -56.81 13.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.135 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -61.33 -29.86 70.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.499 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.31 -63.69 3.3 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.688 HG22 ' O ' ' B' ' 79' ' ' GLY . 98.3 t -57.47 -36.08 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.802 0.334 . . . . 0.0 111.114 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.44 -46.78 78.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.826 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.06 -38.85 92.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.137 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.44 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.04 -56.43 5.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.511 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 80' ' ' VAL . 95.6 t -55.16 -49.95 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.788 0.327 . . . . 0.0 111.133 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.0 mm -62.35 -49.93 81.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -36.17 88.86 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 96.8 m -67.55 -59.17 3.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.724 0.297 . . . . 0.0 111.148 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.2 mt -54.73 -40.04 49.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 14.5 mt -62.77 -56.41 17.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -52.7 -53.56 45.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.0 mt -59.58 -55.25 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.17 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.3 p -55.12 -25.45 31.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -65.17 -27.08 68.46 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -114.02 -59.59 0.39 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.492 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.841 HG22 ' O ' ' A' ' 95' ' ' ILE . 4.6 mp -79.13 54.63 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.825 0.345 . . . . 0.0 111.103 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -174.47 -36.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -90.7 -31.19 16.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.848 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 97.7 mt . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.921 -179.953 . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.624 0.726 . . . . 0.0 110.852 . . . . . . . . . 0 0 . 1 . 014 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -48.59 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.135 0 C-N-CA 122.706 2.271 . . . . 0.0 112.308 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.469 ' CG ' HD11 ' A' ' 75' ' ' LEU . 0.9 OUTLIER -171.31 -63.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.866 -179.97 . . . . . . . . 3 3 . 1 . 014 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 53.7 mt -51.25 -29.43 8.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.133 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 88.0 m -62.7 -50.6 70.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.619 HD22 HD11 ' A' ' 76' ' ' ILE . 6.2 mt -68.16 -38.29 81.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.789 HD11 HD22 ' A' ' 75' ' ' LEU . 59.9 mt -66.26 -44.66 91.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.5 mm -65.8 -57.17 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.2 t80 -60.47 -30.25 69.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.688 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.08 -63.44 3.45 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.501 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.515 ' O ' HG23 ' B' ' 84' ' ' VAL . 39.5 t -57.28 -36.04 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.155 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.3 mmt -65.38 -46.93 78.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.934 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.84 92.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.059 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.575 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.06 -56.33 5.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.474 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.515 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.7 t -54.95 -49.28 72.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.342 . . . . 0.0 111.133 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.505 HG22 HD12 ' B' ' 89' ' ' LEU . 77.6 mt -63.03 -49.4 83.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.171 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.5 -35.66 86.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.486 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.434 ' OG1' HG13 ' A' ' 84' ' ' VAL . 87.1 m -68.97 -58.67 3.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.753 0.311 . . . . 0.0 111.171 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.94 -37.91 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.505 HD12 HG22 ' B' ' 85' ' ' ILE . 16.9 mt -65.12 -53.25 48.13 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.92 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -49.41 71.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.64 -57.02 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.118 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 80.8 p -54.79 -25.18 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.843 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 43.7 t80 -71.56 -54.27 11.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -53.24 -35.63 50.45 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.504 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.8 mm -76.46 -29.36 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.832 0.349 . . . . 0.0 111.159 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 2.5 ttp180 -64.87 -40.47 95.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.87 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 5.9 ttm180 -94.2 40.42 1.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.9 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 2.5 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.935 -179.957 . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 68.2 mm-40 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 121.635 0.731 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 169.03 19.9 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.65 2.233 . . . . 0.0 112.306 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.505 ' HA ' HD13 ' B' ' 75' ' ' LEU . 2.4 mp0 -117.81 -44.77 2.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.686 HG22 HD11 ' A' ' 77' ' ' ILE . 58.2 mt -50.9 -34.25 13.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.134 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.0 m -60.23 -55.18 36.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.159 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.599 HD13 ' HA ' ' B' ' 72' ' ' GLU . 5.0 mt -61.24 -36.71 80.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.925 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.462 HD12 ' HA ' ' A' ' 73' ' ' ILE . 52.3 mt -66.02 -41.31 89.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.137 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.686 HD11 HG22 ' A' ' 73' ' ' ILE . 27.4 mt -66.1 -58.75 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -59.68 -31.06 69.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.913 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.623 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.81 -65.79 2.51 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.466 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.671 HG22 ' O ' ' B' ' 79' ' ' GLY . 99.0 t -55.46 -34.73 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.878 0.371 . . . . 0.0 111.13 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.9 mmt -65.31 -50.21 66.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.11 80.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.526 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.19 -55.36 6.29 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.465 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 80' ' ' VAL . 91.1 t -54.96 -49.99 66.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 111.139 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 1.7 mp -63.45 -47.83 89.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.15 -36.66 91.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.456 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.651 ' OG1' HG13 ' B' ' 84' ' ' VAL . 73.1 m -68.88 -58.73 3.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.775 0.322 . . . . 0.0 111.164 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.57 HG13 HG21 ' B' ' 87' ' ' THR . 72.1 mt -55.61 -38.47 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.9 mt -65.2 -53.41 45.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -55.0 -49.33 71.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.9 mt -64.58 -56.68 14.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 60.6 p -55.24 -24.97 30.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.88 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 26.7 t80 -70.08 -54.36 13.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.93 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -58.15 -29.04 62.13 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.458 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.8 mt -76.48 -29.41 18.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.799 0.333 . . . . 0.0 111.106 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.2 -40.26 93.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.897 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' A' A ' 97' ' ' ARG . . . . . 0.71 ' O ' HD23 ' A' ' 98' ' ' LEU . 0.4 OUTLIER -87.08 -32.76 19.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.84 -179.934 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' A' A ' 98' ' ' LEU . . . . . 0.71 HD23 ' O ' ' A' ' 97' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.915 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 . . . . . 0 C--O 1.232 0.135 0 CA-C-O 121.592 0.711 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 015 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 179.71 3.51 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.69 2.26 . . . . 0.0 112.318 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.599 ' HA ' HD13 ' A' ' 75' ' ' LEU . 12.1 pt-20 -125.85 -44.19 1.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.932 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 73' ' ' ILE . . . . . 0.591 ' HA ' HD12 ' B' ' 76' ' ' ILE . 48.5 mm -51.11 -36.03 15.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.119 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 18.6 m -57.03 -57.03 14.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.179 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.505 HD13 ' HA ' ' A' ' 72' ' ' GLU . 4.6 mt -61.8 -35.79 79.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.947 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.591 HD12 ' HA ' ' B' ' 73' ' ' ILE . 36.6 mt -65.77 -43.33 93.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.126 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.2 mm -65.84 -58.03 8.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.1 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -60.15 -30.29 69.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.671 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.02 -63.83 3.28 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.439 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 79' ' ' GLY . 94.0 t -56.99 -35.81 48.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.808 0.337 . . . . 0.0 111.093 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.4 mmt -65.49 -47.12 77.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.849 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.71 -39.03 92.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.114 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.509 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.82 -56.82 5.68 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.651 HG13 ' OG1' ' A' ' 87' ' ' THR . 91.2 t -55.14 -50.65 62.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.802 0.334 . . . . 0.0 111.146 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.6 mm -61.61 -49.22 85.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -39.27 95.06 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.487 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.57 HG21 HG13 ' A' ' 88' ' ' ILE . 85.5 m -64.66 -58.01 7.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.757 0.313 . . . . 0.0 111.115 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.573 HG13 HG21 ' A' ' 87' ' ' THR . 76.4 mt -54.46 -43.17 62.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.13 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 14.9 mt -59.02 -53.76 54.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.44 -51.71 68.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.401 HG22 ' N ' ' B' ' 92' ' ' SER . 0.8 OUTLIER -56.44 -59.61 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.86 . . . . . . . . 3 3 . 1 . 015 nuclear build full ' B' B ' 92' ' ' SER . . . . . 0.439 ' HA ' HG22 ' B' ' 95' ' ' ILE . 30.9 t -56.34 -27.11 54.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 59.9 t80 -75.1 -51.31 13.79 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.918 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.419 ' O ' HD12 ' B' ' 98' ' ' LEU . . . -68.6 -32.98 75.42 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.529 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 95' ' ' ILE . . . . . 0.439 HG22 ' HA ' ' B' ' 92' ' ' SER . 5.6 tt -75.71 -22.2 16.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.817 0.342 . . . . 0.0 111.135 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 5.2 ttm180 -65.3 -30.65 71.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.932 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 7.9 ttp180 -90.67 -41.81 11.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear build full ' B' B ' 98' ' ' LEU . . . . . 0.419 HD12 ' O ' ' B' ' 94' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 70' ' ' GLU . . . . . 0.529 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 4.7 tt0 . . . . . 0 C--O 1.232 0.141 0 CA-C-O 121.64 0.733 . . . . 0.0 110.869 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 70' ' ' GLU . 53.6 Cg_endo -69.78 -48.44 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.693 2.262 . . . . 0.0 112.361 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -162.37 89.55 0.69 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.718 HG22 ' CD1' ' A' ' 77' ' ' ILE . 2.9 mp -50.21 -32.72 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.127 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.1 m -60.77 -54.19 48.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.101 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 1.061 HD12 HD12 ' B' ' 75' ' ' LEU . 66.3 mt -62.45 -37.97 87.98 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 41.2 mm -66.3 -40.02 85.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.718 ' CD1' HG22 ' A' ' 73' ' ' ILE . 34.2 mt -66.24 -58.26 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.097 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -60.04 -31.44 69.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.867 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.537 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.76 -65.03 2.78 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.525 ' O ' HG23 ' A' ' 84' ' ' VAL . 99.4 t -56.15 -35.45 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.344 . . . . 0.0 111.122 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.39 -47.9 74.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.92 -38.91 90.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.527 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.11 -56.53 5.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.4 t -55.03 -49.33 72.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.844 0.354 . . . . 0.0 111.129 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.51 HG22 HD12 ' A' ' 89' ' ' LEU . 92.7 mt -62.75 -49.71 82.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.074 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.32 -35.66 85.73 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.479 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.426 ' OG1' HG13 ' B' ' 84' ' ' VAL . 86.7 m -68.67 -58.71 3.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.783 0.325 . . . . 0.0 111.154 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.8 mt -56.46 -37.78 53.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.51 HD12 HG22 ' A' ' 85' ' ' ILE . 22.3 mt -65.25 -53.54 42.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.941 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.06 -49.09 72.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.917 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.66 -56.66 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.151 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 92' ' ' SER . . . . . 0.467 ' HA ' HG22 ' A' ' 95' ' ' ILE . 54.4 p -55.56 -24.5 32.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -75.02 -50.87 15.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.916 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.34 -32.72 72.15 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.487 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.467 HG22 ' HA ' ' A' ' 92' ' ' SER . 5.5 tt -75.72 -22.39 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 0.0 111.129 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.16 -30.93 71.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.842 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.5 ttm180 -90.96 -43.42 9.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.92 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.958 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.67 0.748 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 78.5 1.02 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.724 2.283 . . . . 0.0 112.32 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -114.41 -67.95 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.892 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 73' ' ' ILE . . . . . 0.63 HG22 HD11 ' B' ' 77' ' ' ILE . 4.6 mt -50.32 -33.27 10.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.134 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 5.0 m -63.06 -51.36 66.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.153 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 1.061 HD12 HD12 ' A' ' 75' ' ' LEU . 12.1 mt -62.72 -37.21 85.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.892 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 41.6 mm -66.53 -40.14 85.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.094 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 77' ' ' ILE . . . . . 0.63 HD11 HG22 ' B' ' 73' ' ' ILE . 29.2 mt -66.38 -57.86 8.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.125 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -60.52 -31.72 70.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.512 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.58 -64.03 3.26 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.507 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.537 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.2 t -56.78 -35.69 46.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 111.145 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 18.0 mmm -65.33 -47.02 77.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -39.05 93.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.093 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.513 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.05 -56.26 5.87 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.482 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.507 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.6 t -54.97 -49.54 70.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.793 0.33 . . . . 0.0 111.14 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.465 HG22 HD12 ' B' ' 89' ' ' LEU . 33.4 mm -62.72 -49.32 84.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.163 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.71 -35.69 87.1 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.496 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.1 m -68.64 -59.27 3.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.749 0.309 . . . . 0.0 111.126 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 67.5 mt -54.91 -37.95 43.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.465 HD12 HG22 ' B' ' 85' ' ' ILE . 29.0 mt -65.19 -55.44 18.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -53.83 -48.7 69.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.62 -54.68 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 92' ' ' SER . . . . . 0.68 ' O ' HG22 ' B' ' 95' ' ' ILE . 42.8 t -53.76 -27.83 31.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.847 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -75.39 -31.49 60.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -60.86 -22.61 60.2 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.507 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 95' ' ' ILE . . . . . 0.68 HG22 ' O ' ' B' ' 92' ' ' SER . 5.6 tt -75.69 -21.83 16.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.869 0.366 . . . . 0.0 111.15 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.55 -42.56 91.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 39.0 ttp180 -94.58 -36.7 11.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 17.1 mt . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.874 -179.993 . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 C--O 1.232 0.141 0 CA-C-O 121.647 0.737 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 017 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.84 159.54 52.97 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.648 2.232 . . . . 0.0 112.321 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.598 ' H ' HD13 ' B' ' 75' ' ' LEU . 33.2 mt-10 -140.52 102.94 4.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.659 HG22 ' CD1' ' A' ' 77' ' ' ILE . 4.6 mt -50.14 -31.69 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.145 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 11.5 m -63.02 -52.92 61.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.109 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 1.051 HD12 HD12 ' B' ' 75' ' ' LEU . 29.0 mt -62.58 -37.47 86.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.893 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.8 mm -66.52 -40.09 85.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.085 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.659 ' CD1' HG22 ' A' ' 73' ' ' ILE . 37.8 mt -66.33 -58.56 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -60.39 -31.57 70.49 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.897 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.526 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.65 -65.06 2.78 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.521 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.522 ' O ' HG23 ' A' ' 84' ' ' VAL . 72.0 t -56.24 -35.37 42.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 111.118 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 16.4 mtp -65.37 -47.4 76.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.69 -38.78 91.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.484 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.12 -56.48 5.71 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.8 t -55.0 -49.43 71.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.845 0.355 . . . . 0.0 111.158 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.439 HG22 HD12 ' A' ' 89' ' ' LEU . 33.8 mm -62.83 -48.66 87.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -37.8 93.09 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.401 ' OG1' HG13 ' B' ' 84' ' ' VAL . 62.6 m -67.25 -58.93 3.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.788 0.328 . . . . 0.0 111.138 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 78.4 mt -54.24 -38.64 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.152 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.439 HD12 HG22 ' A' ' 85' ' ' ILE . 15.5 mt -64.03 -55.81 19.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.36 -49.8 71.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 84.7 mt -60.51 -53.43 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 36.1 t -64.92 -14.92 61.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -63.33 -19.38 64.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.913 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 130.39 33.19 0.5 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.48 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.601 HG22 ' O ' ' A' ' 95' ' ' ILE . 25.3 mm -78.69 -3.96 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.882 0.372 . . . . 0.0 111.167 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.01 -38.35 0.06 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.839 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.5 ttm-85 -95.41 -5.91 42.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.867 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.952 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 121.614 0.721 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -49.11 0.59 Allowed 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.693 2.262 . . . . 0.0 112.346 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.463 ' HG2' HD11 ' A' ' 75' ' ' LEU . 0.7 OUTLIER -129.28 -37.1 1.67 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.883 -179.985 . . . . . . . . 3 3 . 1 . 017 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 49.3 mm -48.67 -31.08 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.117 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 99.7 m -61.43 -52.6 63.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.099 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 1.051 HD12 HD12 ' A' ' 75' ' ' LEU . 11.4 mt -66.01 -37.86 87.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.912 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.8 mm -66.14 -42.63 91.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.161 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 16.9 mm -66.0 -57.23 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.24 -31.05 69.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.02 -64.52 2.98 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.468 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.526 HG22 ' O ' ' A' ' 79' ' ' GLY . 97.2 t -56.58 -35.55 45.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.817 0.342 . . . . 0.0 111.136 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.3 mmm -65.43 -47.38 76.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -38.75 91.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.503 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.2 -56.63 5.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.509 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.8 t -54.92 -49.54 69.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.853 0.359 . . . . 0.0 111.14 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.433 HG22 HD12 ' B' ' 89' ' ' LEU . 34.4 mm -62.76 -49.61 83.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.31 86.3 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.518 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 91.8 m -68.71 -58.78 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.775 0.321 . . . . 0.0 111.179 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 70.4 mt -56.02 -38.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.102 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.433 HD12 HG22 ' B' ' 85' ' ' ILE . 34.2 mt -65.28 -53.5 43.24 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.14 -49.06 72.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.5 mt -64.71 -56.79 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 28.4 t -55.27 -24.98 30.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -69.46 -51.97 31.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 94' ' ' GLY . . . . . 0.51 ' O ' HD12 ' B' ' 98' ' ' LEU . . . -68.92 -28.16 73.28 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 59.8 mt -76.5 -29.56 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.805 0.336 . . . . 0.0 111.108 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.83 -27.59 68.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 6.9 ttp85 -87.0 -43.07 12.62 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.891 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear build full ' B' B ' 98' ' ' LEU . . . . . 0.51 HD12 ' O ' ' B' ' 94' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.885 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.669 0.747 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 018 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -170.4 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.727 2.285 . . . . 0.0 112.319 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.582 ' CD ' HD11 ' A' ' 76' ' ' ILE . 2.7 tt0 -76.91 -48.37 18.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.883 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.758 HG22 HD11 ' A' ' 77' ' ' ILE . 5.2 mt -51.15 -38.8 19.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.114 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 81.3 m -57.62 -56.11 26.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.168 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.625 HD12 HD12 ' B' ' 75' ' ' LEU . 36.4 mt -59.02 -36.24 74.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.582 HD11 ' CD ' ' A' ' 72' ' ' GLU . 40.6 mt -67.62 -39.54 82.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.145 179.792 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.758 HD11 HG22 ' A' ' 73' ' ' ILE . 20.0 mt -66.35 -58.81 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -61.11 -31.68 71.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.443 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.42 -65.17 2.76 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.458 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.545 HG22 ' O ' ' B' ' 79' ' ' GLY . 77.2 t -56.46 -35.67 44.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.783 0.325 . . . . 0.0 111.116 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 10.8 mmt -65.41 -46.9 78.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.98 93.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.491 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.2 -56.48 5.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 80' ' ' VAL . 99.2 t -54.97 -49.02 74.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.865 0.364 . . . . 0.0 111.147 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.503 HG22 HD12 ' A' ' 89' ' ' LEU . 33.9 mm -63.41 -48.18 88.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.17 -37.38 92.82 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.488 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.554 HG21 HG13 ' B' ' 88' ' ' ILE . 57.4 m -68.0 -58.16 4.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.814 0.34 . . . . 0.0 111.165 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.583 HG13 HG21 ' B' ' 87' ' ' THR . 79.0 mt -55.5 -37.74 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.503 HD12 HG22 ' A' ' 85' ' ' ILE . 15.8 mt -65.19 -55.29 19.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.919 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -53.54 -48.94 68.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.919 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.607 ' CG2' HD12 ' A' ' 95' ' ' ILE . 62.0 mt -64.72 -56.38 16.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.2 t -54.22 -25.59 23.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 15.4 t80 -67.15 -43.59 81.93 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.916 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -107.92 36.83 4.14 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.502 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.607 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.1 mt -156.45 -51.09 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.815 0.34 . . . . 0.0 111.126 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.9 -23.7 60.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.875 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -144.88 27.5 1.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 70' ' ' GLU . . . . . 0.485 ' N ' ' HD2' ' B' ' 71' ' ' PRO . 1.5 mp0 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 121.694 0.759 . . . . 0.0 110.875 . . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 71' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' B' ' 70' ' ' GLU . 54.2 Cg_endo -69.74 178.89 4.1 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.673 2.249 . . . . 0.0 112.343 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -147.88 98.85 3.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 73' ' ' ILE . . . . . 0.695 HG22 ' CD1' ' B' ' 77' ' ' ILE . 47.5 mm -50.75 -34.03 12.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.127 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 25.2 m -60.42 -54.73 42.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.121 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.625 HD12 HD12 ' A' ' 75' ' ' LEU . 24.8 mt -61.51 -37.26 83.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.473 ' O ' HG23 ' B' ' 80' ' ' VAL . 53.6 mt -66.2 -40.44 86.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 77' ' ' ILE . . . . . 0.695 ' CD1' HG22 ' B' ' 73' ' ' ILE . 29.8 mt -66.32 -57.89 8.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.115 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -60.15 -31.35 70.01 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.545 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.75 -64.81 2.88 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.463 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.516 ' O ' HG23 ' B' ' 84' ' ' VAL . 36.3 t -56.51 -35.52 44.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.794 0.33 . . . . 0.0 111.134 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.2 mmm -65.37 -47.59 75.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.834 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.66 -38.33 89.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.521 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.23 -56.12 5.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.45 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.516 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.1 t -54.93 -48.81 74.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 111.144 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.451 HG22 HD12 ' B' ' 89' ' ' LEU . 81.9 mt -63.61 -48.24 87.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.129 179.899 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.99 -37.05 92.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.583 HG21 HG13 ' A' ' 88' ' ' ILE . 54.7 m -68.46 -58.77 3.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.805 0.336 . . . . 0.0 111.202 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.554 HG13 HG21 ' A' ' 87' ' ' THR . 75.5 mt -55.7 -38.19 49.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.151 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.451 HD12 HG22 ' B' ' 85' ' ' ILE . 17.7 mt -65.13 -53.72 40.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.05 -49.08 72.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.959 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.4 mt -64.59 -56.99 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.165 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 50.0 p -55.18 -24.88 29.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -72.37 -53.38 12.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.947 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -58.25 -35.35 77.8 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.549 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.1 mt -76.65 -29.53 18.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.812 0.339 . . . . 0.0 111.108 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.53 -25.5 68.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.885 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 14.0 ttm180 -145.19 42.74 1.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.879 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 2.4 mt . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.877 -179.999 . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.667 0.746 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 177.62 5.36 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.652 2.234 . . . . 0.0 112.383 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.452 ' HA ' HD13 ' B' ' 75' ' ' LEU . 1.5 mp0 -132.42 -43.35 0.93 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 73' ' ' ILE . . . . . 0.584 ' HA ' HD12 ' A' ' 76' ' ' ILE . 51.2 mm -51.08 -36.88 16.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 14.0 m -58.49 -54.87 42.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.577 HD13 ' HA ' ' B' ' 72' ' ' GLU . 12.4 mt -61.05 -36.24 79.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.899 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.584 HD12 ' HA ' ' A' ' 73' ' ' ILE . 38.1 mt -66.27 -41.71 89.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.145 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.9 mm -66.06 -57.86 8.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.123 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -60.15 -31.27 69.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.595 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.66 -64.48 3.04 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.547 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.531 ' O ' HG23 ' A' ' 84' ' ' VAL . 65.7 t -56.56 -35.5 44.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.863 0.363 . . . . 0.0 111.172 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 17.2 mmm -65.29 -47.21 77.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.64 91.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.544 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.5 5.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 95.4 t -54.94 -49.34 71.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.161 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.6 mm -62.99 -47.62 91.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -61.09 -39.33 96.96 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.488 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 87' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 88' ' ' ILE . 54.1 m -65.96 -57.45 7.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.781 0.324 . . . . 0.0 111.139 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 88' ' ' ILE . . . . . 0.532 HG13 HG21 ' B' ' 87' ' ' THR . 79.0 mt -57.15 -45.55 84.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.1 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.47 -52.96 63.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.93 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 90' ' ' LEU . . . . . 0.406 ' HA ' HD22 ' A' ' 90' ' ' LEU . 0.4 OUTLIER -54.7 -55.81 25.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.908 179.871 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 74.8 mt -57.3 -59.42 3.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.7 p -53.07 -27.52 20.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -75.07 -51.5 13.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.949 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.45 -26.81 74.12 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.465 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 mm -76.45 -29.33 18.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.854 0.359 . . . . 0.0 111.159 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.69 -23.23 67.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.878 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 21.4 ttp85 -145.05 43.08 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 . . . . . 0 C--O 1.231 0.084 0 CA-C-O 121.661 0.743 . . . . 0.0 110.879 . . . . . . . . . 0 0 . 1 . 019 nuclear build full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 179.51 3.66 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.631 2.221 . . . . 0.0 112.339 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 72' ' ' GLU . . . . . 0.577 ' HA ' HD13 ' A' ' 75' ' ' LEU . 0.7 OUTLIER 69.31 -75.26 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 -179.99 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.1 mt -50.87 -29.86 8.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.121 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 88.1 m -62.94 -50.24 71.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.169 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.497 ' CD1' HD12 ' A' ' 75' ' ' LEU . 10.7 mt -68.05 -37.32 81.17 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.1 mm -67.19 -44.4 87.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.082 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.1 mm -66.05 -57.7 9.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -61.45 -30.8 70.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.911 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.517 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.16 -64.5 2.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.506 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 79' ' ' GLY . 77.1 t -56.96 -35.83 48.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.789 0.328 . . . . 0.0 111.12 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 1.6 mmt -65.31 -47.21 77.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.49 91.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.107 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.454 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.31 -56.25 5.74 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.478 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.1 t -54.91 -48.85 74.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 111.121 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.5 mm -63.51 -48.6 86.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.7 92.03 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.526 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.532 HG21 HG13 ' A' ' 88' ' ' ILE . 90.0 m -68.12 -58.47 4.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.738 0.304 . . . . 0.0 111.186 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 88' ' ' ILE . . . . . 0.558 HG13 HG21 ' A' ' 87' ' ' THR . 75.7 mt -55.36 -37.88 46.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.132 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 28.7 mt -65.18 -55.06 20.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 90' ' ' LEU . . . . . 0.427 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -53.97 -48.97 69.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.87 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear build full ' B' B ' 91' ' ' ILE . . . . . 0.7 ' CG2' HD12 ' B' ' 95' ' ' ILE . 63.6 mt -64.45 -56.23 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 179.835 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 13.6 t -54.46 -25.55 25.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.86 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 34.6 t80 -64.97 -42.92 94.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.948 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -111.64 39.25 2.95 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.46 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear build full ' B' B ' 95' ' ' ILE . . . . . 0.7 HD12 ' CG2' ' B' ' 91' ' ' ILE . 16.5 mt -156.39 -50.15 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.796 0.331 . . . . 0.0 111.152 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.06 -32.38 61.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.855 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -95.46 26.69 3.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 1.7 mt . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.933 179.974 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 36.8 mm-40 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 121.643 0.735 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 020 nuclear build full ' A' A ' 71' ' ' PRO . . . . . 0.68 ' HG2' HD21 ' B' ' 75' ' ' LEU . 54.0 Cg_endo -69.75 178.25 4.76 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.72 2.28 . . . . 0.0 112.345 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 72' ' ' GLU . . . . . 0.708 ' HB3' HD13 ' B' ' 75' ' ' LEU . 13.8 tp10 52.03 72.13 0.41 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.902 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.2 mm -54.75 -23.85 12.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.128 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 m -69.88 -45.44 67.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.145 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 75' ' ' LEU . . . . . 0.412 HD12 ' HG2' ' A' ' 72' ' ' GLU . 38.7 mt -71.37 -38.94 71.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 76' ' ' ILE . . . . . 0.457 HD11 HD22 ' B' ' 75' ' ' LEU . 37.4 mm -65.68 -48.39 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 77' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 78' ' ' PHE . 1.1 mp -65.32 -54.81 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 78' ' ' PHE . . . . . 0.401 ' N ' HG22 ' A' ' 77' ' ' ILE . 42.7 t80 -60.79 -30.91 70.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.891 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 79' ' ' GLY . . . . . 0.614 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.89 -64.06 3.07 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.496 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 80' ' ' VAL . . . . . 0.649 HG22 ' O ' ' B' ' 79' ' ' GLY . 95.6 t -57.0 -35.64 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 111.145 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.4 mmt -65.66 -47.61 74.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.867 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.95 -39.23 91.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 83' ' ' GLY . . . . . 0.546 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.97 -56.45 5.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.516 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 84' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 80' ' ' VAL . 93.7 t -54.94 -49.38 71.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.809 0.337 . . . . 0.0 111.153 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 85' ' ' ILE . . . . . 0.576 HG22 HD12 ' A' ' 89' ' ' LEU . 33.2 mm -62.52 -49.7 82.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.171 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -35.15 85.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.519 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.7 m -68.57 -59.6 3.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.153 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.9 mt -55.3 -37.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.101 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 89' ' ' LEU . . . . . 0.576 HD12 HG22 ' A' ' 85' ' ' ILE . 13.3 mt -65.12 -55.18 20.21 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.901 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.58 -49.01 68.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.943 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 91' ' ' ILE . . . . . 0.603 ' CG2' HD12 ' A' ' 95' ' ' ILE . 65.2 mt -64.72 -55.77 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 67.3 m -53.97 -26.14 24.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 20.5 t80 -64.81 -38.75 92.02 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.941 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -112.3 43.86 1.63 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.45 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 95' ' ' ILE . . . . . 0.603 HD12 ' CG2' ' A' ' 91' ' ' ILE . 17.1 mt -156.49 -40.42 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.849 0.357 . . . . 0.0 111.13 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 ptt85 -64.6 -28.52 69.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.855 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 13.1 ttp180 -150.8 35.27 0.61 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.879 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 5.3 mp . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.935 -179.949 . . . . . . . . 0 0 . 1 . 020 nuclear build full ' B' B ' 70' ' ' GLU . . . . . 0.491 ' N ' ' HD2' ' B' ' 71' ' ' PRO . 1.3 mt-10 . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.572 0.701 . . . . 0.0 110.812 . . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 71' ' ' PRO . . . . . 0.491 ' HD2' ' N ' ' B' ' 70' ' ' GLU . 53.6 Cg_endo -69.76 162.99 39.94 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.652 2.235 . . . . 0.0 112.392 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -149.62 -49.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 73' ' ' ILE . . . . . 0.578 ' HA ' HD12 ' B' ' 76' ' ' ILE . 51.0 mm -51.69 -38.01 21.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.088 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 35.5 m -58.77 -53.71 55.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.19 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 75' ' ' LEU . . . . . 0.708 HD13 ' HB3' ' A' ' 72' ' ' GLU . 12.5 mt -61.01 -36.24 78.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 76' ' ' ILE . . . . . 0.578 HD12 ' HA ' ' B' ' 73' ' ' ILE . 37.2 mt -66.64 -41.13 87.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.106 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.6 mm -66.11 -56.83 12.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.165 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -31.87 70.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 79' ' ' GLY . . . . . 0.649 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.58 -65.05 2.79 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.515 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 80' ' ' VAL . . . . . 0.614 HG22 ' O ' ' A' ' 79' ' ' GLY . 88.1 t -56.68 -35.07 44.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 111.161 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -47.01 77.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.86 -38.89 92.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.085 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 83' ' ' GLY . . . . . 0.615 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.08 -56.39 5.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.509 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 84' ' ' VAL . . . . . 0.51 HG23 ' O ' ' B' ' 80' ' ' VAL . 97.6 t -54.86 -49.21 71.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.849 0.357 . . . . 0.0 111.119 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 85' ' ' ILE . . . . . 0.524 HG22 HD12 ' B' ' 89' ' ' LEU . 33.0 mm -62.96 -49.29 84.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.133 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.01 -35.31 86.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.495 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 87' ' ' THR . . . . . 0.422 ' OG1' HG13 ' A' ' 84' ' ' VAL . 84.8 m -68.91 -59.17 3.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.762 0.315 . . . . 0.0 111.115 -179.839 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.3 mt -55.85 -38.09 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.135 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 89' ' ' LEU . . . . . 0.524 HD12 HG22 ' B' ' 85' ' ' ILE . 13.7 mt -65.25 -53.56 42.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.889 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -48.96 72.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.1 mt -64.86 -56.89 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.151 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 8.7 t -55.18 -24.94 29.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.834 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 76.4 t80 -72.27 -51.66 19.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.883 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -62.66 -32.06 82.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.507 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 32.9 mt -76.47 -29.59 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.781 0.324 . . . . 0.0 111.125 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.72 -32.56 74.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.839 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear build full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 16.0 ttp180 -90.8 -35.55 14.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear build full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.92 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.846 HD12 HD12 ' B' ' 75' ' ' LEU . 22.8 mt . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.781 0.324 . . . . 0.0 110.863 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 58.8 mt -65.95 -41.99 90.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.187 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.1 mm -66.15 -57.3 11.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.125 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.18 -31.22 69.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.587 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.95 -64.53 2.98 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.459 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.559 HG22 ' O ' ' B' ' 79' ' ' GLY . 78.5 t -56.52 -35.45 44.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.792 0.329 . . . . 0.0 111.111 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.0 mmt -65.4 -47.31 76.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.863 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.43 90.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.087 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.534 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.22 -56.59 5.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 80' ' ' VAL . 99.6 t -54.83 -49.05 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.802 0.334 . . . . 0.0 111.121 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.604 HG22 HD12 ' A' ' 89' ' ' LEU . 34.1 mm -63.44 -48.3 87.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.76 -36.11 91.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.49 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 88' ' ' ILE . 88.8 m -68.58 -58.35 4.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.83 0.348 . . . . 0.0 111.186 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.568 HG13 HG21 ' B' ' 87' ' ' THR . 70.8 mt -56.37 -37.98 53.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.604 HD12 HG22 ' A' ' 85' ' ' ILE . 15.7 mt -65.26 -53.45 44.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.962 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -55.0 -48.95 72.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.9 mt -64.96 -56.74 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.3 t -55.19 -24.8 28.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 41.0 t80 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.907 -179.896 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.846 HD12 HD12 ' A' ' 75' ' ' LEU . 11.0 mt . . . . . 0 C--O 1.232 0.132 0 CA-C-O 120.762 0.315 . . . . 0.0 110.907 . . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.426 HD11 HD22 ' A' ' 75' ' ' LEU . 36.7 mm -66.97 -42.87 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.133 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.3 mm -66.04 -57.62 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.145 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -61.06 -31.03 70.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.559 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.04 -64.6 2.94 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.472 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 79' ' ' GLY . 97.2 t -56.87 -35.66 47.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.802 0.334 . . . . 0.0 111.102 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 42.7 mmm -65.3 -47.08 77.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.6 91.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.507 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.23 -56.41 5.7 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.513 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.6 t -54.89 -49.02 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.813 0.339 . . . . 0.0 111.122 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.619 HG22 HD12 ' B' ' 89' ' ' LEU . 34.0 mm -63.41 -48.34 87.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.17 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.8 -36.18 91.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.5 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.568 HG21 HG13 ' A' ' 88' ' ' ILE . 91.8 m -68.44 -57.51 5.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.775 0.321 . . . . 0.0 111.118 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.558 HG13 HG21 ' A' ' 87' ' ' THR . 76.6 mt -57.69 -37.6 60.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.619 HD12 HG22 ' B' ' 85' ' ' ILE . 16.4 mt -65.23 -53.01 50.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.923 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.2 -49.36 72.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.77 -56.8 14.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 29.8 t -55.16 -24.94 29.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 22.9 t80 . . . . . 0 C--N 1.327 -0.375 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.911 -179.86 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 1.027 HD12 HD12 ' B' ' 75' ' ' LEU . 25.1 mt . . . . . 0 C--O 1.232 0.136 0 CA-C-O 120.792 0.329 . . . . 0.0 110.921 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.4 mm -66.39 -43.02 91.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.155 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.0 mm -66.04 -57.74 9.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.1 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.56 -30.71 69.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.555 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.12 -64.29 3.07 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.474 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.6 HG22 ' O ' ' B' ' 79' ' ' GLY . 91.4 t -56.93 -35.5 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.808 0.337 . . . . 0.0 111.117 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 2.7 mmt -65.54 -47.43 75.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.83 92.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.068 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.511 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.7 -56.62 5.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.523 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.592 HG13 ' OG1' ' B' ' 87' ' ' THR . 99.2 t -54.94 -50.91 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.813 0.339 . . . . 0.0 111.154 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.3 mm -60.45 -50.56 79.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.78 -40.7 95.35 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.478 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.552 HG21 HG13 ' B' ' 88' ' ' ILE . 87.9 m -62.62 -59.02 5.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.728 0.299 . . . . 0.0 111.127 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.565 HG13 HG21 ' B' ' 87' ' ' THR . 77.8 mt -54.14 -44.2 62.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.145 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 12.7 mt -56.46 -51.12 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -59.53 -42.02 91.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.936 179.88 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.9 mm -65.53 -63.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.148 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 3.8 m -51.65 -30.55 22.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.87 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 42.2 t80 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.906 -179.832 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 1.027 HD12 HD12 ' A' ' 75' ' ' LEU . 13.9 mt . . . . . 0 C--O 1.232 0.148 0 CA-C-O 120.762 0.315 . . . . 0.0 110.879 . . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.4 mm -67.08 -39.98 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.152 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 26.9 mt -66.39 -58.49 6.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.097 179.893 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -60.8 -31.5 70.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.6 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.78 -64.92 2.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.432 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.555 HG22 ' O ' ' A' ' 79' ' ' GLY . 82.2 t -56.32 -35.34 42.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.776 0.322 . . . . 0.0 111.115 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 27.8 mmt -65.24 -47.93 75.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.879 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.87 -37.88 88.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.588 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.24 -55.8 6.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.477 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' B' ' 80' ' ' VAL . 92.8 t -54.78 -48.38 73.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.833 0.349 . . . . 0.0 111.146 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.503 HG22 HD12 ' B' ' 89' ' ' LEU . 61.9 mt -63.6 -48.45 86.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.154 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.19 -36.58 91.1 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.464 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.592 ' OG1' HG13 ' A' ' 84' ' ' VAL . 53.0 m -68.46 -58.22 4.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.32 . . . . 0.0 111.144 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.552 HG13 HG21 ' A' ' 87' ' ' THR . 72.6 mt -56.66 -37.8 54.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.136 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.503 HD12 HG22 ' B' ' 85' ' ' ILE . 18.2 mt -65.16 -53.54 43.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -54.97 -49.18 72.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.6 mt -64.67 -57.01 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.852 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 75.7 m -54.97 -25.08 27.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 38.3 t80 . . . . . 0 C--N 1.328 -0.344 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.947 -179.938 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.973 HD12 HD12 ' B' ' 75' ' ' LEU . 27.3 mt . . . . . 0 C--O 1.231 0.103 0 CA-C-O 120.754 0.311 . . . . 0.0 110.908 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.1 mm -66.44 -42.98 91.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.0 mm -65.97 -58.08 8.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.121 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.36 -30.94 69.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.577 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.98 -64.69 2.9 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.563 HG22 ' O ' ' B' ' 79' ' ' GLY . 80.5 t -56.48 -35.6 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 3.0 mmt -65.41 -47.16 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.05 -38.47 91.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.088 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.525 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.12 -56.66 5.61 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.461 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.5 t -54.9 -49.72 67.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.825 0.345 . . . . 0.0 111.134 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.71 -49.12 84.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.02 -35.61 87.79 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.477 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.427 ' OG1' HG13 ' B' ' 84' ' ' VAL . 86.7 m -68.57 -58.19 4.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.769 0.319 . . . . 0.0 111.098 -179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.406 HG13 HG21 ' B' ' 87' ' ' THR . 67.2 mt -56.03 -38.28 52.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.115 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.5 mt -65.21 -53.39 45.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.1 -49.01 72.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.934 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.87 -56.71 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 34.6 t -55.2 -25.04 30.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 68.6 t80 . . . . . 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.93 -179.882 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.973 HD12 HD12 ' A' ' 75' ' ' LEU . 31.3 mt . . . . . 0 C--O 1.231 0.124 0 CA-C-O 120.816 0.341 . . . . 0.0 110.877 . . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 40.2 mm -66.54 -40.46 86.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 25.7 mt -66.28 -58.39 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.117 179.856 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -60.58 -31.33 70.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.563 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.66 -64.7 2.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.515 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 79' ' ' GLY . 79.6 t -56.63 -35.1 44.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.839 0.352 . . . . 0.0 111.137 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.1 mtt -65.34 -48.04 74.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.37 90.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.534 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.62 -56.55 5.96 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.486 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.521 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.9 t -54.88 -51.16 55.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.794 0.331 . . . . 0.0 111.138 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.452 HG22 HD12 ' B' ' 89' ' ' LEU . 62.4 mt -60.13 -50.19 81.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.133 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.27 -41.15 94.8 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.421 ' OG1' HG13 ' A' ' 84' ' ' VAL . 56.0 m -62.67 -59.53 4.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.81 0.338 . . . . 0.0 111.162 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.04 -42.96 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.452 HD12 HG22 ' B' ' 85' ' ' ILE . 20.6 mt -57.48 -50.76 71.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.915 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.7 tt -59.56 -42.48 92.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 27.4 mm -65.42 -62.08 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.106 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 1.3 m -54.9 -26.1 33.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 -179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 83.6 t80 . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.96 -179.916 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 1.078 HD12 HD12 ' B' ' 75' ' ' LEU . 16.8 mt . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.749 0.309 . . . . 0.0 110.865 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.5 mm -66.63 -41.89 88.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.166 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.6 mm -66.2 -57.99 8.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -60.59 -31.23 70.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.871 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.432 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.0 -63.9 3.26 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.513 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.529 ' O ' HG23 ' A' ' 84' ' ' VAL . 71.4 t -56.65 -35.93 46.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.868 0.366 . . . . 0.0 111.131 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 19.7 mtp -65.37 -47.31 76.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.847 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.11 -38.16 90.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.041 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.41 -56.73 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.478 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 80' ' ' VAL . 92.9 t -54.92 -48.91 74.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.811 0.339 . . . . 0.0 111.109 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.45 HG22 HD12 ' A' ' 89' ' ' LEU . 34.8 mm -63.94 -48.13 87.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.145 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.78 -36.76 92.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.51 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.56 HG21 HG13 ' B' ' 88' ' ' ILE . 84.4 m -68.54 -58.73 3.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 111.115 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.581 HG13 HG21 ' B' ' 87' ' ' THR . 80.0 mt -56.12 -37.7 50.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.45 HD12 HG22 ' A' ' 85' ' ' ILE . 15.1 mt -65.27 -54.25 32.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -54.4 -48.66 71.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.7 mt -65.11 -56.29 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.149 179.841 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 83.5 p -55.02 -25.11 27.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.85 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 57.8 t80 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.862 . . . . . . . . 0 0 . 1 . 004 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 1.078 HD12 HD12 ' A' ' 75' ' ' LEU . 10.1 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.843 0.354 . . . . 0.0 110.916 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.3 mm -66.74 -42.4 89.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.169 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 17.3 mm -66.09 -57.86 8.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.112 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 45.8 t80 -60.64 -31.22 70.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.431 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.98 -64.04 3.19 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.472 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.517 ' O ' HG23 ' B' ' 84' ' ' VAL . 72.7 t -56.65 -35.85 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.824 0.345 . . . . 0.0 111.125 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.35 -47.4 76.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.98 -38.12 89.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.105 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.43 -56.64 5.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 93.7 t -54.97 -48.66 75.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.785 0.326 . . . . 0.0 111.134 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.467 HG22 HD12 ' B' ' 89' ' ' LEU . 34.6 mm -64.09 -48.05 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.113 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.92 -36.52 92.26 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.485 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.581 HG21 HG13 ' A' ' 88' ' ' ILE . 86.1 m -68.82 -58.27 4.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.75 0.309 . . . . 0.0 111.113 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.56 HG13 HG21 ' A' ' 87' ' ' THR . 76.9 mt -57.1 -37.78 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.092 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.467 HD12 HG22 ' B' ' 85' ' ' ILE . 16.6 mt -65.18 -53.19 48.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.963 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.04 -49.29 71.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.84 -56.91 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 60.5 p -55.0 -24.95 26.71 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 52.8 t80 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.947 -179.898 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.997 HD12 HD12 ' B' ' 75' ' ' LEU . 36.8 mt . . . . . 0 C--O 1.232 0.155 0 CA-C-O 120.755 0.312 . . . . 0.0 110.901 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 51.2 mt -66.78 -39.91 84.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.114 179.856 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 25.0 mt -66.29 -58.11 7.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.82 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -60.36 -31.7 70.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.639 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.43 -65.05 2.8 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.5 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.567 HG22 ' O ' ' B' ' 79' ' ' GLY . 90.1 t -56.37 -35.28 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.186 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 4.1 mmt -65.43 -47.15 77.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -39.07 92.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.101 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.602 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.54 5.7 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.425 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.9 t -55.17 -49.62 70.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.798 0.332 . . . . 0.0 111.146 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.66 -49.72 82.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.139 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.47 -35.32 84.88 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.427 ' OG1' HG13 ' B' ' 84' ' ' VAL . 91.3 m -68.76 -59.3 3.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.759 0.314 . . . . 0.0 111.127 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.09 -37.98 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.174 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 19.2 mt -65.17 -55.14 20.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.75 -48.9 69.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.889 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.7 -55.92 18.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.871 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.6 p -55.32 -24.5 29.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.817 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 19.8 t80 . . . . . 0 C--N 1.327 -0.384 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.926 -179.896 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.997 HD12 HD12 ' A' ' 75' ' ' LEU . 20.4 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.775 0.321 . . . . 0.0 110.92 . . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.26 -43.38 91.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.2 mm -65.97 -57.36 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.12 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -30.99 70.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.567 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.03 -65.05 2.75 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.533 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.639 HG22 ' O ' ' A' ' 79' ' ' GLY . 93.7 t -56.57 -35.27 44.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.823 0.344 . . . . 0.0 111.169 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 35.0 mmm -65.54 -47.71 74.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.49 -38.56 90.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.101 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.527 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.14 -56.2 5.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.476 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 94.6 t -54.91 -49.39 70.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.832 0.348 . . . . 0.0 111.128 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.475 HG22 HD12 ' B' ' 89' ' ' LEU . 74.7 mt -62.75 -49.98 81.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.56 -35.16 84.6 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.424 ' OG1' HG13 ' A' ' 84' ' ' VAL . 92.7 m -68.61 -58.48 4.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 65.3 mt -56.65 -37.74 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.19 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.475 HD12 HG22 ' B' ' 85' ' ' ILE . 16.7 mt -65.2 -53.53 43.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -55.03 -49.19 72.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.64 -56.81 14.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.135 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 23.0 t -55.19 -24.92 29.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.887 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 77.6 t80 . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.908 -179.875 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.928 HD12 HD12 ' B' ' 75' ' ' LEU . 13.2 mt . . . . . 0 C--O 1.231 0.104 0 CA-C-O 120.773 0.32 . . . . 0.0 110.961 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.56 -44.11 90.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.135 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.93 -58.07 8.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.129 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.94 -30.51 70.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.573 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.21 -64.72 2.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.646 HG22 ' O ' ' B' ' 79' ' ' GLY . 88.8 t -56.73 -35.68 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.856 0.36 . . . . 0.0 111.144 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 11.2 mmt -65.6 -47.05 77.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.79 92.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.432 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.18 -56.48 5.68 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.485 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.1 t -55.02 -49.55 70.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.767 0.318 . . . . 0.0 111.088 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.79 -49.95 81.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -34.95 85.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.49 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 97.5 m -68.79 -59.77 2.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.73 0.3 . . . . 0.0 111.129 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.2 mt -54.93 -38.25 44.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.139 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 16.4 mt -65.05 -54.99 21.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.97 -49.34 69.01 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 66.5 mt -64.07 -56.33 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.107 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.4 t -54.65 -25.56 27.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.837 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 37.1 t80 . . . . . 0 C--N 1.328 -0.36 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.883 . . . . . . . . 0 0 . 1 . 006 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.928 HD12 HD12 ' A' ' 75' ' ' LEU . 12.3 mt . . . . . 0 C--O 1.231 0.107 0 CA-C-O 120.785 0.326 . . . . 0.0 110.895 . . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.401 HD11 HD22 ' A' ' 75' ' ' LEU . 59.2 mt -66.54 -42.75 90.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.101 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.7 mm -66.07 -57.01 12.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -60.33 -31.28 70.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.646 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.88 -64.67 2.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.488 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.1 t -56.57 -35.52 45.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.831 0.348 . . . . 0.0 111.111 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.37 -47.32 76.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.57 91.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.6 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.14 -56.04 5.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.49 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 95.8 t -54.92 -49.06 73.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.806 0.336 . . . . 0.0 111.099 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.525 HG22 HD12 ' B' ' 89' ' ' LEU . 60.4 mt -63.13 -49.33 83.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.77 -35.69 87.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.421 ' OG1' HG13 ' A' ' 84' ' ' VAL . 88.4 m -68.87 -59.29 3.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.762 0.315 . . . . 0.0 111.131 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 73.8 mt -55.53 -38.43 49.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.131 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.525 HD12 HG22 ' B' ' 85' ' ' ILE . 23.0 mt -65.19 -53.44 44.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.881 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.1 -49.26 72.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.56 -57.2 12.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 52.3 p -54.91 -25.08 26.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.849 -179.919 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 75.7 t80 . . . . . 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.904 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.786 HD12 HD12 ' B' ' 75' ' ' LEU . 4.6 mt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.812 0.339 . . . . 0.0 110.923 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.2 mt -66.68 -44.97 89.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.193 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.1 mm -66.02 -57.06 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -61.42 -30.33 70.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.621 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.42 -64.21 3.07 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.653 HG22 ' O ' ' B' ' 79' ' ' GLY . 98.3 t -56.94 -35.95 48.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.808 0.337 . . . . 0.0 111.099 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.4 mmt -65.46 -47.14 77.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.873 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.85 -38.76 92.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.102 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.457 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.25 -56.5 5.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.6 t -54.86 -48.9 73.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.813 0.339 . . . . 0.0 111.171 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.1 mm -63.59 -48.14 88.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.151 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.66 -37.37 93.36 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.492 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.548 HG21 HG13 ' B' ' 88' ' ' ILE . 63.4 m -67.93 -58.65 4.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.758 0.314 . . . . 0.0 111.126 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.56 HG13 HG21 ' B' ' 87' ' ' THR . 77.6 mt -55.02 -37.87 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 27.2 mt -65.04 -55.84 16.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.5 tt -53.16 -49.19 67.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.939 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.8 mt -64.35 -56.11 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.823 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 12.8 t -53.16 -26.95 18.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 11.4 t80 . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.907 -179.846 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.786 HD12 HD12 ' A' ' 75' ' ' LEU . 12.9 mt . . . . . 0 C--O 1.231 0.097 0 CA-C-O 120.781 0.325 . . . . 0.0 110.894 . . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.563 HD11 HD22 ' A' ' 75' ' ' LEU . 56.0 mt -65.95 -43.93 92.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.82 -58.11 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.109 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.44 -30.28 69.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.653 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.15 -64.25 3.08 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.498 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 79' ' ' GLY . 96.2 t -56.92 -35.82 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.83 0.347 . . . . 0.0 111.134 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 9.1 mmt -65.46 -47.01 77.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.897 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.13 -38.45 91.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.138 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.51 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.29 -56.57 5.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.481 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.514 HG23 ' O ' ' B' ' 80' ' ' VAL . 99.0 t -54.86 -48.84 73.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.853 0.359 . . . . 0.0 111.198 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.55 HG22 HD12 ' B' ' 89' ' ' LEU . 34.1 mm -63.74 -47.96 88.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.141 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.7 -37.3 93.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.56 HG21 HG13 ' A' ' 88' ' ' ILE . 61.5 m -68.26 -58.88 3.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.746 0.308 . . . . 0.0 111.12 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.548 HG13 HG21 ' A' ' 87' ' ' THR . 78.7 mt -54.79 -37.73 41.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.14 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.55 HD12 HG22 ' B' ' 85' ' ' ILE . 19.3 mt -65.33 -55.5 17.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.875 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -53.86 -48.13 70.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 67.6 mt -65.12 -55.34 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 57.1 p -57.06 -22.4 38.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 21.8 t80 . . . . . 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.928 -179.892 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.554 HD22 HD11 ' B' ' 76' ' ' ILE . 13.7 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.82 0.343 . . . . 0.0 110.897 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 48.0 mt -65.89 -40.83 88.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.833 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 31.0 mt -66.2 -58.32 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.905 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -59.76 -31.12 69.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.64 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.66 -64.68 2.95 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.466 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.533 HG22 ' O ' ' B' ' 79' ' ' GLY . 67.3 t -56.4 -35.63 44.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.348 . . . . 0.0 111.173 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 13.9 mmt -65.38 -47.06 77.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.868 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.81 91.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.155 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.568 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.22 -56.78 5.49 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.5 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 80' ' ' VAL . 92.3 t -54.89 -49.51 69.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.775 0.321 . . . . 0.0 111.152 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.495 HG22 HD12 ' A' ' 89' ' ' LEU . 34.8 mm -63.03 -49.42 83.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.192 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.44 86.71 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.434 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.446 ' OG1' HG13 ' B' ' 84' ' ' VAL . 90.6 m -68.8 -58.79 3.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 111.17 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 64.7 mt -56.69 -37.91 55.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.074 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.495 HD12 HG22 ' A' ' 85' ' ' ILE . 32.1 mt -65.08 -53.62 42.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.407 ' HA ' HD22 ' A' ' 90' ' ' LEU . 0.4 OUTLIER -54.87 -49.41 71.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 62.4 mt -64.52 -56.92 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.131 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 53.7 p -55.04 -24.94 27.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 55.9 t80 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.944 -179.93 . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 5.7 mt . . . . . 0 C--O 1.231 0.123 0 CA-C-O 120.813 0.34 . . . . 0.0 110.914 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.554 HD11 HD22 ' A' ' 75' ' ' LEU . 58.0 mt -66.13 -43.96 91.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.9 mm -65.9 -57.94 8.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -60.7 -30.34 69.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.533 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.27 -64.67 2.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.48 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.64 HG22 ' O ' ' A' ' 79' ' ' GLY . 87.3 t -56.86 -35.79 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.824 0.345 . . . . 0.0 111.132 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.9 mmm -65.57 -46.99 77.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.871 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.99 -38.74 92.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.1 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.435 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.17 -56.62 5.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.479 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.507 HG23 ' O ' ' B' ' 80' ' ' VAL . 99.3 t -54.93 -49.64 68.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 111.109 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.629 HG22 HD12 ' B' ' 89' ' ' LEU . 34.4 mm -62.73 -49.79 82.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.1 -34.82 85.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.47 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 97.0 m -68.74 -58.73 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.795 0.331 . . . . 0.0 111.201 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 62.1 mt -56.55 -37.79 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.629 HD12 HG22 ' B' ' 85' ' ' ILE . 17.8 mt -65.29 -53.51 42.87 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -54.98 -49.07 72.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 62.9 mt -64.77 -56.74 14.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.149 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.4 m -55.25 -24.87 30.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 66.0 t80 . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.909 -179.893 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.972 HD12 HD12 ' B' ' 75' ' ' LEU . 26.0 mt . . . . . 0 C--O 1.232 0.151 0 CA-C-O 120.834 0.349 . . . . 0.0 110.933 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.8 mt -66.36 -42.97 91.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.109 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.6 mm -66.02 -57.77 9.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.123 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -60.32 -30.98 69.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.866 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.623 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.08 -64.89 2.81 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.56 HG22 ' O ' ' B' ' 79' ' ' GLY . 82.5 t -56.41 -35.2 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.809 0.338 . . . . 0.0 111.124 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 26.8 mmt -65.45 -47.84 74.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.28 89.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.113 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.585 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.05 5.97 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 93.6 t -54.83 -49.25 71.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.427 HG22 HD12 ' A' ' 89' ' ' LEU . 61.3 mt -62.71 -48.68 86.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.127 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.11 -37.45 91.69 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.475 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.525 HG21 HG13 ' B' ' 88' ' ' ILE . 39.1 m -67.94 -57.77 5.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.759 0.314 . . . . 0.0 111.169 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.458 HG13 HG21 ' B' ' 87' ' ' THR . 82.2 mt -55.55 -37.72 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.427 HD12 HG22 ' A' ' 85' ' ' ILE . 17.6 mt -65.21 -55.19 19.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.871 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.84 -48.74 69.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.939 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.73 -56.23 17.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 179.771 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 t -55.31 -24.49 28.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 23.1 t80 . . . . . 0 C--N 1.328 -0.329 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.904 -179.865 . . . . . . . . 0 0 . 1 . 009 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.972 HD12 HD12 ' A' ' 75' ' ' LEU . 10.6 mt . . . . . 0 C--O 1.231 0.129 0 CA-C-O 120.758 0.313 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.2 mm -66.47 -43.02 91.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.148 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.5 mm -66.06 -58.0 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.65 -30.96 70.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.889 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.56 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.07 -65.03 2.75 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.524 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 79' ' ' GLY . 90.8 t -56.46 -35.35 43.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.347 . . . . 0.0 111.15 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.3 mmt -65.47 -47.65 75.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.39 90.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.039 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.516 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.08 -56.02 5.98 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.513 HG23 ' O ' ' B' ' 80' ' ' VAL . 94.4 t -54.89 -48.88 73.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.753 0.311 . . . . 0.0 111.124 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 84.7 mt -63.21 -47.94 89.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.76 -38.66 94.23 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.463 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.458 HG21 HG13 ' A' ' 88' ' ' ILE . 30.9 m -67.34 -58.75 4.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.805 0.336 . . . . 0.0 111.129 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.525 HG13 HG21 ' A' ' 87' ' ' THR . 78.7 mt -54.2 -37.61 36.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.086 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 24.6 mt -65.02 -56.26 14.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.06 -49.94 70.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.925 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 78.2 mt -60.33 -53.74 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.083 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 25.8 p -64.4 -15.48 60.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.976 -179.92 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.591 HD22 ' CG1' ' B' ' 76' ' ' ILE . 14.2 mt . . . . . 0 C--O 1.231 0.102 0 CA-C-O 120.821 0.343 . . . . 0.0 110.955 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 36.4 mm -67.11 -39.95 84.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.134 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 30.7 mt -66.5 -59.04 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.848 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -60.71 -31.6 70.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.611 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.78 -64.91 2.83 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.507 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.533 ' O ' HG23 ' A' ' 84' ' ' VAL . 72.6 t -56.22 -34.88 40.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 111.124 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -65.42 -48.67 71.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.15 -38.7 90.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.082 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.599 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.07 -57.37 5.77 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.533 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.6 t -53.77 -50.54 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.817 0.342 . . . . 0.0 111.154 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.588 HG22 HD12 ' A' ' 89' ' ' LEU . 95.9 mt -60.41 -45.01 97.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.083 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.12 -37.35 91.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.462 HG21 HG13 ' B' ' 88' ' ' ILE . 0.7 OUTLIER -69.56 -58.33 4.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.785 0.326 . . . . 0.0 111.133 -179.859 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 77.0 mt -56.49 -37.96 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.06 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.588 HD12 HG22 ' A' ' 85' ' ' ILE . 17.3 mt -65.19 -54.48 29.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.964 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.87 -49.15 69.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.2 mt -64.85 -56.3 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 179.822 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 56.5 p -54.26 -25.51 23.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.84 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 39.4 t80 . . . . . 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.881 -179.83 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.496 HD12 ' CD1' ' A' ' 75' ' ' LEU . 14.1 mt . . . . . 0 C--O 1.231 0.108 0 CA-C-O 120.769 0.319 . . . . 0.0 110.91 . . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.591 ' CG1' HD22 ' A' ' 75' ' ' LEU . 53.4 mt -65.66 -44.16 93.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.146 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 18.8 mm -65.9 -57.02 12.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.32 -30.3 69.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.921 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.494 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.47 -64.4 2.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.4 t -56.68 -35.94 47.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.34 . . . . 0.0 111.117 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.1 mmt -65.69 -47.7 74.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.54 -39.49 91.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.43 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.87 -57.24 5.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.504 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.496 HG23 ' O ' ' B' ' 80' ' ' VAL . 93.3 t -55.1 -49.92 67.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.461 HG22 HD12 ' B' ' 89' ' ' LEU . 34.8 mm -62.37 -47.36 93.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.26 -38.92 91.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.455 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 19.8 m -68.2 -58.05 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.749 0.309 . . . . 0.0 111.16 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.462 HG13 HG21 ' A' ' 87' ' ' THR . 78.8 mt -55.1 -38.39 46.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.077 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.461 HD12 HG22 ' B' ' 85' ' ' ILE . 19.7 mt -65.18 -54.17 33.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.429 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -54.77 -48.81 72.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.932 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.64 -56.72 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 13.2 t -54.87 -25.54 29.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 -179.917 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.2 t80 . . . . . 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.945 -179.934 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 14.8 mt . . . . . 0 C--O 1.231 0.119 0 CA-C-O 120.767 0.318 . . . . 0.0 110.928 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.547 ' CG1' HD22 ' B' ' 75' ' ' LEU . 57.6 mt -66.02 -41.96 90.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 23.9 mm -66.04 -57.03 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.144 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -60.03 -31.27 69.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.612 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.85 -64.61 2.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.501 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.599 HG22 ' O ' ' B' ' 79' ' ' GLY . 87.0 t -56.64 -35.39 45.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.835 0.35 . . . . 0.0 111.152 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.37 -47.41 76.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.894 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.38 90.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.115 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.555 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.1 -55.89 6.05 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.52 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 94.3 t -54.85 -48.75 73.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.804 0.335 . . . . 0.0 111.168 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.3 mt -63.54 -47.99 88.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.129 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.37 -37.3 92.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.536 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.576 HG21 HG13 ' B' ' 88' ' ' ILE . 48.4 m -68.22 -58.87 3.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.748 0.309 . . . . 0.0 111.142 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.569 HG13 HG21 ' B' ' 87' ' ' THR . 75.8 mt -54.91 -37.84 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 24.9 mt -65.14 -55.78 16.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.37 -49.17 67.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.3 mt -64.19 -55.9 19.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.176 179.843 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 23.3 t -53.2 -27.2 20.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 8.7 t80 . . . . . 0 C--N 1.328 -0.35 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.888 -179.821 . . . . . . . . 0 0 . 1 . 011 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.547 HD22 ' CG1' ' A' ' 76' ' ' ILE . 9.8 mt . . . . . 0 C--O 1.232 0.156 0 CA-C-O 120.782 0.325 . . . . 0.0 110.894 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.8 mm -67.11 -43.35 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.5 mm -66.05 -58.01 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.077 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -61.33 -30.92 70.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.599 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.97 -64.67 2.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.485 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 79' ' ' GLY . 99.1 t -57.02 -35.69 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 0.0 111.091 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.9 mmm -65.49 -46.92 77.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.09 -38.8 92.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.516 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.13 -56.54 5.67 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.507 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.511 HG13 ' OG1' ' A' ' 87' ' ' THR . 97.9 t -54.84 -49.19 71.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.813 0.339 . . . . 0.0 111.163 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.508 HG22 HD12 ' B' ' 89' ' ' LEU . 33.9 mm -63.19 -48.72 86.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.24 90.32 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.451 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.569 HG21 HG13 ' A' ' 88' ' ' ILE . 90.9 m -68.41 -58.38 4.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.777 0.322 . . . . 0.0 111.1 -179.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.576 HG13 HG21 ' A' ' 87' ' ' THR . 75.7 mt -55.15 -38.77 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.508 HD12 HG22 ' B' ' 85' ' ' ILE . 17.9 mt -65.15 -53.41 45.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.916 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -55.08 -48.89 72.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.897 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.6 mt -65.0 -56.86 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.098 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 7.4 t -54.89 -25.35 28.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.858 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 46.6 t80 . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.96 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.512 HD22 HD11 ' B' ' 76' ' ' ILE . 5.0 mt . . . . . 0 C--O 1.232 0.152 0 CA-C-O 120.827 0.346 . . . . 0.0 110.902 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.46 ' O ' HG23 ' A' ' 80' ' ' VAL . 60.6 mt -66.53 -41.18 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 36.2 mt -66.11 -58.62 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.141 179.897 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.64 -30.84 70.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.7 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.74 -64.53 3.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.554 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.521 ' O ' HG23 ' A' ' 84' ' ' VAL . 42.0 t -56.74 -35.81 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 111.154 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.8 mmt -65.43 -46.93 78.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.875 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -39.18 93.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.578 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.8 -56.67 5.78 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.516 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 80' ' ' VAL . 94.7 t -55.2 -50.49 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.139 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.537 HG22 HD12 ' A' ' 89' ' ' LEU . 34.3 mm -61.53 -48.74 87.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.95 -39.5 95.68 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.458 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.551 HG21 HG13 ' B' ' 88' ' ' ILE . 74.9 m -64.8 -58.07 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.799 0.333 . . . . 0.0 111.143 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.9 mt -54.44 -42.3 58.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.13 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.537 HD12 HG22 ' A' ' 85' ' ' ILE . 12.9 mt -59.76 -54.75 42.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.38 -51.07 69.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.936 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 0.8 OUTLIER -57.32 -59.54 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.169 179.825 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 80.4 p -53.67 -29.49 38.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 36.0 t80 . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.937 -179.911 . . . . . . . . 0 0 . 1 . 012 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.401 HD22 HD11 ' A' ' 76' ' ' ILE . 5.9 mt . . . . . 0 C--O 1.231 0.094 0 CA-C-O 120.82 0.343 . . . . 0.0 110.9 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.512 HD11 HD22 ' A' ' 75' ' ' LEU . 53.8 mt -65.04 -43.98 95.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.131 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 24.2 mm -65.75 -57.31 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -59.98 -30.07 68.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.497 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.41 -63.85 3.22 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.501 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.7 HG22 ' O ' ' A' ' 79' ' ' GLY . 99.1 t -56.99 -36.23 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.856 0.36 . . . . 0.0 111.158 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -47.08 77.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.886 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.67 -38.7 91.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.075 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.433 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.25 -56.52 5.63 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.474 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.4 t -54.84 -49.21 71.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.857 0.36 . . . . 0.0 111.194 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.46 HG22 HD12 ' B' ' 89' ' ' LEU . 83.2 mt -63.29 -49.23 83.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.081 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.08 -35.56 87.88 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.475 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.9 m -68.88 -59.28 3.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.755 0.312 . . . . 0.0 111.114 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.551 HG13 HG21 ' A' ' 87' ' ' THR . 76.2 mt -55.62 -38.44 50.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.46 HD12 HG22 ' B' ' 85' ' ' ILE . 26.4 mt -65.12 -53.12 50.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -55.44 -49.0 73.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.913 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.2 mt -64.88 -57.12 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.1 m -55.02 -25.26 29.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.845 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 29.2 t80 . . . . . 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.884 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 1.054 HD12 HD12 ' B' ' 75' ' ' LEU . 15.9 mt . . . . . 0 C--O 1.232 0.139 0 CA-C-O 120.771 0.319 . . . . 0.0 110.911 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 42.5 mm -66.52 -42.71 90.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 21.0 mm -66.03 -57.5 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.171 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -60.74 -31.03 70.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.881 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.09 -64.66 2.91 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.582 HG22 ' O ' ' B' ' 79' ' ' GLY . 90.2 t -56.74 -35.46 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.835 0.35 . . . . 0.0 111.097 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.7 mmt -65.48 -47.56 75.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.64 91.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.12 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.66 -56.84 5.76 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.534 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.1 t -54.84 -51.07 56.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.819 0.342 . . . . 0.0 111.149 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.7 mm -60.41 -50.23 81.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.133 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.73 -41.11 95.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.483 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.542 HG21 HG13 ' B' ' 88' ' ' ILE . 77.0 m -62.7 -59.08 5.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.783 0.325 . . . . 0.0 111.129 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.55 HG13 HG21 ' B' ' 87' ' ' THR . 79.4 mt -54.13 -43.92 61.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.3 mt -56.8 -51.04 70.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -59.52 -42.12 91.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.841 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.6 mm -65.42 -63.85 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.181 179.833 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 2.2 t -51.53 -30.68 21.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 71.2 t80 . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 -179.856 . . . . . . . . 0 0 . 1 . 013 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 1.054 HD12 HD12 ' A' ' 75' ' ' LEU . 17.9 mt . . . . . 0 C--O 1.231 0.087 0 CA-C-O 120.744 0.307 . . . . 0.0 110.935 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 56.4 mt -68.03 -41.41 84.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.099 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.4 mm -66.31 -57.74 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.161 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -61.16 -31.73 71.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.582 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.79 -64.03 3.23 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.517 ' O ' HG23 ' B' ' 84' ' ' VAL . 57.8 t -56.84 -35.6 47.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.094 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.1 mmm -65.29 -47.42 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.857 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.16 90.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.557 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.22 -56.65 5.57 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.442 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 97.5 t -54.8 -48.81 73.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.785 0.326 . . . . 0.0 111.101 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.544 HG22 HD12 ' B' ' 89' ' ' LEU . 33.8 mm -63.52 -47.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.163 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.85 -37.78 93.05 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.504 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.55 HG21 HG13 ' A' ' 88' ' ' ILE . 27.5 m -68.79 -59.51 3.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.757 0.313 . . . . 0.0 111.159 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.542 HG13 HG21 ' A' ' 87' ' ' THR . 72.5 mt -54.92 -38.16 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.132 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.544 HD12 HG22 ' B' ' 85' ' ' ILE . 18.8 mt -65.15 -55.1 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.914 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.91 -48.91 69.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.92 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.0 mt -64.58 -56.32 16.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.162 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 59.1 m -54.15 -25.95 25.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 -179.949 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 18.1 t80 . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 -179.904 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.789 HD22 HD11 ' B' ' 76' ' ' ILE . 17.6 mt . . . . . 0 C--O 1.231 0.109 0 CA-C-O 120.78 0.324 . . . . 0.0 110.887 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.619 HD11 HD22 ' B' ' 75' ' ' LEU . 61.0 mt -66.37 -46.42 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.5 mm -65.73 -56.81 13.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.135 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -61.33 -29.86 70.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.499 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.31 -63.69 3.3 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.688 HG22 ' O ' ' B' ' 79' ' ' GLY . 98.3 t -57.47 -36.08 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.802 0.334 . . . . 0.0 111.114 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.44 -46.78 78.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.826 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.06 -38.85 92.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.137 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.44 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.04 -56.43 5.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.511 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 80' ' ' VAL . 95.6 t -55.16 -49.95 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.788 0.327 . . . . 0.0 111.133 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.0 mm -62.35 -49.93 81.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -36.17 88.86 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 96.8 m -67.55 -59.17 3.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.724 0.297 . . . . 0.0 111.148 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.2 mt -54.73 -40.04 49.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 14.5 mt -62.77 -56.41 17.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -52.7 -53.56 45.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.0 mt -59.58 -55.25 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.17 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.3 p -55.12 -25.45 31.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 3.7 t80 . . . . . 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.879 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.619 HD22 HD11 ' A' ' 76' ' ' ILE . 6.2 mt . . . . . 0 C--O 1.232 0.15 0 CA-C-O 120.764 0.316 . . . . 0.0 110.9 . . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.789 HD11 HD22 ' A' ' 75' ' ' LEU . 59.9 mt -66.26 -44.66 91.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.5 mm -65.8 -57.17 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.2 t80 -60.47 -30.25 69.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.688 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.08 -63.44 3.45 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.501 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.515 ' O ' HG23 ' B' ' 84' ' ' VAL . 39.5 t -57.28 -36.04 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.155 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.3 mmt -65.38 -46.93 78.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.934 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.84 92.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.059 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.575 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.06 -56.33 5.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.474 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.515 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.7 t -54.95 -49.28 72.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.342 . . . . 0.0 111.133 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.505 HG22 HD12 ' B' ' 89' ' ' LEU . 77.6 mt -63.03 -49.4 83.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.171 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.5 -35.66 86.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.486 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.434 ' OG1' HG13 ' A' ' 84' ' ' VAL . 87.1 m -68.97 -58.67 3.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.753 0.311 . . . . 0.0 111.171 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.94 -37.91 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.505 HD12 HG22 ' B' ' 85' ' ' ILE . 16.9 mt -65.12 -53.25 48.13 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.92 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -49.41 71.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.64 -57.02 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.118 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 80.8 p -54.79 -25.18 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.843 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 43.7 t80 . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 -179.879 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.495 ' CD1' HD12 ' B' ' 75' ' ' LEU . 5.0 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.805 0.336 . . . . 0.0 110.925 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.449 HD11 HD22 ' B' ' 75' ' ' LEU . 52.3 mt -66.02 -41.31 89.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.137 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 27.4 mt -66.1 -58.75 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 179.853 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -59.68 -31.06 69.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.913 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.623 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.81 -65.79 2.51 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.466 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.671 HG22 ' O ' ' B' ' 79' ' ' GLY . 99.0 t -55.46 -34.73 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.878 0.371 . . . . 0.0 111.13 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.9 mmt -65.31 -50.21 66.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.11 80.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.526 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.19 -55.36 6.29 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.465 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 80' ' ' VAL . 91.1 t -54.96 -49.99 66.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 111.139 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 1.7 mp -63.45 -47.83 89.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.15 -36.66 91.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.456 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.651 ' OG1' HG13 ' B' ' 84' ' ' VAL . 73.1 m -68.88 -58.73 3.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.775 0.322 . . . . 0.0 111.164 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.57 HG13 HG21 ' B' ' 87' ' ' THR . 72.1 mt -55.61 -38.47 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.9 mt -65.2 -53.41 45.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -55.0 -49.33 71.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.9 mt -64.58 -56.68 14.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 60.6 p -55.24 -24.97 30.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.88 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 26.7 t80 . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.93 -179.872 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.495 HD12 ' CD1' ' A' ' 75' ' ' LEU . 4.6 mt . . . . . 0 C--O 1.232 0.135 0 CA-C-O 120.842 0.353 . . . . 0.0 110.947 . . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.433 HD11 HD22 ' A' ' 75' ' ' LEU . 36.6 mt -65.77 -43.33 93.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.126 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.2 mm -65.84 -58.03 8.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.1 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -60.15 -30.29 69.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.671 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.02 -63.83 3.28 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.439 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 79' ' ' GLY . 94.0 t -56.99 -35.81 48.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.808 0.337 . . . . 0.0 111.093 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.4 mmt -65.49 -47.12 77.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.849 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.71 -39.03 92.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.114 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.509 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.82 -56.82 5.68 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.651 HG13 ' OG1' ' A' ' 87' ' ' THR . 91.2 t -55.14 -50.65 62.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.802 0.334 . . . . 0.0 111.146 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.6 mm -61.61 -49.22 85.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -39.27 95.06 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.487 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.57 HG21 HG13 ' A' ' 88' ' ' ILE . 85.5 m -64.66 -58.01 7.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.757 0.313 . . . . 0.0 111.115 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.573 HG13 HG21 ' A' ' 87' ' ' THR . 76.4 mt -54.46 -43.17 62.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.13 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 14.9 mt -59.02 -53.76 54.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.44 -51.71 68.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . 0.401 HG22 ' N ' ' B' ' 92' ' ' SER . 0.8 OUTLIER -56.44 -59.61 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.86 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . 0.401 ' N ' HG22 ' B' ' 91' ' ' ILE . 30.9 t -56.34 -27.11 54.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 59.9 t80 . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.918 -179.876 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 1.061 HD12 HD12 ' B' ' 75' ' ' LEU . 66.3 mt . . . . . 0 C--O 1.232 0.164 0 CA-C-O 120.746 0.307 . . . . 0.0 110.844 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 41.2 mm -66.3 -40.02 85.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 34.2 mt -66.24 -58.26 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.097 179.865 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -60.04 -31.44 69.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.867 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.537 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.76 -65.03 2.78 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.525 ' O ' HG23 ' A' ' 84' ' ' VAL . 99.4 t -56.15 -35.45 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.344 . . . . 0.0 111.122 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.39 -47.9 74.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.92 -38.91 90.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.527 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.11 -56.53 5.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.4 t -55.03 -49.33 72.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.844 0.354 . . . . 0.0 111.129 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.51 HG22 HD12 ' A' ' 89' ' ' LEU . 92.7 mt -62.75 -49.71 82.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.074 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.32 -35.66 85.73 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.479 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.426 ' OG1' HG13 ' B' ' 84' ' ' VAL . 86.7 m -68.67 -58.71 3.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.783 0.325 . . . . 0.0 111.154 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.8 mt -56.46 -37.78 53.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.51 HD12 HG22 ' A' ' 85' ' ' ILE . 22.3 mt -65.25 -53.54 42.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.941 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.06 -49.09 72.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.917 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.66 -56.66 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.151 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 54.4 p -55.56 -24.5 32.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.927 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.7 t80 . . . . . 0 C--N 1.329 -0.3 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.916 -179.857 . . . . . . . . 0 0 . 1 . 016 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 1.061 HD12 HD12 ' A' ' 75' ' ' LEU . 12.1 mt . . . . . 0 C--O 1.231 0.122 0 CA-C-O 120.825 0.345 . . . . 0.0 110.892 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 41.6 mm -66.53 -40.14 85.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.094 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 29.2 mt -66.38 -57.86 8.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.125 179.867 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -60.52 -31.72 70.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.512 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.58 -64.03 3.26 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.507 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.537 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.2 t -56.78 -35.69 46.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 111.145 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 18.0 mmm -65.33 -47.02 77.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -39.05 93.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.093 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.513 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.05 -56.26 5.87 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.482 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.507 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.6 t -54.97 -49.54 70.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.793 0.33 . . . . 0.0 111.14 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.465 HG22 HD12 ' B' ' 89' ' ' LEU . 33.4 mm -62.72 -49.32 84.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.163 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.71 -35.69 87.1 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.496 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.1 m -68.64 -59.27 3.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.749 0.309 . . . . 0.0 111.126 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 67.5 mt -54.91 -37.95 43.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.465 HD12 HG22 ' B' ' 85' ' ' ILE . 29.0 mt -65.19 -55.44 18.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -53.83 -48.7 69.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.62 -54.68 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 42.8 t -53.76 -27.83 31.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.847 -179.938 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 6.0 t80 . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.869 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 1.051 HD12 HD12 ' B' ' 75' ' ' LEU . 29.0 mt . . . . . 0 C--O 1.231 0.096 0 CA-C-O 120.78 0.324 . . . . 0.0 110.893 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.8 mm -66.52 -40.09 85.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.085 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 37.8 mt -66.33 -58.56 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.868 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -60.39 -31.57 70.49 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.897 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.526 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.65 -65.06 2.78 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.521 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.522 ' O ' HG23 ' A' ' 84' ' ' VAL . 72.0 t -56.24 -35.37 42.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 111.118 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 16.4 mtp -65.37 -47.4 76.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.69 -38.78 91.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.484 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.12 -56.48 5.71 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.8 t -55.0 -49.43 71.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.845 0.355 . . . . 0.0 111.158 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.439 HG22 HD12 ' A' ' 89' ' ' LEU . 33.8 mm -62.83 -48.66 87.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -37.8 93.09 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.401 ' OG1' HG13 ' B' ' 84' ' ' VAL . 62.6 m -67.25 -58.93 3.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.788 0.328 . . . . 0.0 111.138 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 78.4 mt -54.24 -38.64 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.152 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.439 HD12 HG22 ' A' ' 85' ' ' ILE . 15.5 mt -64.03 -55.81 19.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.36 -49.8 71.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 84.7 mt -60.51 -53.43 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 36.1 t -64.92 -14.92 61.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.913 -179.898 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 1.051 HD12 HD12 ' A' ' 75' ' ' LEU . 11.4 mt . . . . . 0 C--O 1.232 0.142 0 CA-C-O 120.728 0.299 . . . . 0.0 110.912 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.8 mm -66.14 -42.63 91.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.161 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 16.9 mm -66.0 -57.23 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.24 -31.05 69.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.02 -64.52 2.98 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.468 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.526 HG22 ' O ' ' A' ' 79' ' ' GLY . 97.2 t -56.58 -35.55 45.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.817 0.342 . . . . 0.0 111.136 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.3 mmm -65.43 -47.38 76.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -38.75 91.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.503 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.2 -56.63 5.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.509 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.8 t -54.92 -49.54 69.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.853 0.359 . . . . 0.0 111.14 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.433 HG22 HD12 ' B' ' 89' ' ' LEU . 34.4 mm -62.76 -49.61 83.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.31 86.3 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.518 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 91.8 m -68.71 -58.78 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.775 0.321 . . . . 0.0 111.179 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 70.4 mt -56.02 -38.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.102 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.433 HD12 HG22 ' B' ' 85' ' ' ILE . 34.2 mt -65.28 -53.5 43.24 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.14 -49.06 72.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.5 mt -64.71 -56.79 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 28.4 t -55.27 -24.98 30.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.9 t80 . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 -179.886 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.625 HD12 HD12 ' B' ' 75' ' ' LEU . 36.4 mt . . . . . 0 C--O 1.231 0.13 0 CA-C-O 120.815 0.34 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.6 mt -67.62 -39.54 82.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.145 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.0 mt -66.35 -58.81 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 179.895 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -61.11 -31.68 71.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.443 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.42 -65.17 2.76 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.458 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.545 HG22 ' O ' ' B' ' 79' ' ' GLY . 77.2 t -56.46 -35.67 44.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.783 0.325 . . . . 0.0 111.116 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 10.8 mmt -65.41 -46.9 78.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.98 93.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.491 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.2 -56.48 5.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 80' ' ' VAL . 99.2 t -54.97 -49.02 74.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.865 0.364 . . . . 0.0 111.147 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.503 HG22 HD12 ' A' ' 89' ' ' LEU . 33.9 mm -63.41 -48.18 88.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.17 -37.38 92.82 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.488 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.554 HG21 HG13 ' B' ' 88' ' ' ILE . 57.4 m -68.0 -58.16 4.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.814 0.34 . . . . 0.0 111.165 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.583 HG13 HG21 ' B' ' 87' ' ' THR . 79.0 mt -55.5 -37.74 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.503 HD12 HG22 ' A' ' 85' ' ' ILE . 15.8 mt -65.19 -55.29 19.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.919 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -53.54 -48.94 68.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.919 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 62.0 mt -64.72 -56.38 16.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.867 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.2 t -54.22 -25.59 23.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 15.4 t80 . . . . . 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.916 -179.882 . . . . . . . . 0 0 . 1 . 018 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.625 HD12 HD12 ' A' ' 75' ' ' LEU . 24.8 mt . . . . . 0 C--O 1.231 0.131 0 CA-C-O 120.746 0.308 . . . . 0.0 110.906 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . 0.473 ' O ' HG23 ' B' ' 80' ' ' VAL . 53.6 mt -66.2 -40.44 86.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 29.8 mt -66.32 -57.89 8.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.115 179.88 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -60.15 -31.35 70.01 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.545 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.75 -64.81 2.88 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.463 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.516 ' O ' HG23 ' B' ' 84' ' ' VAL . 36.3 t -56.51 -35.52 44.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.794 0.33 . . . . 0.0 111.134 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.2 mmm -65.37 -47.59 75.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.834 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.66 -38.33 89.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.521 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.23 -56.12 5.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.45 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.516 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.1 t -54.93 -48.81 74.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 111.144 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.451 HG22 HD12 ' B' ' 89' ' ' LEU . 81.9 mt -63.61 -48.24 87.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.129 179.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.99 -37.05 92.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.583 HG21 HG13 ' A' ' 88' ' ' ILE . 54.7 m -68.46 -58.77 3.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.805 0.336 . . . . 0.0 111.202 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.554 HG13 HG21 ' A' ' 87' ' ' THR . 75.5 mt -55.7 -38.19 49.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.151 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.451 HD12 HG22 ' B' ' 85' ' ' ILE . 17.7 mt -65.13 -53.72 40.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.05 -49.08 72.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.959 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.4 mt -64.59 -56.99 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.165 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 50.0 p -55.18 -24.88 29.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 54.3 t80 . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.947 -179.926 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . 0.497 HD12 ' CD1' ' B' ' 75' ' ' LEU . 12.4 mt . . . . . 0 C--O 1.232 0.158 0 CA-C-O 120.783 0.325 . . . . 0.0 110.899 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.48 HD11 HD22 ' B' ' 75' ' ' LEU . 38.1 mt -66.27 -41.71 89.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.145 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.9 mm -66.06 -57.86 8.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.123 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -60.15 -31.27 69.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.595 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.66 -64.48 3.04 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.547 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.531 ' O ' HG23 ' A' ' 84' ' ' VAL . 65.7 t -56.56 -35.5 44.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.863 0.363 . . . . 0.0 111.172 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 17.2 mmm -65.29 -47.21 77.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.64 91.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.544 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.5 5.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 95.4 t -54.94 -49.34 71.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.161 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.6 mm -62.99 -47.62 91.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -61.09 -39.33 96.96 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.488 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 88' ' ' ILE . 54.1 m -65.96 -57.45 7.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.781 0.324 . . . . 0.0 111.139 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . 0.532 HG13 HG21 ' B' ' 87' ' ' THR . 79.0 mt -57.15 -45.55 84.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.1 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.47 -52.96 63.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.93 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . 0.406 ' HA ' HD22 ' A' ' 90' ' ' LEU . 0.4 OUTLIER -54.7 -55.81 25.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.908 179.871 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 74.8 mt -57.3 -59.42 3.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.7 p -53.07 -27.52 20.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.4 t80 . . . . . 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.949 -179.878 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.497 ' CD1' HD12 ' A' ' 75' ' ' LEU . 10.7 mt . . . . . 0 C--O 1.231 0.105 0 CA-C-O 120.812 0.339 . . . . 0.0 110.942 . . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.1 mm -67.19 -44.4 87.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.082 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.1 mm -66.05 -57.7 9.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -61.45 -30.8 70.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.911 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.517 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.16 -64.5 2.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.506 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 79' ' ' GLY . 77.1 t -56.96 -35.83 48.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.789 0.328 . . . . 0.0 111.12 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 1.6 mmt -65.31 -47.21 77.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.49 91.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.107 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.454 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.31 -56.25 5.74 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.478 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.1 t -54.91 -48.85 74.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 111.121 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.5 mm -63.51 -48.6 86.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.7 92.03 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.526 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.532 HG21 HG13 ' A' ' 88' ' ' ILE . 90.0 m -68.12 -58.47 4.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.738 0.304 . . . . 0.0 111.186 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . 0.558 HG13 HG21 ' A' ' 87' ' ' THR . 75.7 mt -55.36 -37.88 46.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.132 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 28.7 mt -65.18 -55.06 20.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . 0.427 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -53.97 -48.97 69.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.87 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.6 mt -64.45 -56.23 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 179.835 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 13.6 t -54.46 -25.55 25.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.86 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 34.6 t80 . . . . . 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.948 -179.872 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 75' ' ' LEU . . . . . . . . . . . . . 38.7 mt . . . . . 0 C--O 1.231 0.113 0 CA-C-O 120.803 0.335 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' A' A ' 76' ' ' ILE . . . . . 0.457 HD11 HD22 ' B' ' 75' ' ' LEU . 37.4 mm -65.68 -48.39 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 77' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 78' ' ' PHE . 1.1 mp -65.32 -54.81 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 78' ' ' PHE . . . . . 0.401 ' N ' HG22 ' A' ' 77' ' ' ILE . 42.7 t80 -60.79 -30.91 70.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.891 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 79' ' ' GLY . . . . . 0.614 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.89 -64.06 3.07 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.496 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 80' ' ' VAL . . . . . 0.649 HG22 ' O ' ' B' ' 79' ' ' GLY . 95.6 t -57.0 -35.64 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 111.145 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.4 mmt -65.66 -47.61 74.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.867 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.95 -39.23 91.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 83' ' ' GLY . . . . . 0.546 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.97 -56.45 5.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.516 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 84' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 80' ' ' VAL . 93.7 t -54.94 -49.38 71.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.809 0.337 . . . . 0.0 111.153 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 85' ' ' ILE . . . . . 0.576 HG22 HD12 ' A' ' 89' ' ' LEU . 33.2 mm -62.52 -49.7 82.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.171 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -35.15 85.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.519 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.7 m -68.57 -59.6 3.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.153 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.9 mt -55.3 -37.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.101 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 89' ' ' LEU . . . . . 0.576 HD12 HG22 ' A' ' 85' ' ' ILE . 13.3 mt -65.12 -55.18 20.21 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.901 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.58 -49.01 68.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.943 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.2 mt -64.72 -55.77 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.844 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 67.3 m -53.97 -26.14 24.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 20.5 t80 . . . . . 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.941 -179.89 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild core ' B' B ' 75' ' ' LEU . . . . . 0.457 HD22 HD11 ' A' ' 76' ' ' ILE . 12.5 mt . . . . . 0 C--O 1.232 0.157 0 CA-C-O 120.763 0.316 . . . . 0.0 110.913 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 37.2 mt -66.64 -41.13 87.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.106 179.866 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.6 mm -66.11 -56.83 12.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.165 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -31.87 70.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 79' ' ' GLY . . . . . 0.649 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.58 -65.05 2.79 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.515 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 80' ' ' VAL . . . . . 0.614 HG22 ' O ' ' A' ' 79' ' ' GLY . 88.1 t -56.68 -35.07 44.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 111.161 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -47.01 77.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.86 -38.89 92.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.085 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 83' ' ' GLY . . . . . 0.615 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.08 -56.39 5.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.509 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 84' ' ' VAL . . . . . 0.51 HG23 ' O ' ' B' ' 80' ' ' VAL . 97.6 t -54.86 -49.21 71.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.849 0.357 . . . . 0.0 111.119 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 85' ' ' ILE . . . . . 0.524 HG22 HD12 ' B' ' 89' ' ' LEU . 33.0 mm -62.96 -49.29 84.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.133 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.01 -35.31 86.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.495 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 87' ' ' THR . . . . . 0.422 ' OG1' HG13 ' A' ' 84' ' ' VAL . 84.8 m -68.91 -59.17 3.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.762 0.315 . . . . 0.0 111.115 -179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.3 mt -55.85 -38.09 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.135 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 89' ' ' LEU . . . . . 0.524 HD12 HG22 ' B' ' 85' ' ' ILE . 13.7 mt -65.25 -53.56 42.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.889 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild core ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -48.96 72.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.1 mt -64.86 -56.89 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.151 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 8.7 t -55.18 -24.94 29.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.834 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild core ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 76.4 t80 . . . . . 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.883 -179.824 . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 4.9 pm0 . . . . . 0 C--O 1.231 0.131 0 CA-C-O 121.652 0.739 . . . . 0.0 110.903 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 102.48 1.03 Allowed 'Trans proline' 0 C--N 1.342 0.185 0 C-N-CA 122.723 2.282 . . . . 0.0 112.331 179.954 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.542 ' HG2' HD13 ' B' ' 75' ' ' LEU . 0.5 OUTLIER -108.32 -57.96 2.05 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.915 179.959 . . . . . . . . 3 3 . 1 . 001 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 80.1 mt -50.82 -31.53 10.11 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.116 179.978 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 91.8 m -63.96 -50.7 67.6 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.153 179.977 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.846 HD12 HD12 ' B' ' 75' ' ' LEU . 22.8 mt -64.44 -37.31 87.07 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.863 179.974 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 58.8 mt -65.95 -41.99 90.95 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.187 179.834 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.1 mm -66.15 -57.3 11.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.125 179.844 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.18 -31.22 69.93 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.875 179.971 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.587 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.95 -64.53 2.98 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.459 -179.972 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.559 HG22 ' O ' ' B' ' 79' ' ' GLY . 78.5 t -56.52 -35.45 44.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-O 120.792 0.329 . . . . 0.0 111.111 -179.964 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.0 mmt -65.4 -47.31 76.75 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.863 179.934 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.43 90.89 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.292 -0.413 . . . . 0.0 111.087 179.918 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.534 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.22 -56.59 5.6 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.464 -179.921 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.528 HG23 ' O ' ' A' ' 80' ' ' VAL . 99.6 t -54.83 -49.05 72.79 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.279 0 CA-C-O 120.802 0.334 . . . . 0.0 111.121 -179.949 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.604 HG22 HD12 ' A' ' 89' ' ' LEU . 34.1 mm -63.44 -48.3 87.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.168 179.927 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.76 -36.11 91.19 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.49 179.912 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 88' ' ' ILE . 88.8 m -68.58 -58.35 4.4 Favored 'General case' 0 C--N 1.33 -0.256 0 CA-C-O 120.83 0.348 . . . . 0.0 111.186 -179.875 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.568 HG13 HG21 ' B' ' 87' ' ' THR . 70.8 mt -56.37 -37.98 53.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.138 179.861 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.604 HD12 HG22 ' A' ' 85' ' ' ILE . 15.7 mt -65.26 -53.45 44.06 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.962 179.908 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -55.0 -48.95 72.66 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.94 179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.9 mt -64.96 -56.74 14.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.102 179.851 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 30.3 t -55.19 -24.8 28.89 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.855 -179.916 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 41.0 t80 -70.21 -52.93 19.52 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.907 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . 0.475 ' O ' HD12 ' A' ' 98' ' ' LEU . . . -61.7 -26.35 66.73 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.493 179.968 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 44.0 mt -77.25 -27.68 16.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.861 0.363 . . . . 0.0 111.121 -179.955 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -64.4 -24.66 67.71 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.839 179.985 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 9.0 ttm180 -85.04 -36.58 21.15 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.846 -179.896 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.475 HD12 ' O ' ' A' ' 94' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.349 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.927 179.992 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 34.7 mt-10 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.682 0.753 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 001 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.77 167.07 25.51 Favored 'Trans proline' 0 C--N 1.342 0.206 0 C-N-CA 122.672 2.248 . . . . 0.0 112.343 -179.983 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.556 ' HA ' HD13 ' A' ' 75' ' ' LEU . 4.8 mt-10 71.65 -69.45 0.18 Allowed 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.87 -179.999 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 45.0 mm -50.69 -30.76 8.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.131 -0.486 . . . . 0.0 111.112 -179.984 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 85.3 m -65.89 -47.72 73.88 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.141 179.961 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.846 HD12 HD12 ' A' ' 75' ' ' LEU . 11.0 mt -66.24 -36.87 84.14 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.907 179.986 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.426 HD11 HD22 ' A' ' 75' ' ' LEU . 36.7 mm -66.97 -42.87 89.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.133 179.828 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.3 mm -66.04 -57.62 9.86 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.145 179.856 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -61.06 -31.03 70.7 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.897 179.97 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.559 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.04 -64.6 2.94 Favored Glycine 0 N--CA 1.451 -0.359 0 C-N-CA 120.808 -0.71 . . . . 0.0 112.472 -179.989 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.587 HG22 ' O ' ' A' ' 79' ' ' GLY . 97.2 t -56.87 -35.66 47.41 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.273 0 CA-C-O 120.802 0.334 . . . . 0.0 111.102 -179.954 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 42.7 mmm -65.3 -47.08 77.84 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.863 179.906 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.07 -38.6 91.82 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.118 179.956 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.507 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.23 -56.41 5.7 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.761 -0.733 . . . . 0.0 112.491 -179.945 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.513 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.6 t -54.89 -49.02 73.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.813 0.339 . . . . 0.0 111.122 -179.967 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.619 HG22 HD12 ' B' ' 89' ' ' LEU . 34.0 mm -63.41 -48.34 87.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.17 179.902 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.8 -36.18 91.4 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.734 -0.746 . . . . 0.0 112.5 179.907 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.568 HG21 HG13 ' A' ' 88' ' ' ILE . 91.8 m -68.44 -57.51 5.74 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.775 0.321 . . . . 0.0 111.118 -179.867 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.558 HG13 HG21 ' A' ' 87' ' ' THR . 76.6 mt -57.69 -37.6 60.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.154 179.928 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.619 HD12 HG22 ' B' ' 85' ' ' ILE . 16.4 mt -65.23 -53.01 50.9 Favored 'General case' 0 C--N 1.328 -0.358 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.923 179.885 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.2 -49.36 72.12 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.196 -0.456 . . . . 0.0 110.909 179.891 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.77 -56.8 14.1 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.33 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.116 179.837 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 29.8 t -55.16 -24.94 29.05 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.847 -179.883 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 22.9 t80 -75.12 -50.92 14.79 Favored 'General case' 0 C--N 1.327 -0.375 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.911 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.89 -36.18 92.79 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.45 179.997 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.1 tt -75.69 -21.54 15.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.804 0.335 . . . . 0.0 111.136 -179.965 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.05 -26.3 68.19 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.844 -179.998 . . . . . . . . 2 2 . 1 . 001 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 13.5 ttp180 -145.76 42.95 1.25 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.88 -179.86 . . . . . . . . 1 1 . 1 . 001 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 3.4 mt . . . . . 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.926 -179.973 . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 12.9 mt-10 . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.648 0.737 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.79 97.0 0.62 Allowed 'Trans proline' 0 C--N 1.342 0.191 0 C-N-CA 122.695 2.263 . . . . 0.0 112.313 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 8.4 pt-20 -164.08 -48.72 0.03 OUTLIER 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.906 179.969 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 54.5 mt -50.62 -31.05 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.176 -0.465 . . . . 0.0 111.111 179.993 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.0 m -65.49 -48.17 73.5 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.152 -0.476 . . . . 0.0 111.126 179.989 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 1.027 HD12 HD12 ' B' ' 75' ' ' LEU . 25.1 mt -65.95 -37.07 85.08 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.921 -179.999 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.4 mm -66.39 -43.02 91.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.198 -0.455 . . . . 0.0 111.155 179.808 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.0 mm -66.04 -57.74 9.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.1 179.845 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.56 -30.71 69.95 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.859 -179.999 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.555 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.12 -64.29 3.07 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.754 -0.736 . . . . 0.0 112.474 -179.962 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.6 HG22 ' O ' ' B' ' 79' ' ' GLY . 91.4 t -56.93 -35.5 47.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.808 0.337 . . . . 0.0 111.117 -179.942 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 2.7 mmt -65.54 -47.43 75.9 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.851 179.908 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.79 -38.83 92.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.068 179.94 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.511 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.7 -56.62 5.87 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.699 -0.762 . . . . 0.0 112.523 -179.944 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.592 HG13 ' OG1' ' B' ' 87' ' ' THR . 99.2 t -54.94 -50.91 58.43 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-O 120.813 0.339 . . . . 0.0 111.154 -179.99 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.3 mm -60.45 -50.56 79.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.147 179.878 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.78 -40.7 95.35 Favored Glycine 0 N--CA 1.45 -0.376 0 C-N-CA 120.762 -0.733 . . . . 0.0 112.478 179.913 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.552 HG21 HG13 ' B' ' 88' ' ' ILE . 87.9 m -62.62 -59.02 5.51 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-O 120.728 0.299 . . . . 0.0 111.127 -179.844 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.565 HG13 HG21 ' B' ' 87' ' ' THR . 77.8 mt -54.14 -44.2 62.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.263 -0.426 . . . . 0.0 111.145 179.896 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 12.7 mt -56.46 -51.12 69.65 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.898 179.889 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -59.53 -42.02 91.35 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.936 179.88 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 27.9 mm -65.53 -63.7 0.85 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.2 -0.454 . . . . 0.0 111.148 179.868 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 3.8 m -51.65 -30.55 22.04 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.87 -179.959 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 42.2 t80 -70.69 -52.9 18.06 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.096 -0.502 . . . . 0.0 110.906 -179.832 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.71 -25.67 74.96 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.509 179.983 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 18.6 mm -76.87 -29.88 17.98 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.826 0.345 . . . . 0.0 111.132 -179.988 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.1 OUTLIER -67.34 -56.45 9.69 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.879 179.973 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -155.22 43.92 0.47 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.865 -179.922 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.291 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.94 -179.961 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 22.2 tt0 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 121.672 0.749 . . . . 0.0 110.911 . . . . . . . . . 0 0 . 1 . 002 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.77 136.63 33.45 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.663 2.242 . . . . 0.0 112.381 -179.998 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.437 ' HA ' HD13 ' A' ' 75' ' ' LEU . 0.0 OUTLIER -126.21 -51.54 1.53 Allowed 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.888 -179.998 . . . . . . . . 3 3 . 1 . 002 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . 0.633 HG22 HD11 ' B' ' 77' ' ' ILE . 4.4 mt -50.13 -33.57 9.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.149 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 94.5 m -63.29 -51.2 67.05 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.165 -0.471 . . . . 0.0 111.132 179.95 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 1.027 HD12 HD12 ' A' ' 75' ' ' LEU . 13.9 mt -62.35 -36.96 83.86 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.879 179.977 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.4 mm -67.08 -39.98 84.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.152 179.853 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . 0.633 HD11 HG22 ' B' ' 73' ' ' ILE . 26.9 mt -66.39 -58.49 6.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.097 179.893 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -60.8 -31.5 70.89 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.871 179.958 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.6 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.78 -64.92 2.83 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.432 -179.951 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.555 HG22 ' O ' ' A' ' 79' ' ' GLY . 82.2 t -56.32 -35.34 42.81 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.776 0.322 . . . . 0.0 111.115 -179.903 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 27.8 mmt -65.24 -47.93 75.06 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.879 179.899 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.87 -37.88 88.66 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.072 179.942 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.588 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.24 -55.8 6.03 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.477 -179.97 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' B' ' 80' ' ' VAL . 92.8 t -54.78 -48.38 73.26 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.258 0 CA-C-O 120.833 0.349 . . . . 0.0 111.146 -179.955 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.503 HG22 HD12 ' B' ' 89' ' ' LEU . 61.9 mt -63.6 -48.45 86.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.154 179.898 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.19 -36.58 91.1 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.464 179.962 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.592 ' OG1' HG13 ' A' ' 84' ' ' VAL . 53.0 m -68.46 -58.22 4.66 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-O 120.773 0.32 . . . . 0.0 111.144 -179.9 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.552 HG13 HG21 ' A' ' 87' ' ' THR . 72.6 mt -56.66 -37.8 54.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.136 179.887 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.503 HD12 HG22 ' B' ' 85' ' ' ILE . 18.2 mt -65.16 -53.54 43.31 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.938 179.89 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -54.97 -49.18 72.07 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.875 179.919 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.52 HG22 HD12 ' B' ' 95' ' ' ILE . 65.6 mt -64.67 -57.01 13.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.162 179.852 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 75.7 m -54.97 -25.08 27.27 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.86 -179.886 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 38.3 t80 -71.17 -52.61 18.22 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.089 -0.505 . . . . 0.0 110.947 -179.938 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -62.33 -30.88 77.42 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.727 -0.749 . . . . 0.0 112.494 179.943 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . 0.52 HD12 HG22 ' B' ' 91' ' ' ILE . 10.6 mt -76.52 -29.33 18.43 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-O 120.763 0.316 . . . . 0.0 111.145 -179.984 . . . . . . . . 2 2 . 1 . 002 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ttp180 -64.81 -25.67 68.01 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.857 179.974 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 13.1 ttm180 -145.01 43.35 1.33 Allowed 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.842 -179.948 . . . . . . . . 1 1 . 1 . 002 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.889 179.969 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.7 mt-10 . . . . . 0 C--O 1.231 0.128 0 CA-C-O 121.621 0.724 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.83 90.01 0.53 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.695 2.263 . . . . 0.0 112.305 -179.957 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 7.8 pt-20 -179.2 -49.28 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.894 179.995 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 5.4 mt -51.05 -30.29 9.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.161 -0.472 . . . . 0.0 111.103 179.977 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 3.6 m -64.69 -49.66 70.06 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.126 -0.488 . . . . 0.0 111.127 179.983 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.973 HD12 HD12 ' B' ' 75' ' ' LEU . 27.3 mt -66.0 -37.63 86.43 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.259 -0.428 . . . . 0.0 110.908 179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.1 mm -66.44 -42.98 91.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.875 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.0 mm -65.97 -58.08 8.12 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.121 179.862 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.36 -30.94 69.88 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.874 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.577 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.98 -64.69 2.9 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.497 -179.928 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.563 HG22 ' O ' ' B' ' 79' ' ' GLY . 80.5 t -56.48 -35.6 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.866 0.365 . . . . 0.0 111.141 -179.999 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 3.0 mmt -65.41 -47.16 77.22 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.919 179.915 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.05 -38.47 91.32 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-N 116.229 -0.441 . . . . 0.0 111.088 179.92 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.525 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.12 -56.66 5.61 Favored Glycine 0 N--CA 1.452 -0.3 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.461 -179.955 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.527 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.5 t -54.9 -49.72 67.99 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.252 0 CA-C-O 120.825 0.345 . . . . 0.0 111.134 -179.97 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.71 -49.12 84.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.946 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.02 -35.61 87.79 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.477 179.892 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.427 ' OG1' HG13 ' B' ' 84' ' ' VAL . 86.7 m -68.57 -58.19 4.64 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-O 120.769 0.319 . . . . 0.0 111.098 -179.81 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.406 HG13 HG21 ' B' ' 87' ' ' THR . 67.2 mt -56.03 -38.28 52.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.115 179.904 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.5 mt -65.21 -53.39 45.35 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.879 179.951 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.1 -49.01 72.78 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.934 179.907 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.87 -56.71 14.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.141 179.828 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 34.6 t -55.2 -25.04 30.29 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.884 -179.918 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 68.6 t80 -69.48 -51.71 33.44 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.93 -179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.61 -25.21 75.76 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.791 -0.719 . . . . 0.0 112.48 179.94 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.5 mm -75.68 -23.91 16.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.83 0.347 . . . . 0.0 111.102 -179.956 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.52 -12.59 54.21 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.87 -179.966 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.7 OUTLIER -143.67 37.44 1.33 Allowed 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 -179.945 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 93.8 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.915 -179.99 . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 2.1 mt-10 . . . . . 0 C--O 1.231 0.1 0 CA-C-O 121.663 0.744 . . . . 0.0 110.885 . . . . . . . . . 0 0 . 1 . 003 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.72 154.62 67.69 Favored 'Trans proline' 0 C--N 1.341 0.18 0 C-N-CA 122.722 2.281 . . . . 0.0 112.349 179.993 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 12.1 pt-20 -125.11 -42.54 2.01 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 179.996 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . 0.634 HG22 HD11 ' B' ' 77' ' ' ILE . 4.3 mt -50.02 -33.73 9.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.101 179.987 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 93.5 m -62.96 -51.58 66.35 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.151 179.939 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.973 HD12 HD12 ' A' ' 75' ' ' LEU . 31.3 mt -62.21 -36.94 83.48 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.877 -179.988 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 40.2 mm -66.54 -40.46 86.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.158 179.834 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . 0.634 HD11 HG22 ' B' ' 73' ' ' ILE . 25.7 mt -66.28 -58.39 6.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.117 179.856 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 46.3 t80 -60.58 -31.33 70.47 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.885 179.968 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.563 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.66 -64.7 2.94 Favored Glycine 0 N--CA 1.45 -0.379 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.515 -179.981 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.577 HG22 ' O ' ' A' ' 79' ' ' GLY . 79.6 t -56.63 -35.1 44.02 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.251 0 CA-C-O 120.839 0.352 . . . . 0.0 111.137 -179.968 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.1 mtt -65.34 -48.04 74.38 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.874 179.901 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.37 90.04 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.111 179.89 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.534 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.62 -56.55 5.96 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.486 -179.921 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.521 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.9 t -54.88 -51.16 55.51 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.27 0 CA-C-O 120.794 0.331 . . . . 0.0 111.138 -179.977 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.452 HG22 HD12 ' B' ' 89' ' ' LEU . 62.4 mt -60.13 -50.19 81.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.133 179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.27 -41.15 94.8 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.695 -0.764 . . . . 0.0 112.473 179.952 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.421 ' OG1' HG13 ' A' ' 84' ' ' VAL . 56.0 m -62.67 -59.53 4.78 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-O 120.81 0.338 . . . . 0.0 111.162 -179.91 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 77.4 mt -54.04 -42.96 57.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.095 179.944 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.452 HD12 HG22 ' B' ' 85' ' ' ILE . 20.6 mt -57.48 -50.76 71.98 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.915 179.923 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.7 tt -59.56 -42.48 92.53 Favored 'General case' 0 C--N 1.328 -0.346 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.911 179.882 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 27.4 mm -65.42 -62.08 1.4 Allowed 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.106 179.865 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . 0.462 ' HA ' HG22 ' B' ' 95' ' ' ILE . 1.3 m -54.9 -26.1 33.54 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.869 -179.901 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 83.6 t80 -72.47 -57.83 3.86 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.96 -179.916 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -61.8 -36.32 92.58 Favored Glycine 0 N--CA 1.452 -0.276 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.457 179.962 . . . . . . . . 1 1 . 1 . 003 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . 0.462 HG22 ' HA ' ' B' ' 92' ' ' SER . 5.2 tt -75.53 -18.51 15.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.851 0.357 . . . . 0.0 111.138 -179.946 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.21 -42.15 93.8 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.116 -0.493 . . . . 0.0 110.831 179.991 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 1.0 OUTLIER -89.78 -60.05 2.04 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.838 -179.925 . . . . . . . . 2 2 . 1 . 003 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.346 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.923 -179.951 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--O 1.231 0.105 0 CA-C-O 121.641 0.734 . . . . 0.0 110.889 . . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.6 Cg_endo -69.76 78.57 1.0 Allowed 'Trans proline' 0 C--N 1.341 0.144 0 C-N-CA 122.705 2.27 . . . . 0.0 112.344 -179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 37.0 mt-10 -83.47 -44.19 14.99 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.931 -179.996 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 51.0 mm -50.68 -30.77 8.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.144 179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 22.9 m -64.24 -50.12 69.25 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.137 179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 1.078 HD12 HD12 ' B' ' 75' ' ' LEU . 16.8 mt -65.5 -37.51 87.01 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.865 -179.996 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.5 mm -66.63 -41.89 88.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.166 179.831 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 17.6 mm -66.2 -57.99 8.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.125 179.815 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 48.0 t80 -60.59 -31.23 70.39 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.871 179.959 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.432 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.0 -63.9 3.26 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.701 -0.761 . . . . 0.0 112.513 -179.955 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.529 ' O ' HG23 ' A' ' 84' ' ' VAL . 71.4 t -56.65 -35.93 46.89 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-O 120.868 0.366 . . . . 0.0 111.131 179.98 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 19.7 mtp -65.37 -47.31 76.84 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.847 179.914 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.11 -38.16 90.06 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.27 -0.423 . . . . 0.0 111.041 179.984 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.41 -56.73 5.43 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.728 -0.748 . . . . 0.0 112.478 -179.904 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.529 HG23 ' O ' ' A' ' 80' ' ' VAL . 92.9 t -54.92 -48.91 74.31 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.811 0.339 . . . . 0.0 111.109 179.978 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.45 HG22 HD12 ' A' ' 89' ' ' LEU . 34.8 mm -63.94 -48.13 87.51 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.145 179.918 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.78 -36.76 92.45 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.701 -0.762 . . . . 0.0 112.51 179.921 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.56 HG21 HG13 ' B' ' 88' ' ' ILE . 84.4 m -68.54 -58.73 3.87 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.829 0.347 . . . . 0.0 111.115 -179.845 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.581 HG13 HG21 ' B' ' 87' ' ' THR . 80.0 mt -56.12 -37.7 50.45 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.123 179.944 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.45 HD12 HG22 ' A' ' 85' ' ' ILE . 15.1 mt -65.27 -54.25 32.07 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.927 179.912 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -54.4 -48.66 71.33 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.915 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.522 HG23 HD12 ' A' ' 95' ' ' ILE . 64.7 mt -65.11 -56.29 16.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.149 179.841 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 83.5 p -55.02 -25.11 27.95 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.85 -179.908 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 57.8 t80 -65.14 -47.7 76.16 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.91 -179.862 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -105.28 36.98 4.04 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.442 -179.98 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.522 HD12 HG23 ' A' ' 91' ' ' ILE . 16.8 mt -156.5 -48.25 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.843 0.354 . . . . 0.0 111.185 179.954 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.79 -42.16 58.64 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.113 -0.494 . . . . 0.0 110.869 179.947 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -90.72 -40.91 11.58 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.83 -179.873 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.316 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.911 -179.956 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 6.1 mt-10 . . . . . 0 C--O 1.231 0.094 0 CA-C-O 121.676 0.751 . . . . 0.0 110.847 . . . . . . . . . 0 0 . 1 . 004 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.8 -47.48 0.91 Allowed 'Trans proline' 0 C--N 1.342 0.216 0 C-N-CA 122.693 2.262 . . . . 0.0 112.32 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.468 ' HG2' HD11 ' A' ' 75' ' ' LEU . 53.9 mt-10 -53.54 -46.87 70.33 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.258 -0.428 . . . . 0.0 110.893 -180.0 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 80.7 mt -50.96 -30.02 8.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.133 179.96 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 2.6 m -64.79 -49.34 71.08 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.108 179.994 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 1.078 HD12 HD12 ' A' ' 75' ' ' LEU . 10.1 mt -66.49 -37.87 86.02 Favored 'General case' 0 C--N 1.327 -0.38 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.916 179.961 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.3 mm -66.74 -42.4 89.37 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.275 0 CA-C-N 116.168 -0.469 . . . . 0.0 111.169 179.851 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 17.3 mm -66.09 -57.86 8.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.112 179.853 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 45.8 t80 -60.64 -31.22 70.44 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.854 179.985 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.431 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.98 -64.04 3.19 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.472 -179.962 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.517 ' O ' HG23 ' B' ' 84' ' ' VAL . 72.7 t -56.65 -35.85 46.63 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.824 0.345 . . . . 0.0 111.125 -179.953 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.5 OUTLIER -65.35 -47.4 76.56 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.875 179.904 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.98 -38.12 89.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.105 179.949 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . . . . . . . . . . . -73.43 -56.64 5.47 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.507 -179.977 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 93.7 t -54.97 -48.66 75.18 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-O 120.785 0.326 . . . . 0.0 111.134 -179.983 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.467 HG22 HD12 ' B' ' 89' ' ' LEU . 34.6 mm -64.09 -48.05 87.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.338 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.113 179.892 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.92 -36.52 92.26 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.767 -0.73 . . . . 0.0 112.485 179.963 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.581 HG21 HG13 ' A' ' 88' ' ' ILE . 86.1 m -68.82 -58.27 4.41 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.75 0.309 . . . . 0.0 111.113 -179.826 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.56 HG13 HG21 ' A' ' 87' ' ' THR . 76.9 mt -57.1 -37.78 57.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.243 -0.435 . . . . 0.0 111.092 179.936 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.467 HD12 HG22 ' B' ' 85' ' ' ILE . 16.6 mt -65.18 -53.19 48.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.963 179.865 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.04 -49.29 71.95 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.901 179.866 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.84 -56.91 13.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.109 179.868 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 60.5 p -55.0 -24.95 26.71 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.245 -0.434 . . . . 0.0 110.844 -179.941 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 52.8 t80 -74.0 -51.44 15.92 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.947 -179.898 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -70.11 -27.06 73.45 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.773 -0.727 . . . . 0.0 112.509 179.915 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.8 mm -76.48 -29.21 18.42 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.793 0.33 . . . . 0.0 111.1 -179.952 . . . . . . . . 1 1 . 1 . 004 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.87 -23.29 67.19 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.856 179.986 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -145.54 59.47 1.27 Allowed 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.89 -179.945 . . . . . . . . 2 2 . 1 . 004 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.905 -179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.1 pm0 . . . . . 0 C--O 1.231 0.098 0 CA-C-O 121.663 0.744 . . . . 0.0 110.898 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.9 Cg_endo -69.75 -179.46 2.92 Favored 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.682 2.254 . . . . 0.0 112.376 179.978 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.52 ' H ' HD13 ' B' ' 75' ' ' LEU . 34.4 mm-40 -140.03 101.83 4.25 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.867 -179.966 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.76 HG22 HD11 ' A' ' 77' ' ' ILE . 2.9 mp -50.84 -35.85 14.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.099 -0.5 . . . . 0.0 111.075 -179.976 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.7 m -58.5 -56.05 27.11 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.201 -0.454 . . . . 0.0 111.101 179.992 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.997 HD12 HD12 ' B' ' 75' ' ' LEU . 36.8 mt -60.72 -36.92 80.05 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.901 179.967 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.43 HD12 ' HA ' ' A' ' 73' ' ' ILE . 51.2 mt -66.78 -39.91 84.73 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.114 179.856 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.76 HD11 HG22 ' A' ' 73' ' ' ILE . 25.0 mt -66.29 -58.11 7.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.144 179.82 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.1 t80 -60.36 -31.7 70.57 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.88 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.639 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.43 -65.05 2.8 Favored Glycine 0 N--CA 1.451 -0.301 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.5 -179.978 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.567 HG22 ' O ' ' B' ' 79' ' ' GLY . 90.1 t -56.37 -35.28 42.94 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.278 0 CA-C-O 120.829 0.347 . . . . 0.0 111.186 179.987 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 4.1 mmt -65.43 -47.15 77.21 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.848 179.909 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -39.07 92.45 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.261 -0.427 . . . . 0.0 111.101 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.602 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.54 5.7 Favored Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.425 -179.941 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.9 t -55.17 -49.62 70.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.798 0.332 . . . . 0.0 111.146 -179.91 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.66 -49.72 82.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.139 179.907 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.47 -35.32 84.88 Favored Glycine 0 N--CA 1.451 -0.304 0 C-N-CA 120.697 -0.763 . . . . 0.0 112.464 179.917 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.427 ' OG1' HG13 ' B' ' 84' ' ' VAL . 91.3 m -68.76 -59.3 3.19 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.759 0.314 . . . . 0.0 111.127 -179.844 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.7 mt -55.09 -37.98 44.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.231 -0.44 . . . . 0.0 111.174 179.869 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 19.2 mt -65.17 -55.14 20.34 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.921 179.899 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.75 -48.9 69.24 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.889 179.901 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.523 ' CG2' HD12 ' A' ' 95' ' ' ILE . 65.9 mt -64.7 -55.92 18.66 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.098 179.871 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.6 p -55.32 -24.5 29.17 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.18 -0.464 . . . . 0.0 110.817 -179.882 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 19.8 t80 -64.88 -43.97 91.18 Favored 'General case' 0 C--N 1.327 -0.384 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.926 -179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -109.85 37.38 3.8 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.452 -179.985 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.523 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.3 mt -156.57 -52.44 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.862 0.363 . . . . 0.0 111.161 -179.972 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.13 -26.74 65.04 Favored 'General case' 0 C--N 1.329 -0.303 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.882 179.971 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.2 tpm_? -153.1 26.7 0.53 Allowed 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.894 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 1.2 mt . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.95 -179.959 . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mt-10 . . . . . 0 C--O 1.232 0.132 0 CA-C-O 121.66 0.743 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 005 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -178.24 2.26 Favored 'Trans proline' 0 C--N 1.341 0.173 0 C-N-CA 122.677 2.251 . . . . 0.0 112.336 179.99 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 1.1 mt-10 69.11 -75.77 0.07 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.231 -0.441 . . . . 0.0 110.833 179.982 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 51.0 mm -51.04 -29.91 8.6 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.138 -0.483 . . . . 0.0 111.158 179.997 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 42.5 m -65.42 -48.85 71.38 Favored 'General case' 0 C--N 1.329 -0.283 0 CA-C-N 116.169 -0.468 . . . . 0.0 111.122 179.959 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.997 HD12 HD12 ' A' ' 75' ' ' LEU . 20.4 mt -66.5 -37.44 85.06 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.187 -0.46 . . . . 0.0 110.92 179.986 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.26 -43.38 91.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.14 179.845 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.2 mm -65.97 -57.36 10.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.12 179.872 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -30.99 70.01 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.858 179.922 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.567 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.03 -65.05 2.75 Favored Glycine 0 N--CA 1.451 -0.36 0 C-N-CA 120.792 -0.718 . . . . 0.0 112.533 -179.992 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.639 HG22 ' O ' ' A' ' 79' ' ' GLY . 93.7 t -56.57 -35.27 44.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.255 0 CA-C-O 120.823 0.344 . . . . 0.0 111.169 -179.979 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 35.0 mmm -65.54 -47.71 74.98 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.901 179.858 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.49 -38.56 90.36 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.101 179.896 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.527 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.14 -56.2 5.85 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.476 -179.919 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 94.6 t -54.91 -49.39 70.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.832 0.348 . . . . 0.0 111.128 -179.973 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.475 HG22 HD12 ' B' ' 89' ' ' LEU . 74.7 mt -62.75 -49.98 81.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.894 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.56 -35.16 84.6 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.502 179.867 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.424 ' OG1' HG13 ' A' ' 84' ' ' VAL . 92.7 m -68.61 -58.48 4.2 Favored 'General case' 0 C--N 1.33 -0.267 0 CA-C-O 120.768 0.318 . . . . 0.0 111.166 -179.862 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 65.3 mt -56.65 -37.74 54.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.19 179.855 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.475 HD12 HG22 ' B' ' 85' ' ' ILE . 16.7 mt -65.2 -53.53 43.29 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.874 179.903 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -55.03 -49.19 72.18 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.905 179.937 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.8 mt -64.64 -56.81 14.11 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.135 179.809 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 23.0 t -55.19 -24.92 29.47 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.243 -0.435 . . . . 0.0 110.887 -179.929 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 77.6 t80 -69.89 -51.82 29.94 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.115 -0.493 . . . . 0.0 110.908 -179.875 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -77.69 -22.82 68.67 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.473 179.974 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.5 mm -76.54 -29.45 18.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.815 0.341 . . . . 0.0 111.134 -179.966 . . . . . . . . 1 1 . 1 . 005 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.85 -28.32 69.47 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.866 179.97 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -87.86 -61.15 1.78 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.882 -179.939 . . . . . . . . 2 2 . 1 . 005 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.348 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.935 -179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.5 mp0 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 121.666 0.746 . . . . 0.0 110.917 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.76 78.8 0.99 Allowed 'Trans proline' 0 C--N 1.341 0.171 0 C-N-CA 122.664 2.242 . . . . 0.0 112.333 -179.997 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.614 ' HB3' HD13 ' B' ' 75' ' ' LEU . 27.8 mt-10 -123.82 -44.03 2.09 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.891 -179.999 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 50.7 mm -50.8 -30.79 9.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.113 179.983 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 2.3 m -62.4 -51.81 66.09 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 179.97 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.928 HD12 HD12 ' B' ' 75' ' ' LEU . 13.2 mt -66.17 -36.65 83.65 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.961 179.909 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 38.6 mm -66.56 -44.11 90.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.135 179.835 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.93 -58.07 8.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.129 179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 52.2 t80 -60.94 -30.51 70.27 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.883 179.938 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.573 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.21 -64.72 2.87 Favored Glycine 0 N--CA 1.452 -0.284 0 C-N-CA 120.707 -0.759 . . . . 0.0 112.492 -179.973 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.646 HG22 ' O ' ' B' ' 79' ' ' GLY . 88.8 t -56.73 -35.68 46.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.856 0.36 . . . . 0.0 111.144 179.984 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 11.2 mmt -65.6 -47.05 77.0 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.851 179.955 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.79 92.32 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.128 179.879 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.432 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.18 -56.48 5.68 Favored Glycine 0 N--CA 1.451 -0.345 0 C-N-CA 120.743 -0.741 . . . . 0.0 112.485 -179.931 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.1 t -55.02 -49.55 70.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.767 0.318 . . . . 0.0 111.088 -179.949 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.3 mm -62.79 -49.95 81.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.136 179.916 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -34.95 85.18 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.786 -0.721 . . . . 0.0 112.49 179.93 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 97.5 m -68.79 -59.77 2.86 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.73 0.3 . . . . 0.0 111.129 -179.874 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 63.2 mt -54.93 -38.25 44.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.139 179.913 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 16.4 mt -65.05 -54.99 21.61 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.898 179.937 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.97 -49.34 69.01 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.907 179.872 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.576 ' CG2' HD12 ' A' ' 95' ' ' ILE . 66.5 mt -64.07 -56.33 17.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.107 179.874 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.4 t -54.65 -25.56 27.65 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.837 -179.864 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 37.1 t80 -65.36 -42.72 92.47 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.126 -0.488 . . . . 0.0 110.956 -179.883 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -109.32 38.85 3.13 Favored Glycine 0 N--CA 1.451 -0.327 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.515 179.915 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.576 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.3 mt -156.6 -49.91 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.839 0.352 . . . . 0.0 111.126 -179.996 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.15 -26.43 59.13 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.872 179.988 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -88.01 -62.8 1.41 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.925 -179.957 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.923 179.99 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 64.0 mt-10 . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.676 0.75 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 006 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.73 131.1 20.57 Favored 'Trans proline' 0 C--N 1.342 0.201 0 C-N-CA 122.69 2.26 . . . . 0.0 112.346 179.999 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 11.0 tt0 -111.36 -61.48 1.69 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.906 179.984 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 69.4 mt -51.17 -30.05 9.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.146 179.973 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 84.9 m -66.59 -46.75 74.93 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.114 179.971 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.928 HD12 HD12 ' A' ' 75' ' ' LEU . 12.3 mt -67.12 -37.97 84.8 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.895 -179.997 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.401 HD11 HD22 ' A' ' 75' ' ' LEU . 59.2 mt -66.54 -42.75 90.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.101 179.853 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.7 mm -66.07 -57.01 12.2 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.104 179.917 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.3 t80 -60.33 -31.28 70.15 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.9 179.951 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.646 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.88 -64.67 2.93 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.719 -0.753 . . . . 0.0 112.488 -179.971 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.573 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.1 t -56.57 -35.52 45.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.831 0.348 . . . . 0.0 111.111 -179.958 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.37 -47.32 76.81 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.147 -0.478 . . . . 0.0 110.89 179.921 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.57 91.14 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.122 179.885 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.6 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.14 -56.04 5.94 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.49 -179.978 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 95.8 t -54.92 -49.06 73.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.806 0.336 . . . . 0.0 111.099 -179.947 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.525 HG22 HD12 ' B' ' 89' ' ' LEU . 60.4 mt -63.13 -49.33 83.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.127 179.943 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.77 -35.69 87.29 Favored Glycine 0 N--CA 1.451 -0.326 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.464 179.939 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.421 ' OG1' HG13 ' A' ' 84' ' ' VAL . 88.4 m -68.87 -59.29 3.17 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-O 120.762 0.315 . . . . 0.0 111.131 -179.816 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 73.8 mt -55.53 -38.43 49.5 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.131 179.87 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.525 HD12 HG22 ' B' ' 85' ' ' ILE . 23.0 mt -65.19 -53.44 44.74 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.881 179.953 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.1 -49.26 72.14 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.888 179.935 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.5 mt -64.56 -57.2 12.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.341 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.128 179.831 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . 0.452 ' HA ' HG22 ' B' ' 95' ' ' ILE . 52.3 p -54.91 -25.08 26.83 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.849 -179.919 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 75.7 t80 -74.53 -51.58 14.31 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.889 -179.904 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -67.79 -35.04 84.5 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.693 -0.765 . . . . 0.0 112.483 -179.987 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . 0.452 HG22 ' HA ' ' B' ' 92' ' ' SER . 5.7 tt -75.51 -16.96 15.75 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-O 120.82 0.343 . . . . 0.0 111.128 -179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -67.38 -13.79 62.33 Favored 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.869 179.965 . . . . . . . . 2 2 . 1 . 006 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 45.5 ttm-85 -144.79 -67.46 0.32 Allowed 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.845 -179.925 . . . . . . . . 1 1 . 1 . 006 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.34 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.915 -179.973 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 7.1 mt-10 . . . . . 0 C--O 1.231 0.127 0 CA-C-O 121.619 0.723 . . . . 0.0 110.918 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.74 154.35 67.94 Favored 'Trans proline' 0 C--N 1.341 0.16 0 C-N-CA 122.644 2.23 . . . . 0.0 112.328 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.42 ' HB3' HD13 ' B' ' 75' ' ' LEU . 39.3 mt-10 -102.93 -47.83 4.25 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.854 -179.996 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 3.4 mt -53.75 -26.47 13.8 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.115 -179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.6 m -66.35 -48.75 69.23 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.191 -0.459 . . . . 0.0 111.122 179.969 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.786 HD12 HD12 ' B' ' 75' ' ' LEU . 4.6 mt -69.52 -38.96 77.79 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.923 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.2 mt -66.68 -44.97 89.32 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.28 0 CA-C-N 116.158 -0.474 . . . . 0.0 111.193 179.826 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 18.1 mm -66.02 -57.06 12.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.138 179.842 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.3 t80 -61.42 -30.33 70.5 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.218 -0.446 . . . . 0.0 110.888 179.978 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.621 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.42 -64.21 3.07 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.465 -179.972 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.653 HG22 ' O ' ' B' ' 79' ' ' GLY . 98.3 t -56.94 -35.95 48.81 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.261 0 CA-C-O 120.808 0.337 . . . . 0.0 111.099 -179.963 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.4 mmt -65.46 -47.14 77.17 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.873 179.962 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.85 -38.76 92.09 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.102 179.88 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.457 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.25 -56.5 5.63 Favored Glycine 0 N--CA 1.452 -0.297 0 C-N-CA 120.732 -0.747 . . . . 0.0 112.489 -179.971 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.6 t -54.86 -48.9 73.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.813 0.339 . . . . 0.0 111.171 -179.994 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.1 mm -63.59 -48.14 88.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.151 179.878 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.66 -37.37 93.36 Favored Glycine 0 N--CA 1.452 -0.287 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.492 179.886 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.548 HG21 HG13 ' B' ' 88' ' ' ILE . 63.4 m -67.93 -58.65 4.2 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-O 120.758 0.314 . . . . 0.0 111.126 -179.844 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.56 HG13 HG21 ' B' ' 87' ' ' THR . 77.6 mt -55.02 -37.87 43.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.213 -0.449 . . . . 0.0 111.12 179.959 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 27.2 mt -65.04 -55.84 16.58 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.912 179.891 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.5 tt -53.16 -49.19 67.14 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.939 179.917 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.595 ' CG2' HD12 ' A' ' 95' ' ' ILE . 63.8 mt -64.35 -56.11 18.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.143 179.823 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 12.8 t -53.16 -26.95 18.86 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 -179.924 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 11.4 t80 -64.81 -36.08 83.17 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.907 -179.846 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -114.5 40.19 2.55 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.501 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.595 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.5 mt -156.53 -52.13 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-O 120.825 0.345 . . . . 0.0 111.161 179.997 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 2.8 mtp180 -68.48 -44.94 73.66 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.146 -0.479 . . . . 0.0 110.872 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 5.4 ttm180 -95.26 27.28 3.35 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.829 -179.844 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 3.1 mp . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.218 -0.447 . . . . 0.0 110.909 -179.972 . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 . . . . . 0 C--O 1.231 0.105 0 CA-C-O 121.618 0.723 . . . . 0.0 110.894 . . . . . . . . . 0 0 . 1 . 007 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.74 -171.0 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.687 2.258 . . . . 0.0 112.325 -179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.464 ' HA ' HD13 ' A' ' 75' ' ' LEU . 0.6 OUTLIER -57.71 -44.0 85.62 Favored 'General case' 0 C--N 1.33 -0.261 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.912 179.992 . . . . . . . . 3 3 . 1 . 007 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 50.9 mm -51.12 -30.44 9.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.123 -0.49 . . . . 0.0 111.168 179.952 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 81.8 m -63.88 -50.92 66.87 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.117 179.989 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.786 HD12 HD12 ' A' ' 75' ' ' LEU . 12.9 mt -65.75 -37.14 85.56 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.894 179.999 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.563 HD11 HD22 ' A' ' 75' ' ' LEU . 56.0 mt -65.95 -43.93 92.59 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.333 0 CA-C-N 116.184 -0.462 . . . . 0.0 111.178 179.807 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.4 mm -65.82 -58.11 8.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.136 -0.483 . . . . 0.0 111.109 179.863 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.8 t80 -60.44 -30.28 69.54 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.991 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.653 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.15 -64.25 3.08 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.742 -0.742 . . . . 0.0 112.498 -179.969 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.621 HG22 ' O ' ' A' ' 79' ' ' GLY . 96.2 t -56.92 -35.82 48.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.83 0.347 . . . . 0.0 111.134 -179.973 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 9.1 mmt -65.46 -47.01 77.61 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.897 179.882 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.13 -38.45 91.23 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.158 -0.473 . . . . 0.0 111.138 179.902 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.51 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.29 -56.57 5.57 Favored Glycine 0 N--CA 1.451 -0.347 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.481 -179.987 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.514 HG23 ' O ' ' B' ' 80' ' ' VAL . 99.0 t -54.86 -48.84 73.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.853 0.359 . . . . 0.0 111.198 -179.985 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.55 HG22 HD12 ' B' ' 89' ' ' LEU . 34.1 mm -63.74 -47.96 88.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.153 -0.476 . . . . 0.0 111.141 179.905 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.7 -37.3 93.31 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.492 179.919 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.56 HG21 HG13 ' A' ' 88' ' ' ILE . 61.5 m -68.26 -58.88 3.71 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.746 0.308 . . . . 0.0 111.12 -179.846 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.548 HG13 HG21 ' A' ' 87' ' ' THR . 78.7 mt -54.79 -37.73 41.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.255 -0.43 . . . . 0.0 111.14 179.883 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.55 HD12 HG22 ' B' ' 85' ' ' ILE . 19.3 mt -65.33 -55.5 17.86 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.875 179.924 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -53.86 -48.13 70.31 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.939 179.934 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 67.6 mt -65.12 -55.34 21.02 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.149 179.838 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 57.1 p -57.06 -22.4 38.87 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.827 -179.898 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 21.8 t80 -64.71 -54.82 25.61 Favored 'General case' 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 110.928 -179.892 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -162.24 67.37 0.24 Allowed Glycine 0 N--CA 1.451 -0.305 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.463 179.947 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 16.1 mt -156.59 -45.88 0.03 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.285 0 CA-C-O 120.805 0.336 . . . . 0.0 111.101 -179.984 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 1.2 mtm180 -64.94 -33.49 76.16 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.869 179.977 . . . . . . . . 1 1 . 1 . 007 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.8 OUTLIER -85.51 -61.54 1.74 Allowed 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.143 -0.48 . . . . 0.0 110.857 -179.891 . . . . . . . . 2 2 . 1 . 007 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.322 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.936 -179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 26.6 mt-10 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.623 0.725 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 008 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.75 -171.2 0.45 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.672 2.248 . . . . 0.0 112.367 179.996 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.6 tt0 -140.52 101.86 4.2 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.885 179.96 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.706 HG22 ' CD1' ' A' ' 77' ' ' ILE . 45.7 mm -51.03 -33.55 13.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.128 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 17.1 m -59.84 -56.74 18.08 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.146 179.963 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.554 HD22 HD11 ' B' ' 76' ' ' ILE . 13.7 mt -60.76 -36.92 80.15 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.897 179.976 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.469 HD12 ' HA ' ' A' ' 73' ' ' ILE . 48.0 mt -65.89 -40.83 88.63 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.833 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.706 ' CD1' HG22 ' A' ' 73' ' ' ILE . 31.0 mt -66.2 -58.32 7.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.144 179.905 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -59.76 -31.12 69.37 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.884 179.939 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.64 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.66 -64.68 2.95 Favored Glycine 0 N--CA 1.451 -0.357 0 C-N-CA 120.757 -0.735 . . . . 0.0 112.466 -179.917 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.533 HG22 ' O ' ' B' ' 79' ' ' GLY . 67.3 t -56.4 -35.63 44.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.832 0.348 . . . . 0.0 111.173 -179.997 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 13.9 mmt -65.38 -47.06 77.65 Favored 'General case' 0 C--N 1.33 -0.273 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.868 179.887 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.65 -38.81 91.77 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.155 179.911 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.568 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.22 -56.78 5.49 Favored Glycine 0 N--CA 1.452 -0.278 0 C-N-CA 120.667 -0.778 . . . . 0.0 112.5 -179.984 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.524 HG23 ' O ' ' A' ' 80' ' ' VAL . 92.3 t -54.89 -49.51 69.66 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.775 0.321 . . . . 0.0 111.152 179.975 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.495 HG22 HD12 ' A' ' 89' ' ' LEU . 34.8 mm -63.03 -49.42 83.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.192 179.882 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.44 86.71 Favored Glycine 0 N--CA 1.452 -0.294 0 C-N-CA 120.775 -0.726 . . . . 0.0 112.434 179.928 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.446 ' OG1' HG13 ' B' ' 84' ' ' VAL . 90.6 m -68.8 -58.79 3.69 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-O 120.791 0.329 . . . . 0.0 111.17 -179.883 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 64.7 mt -56.69 -37.91 55.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.074 179.938 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.495 HD12 HG22 ' A' ' 85' ' ' ILE . 32.1 mt -65.08 -53.62 42.7 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.2 -0.454 . . . . 0.0 110.95 179.896 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.407 ' HA ' HD22 ' A' ' 90' ' ' LEU . 0.4 OUTLIER -54.87 -49.41 71.22 Favored 'General case' 0 C--N 1.328 -0.336 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.895 179.907 . . . . . . . . 3 3 . 1 . 008 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 62.4 mt -64.52 -56.92 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.24 -0.437 . . . . 0.0 111.131 179.859 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 53.7 p -55.04 -24.94 27.32 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.859 -179.933 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 55.9 t80 -70.74 -51.91 24.25 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.944 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -58.27 -40.45 93.96 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.477 179.961 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 3.9 mt -75.18 -21.74 16.59 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-O 120.819 0.342 . . . . 0.0 111.132 -179.97 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.41 -14.89 59.15 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.877 179.971 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 15.2 ttm180 -144.18 -69.8 0.31 Allowed 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.846 -179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.323 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.937 -179.949 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.699 0.761 . . . . 0.0 110.897 . . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.81 82.12 0.78 Allowed 'Trans proline' 0 C--N 1.342 0.219 0 C-N-CA 122.654 2.236 . . . . 0.0 112.328 179.998 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.408 ' HA ' HD13 ' A' ' 75' ' ' LEU . 33.8 mt-10 -115.77 -49.21 2.73 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.234 -0.439 . . . . 0.0 110.907 179.973 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.0 mt -51.1 -30.42 9.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.088 179.999 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 22.3 m -64.2 -50.35 68.41 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.184 179.964 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . . . . . . . . . 5.7 mt -66.0 -36.99 84.8 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.914 179.952 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.554 HD11 HD22 ' A' ' 75' ' ' LEU . 58.0 mt -66.13 -43.96 91.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.842 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.9 mm -65.9 -57.94 8.68 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.119 179.849 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -60.7 -30.34 69.88 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.904 179.962 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.533 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.27 -64.67 2.89 Favored Glycine 0 N--CA 1.451 -0.307 0 C-N-CA 120.73 -0.747 . . . . 0.0 112.48 -179.965 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.64 HG22 ' O ' ' A' ' 79' ' ' GLY . 87.3 t -56.86 -35.79 47.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-O 120.824 0.345 . . . . 0.0 111.132 -179.98 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.9 mmm -65.57 -46.99 77.3 Favored 'General case' 0 C--N 1.329 -0.31 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.871 179.941 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.99 -38.74 92.4 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.218 -0.446 . . . . 0.0 111.1 179.904 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.435 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.17 -56.62 5.61 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.479 -179.938 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.507 HG23 ' O ' ' B' ' 80' ' ' VAL . 99.3 t -54.93 -49.64 68.97 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.822 0.344 . . . . 0.0 111.109 -179.951 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.629 HG22 HD12 ' B' ' 89' ' ' LEU . 34.4 mm -62.73 -49.79 82.32 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.182 179.891 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.1 -34.82 85.52 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.47 179.896 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 97.0 m -68.74 -58.73 3.79 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.795 0.331 . . . . 0.0 111.201 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 62.1 mt -56.55 -37.79 53.72 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.182 179.864 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.629 HD12 HG22 ' B' ' 85' ' ' ILE . 17.8 mt -65.29 -53.51 42.87 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.912 179.911 . . . . . . . . 2 2 . 1 . 008 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -54.98 -49.07 72.34 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.917 179.842 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 62.9 mt -64.77 -56.74 14.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.149 179.825 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.4 m -55.25 -24.87 30.07 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.837 -179.907 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 66.0 t80 -69.74 -51.74 31.52 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.909 -179.893 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.59 -22.4 75.12 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.485 -179.984 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 mm -76.66 -27.96 17.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.812 0.339 . . . . 0.0 111.118 -179.994 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 1.9 ttp180 -80.64 24.07 0.49 Allowed 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.855 -179.977 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 6.4 ttm180 -149.43 -48.43 0.14 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.196 -0.457 . . . . 0.0 110.867 -179.93 . . . . . . . . 1 1 . 1 . 008 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.328 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.929 -179.988 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 2.0 mp0 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 121.662 0.744 . . . . 0.0 110.874 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.74 139.91 41.45 Favored 'Trans proline' 0 C--N 1.342 0.21 0 C-N-CA 122.69 2.26 . . . . 0.0 112.377 179.962 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 1.0 OUTLIER -108.11 -48.75 3.31 Favored 'General case' 0 C--N 1.33 -0.26 0 CA-C-N 116.26 -0.427 . . . . 0.0 110.867 -179.948 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 79.3 mt -51.27 -29.84 9.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.141 179.955 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.9 m -66.22 -48.0 72.0 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.141 179.973 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.972 HD12 HD12 ' B' ' 75' ' ' LEU . 26.0 mt -66.5 -37.69 85.6 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.206 -0.452 . . . . 0.0 110.933 179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 60.8 mt -66.36 -42.97 91.52 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.109 179.851 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 19.6 mm -66.02 -57.77 9.31 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.123 179.866 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.6 t80 -60.32 -30.98 69.86 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.866 179.952 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.623 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.08 -64.89 2.81 Favored Glycine 0 N--CA 1.451 -0.3 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.469 -179.933 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.56 HG22 ' O ' ' B' ' 79' ' ' GLY . 82.5 t -56.41 -35.2 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.809 0.338 . . . . 0.0 111.124 -179.962 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 26.8 mmt -65.45 -47.84 74.76 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.128 -0.487 . . . . 0.0 110.892 179.927 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.62 -38.28 89.62 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.113 179.889 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.585 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.05 5.97 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.484 -179.958 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 93.6 t -54.83 -49.25 71.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.972 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.427 HG22 HD12 ' A' ' 89' ' ' LEU . 61.3 mt -62.71 -48.68 86.99 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.127 179.905 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.11 -37.45 91.69 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.785 -0.721 . . . . 0.0 112.475 179.914 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.525 HG21 HG13 ' B' ' 88' ' ' ILE . 39.1 m -67.94 -57.77 5.66 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-O 120.759 0.314 . . . . 0.0 111.169 -179.882 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.458 HG13 HG21 ' B' ' 87' ' ' THR . 82.2 mt -55.55 -37.72 46.79 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.122 179.915 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.427 HD12 HG22 ' A' ' 85' ' ' ILE . 17.6 mt -65.21 -55.19 19.93 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.871 179.931 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.84 -48.74 69.67 Favored 'General case' 0 C--N 1.328 -0.333 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.939 179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.677 ' CG2' HD12 ' A' ' 95' ' ' ILE . 65.9 mt -64.73 -56.23 17.04 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.162 179.771 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 14.4 t -55.31 -24.49 28.97 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.858 -179.907 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 23.1 t80 -65.1 -45.16 86.31 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.117 -0.492 . . . . 0.0 110.904 -179.865 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -110.66 40.58 2.5 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.467 179.964 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.677 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.3 mt -156.58 -48.21 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.834 0.349 . . . . 0.0 111.131 -179.995 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.14 -27.97 59.98 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.861 179.975 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 23.4 ttm180 -86.27 -42.54 13.67 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.862 -179.868 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.321 0 CA-C-N 116.231 -0.44 . . . . 0.0 110.902 -179.99 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.2 mp0 . . . . . 0 C--O 1.232 0.147 0 CA-C-O 121.638 0.732 . . . . 0.0 110.89 . . . . . . . . . 0 0 . 1 . 009 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 78.89 0.98 Allowed 'Trans proline' 0 N--CA 1.465 -0.178 0 C-N-CA 122.694 2.263 . . . . 0.0 112.34 -179.993 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 25.7 mt-10 -106.58 -43.76 4.65 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.93 179.976 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 2.8 mt -50.69 -30.87 8.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.137 179.935 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 9.5 m -65.3 -49.07 70.89 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.141 179.979 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.972 HD12 HD12 ' A' ' 75' ' ' LEU . 10.6 mt -65.48 -36.68 84.6 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.197 -0.456 . . . . 0.0 110.913 179.922 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 39.2 mm -66.47 -43.02 91.18 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.148 179.82 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 21.5 mm -66.06 -58.0 8.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.177 179.858 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 44.1 t80 -60.65 -30.96 70.21 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.889 179.898 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.56 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.07 -65.03 2.75 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.524 -179.987 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 79' ' ' GLY . 90.8 t -56.46 -35.35 43.74 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.83 0.347 . . . . 0.0 111.15 -180.0 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.3 mmt -65.47 -47.65 75.38 Favored 'General case' 0 C--N 1.328 -0.326 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.881 179.929 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.78 -38.39 90.44 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.202 -0.453 . . . . 0.0 111.039 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.516 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.08 -56.02 5.98 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.458 -179.935 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.513 HG23 ' O ' ' B' ' 80' ' ' VAL . 94.4 t -54.89 -48.88 73.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-O 120.753 0.311 . . . . 0.0 111.124 -179.952 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 84.7 mt -63.21 -47.94 89.92 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.187 -0.461 . . . . 0.0 111.118 179.945 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.76 -38.66 94.23 Favored Glycine 0 N--CA 1.451 -0.349 0 C-N-CA 120.728 -0.749 . . . . 0.0 112.463 179.934 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.458 HG21 HG13 ' A' ' 88' ' ' ILE . 30.9 m -67.34 -58.75 4.22 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-O 120.805 0.336 . . . . 0.0 111.129 -179.86 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.525 HG13 HG21 ' A' ' 87' ' ' THR . 78.7 mt -54.2 -37.61 36.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.086 179.938 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 24.6 mt -65.02 -56.26 14.17 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.899 179.938 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.06 -49.94 70.36 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.925 179.872 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 78.2 mt -60.33 -53.74 44.54 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.083 179.855 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 25.8 p -64.4 -15.48 60.6 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.862 -179.885 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 0.9 OUTLIER -63.43 -19.23 64.52 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.976 -179.92 . . . . . . . . 2 2 . 1 . 009 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . 130.23 33.56 0.49 Allowed Glycine 0 N--CA 1.451 -0.342 0 C-N-CA 120.788 -0.72 . . . . 0.0 112.469 179.937 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.3 mm -77.8 -27.97 15.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-O 120.842 0.353 . . . . 0.0 111.156 179.965 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 2.2 ptp180 -64.47 -26.44 68.44 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.866 179.995 . . . . . . . . 1 1 . 1 . 009 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . 0.714 ' O ' HD23 ' B' ' 98' ' ' LEU . 0.8 OUTLIER -85.41 -65.56 1.0 Allowed 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.822 -179.89 . . . . . . . . 3 3 . 1 . 009 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . 0.714 HD23 ' O ' ' B' ' 97' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.365 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.918 -179.941 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.3 mp0 . . . . . 0 C--O 1.231 0.096 0 CA-C-O 121.616 0.722 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.2 Cg_endo -69.74 -171.06 0.43 Allowed 'Trans proline' 0 C--N 1.341 0.179 0 C-N-CA 122.713 2.275 . . . . 0.0 112.389 179.945 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.401 ' HB3' HD12 ' A' ' 75' ' ' LEU . 10.9 tt0 -137.96 103.45 4.98 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.267 -0.424 . . . . 0.0 110.901 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.738 HG22 HD11 ' A' ' 77' ' ' ILE . 2.9 mp -49.67 -33.94 8.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.202 -0.454 . . . . 0.0 111.188 179.94 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 4.5 m -60.08 -54.64 43.55 Favored 'General case' 0 C--N 1.33 -0.254 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.106 179.987 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.591 HD22 ' CG1' ' B' ' 76' ' ' ILE . 14.2 mt -61.92 -37.03 83.11 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.268 -0.424 . . . . 0.0 110.955 179.922 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 36.4 mm -67.11 -39.95 84.3 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.134 179.859 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.738 HD11 HG22 ' A' ' 73' ' ' ILE . 30.7 mt -66.5 -59.04 4.41 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.153 179.848 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 47.1 t80 -60.71 -31.6 70.88 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.611 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.78 -64.91 2.83 Favored Glycine 0 N--CA 1.451 -0.34 0 C-N-CA 120.759 -0.734 . . . . 0.0 112.507 -179.976 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.533 ' O ' HG23 ' A' ' 84' ' ' VAL . 72.6 t -56.22 -34.88 40.74 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.267 0 CA-C-O 120.831 0.348 . . . . 0.0 111.124 -179.969 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.1 OUTLIER -65.42 -48.67 71.98 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.887 179.9 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.15 -38.7 90.0 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.082 179.923 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.599 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.07 -57.37 5.77 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.712 -0.756 . . . . 0.0 112.499 -179.966 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.533 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.6 t -53.77 -50.54 51.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.817 0.342 . . . . 0.0 111.154 179.989 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.588 HG22 HD12 ' A' ' 89' ' ' LEU . 95.9 mt -60.41 -45.01 97.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.083 179.936 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.12 -37.35 91.56 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.725 -0.75 . . . . 0.0 112.501 179.927 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.462 HG21 HG13 ' B' ' 88' ' ' ILE . 0.7 OUTLIER -69.56 -58.33 4.09 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.785 0.326 . . . . 0.0 111.133 -179.859 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 77.0 mt -56.49 -37.96 54.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.222 -0.445 . . . . 0.0 111.06 179.931 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.588 HD12 HG22 ' A' ' 85' ' ' ILE . 17.3 mt -65.19 -54.48 29.0 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.198 -0.456 . . . . 0.0 110.964 179.893 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.87 -49.15 69.15 Favored 'General case' 0 C--N 1.328 -0.354 0 CA-C-N 116.155 -0.475 . . . . 0.0 110.926 179.856 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.518 ' CG2' HD12 ' A' ' 95' ' ' ILE . 64.2 mt -64.85 -56.3 16.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.171 179.822 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 56.5 p -54.26 -25.51 23.76 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.84 -179.926 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 39.4 t80 -64.94 -43.7 91.86 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.881 -179.83 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -108.54 36.24 4.48 Favored Glycine 0 N--CA 1.451 -0.308 0 C-N-CA 120.726 -0.749 . . . . 0.0 112.481 179.944 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.518 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.8 mt -156.47 -52.63 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-O 120.801 0.334 . . . . 0.0 111.129 -179.997 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -69.45 -31.05 69.11 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.854 179.999 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.9 OUTLIER -147.35 26.98 1.04 Allowed 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.853 -179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 4.7 mp . . . . . 0 C--N 1.329 -0.309 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.932 -179.982 . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.1 tp10 . . . . . 0 C--O 1.231 0.104 0 CA-C-O 121.671 0.748 . . . . 0.0 110.87 . . . . . . . . . 0 0 . 1 . 010 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.8 -177.04 1.7 Allowed 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.657 2.238 . . . . 0.0 112.338 -179.96 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.483 ' HA ' HD13 ' A' ' 75' ' ' LEU . 0.0 OUTLIER 69.26 -75.36 0.07 Allowed 'General case' 0 C--N 1.33 -0.267 0 CA-C-N 116.23 -0.441 . . . . 0.0 110.871 179.986 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 50.9 mm -51.56 -29.85 10.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.111 179.982 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 23.5 m -62.69 -52.54 62.91 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.16 179.943 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.496 HD12 ' CD1' ' A' ' 75' ' ' LEU . 14.1 mt -66.31 -37.52 85.58 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.91 179.945 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.591 ' CG1' HD22 ' A' ' 75' ' ' LEU . 53.4 mt -65.66 -44.16 93.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.146 179.843 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 18.8 mm -65.9 -57.02 12.24 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-N 116.16 -0.473 . . . . 0.0 111.145 179.868 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.32 -30.3 69.42 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.921 179.94 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.494 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.47 -64.4 2.98 Favored Glycine 0 N--CA 1.451 -0.306 0 C-N-CA 120.724 -0.75 . . . . 0.0 112.492 -179.994 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.611 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.4 t -56.68 -35.94 47.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.815 0.34 . . . . 0.0 111.117 -179.946 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.1 mmt -65.69 -47.7 74.55 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.877 179.903 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.54 -39.49 91.27 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.242 -0.435 . . . . 0.0 111.108 179.908 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.43 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.87 -57.24 5.42 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.504 -179.977 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.496 HG23 ' O ' ' B' ' 80' ' ' VAL . 93.3 t -55.1 -49.92 67.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.833 0.349 . . . . 0.0 111.136 -179.971 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.461 HG22 HD12 ' B' ' 89' ' ' LEU . 34.8 mm -62.37 -47.36 93.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.119 179.913 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.26 -38.92 91.65 Favored Glycine 0 N--CA 1.451 -0.319 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.455 179.932 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 19.8 m -68.2 -58.05 5.05 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-O 120.749 0.309 . . . . 0.0 111.16 -179.855 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.462 HG13 HG21 ' A' ' 87' ' ' THR . 78.8 mt -55.1 -38.39 46.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.343 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.077 179.898 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.461 HD12 HG22 ' B' ' 85' ' ' ILE . 19.7 mt -65.18 -54.17 33.78 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.904 179.923 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.429 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -54.77 -48.81 72.2 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.248 -0.433 . . . . 0.0 110.896 179.932 . . . . . . . . 3 3 . 1 . 010 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.64 -56.72 14.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.209 -0.451 . . . . 0.0 111.187 179.812 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . 0.46 ' HA ' HG22 ' B' ' 95' ' ' ILE . 13.2 t -54.87 -25.54 29.48 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.137 -0.483 . . . . 0.0 110.852 -179.917 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.2 t80 -75.19 -47.62 27.44 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.094 -0.503 . . . . 0.0 110.945 -179.934 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -73.01 -31.39 61.92 Favored Glycine 0 N--CA 1.452 -0.274 0 C-N-CA 120.723 -0.751 . . . . 0.0 112.502 179.922 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . 0.46 HG22 ' HA ' ' B' ' 92' ' ' SER . 5.4 tt -75.55 -23.59 16.77 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-O 120.884 0.373 . . . . 0.0 111.161 -179.993 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.91 -25.42 67.88 Favored 'General case' 0 C--N 1.33 -0.28 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.863 180.0 . . . . . . . . 2 2 . 1 . 010 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 10.2 ttm180 -147.44 41.14 1.04 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.886 -179.925 . . . . . . . . 1 1 . 1 . 010 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.32 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.891 -179.962 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 0.8 OUTLIER . . . . . 0 C--O 1.23 0.074 0 CA-C-O 121.643 0.735 . . . . 0.0 110.873 . . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.76 -46.52 1.19 Allowed 'Trans proline' 0 C--N 1.341 0.146 0 C-N-CA 122.682 2.255 . . . . 0.0 112.343 179.992 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.525 ' HA ' HD13 ' B' ' 75' ' ' LEU . 5.6 mt-10 71.57 -69.26 0.19 Allowed 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.221 -0.445 . . . . 0.0 110.903 -179.974 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.441 ' HA ' HD12 ' A' ' 76' ' ' ILE . 50.0 mm -50.31 -34.28 11.14 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.149 -0.478 . . . . 0.0 111.117 179.995 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 94.5 m -62.75 -50.29 71.64 Favored 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.135 179.932 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.611 HD13 ' HA ' ' B' ' 72' ' ' GLU . 14.8 mt -63.13 -36.76 84.68 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.928 179.936 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.547 ' CG1' HD22 ' B' ' 75' ' ' LEU . 57.6 mt -66.02 -41.96 90.72 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.117 179.863 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 23.9 mm -66.04 -57.03 12.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.144 179.844 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 40.7 t80 -60.03 -31.27 69.8 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.148 -0.478 . . . . 0.0 110.881 179.934 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.612 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.85 -64.61 2.96 Favored Glycine 0 N--CA 1.451 -0.344 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.501 -179.968 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.599 HG22 ' O ' ' B' ' 79' ' ' GLY . 87.0 t -56.64 -35.39 45.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.835 0.35 . . . . 0.0 111.152 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 8.2 mtp -65.37 -47.41 76.5 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.216 -0.447 . . . . 0.0 110.894 179.898 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.38 90.52 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.238 -0.437 . . . . 0.0 111.115 179.909 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.555 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.1 -55.89 6.05 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.747 -0.739 . . . . 0.0 112.52 179.992 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 94.3 t -54.85 -48.75 73.68 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.804 0.335 . . . . 0.0 111.168 -179.994 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 68.3 mt -63.54 -47.99 88.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.136 -0.484 . . . . 0.0 111.129 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.37 -37.3 92.91 Favored Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.536 179.87 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.576 HG21 HG13 ' B' ' 88' ' ' ILE . 48.4 m -68.22 -58.87 3.75 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-O 120.748 0.309 . . . . 0.0 111.142 -179.864 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.569 HG13 HG21 ' B' ' 87' ' ' THR . 75.8 mt -54.91 -37.84 42.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.151 179.9 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 24.9 mt -65.14 -55.78 16.68 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.885 179.94 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER -53.37 -49.17 67.74 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.189 -0.46 . . . . 0.0 110.872 179.935 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.489 HG22 HD12 ' A' ' 95' ' ' ILE . 65.3 mt -64.19 -55.9 19.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.176 179.843 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 23.3 t -53.2 -27.2 20.5 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.871 -179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 8.7 t80 -64.91 -32.79 74.67 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.112 -0.495 . . . . 0.0 110.888 -179.821 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -113.94 45.16 1.35 Allowed Glycine 0 N--CA 1.451 -0.309 0 C-N-CA 120.703 -0.76 . . . . 0.0 112.465 179.981 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.489 HD12 HG22 ' A' ' 91' ' ' ILE . 16.7 mt -156.45 -40.5 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-O 120.893 0.377 . . . . 0.0 111.203 179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 4.4 ptm180 -64.47 -25.42 67.99 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.862 179.947 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 9.8 ttp85 -87.55 -39.73 14.87 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.222 -0.444 . . . . 0.0 110.872 -179.923 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.337 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.934 179.998 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 3.7 mp0 . . . . . 0 C--O 1.232 0.146 0 CA-C-O 121.627 0.727 . . . . 0.0 110.893 . . . . . . . . . 0 0 . 1 . 011 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 54.1 Cg_endo -69.71 165.38 31.09 Favored 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.742 2.295 . . . . 0.0 112.324 -179.982 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.611 ' HA ' HD13 ' A' ' 75' ' ' LEU . 3.2 mt-10 71.57 -69.44 0.18 Allowed 'General case' 0 C--N 1.33 -0.257 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.907 -179.999 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.7 mt -50.15 -31.69 8.07 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.342 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.116 179.975 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 94.4 m -65.76 -47.16 76.15 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.2 179.901 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.547 HD22 ' CG1' ' A' ' 76' ' ' ILE . 9.8 mt -66.09 -36.56 83.52 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.209 -0.45 . . . . 0.0 110.894 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.8 mm -67.11 -43.35 88.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.148 179.826 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.5 mm -66.05 -58.01 8.38 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.134 -0.484 . . . . 0.0 111.077 179.9 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.9 t80 -61.33 -30.92 70.81 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.154 -0.475 . . . . 0.0 110.892 179.959 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.599 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.97 -64.67 2.92 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.747 -0.74 . . . . 0.0 112.485 -179.959 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.612 HG22 ' O ' ' A' ' 79' ' ' GLY . 99.1 t -57.02 -35.69 48.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-O 120.828 0.347 . . . . 0.0 111.091 -179.961 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.9 mmm -65.49 -46.92 77.84 Favored 'General case' 0 C--N 1.329 -0.297 0 CA-C-N 116.22 -0.446 . . . . 0.0 110.876 179.92 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.09 -38.8 92.61 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.125 179.916 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.516 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.13 -56.54 5.67 Favored Glycine 0 N--CA 1.45 -0.367 0 C-N-CA 120.777 -0.725 . . . . 0.0 112.507 -179.982 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.511 HG13 ' OG1' ' A' ' 87' ' ' THR . 97.9 t -54.84 -49.19 71.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.298 0 CA-C-O 120.813 0.339 . . . . 0.0 111.163 -179.979 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.508 HG22 HD12 ' B' ' 89' ' ' LEU . 33.9 mm -63.19 -48.72 86.28 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.329 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.137 179.895 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.28 -36.24 90.32 Favored Glycine 0 N--CA 1.452 -0.272 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.451 179.928 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.569 HG21 HG13 ' A' ' 88' ' ' ILE . 90.9 m -68.41 -58.38 4.44 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-O 120.777 0.322 . . . . 0.0 111.1 -179.825 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.576 HG13 HG21 ' A' ' 87' ' ' THR . 75.7 mt -55.15 -38.77 48.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.181 -0.463 . . . . 0.0 111.113 179.925 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.508 HD12 HG22 ' B' ' 85' ' ' ILE . 17.9 mt -65.15 -53.41 45.38 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.916 179.912 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.428 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -55.08 -48.89 72.92 Favored 'General case' 0 C--N 1.328 -0.366 0 CA-C-N 116.208 -0.451 . . . . 0.0 110.905 179.897 . . . . . . . . 3 3 . 1 . 011 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.6 mt -65.0 -56.86 13.65 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.337 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.098 179.852 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 7.4 t -54.89 -25.35 28.46 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.18 -0.463 . . . . 0.0 110.858 -179.853 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 46.6 t80 -68.16 -50.92 51.39 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.926 -179.96 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -80.74 -19.32 68.31 Favored Glycine 0 N--CA 1.452 -0.267 0 C-N-CA 120.718 -0.753 . . . . 0.0 112.511 179.957 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.8 mm -77.12 -27.54 16.22 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.846 0.355 . . . . 0.0 111.107 -179.967 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -64.47 -25.6 68.07 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.87 179.965 . . . . . . . . 2 2 . 1 . 011 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 30.9 ttm180 -145.04 41.45 1.28 Allowed 'General case' 0 C--N 1.329 -0.307 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.875 -179.913 . . . . . . . . 1 1 . 1 . 011 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.307 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.928 -179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 3.2 mm-40 . . . . . 0 C--O 1.231 0.125 0 CA-C-O 121.638 0.733 . . . . 0.0 110.907 . . . . . . . . . 0 0 . 1 . 012 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.79 -32.07 19.14 Favored 'Trans proline' 0 C--N 1.341 0.178 0 C-N-CA 122.651 2.234 . . . . 0.0 112.371 179.972 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.489 ' HA ' HD13 ' B' ' 75' ' ' LEU . 8.7 tt0 -58.78 -63.96 1.11 Allowed 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.219 -0.446 . . . . 0.0 110.897 179.974 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.605 HG22 HD11 ' A' ' 77' ' ' ILE . 47.2 mm -50.47 -31.79 9.25 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.134 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 33.5 m -64.32 -50.61 67.13 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.16 179.988 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.512 HD22 HD11 ' B' ' 76' ' ' ILE . 5.0 mt -63.59 -37.31 86.83 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.902 179.96 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.46 ' O ' HG23 ' A' ' 80' ' ' VAL . 60.6 mt -66.53 -41.18 88.06 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.082 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.605 HD11 HG22 ' A' ' 73' ' ' ILE . 36.2 mt -66.11 -58.62 6.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.178 -0.464 . . . . 0.0 111.141 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.64 -30.84 70.12 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.889 179.94 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.7 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.74 -64.53 3.01 Favored Glycine 0 N--CA 1.451 -0.316 0 C-N-CA 120.711 -0.757 . . . . 0.0 112.554 179.98 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.521 ' O ' HG23 ' A' ' 84' ' ' VAL . 42.0 t -56.74 -35.81 47.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.85 0.357 . . . . 0.0 111.154 -179.999 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.8 mmt -65.43 -46.93 78.0 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.14 -0.482 . . . . 0.0 110.875 179.905 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -39.18 93.71 Favored 'General case' 0 C--N 1.33 -0.271 0 CA-C-N 116.208 -0.451 . . . . 0.0 111.102 179.936 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.578 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.8 -56.67 5.78 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.516 -179.987 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.521 HG23 ' O ' ' A' ' 80' ' ' VAL . 94.7 t -55.2 -50.49 63.84 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.814 0.34 . . . . 0.0 111.139 -179.982 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.537 HG22 HD12 ' A' ' 89' ' ' LEU . 34.3 mm -61.53 -48.74 87.4 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-N 116.148 -0.478 . . . . 0.0 111.126 179.897 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.95 -39.5 95.68 Favored Glycine 0 N--CA 1.452 -0.273 0 C-N-CA 120.737 -0.744 . . . . 0.0 112.458 179.929 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.551 HG21 HG13 ' B' ' 88' ' ' ILE . 74.9 m -64.8 -58.07 7.22 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-O 120.799 0.333 . . . . 0.0 111.143 -179.861 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 81.9 mt -54.44 -42.3 58.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.13 179.952 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.537 HD12 HG22 ' A' ' 85' ' ' ILE . 12.9 mt -59.76 -54.75 42.66 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.192 -0.458 . . . . 0.0 110.886 179.87 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 0.3 OUTLIER -56.38 -51.07 69.68 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.244 -0.434 . . . . 0.0 110.936 179.879 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.758 HG23 HD12 ' A' ' 95' ' ' ILE . 0.8 OUTLIER -57.32 -59.54 3.1 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.169 179.825 . . . . . . . . 3 3 . 1 . 012 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 80.4 p -53.67 -29.49 38.82 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.9 -179.955 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 36.0 t80 -65.03 -43.32 92.78 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.123 -0.489 . . . . 0.0 110.937 -179.911 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -107.0 35.22 5.17 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.746 -0.74 . . . . 0.0 112.494 179.982 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.758 HD12 HG23 ' A' ' 91' ' ' ILE . 16.0 mt -156.57 -52.86 0.01 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.858 0.361 . . . . 0.0 111.157 -179.946 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -74.77 -37.33 62.45 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.122 -0.49 . . . . 0.0 110.876 179.963 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 2.4 tpp180 -92.3 -50.09 5.83 Favored 'General case' 0 C--N 1.329 -0.301 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.895 -179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.881 179.991 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.6 OUTLIER . . . . . 0 C--O 1.232 0.145 0 CA-C-O 121.657 0.741 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.76 174.89 8.85 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.71 2.273 . . . . 0.0 112.343 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.428 ' HA ' HD13 ' A' ' 75' ' ' LEU . 10.9 pt-20 -126.07 -45.15 1.72 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.239 -0.437 . . . . 0.0 110.898 -179.989 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . 0.515 ' HA ' HD12 ' B' ' 76' ' ' ILE . 2.7 mp -50.99 -32.85 12.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.107 179.991 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 27.2 m -61.74 -52.96 62.09 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.172 179.928 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.489 HD13 ' HA ' ' A' ' 72' ' ' GLU . 5.9 mt -63.45 -36.39 83.6 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.9 179.971 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.515 HD12 ' HA ' ' B' ' 73' ' ' ILE . 53.8 mt -65.04 -43.98 95.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.47 . . . . 0.0 111.131 179.88 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 24.2 mm -65.75 -57.31 11.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.126 179.836 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -59.98 -30.07 68.87 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.181 -0.463 . . . . 0.0 110.856 179.977 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.497 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.41 -63.85 3.22 Favored Glycine 0 N--CA 1.451 -0.366 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.501 -179.929 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.7 HG22 ' O ' ' A' ' 79' ' ' GLY . 99.1 t -56.99 -36.23 50.01 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.856 0.36 . . . . 0.0 111.158 179.968 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.46 -47.08 77.35 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.886 179.92 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.67 -38.7 91.35 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.225 -0.443 . . . . 0.0 111.075 179.933 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.433 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.25 -56.52 5.63 Favored Glycine 0 N--CA 1.451 -0.358 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.474 -179.931 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.4 t -54.84 -49.21 71.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.284 0 CA-C-O 120.857 0.36 . . . . 0.0 111.194 179.962 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.46 HG22 HD12 ' B' ' 89' ' ' LEU . 83.2 mt -63.29 -49.23 83.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.292 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.081 179.933 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.08 -35.56 87.88 Favored Glycine 0 N--CA 1.451 -0.341 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.475 179.964 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.9 m -68.88 -59.28 3.18 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-O 120.755 0.312 . . . . 0.0 111.114 -179.856 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.551 HG13 HG21 ' A' ' 87' ' ' THR . 76.2 mt -55.62 -38.44 50.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.111 179.916 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.46 HD12 HG22 ' B' ' 85' ' ' ILE . 26.4 mt -65.12 -53.12 50.14 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.937 179.895 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.7 tt -55.44 -49.0 73.59 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.144 -0.48 . . . . 0.0 110.913 179.944 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.2 mt -64.88 -57.12 12.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.076 179.876 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 66.1 m -55.02 -25.26 29.03 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.845 -179.89 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 29.2 t80 -75.13 -51.37 13.61 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.141 -0.481 . . . . 0.0 110.892 -179.884 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.472 ' O ' HD12 ' B' ' 98' ' ' LEU . . . -62.67 -37.53 94.94 Favored Glycine 0 N--CA 1.451 -0.313 0 C-N-CA 120.75 -0.738 . . . . 0.0 112.487 179.97 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.4 tt -75.77 -21.25 15.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.838 0.351 . . . . 0.0 111.149 -179.974 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.01 -27.78 69.05 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.186 -0.461 . . . . 0.0 110.916 179.937 . . . . . . . . 2 2 . 1 . 012 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 16.4 ttm180 -87.04 -34.47 19.19 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.869 -179.939 . . . . . . . . 1 1 . 1 . 012 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . 0.472 HD12 ' O ' ' B' ' 94' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.329 -0.315 0 CA-C-N 116.229 -0.442 . . . . 0.0 110.942 -179.937 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.424 ' HG2' HG21 ' A' ' 74' ' ' THR . 38.4 mt-10 . . . . . 0 C--O 1.231 0.099 0 CA-C-O 121.641 0.734 . . . . 0.0 110.945 . . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.0 Cg_endo -69.74 -43.29 2.76 Favored 'Trans proline' 0 C--N 1.341 0.159 0 C-N-CA 122.678 2.252 . . . . 0.0 112.374 -179.989 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.671 ' HG3' HD13 ' B' ' 75' ' ' LEU . 5.9 tt0 -177.74 -51.42 0.01 OUTLIER 'General case' 0 C--N 1.33 -0.282 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.913 179.999 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 51.0 mm -50.54 -30.93 8.51 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.319 0 CA-C-N 116.169 -0.469 . . . . 0.0 111.102 179.994 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . 0.424 HG21 ' HG2' ' A' ' 70' ' ' GLU . 89.9 m -65.44 -48.53 72.4 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.176 -0.466 . . . . 0.0 111.111 179.938 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 1.054 HD12 HD12 ' B' ' 75' ' ' LEU . 15.9 mt -65.79 -36.94 84.94 Favored 'General case' 0 C--N 1.328 -0.342 0 CA-C-N 116.233 -0.44 . . . . 0.0 110.911 179.998 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 42.5 mm -66.52 -42.71 90.55 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.209 -0.45 . . . . 0.0 111.099 179.849 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 21.0 mm -66.03 -57.5 10.33 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.187 -0.46 . . . . 0.0 111.171 179.835 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 41.8 t80 -60.74 -31.03 70.37 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.881 179.956 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . . . . . . . . . . . -69.09 -64.66 2.91 Favored Glycine 0 N--CA 1.451 -0.35 0 C-N-CA 120.744 -0.741 . . . . 0.0 112.511 -179.972 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.582 HG22 ' O ' ' B' ' 79' ' ' GLY . 90.2 t -56.74 -35.46 45.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.835 0.35 . . . . 0.0 111.097 -179.939 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 1.7 mmt -65.48 -47.56 75.65 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.865 179.916 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -38.64 91.6 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.273 -0.422 . . . . 0.0 111.12 179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . . . . . . . . . . . -72.66 -56.84 5.76 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.534 179.983 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.526 HG23 ' O ' ' A' ' 80' ' ' VAL . 98.1 t -54.84 -51.07 56.15 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.272 0 CA-C-O 120.819 0.342 . . . . 0.0 111.149 -179.983 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.7 mm -60.41 -50.23 81.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.133 179.903 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -58.73 -41.11 95.71 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.483 179.96 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.542 HG21 HG13 ' B' ' 88' ' ' ILE . 77.0 m -62.7 -59.08 5.4 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.783 0.325 . . . . 0.0 111.129 -179.847 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.55 HG13 HG21 ' B' ' 87' ' ' THR . 79.4 mt -54.13 -43.92 61.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.269 -0.423 . . . . 0.0 111.12 179.905 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 29.3 mt -56.8 -51.04 70.49 Favored 'General case' 0 C--N 1.328 -0.353 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.926 179.911 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.441 HD13 ' O ' ' A' ' 90' ' ' LEU . 0.4 OUTLIER -59.52 -42.12 91.51 Favored 'General case' 0 C--N 1.328 -0.33 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.915 179.841 . . . . . . . . 3 3 . 1 . 013 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.523 HG22 HD12 ' A' ' 95' ' ' ILE . 27.6 mm -65.42 -63.85 0.82 Allowed 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.181 179.833 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 2.2 t -51.53 -30.68 21.32 Favored 'General case' 0 C--N 1.33 -0.27 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.892 -179.954 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 71.2 t80 -70.42 -51.99 25.46 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.099 -0.501 . . . . 0.0 110.92 -179.856 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -64.08 -28.12 72.39 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.461 179.992 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.523 HD12 HG22 ' A' ' 91' ' ' ILE . 43.6 mt -76.42 -29.6 18.88 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.827 0.346 . . . . 0.0 111.128 -179.982 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 1.9 ttm180 -64.81 -32.07 73.6 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.901 179.927 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 18.6 ttp85 -86.24 -46.12 10.65 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.864 -179.906 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.336 0 CA-C-N 116.191 -0.458 . . . . 0.0 110.909 179.998 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . 0.683 ' N ' ' HG1' ' B' ' 74' ' ' THR . 0.3 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.669 0.747 . . . . 0.0 110.879 . . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' B' ' 70' ' ' GLU . 53.8 Cg_endo -69.79 -49.93 0.51 Allowed 'Trans proline' 0 C--N 1.342 0.192 0 C-N-CA 122.652 2.235 . . . . 0.0 112.322 -179.977 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 5.9 pt-20 177.52 -45.58 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.236 -0.438 . . . . 0.0 110.87 -179.996 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.4 mt -49.62 -32.2 6.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.13 -0.486 . . . . 0.0 111.165 179.97 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . 0.683 ' HG1' ' N ' ' B' ' 70' ' ' GLU . 99.6 m -66.39 -45.69 79.18 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.141 -0.481 . . . . 0.0 111.145 179.974 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 1.054 HD12 HD12 ' A' ' 75' ' ' LEU . 17.9 mt -66.59 -37.64 85.33 Favored 'General case' 0 C--N 1.328 -0.35 0 CA-C-N 116.21 -0.45 . . . . 0.0 110.935 179.922 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 56.4 mt -68.03 -41.41 84.46 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.099 179.878 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.4 mm -66.31 -57.74 9.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.349 0 CA-C-N 116.224 -0.444 . . . . 0.0 111.161 179.819 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.7 t80 -61.16 -31.73 71.46 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.857 179.926 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.582 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.79 -64.03 3.23 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.48 -179.96 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.517 ' O ' HG23 ' B' ' 84' ' ' VAL . 57.8 t -56.84 -35.6 47.04 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.268 0 CA-C-O 120.867 0.365 . . . . 0.0 111.094 -179.911 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.1 mmm -65.29 -47.42 76.7 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.857 179.952 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.16 90.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.117 179.923 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.557 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.22 -56.65 5.57 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.442 -179.94 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.517 HG23 ' O ' ' B' ' 80' ' ' VAL . 97.5 t -54.8 -48.81 73.0 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-O 120.785 0.326 . . . . 0.0 111.101 -179.946 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.544 HG22 HD12 ' B' ' 89' ' ' LEU . 33.8 mm -63.52 -47.36 91.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.163 179.909 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.85 -37.78 93.05 Favored Glycine 0 N--CA 1.452 -0.277 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.504 179.886 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.55 HG21 HG13 ' A' ' 88' ' ' ILE . 27.5 m -68.79 -59.51 3.04 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-O 120.757 0.313 . . . . 0.0 111.159 -179.843 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.542 HG13 HG21 ' A' ' 87' ' ' THR . 72.5 mt -54.92 -38.16 44.13 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 111.132 179.864 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.544 HD12 HG22 ' B' ' 85' ' ' ILE . 18.8 mt -65.15 -55.1 20.61 Favored 'General case' 0 C--N 1.328 -0.344 0 CA-C-N 116.149 -0.478 . . . . 0.0 110.914 179.893 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -53.91 -48.91 69.69 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.194 -0.457 . . . . 0.0 110.92 179.924 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.0 mt -64.58 -56.32 16.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.162 179.801 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . 0.704 ' O ' HG22 ' B' ' 95' ' ' ILE . 59.1 m -54.15 -25.95 25.16 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.147 -0.479 . . . . 0.0 110.844 -179.949 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 18.1 t80 -75.02 -41.97 58.27 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.176 -0.465 . . . . 0.0 110.93 -179.904 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -88.61 -3.24 77.95 Favored Glycine 0 N--CA 1.451 -0.311 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.503 179.973 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . 0.704 HG22 ' O ' ' B' ' 92' ' ' SER . 5.3 tt -76.46 -13.48 14.65 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-O 120.825 0.345 . . . . 0.0 111.102 179.987 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -66.55 -13.21 60.69 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.854 -179.996 . . . . . . . . 2 2 . 1 . 013 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 18.8 ttm180 -88.42 -39.94 13.88 Favored 'General case' 0 C--N 1.329 -0.312 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.877 -179.895 . . . . . . . . 1 1 . 1 . 013 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.331 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.918 -179.98 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 29.9 mt-10 . . . . . 0 C--O 1.231 0.109 0 CA-C-O 121.66 0.743 . . . . 0.0 110.859 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.74 -173.44 0.72 Allowed 'Trans proline' 0 C--N 1.341 0.157 0 C-N-CA 122.665 2.244 . . . . 0.0 112.348 179.957 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.478 ' HB2' HD12 ' A' ' 75' ' ' LEU . 46.1 mm-40 -141.9 102.49 4.16 Favored 'General case' 0 C--N 1.329 -0.321 0 CA-C-N 116.232 -0.44 . . . . 0.0 110.91 -179.998 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 51.1 mm -53.61 -26.53 13.47 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.137 -0.483 . . . . 0.0 111.143 179.974 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 8.6 m -64.69 -50.36 67.3 Favored 'General case' 0 C--N 1.33 -0.243 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.116 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.789 HD22 HD11 ' B' ' 76' ' ' ILE . 17.6 mt -69.86 -38.68 76.53 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.241 -0.436 . . . . 0.0 110.887 -179.988 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.619 HD11 HD22 ' B' ' 75' ' ' LEU . 61.0 mt -66.37 -46.42 86.95 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.195 -0.457 . . . . 0.0 111.11 179.835 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 20.5 mm -65.73 -56.81 13.34 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.344 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.135 179.856 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 44.5 t80 -61.33 -29.86 70.15 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.851 179.981 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.499 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.31 -63.69 3.3 Favored Glycine 0 N--CA 1.45 -0.371 0 C-N-CA 120.778 -0.725 . . . . 0.0 112.532 179.999 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.688 HG22 ' O ' ' B' ' 79' ' ' GLY . 98.3 t -57.47 -36.08 52.08 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.802 0.334 . . . . 0.0 111.114 -179.985 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 6.3 mmt -65.44 -46.78 78.56 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.826 179.943 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.06 -38.85 92.84 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.24 -0.436 . . . . 0.0 111.137 179.925 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.44 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.04 -56.43 5.78 Favored Glycine 0 N--CA 1.451 -0.324 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.511 -179.983 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 80' ' ' VAL . 95.6 t -55.16 -49.95 67.96 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.788 0.327 . . . . 0.0 111.133 -179.969 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 34.0 mm -62.35 -49.93 81.96 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.137 179.912 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -36.17 88.86 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.769 -0.729 . . . . 0.0 112.467 179.913 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 96.8 m -67.55 -59.17 3.58 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-O 120.724 0.297 . . . . 0.0 111.148 -179.866 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 72.2 mt -54.73 -40.04 49.87 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.226 -0.443 . . . . 0.0 111.099 179.922 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 14.5 mt -62.77 -56.41 17.77 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.95 179.869 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -52.7 -53.56 45.92 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.163 -0.471 . . . . 0.0 110.896 179.904 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 60.0 mt -59.58 -55.25 25.08 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.17 179.824 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 92.3 p -55.12 -25.45 31.85 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.863 -179.891 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 3.7 t80 -65.17 -27.08 68.46 Favored 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.876 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -114.02 -59.59 0.39 Allowed Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.749 -0.739 . . . . 0.0 112.492 179.995 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.841 HG22 ' O ' ' A' ' 95' ' ' ILE . 4.6 mp -79.13 54.63 0.08 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-O 120.825 0.345 . . . . 0.0 111.103 -179.976 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -174.47 -36.06 0.01 OUTLIER 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.873 179.948 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 39.4 ttm180 -90.7 -31.19 16.69 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.848 -179.875 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 97.7 mt . . . . . 0 C--N 1.329 -0.318 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.921 -179.953 . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 pm0 . . . . . 0 C--O 1.231 0.111 0 CA-C-O 121.624 0.726 . . . . 0.0 110.852 . . . . . . . . . 0 0 . 1 . 014 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.73 -48.59 0.69 Allowed 'Trans proline' 0 C--N 1.341 0.135 0 C-N-CA 122.706 2.271 . . . . 0.0 112.308 -179.971 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.469 ' CG ' HD11 ' A' ' 75' ' ' LEU . 0.9 OUTLIER -171.31 -63.86 0.02 OUTLIER 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.866 -179.97 . . . . . . . . 3 3 . 1 . 014 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 53.7 mt -51.25 -29.43 8.7 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-N 116.143 -0.481 . . . . 0.0 111.133 -179.998 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 88.0 m -62.7 -50.6 70.5 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.124 179.953 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.619 HD22 HD11 ' A' ' 76' ' ' ILE . 6.2 mt -68.16 -38.29 81.93 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.9 179.97 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.789 HD11 HD22 ' A' ' 75' ' ' LEU . 59.9 mt -66.26 -44.66 91.13 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.321 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.175 179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 19.5 mm -65.8 -57.17 11.76 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.141 179.814 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.2 t80 -60.47 -30.25 69.57 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.885 179.956 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.688 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.08 -63.44 3.45 Favored Glycine 0 N--CA 1.452 -0.292 0 C-N-CA 120.771 -0.728 . . . . 0.0 112.501 -179.997 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.515 ' O ' HG23 ' B' ' 84' ' ' VAL . 39.5 t -57.28 -36.04 50.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.83 0.348 . . . . 0.0 111.155 179.993 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.3 mmt -65.38 -46.93 78.16 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.934 179.871 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.84 92.53 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.235 -0.439 . . . . 0.0 111.059 179.886 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.575 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.06 -56.33 5.82 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.802 -0.713 . . . . 0.0 112.474 -179.926 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.515 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.7 t -54.95 -49.28 72.14 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.819 0.342 . . . . 0.0 111.133 -179.947 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.505 HG22 HD12 ' B' ' 89' ' ' LEU . 77.6 mt -63.03 -49.4 83.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.171 179.896 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.5 -35.66 86.31 Favored Glycine 0 N--CA 1.452 -0.296 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.486 179.905 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.434 ' OG1' HG13 ' A' ' 84' ' ' VAL . 87.1 m -68.97 -58.67 3.79 Favored 'General case' 0 C--N 1.33 -0.281 0 CA-C-O 120.753 0.311 . . . . 0.0 111.171 -179.847 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 68.4 mt -56.94 -37.91 56.93 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.129 179.894 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.505 HD12 HG22 ' B' ' 85' ' ' ILE . 16.9 mt -65.12 -53.25 48.13 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.92 179.907 . . . . . . . . 2 2 . 1 . 014 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -49.41 71.62 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.934 179.864 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 64.3 mt -64.64 -57.02 13.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.308 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.118 179.846 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 80.8 p -54.79 -25.18 26.46 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.214 -0.448 . . . . 0.0 110.843 -179.914 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 43.7 t80 -71.56 -54.27 11.04 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.91 -179.879 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -53.24 -35.63 50.45 Favored Glycine 0 N--CA 1.451 -0.303 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.504 179.968 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 18.8 mm -76.46 -29.36 18.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-O 120.832 0.349 . . . . 0.0 111.159 -180.0 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 2.5 ttp180 -64.87 -40.47 95.18 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.87 179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 5.9 ttm180 -94.2 40.42 1.08 Allowed 'General case' 0 C--N 1.33 -0.281 0 CA-C-N 116.198 -0.455 . . . . 0.0 110.9 -179.937 . . . . . . . . 1 1 . 1 . 014 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 2.5 mt . . . . . 0 C--N 1.329 -0.319 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.935 -179.957 . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 68.2 mm-40 . . . . . 0 C--O 1.231 0.103 0 CA-C-O 121.635 0.731 . . . . 0.0 110.895 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.3 Cg_endo -69.78 169.03 19.9 Favored 'Trans proline' 0 C--N 1.341 0.182 0 C-N-CA 122.65 2.233 . . . . 0.0 112.306 -179.956 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.505 ' HA ' HD13 ' B' ' 75' ' ' LEU . 2.4 mp0 -117.81 -44.77 2.71 Favored 'General case' 0 C--N 1.33 -0.245 0 CA-C-N 116.211 -0.449 . . . . 0.0 110.892 -179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.686 HG22 HD11 ' A' ' 77' ' ' ILE . 58.2 mt -50.9 -34.25 13.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.134 179.983 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 25.0 m -60.23 -55.18 36.88 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.159 179.967 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.599 HD13 ' HA ' ' B' ' 72' ' ' GLU . 5.0 mt -61.24 -36.71 80.72 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.193 -0.458 . . . . 0.0 110.925 179.912 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.462 HD12 ' HA ' ' A' ' 73' ' ' ILE . 52.3 mt -66.02 -41.31 89.44 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.218 -0.447 . . . . 0.0 111.137 179.848 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.686 HD11 HG22 ' A' ' 73' ' ' ILE . 27.4 mt -66.1 -58.75 5.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.088 179.853 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -59.68 -31.06 69.22 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.913 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.623 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.81 -65.79 2.51 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.835 -0.698 . . . . 0.0 112.466 -179.939 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.671 HG22 ' O ' ' B' ' 79' ' ' GLY . 99.0 t -55.46 -34.73 35.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-O 120.878 0.371 . . . . 0.0 111.13 -179.992 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.9 mmt -65.31 -50.21 66.52 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 110.918 179.908 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.06 -36.11 80.64 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.139 179.87 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.526 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.19 -55.36 6.29 Favored Glycine 0 N--CA 1.451 -0.31 0 C-N-CA 120.73 -0.748 . . . . 0.0 112.465 -179.955 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.561 HG23 ' O ' ' A' ' 80' ' ' VAL . 91.1 t -54.96 -49.99 66.35 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.831 0.348 . . . . 0.0 111.139 -179.963 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 1.7 mp -63.45 -47.83 89.9 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.134 179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.15 -36.66 91.23 Favored Glycine 0 N--CA 1.451 -0.322 0 C-N-CA 120.703 -0.761 . . . . 0.0 112.456 179.965 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.651 ' OG1' HG13 ' B' ' 84' ' ' VAL . 73.1 m -68.88 -58.73 3.75 Favored 'General case' 0 C--N 1.33 -0.269 0 CA-C-O 120.775 0.322 . . . . 0.0 111.164 -179.894 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.57 HG13 HG21 ' B' ' 87' ' ' THR . 72.1 mt -55.61 -38.47 50.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.156 179.885 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 17.9 mt -65.2 -53.41 45.03 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.895 179.899 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.1 tt -55.0 -49.33 71.77 Favored 'General case' 0 C--N 1.327 -0.37 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.927 179.875 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 63.9 mt -64.58 -56.68 14.83 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.347 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.158 179.82 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 60.6 p -55.24 -24.97 30.58 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.88 -179.901 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 26.7 t80 -70.08 -54.36 13.43 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.108 -0.497 . . . . 0.0 110.93 -179.872 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -58.15 -29.04 62.13 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.741 -0.742 . . . . 0.0 112.458 179.985 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 14.8 mt -76.48 -29.41 18.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.348 0 CA-C-O 120.799 0.333 . . . . 0.0 111.106 -179.964 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.2 -40.26 93.93 Favored 'General case' 0 C--N 1.329 -0.319 0 CA-C-N 116.182 -0.463 . . . . 0.0 110.897 179.978 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . 0.71 ' O ' HD23 ' A' ' 98' ' ' LEU . 0.4 OUTLIER -87.08 -32.76 19.77 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.84 -179.934 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . 0.71 HD23 ' O ' ' A' ' 97' ' ' ARG . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.367 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.915 -179.948 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 3.2 mt-10 . . . . . 0 C--O 1.232 0.135 0 CA-C-O 121.592 0.711 . . . . 0.0 110.889 . . . . . . . . . 0 0 . 1 . 015 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.76 179.71 3.51 Favored 'Trans proline' 0 C--N 1.34 0.125 0 C-N-CA 122.69 2.26 . . . . 0.0 112.318 -179.983 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.599 ' HA ' HD13 ' A' ' 75' ' ' LEU . 12.1 pt-20 -125.85 -44.19 1.81 Allowed 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.932 179.977 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . 0.591 ' HA ' HD12 ' B' ' 76' ' ' ILE . 48.5 mm -51.11 -36.03 15.85 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.121 -0.491 . . . . 0.0 111.119 179.982 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 18.6 m -57.03 -57.03 14.33 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.179 179.952 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.505 HD13 ' HA ' ' A' ' 72' ' ' GLU . 4.6 mt -61.8 -35.79 79.21 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.947 179.934 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.591 HD12 ' HA ' ' B' ' 73' ' ' ILE . 36.6 mt -65.77 -43.33 93.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.179 -0.464 . . . . 0.0 111.126 179.871 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.2 mm -65.84 -58.03 8.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.286 0 CA-C-N 116.196 -0.456 . . . . 0.0 111.1 179.862 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 43.1 t80 -60.15 -30.29 69.22 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.865 -179.995 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.671 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.02 -63.83 3.28 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.439 -179.926 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.623 HG22 ' O ' ' A' ' 79' ' ' GLY . 94.0 t -56.99 -35.81 48.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.265 0 CA-C-O 120.808 0.337 . . . . 0.0 111.093 -179.917 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 8.4 mmt -65.49 -47.12 77.11 Favored 'General case' 0 C--N 1.329 -0.322 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.849 179.942 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.71 -39.03 92.76 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.194 -0.457 . . . . 0.0 111.114 179.923 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.509 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -72.82 -56.82 5.68 Favored Glycine 0 N--CA 1.452 -0.298 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.5 -179.966 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.651 HG13 ' OG1' ' A' ' 87' ' ' THR . 91.2 t -55.14 -50.65 62.11 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.269 0 CA-C-O 120.802 0.334 . . . . 0.0 111.146 -179.993 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 34.6 mm -61.61 -49.22 85.25 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.121 179.958 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.74 -39.27 95.06 Favored Glycine 0 N--CA 1.452 -0.293 0 C-N-CA 120.762 -0.732 . . . . 0.0 112.487 179.897 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.57 HG21 HG13 ' A' ' 88' ' ' ILE . 85.5 m -64.66 -58.01 7.49 Favored 'General case' 0 C--N 1.33 -0.249 0 CA-C-O 120.757 0.313 . . . . 0.0 111.115 -179.857 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.573 HG13 HG21 ' A' ' 87' ' ' THR . 76.4 mt -54.46 -43.17 62.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-N 116.231 -0.441 . . . . 0.0 111.13 179.911 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 14.9 mt -59.02 -53.76 54.71 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.904 179.954 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 0.9 OUTLIER -57.44 -51.71 68.31 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.892 179.893 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.401 HG22 ' N ' ' B' ' 92' ' ' SER . 0.8 OUTLIER -56.44 -59.61 2.73 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.146 179.86 . . . . . . . . 3 3 . 1 . 015 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . 0.439 ' HA ' HG22 ' B' ' 95' ' ' ILE . 30.9 t -56.34 -27.11 54.8 Favored 'General case' 0 C--N 1.329 -0.294 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.88 -179.961 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 59.9 t80 -75.1 -51.31 13.79 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.114 -0.494 . . . . 0.0 110.918 -179.876 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.419 ' O ' HD12 ' B' ' 98' ' ' LEU . . . -68.6 -32.98 75.42 Favored Glycine 0 N--CA 1.451 -0.339 0 C-N-CA 120.763 -0.732 . . . . 0.0 112.529 179.967 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . 0.439 HG22 ' HA ' ' B' ' 92' ' ' SER . 5.6 tt -75.71 -22.2 16.12 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.322 0 CA-C-O 120.817 0.342 . . . . 0.0 111.135 179.995 . . . . . . . . 2 2 . 1 . 015 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 5.2 ttm180 -65.3 -30.65 71.53 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.159 -0.473 . . . . 0.0 110.932 179.975 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 7.9 ttp180 -90.67 -41.81 11.09 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.134 -0.484 . . . . 0.0 110.864 -179.921 . . . . . . . . 1 1 . 1 . 015 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . 0.419 HD12 ' O ' ' B' ' 94' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.359 0 CA-C-N 116.199 -0.455 . . . . 0.0 110.886 -179.904 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . 0.529 ' N ' ' HD2' ' A' ' 71' ' ' PRO . 4.7 tt0 . . . . . 0 C--O 1.232 0.141 0 CA-C-O 121.64 0.733 . . . . 0.0 110.869 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.529 ' HD2' ' N ' ' A' ' 70' ' ' GLU . 53.6 Cg_endo -69.78 -48.44 0.71 Allowed 'Trans proline' 0 C--N 1.341 0.151 0 C-N-CA 122.693 2.262 . . . . 0.0 112.361 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . . . . . . . . . 3.7 tp10 -162.37 89.55 0.69 Allowed 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.894 -179.993 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.718 HG22 ' CD1' ' A' ' 77' ' ' ILE . 2.9 mp -50.21 -32.72 9.36 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.302 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.127 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 93.1 m -60.77 -54.19 48.26 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.101 179.984 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 1.061 HD12 HD12 ' B' ' 75' ' ' LEU . 66.3 mt -62.45 -37.97 87.98 Favored 'General case' 0 C--N 1.328 -0.36 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.844 -179.988 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 41.2 mm -66.3 -40.02 85.71 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.339 0 CA-C-N 116.217 -0.447 . . . . 0.0 111.121 179.878 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.718 ' CD1' HG22 ' A' ' 73' ' ' ILE . 34.2 mt -66.24 -58.26 7.3 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.211 -0.45 . . . . 0.0 111.097 179.865 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.3 t80 -60.04 -31.44 69.97 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.178 -0.464 . . . . 0.0 110.867 -179.995 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.537 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.76 -65.03 2.78 Favored Glycine 0 N--CA 1.451 -0.312 0 C-N-CA 120.756 -0.735 . . . . 0.0 112.491 -179.97 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.525 ' O ' HG23 ' A' ' 84' ' ' VAL . 99.4 t -56.15 -35.45 42.09 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.263 0 CA-C-O 120.821 0.344 . . . . 0.0 111.122 179.996 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 0.4 OUTLIER -65.39 -47.9 74.72 Favored 'General case' 0 C--N 1.329 -0.324 0 CA-C-N 116.169 -0.469 . . . . 0.0 110.896 179.937 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.92 -38.91 90.17 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.21 -0.45 . . . . 0.0 111.115 179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.527 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.11 -56.53 5.69 Favored Glycine 0 N--CA 1.452 -0.285 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.468 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.525 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.4 t -55.03 -49.33 72.43 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.844 0.354 . . . . 0.0 111.129 -179.898 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.51 HG22 HD12 ' A' ' 89' ' ' LEU . 92.7 mt -62.75 -49.71 82.61 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.163 -0.471 . . . . 0.0 111.074 179.935 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.32 -35.66 85.73 Favored Glycine 0 N--CA 1.452 -0.286 0 C-N-CA 120.711 -0.756 . . . . 0.0 112.479 179.961 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.426 ' OG1' HG13 ' B' ' 84' ' ' VAL . 86.7 m -68.67 -58.71 3.84 Favored 'General case' 0 C--N 1.33 -0.276 0 CA-C-O 120.783 0.325 . . . . 0.0 111.154 -179.837 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 67.8 mt -56.46 -37.78 53.05 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.309 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.12 179.908 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.51 HD12 HG22 ' A' ' 85' ' ' ILE . 22.3 mt -65.25 -53.54 42.75 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.151 -0.477 . . . . 0.0 110.941 179.9 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.06 -49.09 72.5 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.177 -0.465 . . . . 0.0 110.917 179.848 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 65.5 mt -64.66 -56.66 14.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.151 179.836 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . 0.467 ' HA ' HG22 ' A' ' 95' ' ' ILE . 54.4 p -55.56 -24.5 32.77 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.2 -0.455 . . . . 0.0 110.893 -179.927 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.7 t80 -75.02 -50.87 15.11 Favored 'General case' 0 C--N 1.329 -0.3 0 CA-C-N 116.085 -0.507 . . . . 0.0 110.916 -179.857 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -69.34 -32.72 72.15 Favored Glycine 0 N--CA 1.451 -0.335 0 C-N-CA 120.706 -0.759 . . . . 0.0 112.487 179.988 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.467 HG22 ' HA ' ' A' ' 92' ' ' SER . 5.5 tt -75.72 -22.39 16.15 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-O 120.846 0.355 . . . . 0.0 111.129 -179.965 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -65.16 -30.93 71.9 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.842 179.989 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 1.5 ttm180 -90.96 -43.42 9.99 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.92 -179.93 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.329 -0.303 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.958 -179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.0 OUTLIER . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.67 0.748 . . . . 0.0 110.927 . . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.2 Cg_endo -69.81 78.5 1.02 Allowed 'Trans proline' 0 C--N 1.341 0.181 0 C-N-CA 122.724 2.283 . . . . 0.0 112.32 -179.948 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 0.3 OUTLIER -114.41 -67.95 0.96 Allowed 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.223 -0.444 . . . . 0.0 110.892 -179.986 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . 0.63 HG22 HD11 ' B' ' 77' ' ' ILE . 4.6 mt -50.32 -33.27 10.26 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.331 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.134 179.985 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 5.0 m -63.06 -51.36 66.98 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.19 -0.459 . . . . 0.0 111.153 179.923 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 1.061 HD12 HD12 ' A' ' 75' ' ' LEU . 12.1 mt -62.72 -37.21 85.64 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.892 179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 41.6 mm -66.53 -40.14 85.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.164 -0.471 . . . . 0.0 111.094 179.859 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . 0.63 HD11 HG22 ' B' ' 73' ' ' ILE . 29.2 mt -66.38 -57.86 8.77 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.189 -0.46 . . . . 0.0 111.125 179.867 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.1 t80 -60.52 -31.72 70.78 Favored 'General case' 0 C--N 1.328 -0.331 0 CA-C-N 116.203 -0.453 . . . . 0.0 110.894 179.99 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.512 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.58 -64.03 3.26 Favored Glycine 0 N--CA 1.451 -0.336 0 C-N-CA 120.72 -0.752 . . . . 0.0 112.507 -179.99 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.537 HG22 ' O ' ' A' ' 79' ' ' GLY . 95.2 t -56.78 -35.69 46.94 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.303 0 CA-C-O 120.789 0.328 . . . . 0.0 111.145 -179.991 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 18.0 mmm -65.33 -47.02 77.98 Favored 'General case' 0 C--N 1.328 -0.349 0 CA-C-N 116.16 -0.473 . . . . 0.0 110.871 179.919 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.84 -39.05 93.17 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.237 -0.438 . . . . 0.0 111.093 179.921 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.513 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.05 -56.26 5.87 Favored Glycine 0 N--CA 1.452 -0.265 0 C-N-CA 120.702 -0.761 . . . . 0.0 112.482 -179.978 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.507 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.6 t -54.97 -49.54 70.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.271 0 CA-C-O 120.793 0.33 . . . . 0.0 111.14 -179.949 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.465 HG22 HD12 ' B' ' 89' ' ' LEU . 33.4 mm -62.72 -49.32 84.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.135 -0.484 . . . . 0.0 111.163 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.71 -35.69 87.1 Favored Glycine 0 N--CA 1.452 -0.27 0 C-N-CA 120.731 -0.747 . . . . 0.0 112.496 179.874 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 86.1 m -68.64 -59.27 3.24 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-O 120.749 0.309 . . . . 0.0 111.126 -179.877 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 67.5 mt -54.91 -37.95 43.27 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.359 0 CA-C-N 116.2 -0.455 . . . . 0.0 111.103 179.911 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.465 HD12 HG22 ' B' ' 85' ' ' ILE . 29.0 mt -65.19 -55.44 18.56 Favored 'General case' 0 C--N 1.328 -0.367 0 CA-C-N 116.185 -0.461 . . . . 0.0 110.925 179.914 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.4 tt -53.83 -48.7 69.67 Favored 'General case' 0 C--N 1.328 -0.347 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.885 179.907 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.9 mt -64.62 -54.68 27.45 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.157 -0.474 . . . . 0.0 111.136 179.844 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . 0.68 ' O ' HG22 ' B' ' 95' ' ' ILE . 42.8 t -53.76 -27.83 31.03 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.847 -179.938 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 6.0 t80 -75.39 -31.49 60.46 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.927 -179.869 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -60.86 -22.61 60.2 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.768 -0.73 . . . . 0.0 112.507 179.979 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . 0.68 HG22 ' O ' ' B' ' 92' ' ' SER . 5.6 tt -75.69 -21.83 16.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.299 0 CA-C-O 120.869 0.366 . . . . 0.0 111.15 179.999 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.4 OUTLIER -65.55 -42.56 91.75 Favored 'General case' 0 C--N 1.33 -0.275 0 CA-C-N 116.17 -0.468 . . . . 0.0 110.862 179.997 . . . . . . . . 2 2 . 1 . 016 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 39.0 ttp180 -94.58 -36.7 11.7 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.212 -0.449 . . . . 0.0 110.903 -179.951 . . . . . . . . 1 1 . 1 . 016 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 17.1 mt . . . . . 0 C--N 1.328 -0.327 0 CA-C-N 116.142 -0.481 . . . . 0.0 110.874 -179.993 . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 1.5 mp0 . . . . . 0 C--O 1.232 0.141 0 CA-C-O 121.647 0.737 . . . . 0.0 110.878 . . . . . . . . . 0 0 . 1 . 017 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.5 Cg_endo -69.84 159.54 52.97 Favored 'Trans proline' 0 C--N 1.342 0.211 0 C-N-CA 122.648 2.232 . . . . 0.0 112.321 -179.989 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.598 ' H ' HD13 ' B' ' 75' ' ' LEU . 33.2 mt-10 -140.52 102.94 4.44 Favored 'General case' 0 C--N 1.329 -0.285 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.877 -179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.659 HG22 ' CD1' ' A' ' 77' ' ' ILE . 4.6 mt -50.14 -31.69 8.04 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.145 -0.48 . . . . 0.0 111.145 179.983 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 11.5 m -63.02 -52.92 61.02 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.182 -0.463 . . . . 0.0 111.109 179.975 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 1.051 HD12 HD12 ' B' ' 75' ' ' LEU . 29.0 mt -62.58 -37.47 86.33 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.227 -0.442 . . . . 0.0 110.893 -179.995 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . . . . . . . . . 40.8 mm -66.52 -40.09 85.57 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.18 -0.464 . . . . 0.0 111.085 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.659 ' CD1' HG22 ' A' ' 73' ' ' ILE . 37.8 mt -66.33 -58.56 6.14 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.175 -0.466 . . . . 0.0 111.136 179.868 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 54.8 t80 -60.39 -31.57 70.49 Favored 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.158 -0.474 . . . . 0.0 110.897 179.962 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.526 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.65 -65.06 2.78 Favored Glycine 0 N--CA 1.451 -0.356 0 C-N-CA 120.707 -0.758 . . . . 0.0 112.521 -179.971 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.522 ' O ' HG23 ' A' ' 84' ' ' VAL . 72.0 t -56.24 -35.37 42.41 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.297 0 CA-C-O 120.828 0.347 . . . . 0.0 111.118 179.982 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 16.4 mtp -65.37 -47.4 76.53 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.878 179.907 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.69 -38.78 91.75 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.268 -0.424 . . . . 0.0 111.117 179.911 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.484 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.12 -56.48 5.71 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.505 -179.979 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.522 HG23 ' O ' ' A' ' 80' ' ' VAL . 97.8 t -55.0 -49.43 71.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-O 120.845 0.355 . . . . 0.0 111.158 179.992 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.439 HG22 HD12 ' A' ' 89' ' ' LEU . 33.8 mm -62.83 -48.66 87.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.287 0 CA-C-N 116.212 -0.449 . . . . 0.0 111.158 179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -37.8 93.09 Favored Glycine 0 N--CA 1.452 -0.291 0 C-N-CA 120.76 -0.733 . . . . 0.0 112.467 179.905 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.401 ' OG1' HG13 ' B' ' 84' ' ' VAL . 62.6 m -67.25 -58.93 3.92 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-O 120.788 0.328 . . . . 0.0 111.138 -179.879 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 78.4 mt -54.24 -38.64 40.09 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-N 116.227 -0.442 . . . . 0.0 111.152 179.897 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.439 HD12 HG22 ' A' ' 85' ' ' ILE . 15.5 mt -64.03 -55.81 19.53 Favored 'General case' 0 C--N 1.329 -0.309 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.914 179.919 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.3 tt -55.36 -49.8 71.33 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.204 -0.453 . . . . 0.0 110.914 179.887 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 84.7 mt -60.51 -53.43 48.98 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.34 0 CA-C-N 116.188 -0.46 . . . . 0.0 111.131 179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 36.1 t -64.92 -14.92 61.3 Favored 'General case' 0 C--N 1.329 -0.289 0 CA-C-N 116.172 -0.467 . . . . 0.0 110.925 -179.956 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 0.8 OUTLIER -63.33 -19.38 64.57 Favored 'General case' 0 C--N 1.329 -0.325 0 CA-C-N 116.093 -0.503 . . . . 0.0 110.913 -179.898 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . 130.39 33.19 0.5 Allowed Glycine 0 N--CA 1.451 -0.361 0 C-N-CA 120.722 -0.752 . . . . 0.0 112.48 179.983 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.601 HG22 ' O ' ' A' ' 95' ' ' ILE . 25.3 mm -78.69 -3.96 6.37 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.882 0.372 . . . . 0.0 111.167 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.3 OUTLIER -159.01 -38.35 0.06 Allowed 'General case' 0 C--N 1.33 -0.266 0 CA-C-N 116.125 -0.488 . . . . 0.0 110.839 179.974 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 6.5 ttm-85 -95.41 -5.91 42.12 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.213 -0.448 . . . . 0.0 110.867 -179.889 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.335 0 CA-C-N 116.154 -0.476 . . . . 0.0 110.952 -179.976 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 0.1 OUTLIER . . . . . 0 C--O 1.231 0.13 0 CA-C-O 121.614 0.721 . . . . 0.0 110.919 . . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.7 Cg_endo -69.76 -49.11 0.59 Allowed 'Trans proline' 0 C--N 1.341 0.139 0 C-N-CA 122.693 2.262 . . . . 0.0 112.346 179.992 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.463 ' HG2' HD11 ' A' ' 75' ' ' LEU . 0.7 OUTLIER -129.28 -37.1 1.67 Allowed 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.24 -0.437 . . . . 0.0 110.883 -179.985 . . . . . . . . 3 3 . 1 . 017 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 49.3 mm -48.67 -31.08 3.49 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.117 179.988 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 99.7 m -61.43 -52.6 63.9 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.173 -0.467 . . . . 0.0 111.099 179.994 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 1.051 HD12 HD12 ' A' ' 75' ' ' LEU . 11.4 mt -66.01 -37.86 87.0 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.261 -0.427 . . . . 0.0 110.912 179.959 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 38.8 mm -66.14 -42.63 91.61 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.326 0 CA-C-N 116.223 -0.444 . . . . 0.0 111.161 179.823 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 16.9 mm -66.0 -57.23 11.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.325 0 CA-C-N 116.177 -0.465 . . . . 0.0 111.119 179.845 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -60.24 -31.05 69.83 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.167 -0.47 . . . . 0.0 110.895 179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.5 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.02 -64.52 2.98 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.468 180.0 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.526 HG22 ' O ' ' A' ' 79' ' ' GLY . 97.2 t -56.58 -35.55 45.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-O 120.817 0.342 . . . . 0.0 111.136 -179.933 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 3.3 mmm -65.43 -47.38 76.42 Favored 'General case' 0 C--N 1.328 -0.328 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.885 179.894 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.54 -38.75 91.26 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.228 -0.442 . . . . 0.0 111.138 179.857 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.503 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.2 -56.63 5.59 Favored Glycine 0 N--CA 1.451 -0.348 0 C-N-CA 120.765 -0.731 . . . . 0.0 112.509 -179.945 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 98.8 t -54.92 -49.54 69.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-O 120.853 0.359 . . . . 0.0 111.14 179.994 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.433 HG22 HD12 ' B' ' 89' ' ' LEU . 34.4 mm -62.76 -49.61 83.03 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.147 179.907 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.86 -35.31 86.3 Favored Glycine 0 N--CA 1.452 -0.299 0 C-N-CA 120.751 -0.738 . . . . 0.0 112.518 179.913 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . . . . . . . . . 91.8 m -68.71 -58.78 3.74 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-O 120.775 0.321 . . . . 0.0 111.179 -179.86 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 70.4 mt -56.02 -38.05 51.33 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.189 -0.459 . . . . 0.0 111.102 179.896 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.433 HD12 HG22 ' B' ' 85' ' ' ILE . 34.2 mt -65.28 -53.5 43.24 Favored 'General case' 0 C--N 1.328 -0.365 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.898 179.929 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -55.14 -49.06 72.77 Favored 'General case' 0 C--N 1.328 -0.361 0 CA-C-N 116.207 -0.451 . . . . 0.0 110.864 179.906 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.5 mt -64.71 -56.79 14.18 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.313 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.126 179.87 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 28.4 t -55.27 -24.98 30.99 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.165 -0.47 . . . . 0.0 110.879 -179.925 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 50.9 t80 -69.46 -51.97 31.09 Favored 'General case' 0 C--N 1.328 -0.332 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.884 -179.886 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . 0.51 ' O ' HD12 ' B' ' 98' ' ' LEU . . . -68.92 -28.16 73.28 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.755 -0.736 . . . . 0.0 112.457 -179.984 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 59.8 mt -76.5 -29.56 18.67 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-O 120.805 0.336 . . . . 0.0 111.108 -179.969 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.83 -27.59 68.98 Favored 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.19 -0.459 . . . . 0.0 110.868 -179.987 . . . . . . . . 2 2 . 1 . 017 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 6.9 ttp85 -87.0 -43.07 12.62 Favored 'General case' 0 C--N 1.33 -0.262 0 CA-C-N 116.178 -0.465 . . . . 0.0 110.891 -179.92 . . . . . . . . 1 1 . 1 . 017 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . 0.51 HD12 ' O ' ' B' ' 94' ' ' GLY . 0.0 OUTLIER . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.229 -0.441 . . . . 0.0 110.885 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.6 tp10 . . . . . 0 C--O 1.231 0.11 0 CA-C-O 121.669 0.747 . . . . 0.0 110.884 . . . . . . . . . 0 0 . 1 . 018 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 53.4 Cg_endo -69.81 -170.4 0.39 Allowed 'Trans proline' 0 C--N 1.341 0.166 0 C-N-CA 122.727 2.285 . . . . 0.0 112.319 -179.997 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.582 ' CD ' HD11 ' A' ' 76' ' ' ILE . 2.7 tt0 -76.91 -48.37 18.43 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.217 -0.447 . . . . 0.0 110.883 -179.939 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.758 HG22 HD11 ' A' ' 77' ' ' ILE . 5.2 mt -51.15 -38.8 19.37 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.328 0 CA-C-N 116.118 -0.492 . . . . 0.0 111.114 179.99 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 81.3 m -57.62 -56.11 26.13 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-N 116.151 -0.477 . . . . 0.0 111.168 179.967 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.625 HD12 HD12 ' B' ' 75' ' ' LEU . 36.4 mt -59.02 -36.24 74.64 Favored 'General case' 0 C--N 1.329 -0.32 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.919 179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.582 HD11 ' CD ' ' A' ' 72' ' ' GLU . 40.6 mt -67.62 -39.54 82.44 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.32 0 CA-C-N 116.183 -0.462 . . . . 0.0 111.145 179.792 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.758 HD11 HG22 ' A' ' 73' ' ' ILE . 20.0 mt -66.35 -58.81 5.2 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.17 -0.468 . . . . 0.0 111.124 179.895 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 42.6 t80 -61.11 -31.68 71.37 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.167 -0.469 . . . . 0.0 110.838 179.959 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.443 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.42 -65.17 2.76 Favored Glycine 0 N--CA 1.452 -0.29 0 C-N-CA 120.748 -0.739 . . . . 0.0 112.458 -179.944 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.545 HG22 ' O ' ' B' ' 79' ' ' GLY . 77.2 t -56.46 -35.67 44.82 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.315 0 CA-C-O 120.783 0.325 . . . . 0.0 111.116 -179.994 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 10.8 mmt -65.41 -46.9 78.2 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.884 179.951 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.9 -38.98 93.1 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.206 -0.452 . . . . 0.0 111.087 179.93 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.491 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.2 -56.48 5.67 Favored Glycine 0 N--CA 1.451 -0.355 0 C-N-CA 120.738 -0.744 . . . . 0.0 112.495 -179.954 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.52 HG23 ' O ' ' A' ' 80' ' ' VAL . 99.2 t -54.97 -49.02 74.6 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.865 0.364 . . . . 0.0 111.147 -179.982 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.503 HG22 HD12 ' A' ' 89' ' ' LEU . 33.9 mm -63.41 -48.18 88.39 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.3 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.133 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.17 -37.38 92.82 Favored Glycine 0 N--CA 1.452 -0.282 0 C-N-CA 120.72 -0.753 . . . . 0.0 112.488 179.904 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.554 HG21 HG13 ' B' ' 88' ' ' ILE . 57.4 m -68.0 -58.16 4.98 Favored 'General case' 0 C--N 1.329 -0.287 0 CA-C-O 120.814 0.34 . . . . 0.0 111.165 -179.826 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.583 HG13 HG21 ' B' ' 87' ' ' THR . 79.0 mt -55.5 -37.74 46.56 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.204 -0.453 . . . . 0.0 111.179 179.872 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.503 HD12 HG22 ' A' ' 85' ' ' ILE . 15.8 mt -65.19 -55.29 19.43 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.143 -0.481 . . . . 0.0 110.919 179.916 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 1.1 tt -53.54 -48.94 68.62 Favored 'General case' 0 C--N 1.328 -0.329 0 CA-C-N 116.176 -0.466 . . . . 0.0 110.919 179.876 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.607 ' CG2' HD12 ' A' ' 95' ' ' ILE . 62.0 mt -64.72 -56.38 16.28 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.317 0 CA-C-N 116.193 -0.458 . . . . 0.0 111.113 179.867 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 13.2 t -54.22 -25.59 23.88 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.175 -0.466 . . . . 0.0 110.833 -179.877 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 15.4 t80 -67.15 -43.59 81.93 Favored 'General case' 0 C--N 1.328 -0.356 0 CA-C-N 116.129 -0.487 . . . . 0.0 110.916 -179.882 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -107.92 36.83 4.14 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.709 -0.758 . . . . 0.0 112.502 179.992 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.607 HD12 ' CG2' ' A' ' 91' ' ' ILE . 16.1 mt -156.45 -51.09 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.815 0.34 . . . . 0.0 111.126 -179.966 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -72.9 -23.7 60.74 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.138 -0.483 . . . . 0.0 110.875 179.993 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 0.6 OUTLIER -144.88 27.5 1.31 Allowed 'General case' 0 C--N 1.329 -0.295 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.899 -179.91 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.4 OUTLIER . . . . . 0 C--N 1.328 -0.333 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.884 -179.965 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . 0.485 ' N ' ' HD2' ' B' ' 71' ' ' PRO . 1.5 mp0 . . . . . 0 C--O 1.231 0.089 0 CA-C-O 121.694 0.759 . . . . 0.0 110.875 . . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . 0.485 ' HD2' ' N ' ' B' ' 70' ' ' GLU . 54.2 Cg_endo -69.74 178.89 4.1 Favored 'Trans proline' 0 C--N 1.341 0.176 0 C-N-CA 122.673 2.249 . . . . 0.0 112.343 -179.975 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 10.4 tt0 -147.88 98.85 3.01 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.215 -0.448 . . . . 0.0 110.898 179.975 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . 0.695 HG22 ' CD1' ' B' ' 77' ' ' ILE . 47.5 mm -50.75 -34.03 12.56 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.35 0 CA-C-N 116.15 -0.477 . . . . 0.0 111.127 179.967 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 25.2 m -60.42 -54.73 42.09 Favored 'General case' 0 C--N 1.329 -0.296 0 CA-C-N 116.139 -0.482 . . . . 0.0 111.121 -179.99 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.625 HD12 HD12 ' A' ' 75' ' ' LEU . 24.8 mt -61.51 -37.26 83.04 Favored 'General case' 0 C--N 1.329 -0.306 0 CA-C-N 116.226 -0.443 . . . . 0.0 110.906 179.949 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.473 ' O ' HG23 ' B' ' 80' ' ' VAL . 53.6 mt -66.2 -40.44 86.97 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.353 0 CA-C-N 116.234 -0.439 . . . . 0.0 111.137 179.844 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . 0.695 ' CD1' HG22 ' B' ' 73' ' ' ILE . 29.8 mt -66.32 -57.89 8.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.295 0 CA-C-N 116.122 -0.49 . . . . 0.0 111.115 179.88 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.0 t80 -60.15 -31.35 70.01 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.904 179.932 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.545 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.75 -64.81 2.88 Favored Glycine 0 N--CA 1.451 -0.325 0 C-N-CA 120.764 -0.732 . . . . 0.0 112.463 -179.932 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.516 ' O ' HG23 ' B' ' 84' ' ' VAL . 36.3 t -56.51 -35.52 44.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.283 0 CA-C-O 120.794 0.33 . . . . 0.0 111.134 -179.936 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 2.2 mmm -65.37 -47.59 75.88 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.834 179.909 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.66 -38.33 89.91 Favored 'General case' 0 C--N 1.329 -0.316 0 CA-C-N 116.242 -0.436 . . . . 0.0 111.112 179.931 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.521 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.23 -56.12 5.85 Favored Glycine 0 N--CA 1.451 -0.33 0 C-N-CA 120.736 -0.745 . . . . 0.0 112.45 -179.919 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.516 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.1 t -54.93 -48.81 74.55 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.83 0.348 . . . . 0.0 111.144 -179.962 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.451 HG22 HD12 ' B' ' 89' ' ' LEU . 81.9 mt -63.61 -48.24 87.68 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.291 0 CA-C-N 116.146 -0.479 . . . . 0.0 111.129 179.899 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.99 -37.05 92.11 Favored Glycine 0 N--CA 1.452 -0.289 0 C-N-CA 120.753 -0.737 . . . . 0.0 112.488 179.899 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.583 HG21 HG13 ' A' ' 88' ' ' ILE . 54.7 m -68.46 -58.77 3.82 Favored 'General case' 0 C--N 1.33 -0.277 0 CA-C-O 120.805 0.336 . . . . 0.0 111.202 -179.873 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.554 HG13 HG21 ' A' ' 87' ' ' THR . 75.5 mt -55.7 -38.19 49.71 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.281 0 CA-C-N 116.167 -0.469 . . . . 0.0 111.151 179.887 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.451 HD12 HG22 ' B' ' 85' ' ' ILE . 17.7 mt -65.13 -53.72 40.92 Favored 'General case' 0 C--N 1.328 -0.343 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.919 179.907 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.4 tt -55.05 -49.08 72.49 Favored 'General case' 0 C--N 1.329 -0.302 0 CA-C-N 116.156 -0.474 . . . . 0.0 110.959 179.889 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 63.4 mt -64.59 -56.99 13.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.293 0 CA-C-N 116.174 -0.466 . . . . 0.0 111.165 179.792 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 50.0 p -55.18 -24.88 29.11 Favored 'General case' 0 C--N 1.329 -0.317 0 CA-C-N 116.211 -0.45 . . . . 0.0 110.869 -179.941 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 54.3 t80 -72.37 -53.38 12.47 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.132 -0.485 . . . . 0.0 110.947 -179.926 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -58.25 -35.35 77.8 Favored Glycine 0 N--CA 1.451 -0.346 0 C-N-CA 120.717 -0.754 . . . . 0.0 112.549 179.915 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 5.1 mt -76.65 -29.53 18.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.318 0 CA-C-O 120.812 0.339 . . . . 0.0 111.108 -179.961 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.53 -25.5 68.01 Favored 'General case' 0 C--N 1.329 -0.313 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.885 179.946 . . . . . . . . 2 2 . 1 . 018 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 14.0 ttm180 -145.19 42.74 1.3 Allowed 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.879 -179.923 . . . . . . . . 1 1 . 1 . 018 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 2.4 mt . . . . . 0 C--N 1.328 -0.332 0 CA-C-N 116.187 -0.461 . . . . 0.0 110.877 -179.999 . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 5.1 mt-10 . . . . . 0 C--O 1.231 0.095 0 CA-C-O 121.667 0.746 . . . . 0.0 110.892 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . . . . . . . . . 54.3 Cg_endo -69.7 177.62 5.36 Favored 'Trans proline' 0 C--N 1.342 0.194 0 C-N-CA 122.652 2.234 . . . . 0.0 112.383 179.963 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.452 ' HA ' HD13 ' B' ' 75' ' ' LEU . 1.5 mp0 -132.42 -43.35 0.93 Allowed 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.896 -179.95 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . 0.584 ' HA ' HD12 ' A' ' 76' ' ' ILE . 51.2 mm -51.08 -36.88 16.62 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.133 -0.485 . . . . 0.0 111.113 179.975 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 14.0 m -58.49 -54.87 42.17 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.192 -0.458 . . . . 0.0 111.091 -179.987 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.577 HD13 ' HA ' ' B' ' 72' ' ' GLU . 12.4 mt -61.05 -36.24 79.07 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.238 -0.437 . . . . 0.0 110.899 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.584 HD12 ' HA ' ' A' ' 73' ' ' ILE . 38.1 mt -66.27 -41.71 89.57 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.232 -0.44 . . . . 0.0 111.145 179.828 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . . . . . . . . . 22.9 mm -66.06 -57.86 8.91 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-N 116.154 -0.476 . . . . 0.0 111.123 179.856 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . . . . . . . . . 43.9 t80 -60.15 -31.27 69.93 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.165 -0.471 . . . . 0.0 110.901 179.994 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.595 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -68.66 -64.48 3.04 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.547 -180.0 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.531 ' O ' HG23 ' A' ' 84' ' ' VAL . 65.7 t -56.56 -35.5 44.92 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-O 120.863 0.363 . . . . 0.0 111.172 179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 17.2 mmm -65.29 -47.21 77.43 Favored 'General case' 0 C--N 1.33 -0.264 0 CA-C-N 116.132 -0.486 . . . . 0.0 110.873 179.927 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.89 -38.64 91.74 Favored 'General case' 0 C--N 1.329 -0.315 0 CA-C-N 116.216 -0.447 . . . . 0.0 111.135 179.914 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.544 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -73.08 -56.5 5.72 Favored Glycine 0 N--CA 1.451 -0.353 0 C-N-CA 120.772 -0.728 . . . . 0.0 112.489 -179.964 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.531 HG23 ' O ' ' A' ' 80' ' ' VAL . 95.4 t -54.94 -49.34 71.57 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.276 0 CA-C-O 120.814 0.34 . . . . 0.0 111.161 179.966 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . . . . . . . . . 33.6 mm -62.99 -47.62 91.9 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.336 0 CA-C-N 116.142 -0.481 . . . . 0.0 111.116 179.935 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -61.09 -39.33 96.96 Favored Glycine 0 N--CA 1.451 -0.321 0 C-N-CA 120.733 -0.746 . . . . 0.0 112.488 179.928 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . 0.558 HG21 HG13 ' B' ' 88' ' ' ILE . 54.1 m -65.96 -57.45 7.79 Favored 'General case' 0 C--N 1.329 -0.295 0 CA-C-O 120.781 0.324 . . . . 0.0 111.139 -179.873 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . 0.532 HG13 HG21 ' B' ' 87' ' ' THR . 79.0 mt -57.15 -45.55 84.46 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.316 0 CA-C-N 116.26 -0.427 . . . . 0.0 111.1 179.927 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . . . . . . . . . 0.2 OUTLIER -57.47 -52.96 63.25 Favored 'General case' 0 C--N 1.328 -0.345 0 CA-C-N 116.189 -0.459 . . . . 0.0 110.93 179.907 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . 0.406 ' HA ' HD22 ' A' ' 90' ' ' LEU . 0.4 OUTLIER -54.7 -55.81 25.8 Favored 'General case' 0 C--N 1.328 -0.335 0 CA-C-N 116.202 -0.453 . . . . 0.0 110.908 179.871 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . . . . . . . . . 74.8 mt -57.3 -59.42 3.24 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.162 -0.472 . . . . 0.0 111.16 179.821 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 59.7 p -53.07 -27.52 20.52 Favored 'General case' 0 C--N 1.329 -0.291 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.855 -179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 73.4 t80 -75.07 -51.5 13.37 Favored 'General case' 0 C--N 1.328 -0.339 0 CA-C-N 116.134 -0.485 . . . . 0.0 110.949 -179.878 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -68.45 -26.81 74.12 Favored Glycine 0 N--CA 1.452 -0.275 0 C-N-CA 120.726 -0.75 . . . . 0.0 112.465 179.954 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . . . . . . . . . 19.0 mm -76.45 -29.33 18.58 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.351 0 CA-C-O 120.854 0.359 . . . . 0.0 111.159 -179.959 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.69 -23.23 67.19 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.109 -0.496 . . . . 0.0 110.878 179.972 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 21.4 ttp85 -145.05 43.08 1.32 Allowed 'General case' 0 C--N 1.328 -0.338 0 CA-C-N 116.188 -0.46 . . . . 0.0 110.861 -179.95 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.345 0 CA-C-N 116.184 -0.462 . . . . 0.0 110.893 179.964 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . . . . . . . . . 11.8 mt-10 . . . . . 0 C--O 1.231 0.084 0 CA-C-O 121.661 0.743 . . . . 0.0 110.879 . . . . . . . . . 0 0 . 1 . 019 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . . . . . . . . . 53.8 Cg_endo -69.78 179.51 3.66 Favored 'Trans proline' 0 C--N 1.342 0.198 0 C-N-CA 122.631 2.221 . . . . 0.0 112.339 -179.992 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . 0.577 ' HA ' HD13 ' A' ' 75' ' ' LEU . 0.7 OUTLIER 69.31 -75.26 0.07 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.222 -0.445 . . . . 0.0 110.889 -179.99 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . . . . . . . . . 3.1 mt -50.87 -29.86 8.05 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.283 0 CA-C-N 116.154 -0.475 . . . . 0.0 111.121 179.968 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 88.1 m -62.94 -50.24 71.58 Favored 'General case' 0 C--N 1.329 -0.29 0 CA-C-N 116.199 -0.455 . . . . 0.0 111.169 179.946 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.497 ' CD1' HD12 ' A' ' 75' ' ' LEU . 10.7 mt -68.05 -37.32 81.17 Favored 'General case' 0 C--N 1.328 -0.337 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.942 179.93 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . . . . . . . . . 35.1 mm -67.19 -44.4 87.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.311 0 CA-C-N 116.159 -0.473 . . . . 0.0 111.082 179.869 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 20.1 mm -66.05 -57.7 9.53 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.214 -0.448 . . . . 0.0 111.147 179.861 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 42.4 t80 -61.45 -30.8 70.82 Favored 'General case' 0 C--N 1.329 -0.292 0 CA-C-N 116.163 -0.472 . . . . 0.0 110.911 179.948 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.517 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -69.16 -64.5 2.97 Favored Glycine 0 N--CA 1.451 -0.314 0 C-N-CA 120.708 -0.758 . . . . 0.0 112.506 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.595 HG22 ' O ' ' A' ' 79' ' ' GLY . 77.1 t -56.96 -35.83 48.48 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.282 0 CA-C-O 120.789 0.328 . . . . 0.0 111.12 -179.983 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 1.6 mmt -65.31 -47.21 77.36 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.916 179.89 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -63.08 -38.49 91.4 Favored 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.22 -0.446 . . . . 0.0 111.107 179.876 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.454 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.31 -56.25 5.74 Favored Glycine 0 N--CA 1.452 -0.28 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.478 -179.98 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.508 HG23 ' O ' ' B' ' 80' ' ' VAL . 96.1 t -54.91 -48.85 74.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.314 0 CA-C-O 120.799 0.333 . . . . 0.0 111.121 -179.956 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . . . . . . . . . 33.5 mm -63.51 -48.6 86.26 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.144 179.913 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.58 -36.7 92.03 Favored Glycine 0 N--CA 1.452 -0.271 0 C-N-CA 120.686 -0.768 . . . . 0.0 112.526 179.921 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.532 HG21 HG13 ' A' ' 88' ' ' ILE . 90.0 m -68.12 -58.47 4.42 Favored 'General case' 0 C--N 1.33 -0.263 0 CA-C-O 120.738 0.304 . . . . 0.0 111.186 -179.937 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . 0.558 HG13 HG21 ' A' ' 87' ' ' THR . 75.7 mt -55.36 -37.88 46.21 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.31 0 CA-C-N 116.219 -0.446 . . . . 0.0 111.132 179.906 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . . . . . . . . . 28.7 mt -65.18 -55.06 20.72 Favored 'General case' 0 C--N 1.329 -0.318 0 CA-C-N 116.133 -0.485 . . . . 0.0 110.935 179.903 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . 0.427 HD22 ' HA ' ' B' ' 90' ' ' LEU . 0.4 OUTLIER -53.97 -48.97 69.77 Favored 'General case' 0 C--N 1.328 -0.357 0 CA-C-N 116.242 -0.435 . . . . 0.0 110.87 179.896 . . . . . . . . 3 3 . 1 . 019 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . 0.7 ' CG2' HD12 ' B' ' 95' ' ' ILE . 63.6 mt -64.45 -56.23 17.31 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.186 -0.461 . . . . 0.0 111.142 179.835 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 13.6 t -54.46 -25.55 25.84 Favored 'General case' 0 C--N 1.329 -0.308 0 CA-C-N 116.202 -0.454 . . . . 0.0 110.86 -179.92 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 34.6 t80 -64.97 -42.92 94.14 Favored 'General case' 0 C--N 1.329 -0.299 0 CA-C-N 116.121 -0.491 . . . . 0.0 110.948 -179.872 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -111.64 39.25 2.95 Favored Glycine 0 N--CA 1.451 -0.343 0 C-N-CA 120.739 -0.743 . . . . 0.0 112.46 179.967 . . . . . . . . 1 1 . 1 . 019 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . 0.7 HD12 ' CG2' ' B' ' 91' ' ' ILE . 16.5 mt -156.39 -50.15 0.02 OUTLIER 'Isoleucine or valine' 0 C--N 1.328 -0.334 0 CA-C-O 120.796 0.331 . . . . 0.0 111.152 -179.986 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -75.06 -32.38 61.51 Favored 'General case' 0 C--N 1.329 -0.314 0 CA-C-N 116.195 -0.457 . . . . 0.0 110.855 179.984 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 0.5 OUTLIER -95.46 26.69 3.74 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.171 -0.468 . . . . 0.0 110.877 -179.897 . . . . . . . . 2 2 . 1 . 019 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 1.7 mt . . . . . 0 C--N 1.329 -0.306 0 CA-C-N 116.157 -0.474 . . . . 0.0 110.933 179.974 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 70' ' ' GLU . . . . . . . . . . . . . 36.8 mm-40 . . . . . 0 C--O 1.231 0.087 0 CA-C-O 121.643 0.735 . . . . 0.0 110.91 . . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' A' A ' 71' ' ' PRO . . . . . 0.68 ' HG2' HD21 ' B' ' 75' ' ' LEU . 54.0 Cg_endo -69.75 178.25 4.76 Favored 'Trans proline' 0 C--N 1.341 0.147 0 C-N-CA 122.72 2.28 . . . . 0.0 112.345 -179.981 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 72' ' ' GLU . . . . . 0.708 ' HB3' HD13 ' B' ' 75' ' ' LEU . 13.8 tp10 52.03 72.13 0.41 Allowed 'General case' 0 C--N 1.329 -0.284 0 CA-C-N 116.228 -0.442 . . . . 0.0 110.902 -179.966 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 73' ' ' ILE . . . . . . . . . . . . . 49.2 mm -54.75 -23.85 12.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.128 179.956 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 74' ' ' THR . . . . . . . . . . . . . 1.3 m -69.88 -45.44 67.68 Favored 'General case' 0 C--N 1.33 -0.268 0 CA-C-N 116.203 -0.453 . . . . 0.0 111.145 179.944 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 75' ' ' LEU . . . . . 0.412 HD12 ' HG2' ' A' ' 72' ' ' GLU . 38.7 mt -71.37 -38.94 71.54 Favored 'General case' 0 C--N 1.329 -0.298 0 CA-C-N 116.205 -0.452 . . . . 0.0 110.884 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 76' ' ' ILE . . . . . 0.457 HD11 HD22 ' B' ' 75' ' ' LEU . 37.4 mm -65.68 -48.39 82.64 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.288 0 CA-C-N 116.172 -0.467 . . . . 0.0 111.143 179.873 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 77' ' ' ILE . . . . . 0.401 HG22 ' N ' ' A' ' 78' ' ' PHE . 1.1 mp -65.32 -54.81 24.5 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.312 0 CA-C-N 116.166 -0.47 . . . . 0.0 111.135 179.819 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 78' ' ' PHE . . . . . 0.401 ' N ' HG22 ' A' ' 77' ' ' ILE . 42.7 t80 -60.79 -30.91 70.34 Favored 'General case' 0 C--N 1.329 -0.304 0 CA-C-N 116.162 -0.472 . . . . 0.0 110.891 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 79' ' ' GLY . . . . . 0.614 ' O ' HG22 ' B' ' 80' ' ' VAL . . . -69.89 -64.06 3.07 Favored Glycine 0 N--CA 1.451 -0.315 0 C-N-CA 120.729 -0.748 . . . . 0.0 112.496 -179.963 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 80' ' ' VAL . . . . . 0.649 HG22 ' O ' ' B' ' 79' ' ' GLY . 95.6 t -57.0 -35.64 48.16 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-O 120.867 0.365 . . . . 0.0 111.145 -179.993 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 81' ' ' MET . . . . . . . . . . . . . 7.4 mmt -65.66 -47.61 74.92 Favored 'General case' 0 C--N 1.33 -0.265 0 CA-C-N 116.15 -0.477 . . . . 0.0 110.867 179.927 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 82' ' ' ALA . . . . . . . . . . . . . . . -61.95 -39.23 91.39 Favored 'General case' 0 C--N 1.33 -0.279 0 CA-C-N 116.236 -0.438 . . . . 0.0 111.057 179.957 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 83' ' ' GLY . . . . . 0.546 ' HA3' HG13 ' B' ' 80' ' ' VAL . . . -72.97 -56.45 5.8 Favored Glycine 0 N--CA 1.451 -0.32 0 C-N-CA 120.74 -0.743 . . . . 0.0 112.516 -179.958 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 84' ' ' VAL . . . . . 0.515 HG23 ' O ' ' A' ' 80' ' ' VAL . 93.7 t -54.94 -49.38 71.2 Favored 'Isoleucine or valine' 0 C--N 1.33 -0.249 0 CA-C-O 120.809 0.337 . . . . 0.0 111.153 -179.954 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 85' ' ' ILE . . . . . 0.576 HG22 HD12 ' A' ' 89' ' ' LEU . 33.2 mm -62.52 -49.7 82.78 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.296 0 CA-C-N 116.207 -0.451 . . . . 0.0 111.171 179.876 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 86' ' ' GLY . . . . . . . . . . . . . . . -59.89 -35.15 85.89 Favored Glycine 0 N--CA 1.45 -0.375 0 C-N-CA 120.766 -0.731 . . . . 0.0 112.519 179.877 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 87' ' ' THR . . . . . . . . . . . . . 90.7 m -68.57 -59.6 3.02 Favored 'General case' 0 C--N 1.33 -0.266 0 CA-C-O 120.765 0.317 . . . . 0.0 111.153 -179.882 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 88' ' ' ILE . . . . . . . . . . . . . 70.9 mt -55.3 -37.87 45.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.304 0 CA-C-N 116.197 -0.456 . . . . 0.0 111.101 179.907 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 89' ' ' LEU . . . . . 0.576 HD12 HG22 ' A' ' 85' ' ' ILE . 13.3 mt -65.12 -55.18 20.21 Favored 'General case' 0 C--N 1.328 -0.348 0 CA-C-N 116.225 -0.443 . . . . 0.0 110.901 179.925 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 90' ' ' LEU . . . . . . . . . . . . . 2.2 tt -53.58 -49.01 68.65 Favored 'General case' 0 C--N 1.329 -0.323 0 CA-C-N 116.201 -0.454 . . . . 0.0 110.943 179.876 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 91' ' ' ILE . . . . . 0.603 ' CG2' HD12 ' A' ' 95' ' ' ILE . 65.2 mt -64.72 -55.77 19.42 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.323 0 CA-C-N 116.155 -0.475 . . . . 0.0 111.148 179.844 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 92' ' ' SER . . . . . . . . . . . . . 67.3 m -53.97 -26.14 24.28 Favored 'General case' 0 C--N 1.328 -0.327 0 CA-C-N 116.183 -0.462 . . . . 0.0 110.842 -179.939 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 93' ' ' TYR . . . . . . . . . . . . . 20.5 t80 -64.81 -38.75 92.02 Favored 'General case' 0 C--N 1.328 -0.369 0 CA-C-N 116.161 -0.472 . . . . 0.0 110.941 -179.89 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 94' ' ' GLY . . . . . . . . . . . . . . . -112.3 43.86 1.63 Allowed Glycine 0 N--CA 1.451 -0.318 0 C-N-CA 120.714 -0.755 . . . . 0.0 112.45 -179.99 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 95' ' ' ILE . . . . . 0.603 HD12 ' CG2' ' A' ' 91' ' ' ILE . 17.1 mt -156.49 -40.42 0.04 OUTLIER 'Isoleucine or valine' 0 C--N 1.329 -0.289 0 CA-C-O 120.849 0.357 . . . . 0.0 111.13 -179.99 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' A' A ' 96' ' ' ARG . . . . . . . . . . . . . 10.2 ptt85 -64.6 -28.52 69.69 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.153 -0.476 . . . . 0.0 110.855 179.993 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 97' ' ' ARG . . . . . . . . . . . . . 13.1 ttp180 -150.8 35.27 0.61 Allowed 'General case' 0 C--N 1.329 -0.305 0 CA-C-N 116.213 -0.449 . . . . 0.0 110.879 -179.928 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' A' A ' 98' ' ' LEU . . . . . . . . . . . . . 5.3 mp . . . . . 0 C--N 1.328 -0.341 0 CA-C-N 116.156 -0.475 . . . . 0.0 110.935 -179.949 . . . . . . . . 0 0 . 1 . 020 nuclear nobuild full ' B' B ' 70' ' ' GLU . . . . . 0.491 ' N ' ' HD2' ' B' ' 71' ' ' PRO . 1.3 mt-10 . . . . . 0 C--O 1.231 0.121 0 CA-C-O 121.572 0.701 . . . . 0.0 110.812 . . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 71' ' ' PRO . . . . . 0.491 ' HD2' ' N ' ' B' ' 70' ' ' GLU . 53.6 Cg_endo -69.76 162.99 39.94 Favored 'Trans proline' 0 C--O 1.231 0.171 0 C-N-CA 122.652 2.235 . . . . 0.0 112.392 -179.991 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 72' ' ' GLU . . . . . . . . . . . . . 15.6 pt-20 -149.62 -49.64 0.14 Allowed 'General case' 0 C--N 1.33 -0.274 0 CA-C-N 116.281 -0.418 . . . . 0.0 110.897 -179.94 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 73' ' ' ILE . . . . . 0.578 ' HA ' HD12 ' B' ' 76' ' ' ILE . 51.0 mm -51.69 -38.01 21.17 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.324 0 CA-C-N 116.156 -0.475 . . . . 0.0 111.088 179.979 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 74' ' ' THR . . . . . . . . . . . . . 35.5 m -58.77 -53.71 55.26 Favored 'General case' 0 C--N 1.33 -0.278 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.19 179.929 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 75' ' ' LEU . . . . . 0.708 HD13 ' HB3' ' A' ' 72' ' ' GLU . 12.5 mt -61.01 -36.24 78.98 Favored 'General case' 0 C--N 1.328 -0.334 0 CA-C-N 116.191 -0.459 . . . . 0.0 110.913 179.931 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 76' ' ' ILE . . . . . 0.578 HD12 ' HA ' ' B' ' 73' ' ' ILE . 37.2 mt -66.64 -41.13 87.74 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.327 0 CA-C-N 116.215 -0.448 . . . . 0.0 111.106 179.866 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 77' ' ' ILE . . . . . . . . . . . . . 23.6 mm -66.11 -56.83 12.93 Favored 'Isoleucine or valine' 0 C--N 1.328 -0.355 0 CA-C-N 116.185 -0.461 . . . . 0.0 111.165 179.846 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 78' ' ' PHE . . . . . . . . . . . . . 41.2 t80 -60.46 -31.87 70.85 Favored 'General case' 0 C--N 1.329 -0.293 0 CA-C-N 116.173 -0.467 . . . . 0.0 110.859 179.947 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 79' ' ' GLY . . . . . 0.649 ' O ' HG22 ' A' ' 80' ' ' VAL . . . -68.58 -65.05 2.79 Favored Glycine 0 N--CA 1.451 -0.332 0 C-N-CA 120.806 -0.712 . . . . 0.0 112.515 179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 80' ' ' VAL . . . . . 0.614 HG22 ' O ' ' A' ' 79' ' ' GLY . 88.1 t -56.68 -35.07 44.27 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.29 0 CA-C-O 120.87 0.367 . . . . 0.0 111.161 -179.995 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 81' ' ' MET . . . . . . . . . . . . . 0.0 OUTLIER -65.35 -47.01 77.93 Favored 'General case' 0 C--N 1.329 -0.286 0 CA-C-N 116.179 -0.464 . . . . 0.0 110.905 179.888 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 82' ' ' ALA . . . . . . . . . . . . . . . -62.86 -38.89 92.63 Favored 'General case' 0 C--N 1.33 -0.272 0 CA-C-N 116.205 -0.452 . . . . 0.0 111.085 179.924 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 83' ' ' GLY . . . . . 0.615 ' HA3' HG13 ' A' ' 80' ' ' VAL . . . -73.08 -56.39 5.78 Favored Glycine 0 N--CA 1.451 -0.351 0 C-N-CA 120.77 -0.729 . . . . 0.0 112.509 -179.967 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 84' ' ' VAL . . . . . 0.51 HG23 ' O ' ' B' ' 80' ' ' VAL . 97.6 t -54.86 -49.21 71.71 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.306 0 CA-C-O 120.849 0.357 . . . . 0.0 111.119 -179.978 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 85' ' ' ILE . . . . . 0.524 HG22 HD12 ' B' ' 89' ' ' LEU . 33.0 mm -62.96 -49.29 84.19 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.301 0 CA-C-N 116.129 -0.487 . . . . 0.0 111.133 179.913 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 86' ' ' GLY . . . . . . . . . . . . . . . -60.01 -35.31 86.86 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.713 -0.756 . . . . 0.0 112.495 179.945 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 87' ' ' THR . . . . . 0.422 ' OG1' HG13 ' A' ' 84' ' ' VAL . 84.8 m -68.91 -59.17 3.25 Favored 'General case' 0 C--N 1.33 -0.253 0 CA-C-O 120.762 0.315 . . . . 0.0 111.115 -179.839 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 88' ' ' ILE . . . . . . . . . . . . . 78.3 mt -55.85 -38.09 50.34 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.294 0 CA-C-N 116.196 -0.457 . . . . 0.0 111.135 179.935 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 89' ' ' LEU . . . . . 0.524 HD12 HG22 ' B' ' 85' ' ' ILE . 13.7 mt -65.25 -53.56 42.38 Favored 'General case' 0 C--N 1.328 -0.363 0 CA-C-N 116.166 -0.47 . . . . 0.0 110.889 179.916 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 90' ' ' LEU . . . . . . . . . . . . . 1.9 tt -55.02 -48.96 72.69 Favored 'General case' 0 C--N 1.328 -0.341 0 CA-C-N 116.22 -0.445 . . . . 0.0 110.897 179.91 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 91' ' ' ILE . . . . . . . . . . . . . 65.1 mt -64.86 -56.89 13.58 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.305 0 CA-C-N 116.171 -0.468 . . . . 0.0 111.151 179.852 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 92' ' ' SER . . . . . . . . . . . . . 8.7 t -55.18 -24.94 29.49 Favored 'General case' 0 C--N 1.329 -0.311 0 CA-C-N 116.168 -0.469 . . . . 0.0 110.834 -179.919 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 93' ' ' TYR . . . . . . . . . . . . . 76.4 t80 -72.27 -51.66 19.88 Favored 'General case' 0 C--N 1.328 -0.351 0 CA-C-N 116.145 -0.479 . . . . 0.0 110.883 -179.824 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 94' ' ' GLY . . . . . . . . . . . . . . . -62.66 -32.06 82.14 Favored Glycine 0 N--CA 1.451 -0.331 0 C-N-CA 120.716 -0.754 . . . . 0.0 112.507 179.961 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 95' ' ' ILE . . . . . . . . . . . . . 32.9 mt -76.47 -29.59 18.75 Favored 'Isoleucine or valine' 0 C--N 1.329 -0.307 0 CA-C-O 120.781 0.324 . . . . 0.0 111.125 179.983 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 96' ' ' ARG . . . . . . . . . . . . . 0.0 OUTLIER -64.72 -32.56 74.3 Favored 'General case' 0 C--N 1.328 -0.34 0 CA-C-N 116.224 -0.444 . . . . 0.0 110.839 179.982 . . . . . . . . 2 2 . 1 . 020 nuclear nobuild full ' B' B ' 97' ' ' ARG . . . . . . . . . . . . . 16.0 ttp180 -90.8 -35.55 14.77 Favored 'General case' 0 C--N 1.329 -0.288 0 CA-C-N 116.152 -0.476 . . . . 0.0 110.894 -179.861 . . . . . . . . 1 1 . 1 . 020 nuclear nobuild full ' B' B ' 98' ' ' LEU . . . . . . . . . . . . . 0.5 OUTLIER . . . . . 0 C--N 1.328 -0.342 0 CA-C-N 116.174 -0.466 . . . . 0.0 110.92 -179.983 . . . . . . . . 1 1 . 1 stop_ save_